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ABSTRACT (ENGLISH) 
 
 
The benefits of exercise training for patients with chronic obstructive pulmonary 
disease (COPD) are well-documented.  In South Africa, exercise programmes for 
COPD patients are limited and often expensive and inaccessible to the broader 
community.  The purpose of this study was to assess the responses of COPD 
patients to an exercise programme and to determine if the same results can be 
obtained through a less costly programme.  In the primary programme of the study, 
22 subjects were subjected to 12 weeks of exercise training.  Each subject 
underwent comprehensive pre- and post-intervention assessments, which included 
the measurement of overall health status by a physician, level of dyspnoea, forced 
expiratory lung function, exercise capacity, body mass index and health-related 
quality of life.  Exercise sessions included aerobic and strength training exercises 
and involved three, hour-long exercise sessions a week.  In the modified 
programme, 18 subjects were randomly divided into an experimental and control 
group.  Eleven subjects were included in the experimental group and seven 
subjects in the control group.  Subjects had to complete 32, hour-long exercise 
sessions in a 10-week period.  The experimental group’s exercise programme was 
adapted so that no specialised equipment was used, while the control group 
exercised in a well-equipped exercise- and rehabilitation centre.  All subjects were 
subjected to the same pre- and post-intervention assessment as in the primary 
programme.  In the primary programme, there were significant improvements in the 
physician’s evaluation of overall health status (p < 0.0001), level of dyspnoea (p < 
0.05), exercise capacity (p < 0.000001) and health-related quality of life (p < 
0.001).  No significant changes occurred in the forced expiratory lung function and 
body mass index.  In the modified programme, there were significant 
improvements in the physician’s evaluation of overall health status (p < 0.000001), 
level of dyspnoea (p < 0.0001), exercise capacity (p < 0.000001) and health-
related quality of life (p < 0.001).  Consistent with the primary programme, no 
significant changes occurred in the forced expiratory lung function and body mass 
 iii
index.  There was no significant difference between the results obtained by the 
experimental and control group on the physician’s evaluation of overall health 
status (p = 0.96), level of dyspnoea (p = 0.99), exercise capacity (p = 0.30), health-
related quality of life (p = 0.50), lung function and body mass index (p = 0.23).  The 
study concluded that a 12-week exercise programme, that included aerobic and 
strength training, improves the overall health-status, level of dyspnoea, exercise 
capacity and health-related quality of life of patients with COPD.  Furthermore, the 
same results can be obtained through a low-cost programme that utilises no 
specialised equipment.  The implementation of low-cost exercise programmes in 
South Africa has great potential benefit for all patients with COPD. 
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OPSOMMING (AFRIKAANS) 
 
Verskeie navorsing is al gewy aan die voordele wat oefenprogramme inhou vir 
pasiënte met kroniese obstruktiewe lugweg siekte (KOLS).  In Suid-Afrika is 
soortgelyke programme egter uiters beperk en meestal ontoeganklik en 
onbekostigbaar vir die breë publiek.  Die doel van hierdie studie was om die 
uitwerking van oefening op KOLS pasiënte te bepaal, sowel as om te bepaal of 
dieselfde resultate deur ‘n goedkoper program bereik kan word.  Twee-en-twintig 
proefpersone was in die primêre program van die studie ingesluit, waartydens 
proefpersone onderwerp was aan ‘n 12-weke oefenprogram.  Omvattende 
evaluasies is voor en na die intervensieprogram uitgevoer.  Metings tydens hierdie 
evaluasies het ingesluit die evaluasie van persone se algemene 
gesondheidstoestand deur ‘n internis, omvang van asemnood, geforseerde 
ekspirasie longfunksie, oefeningskapasiteit, liggaamsmassa-indeks en 
gesondheidsverwante lewenskwaliteit.  Oefensessies wat aerobies- and 
versterkingsoefeninge ingesluit het, is drie maal per week vir ‘n uur lank uitgevoer.  
In die aangepaste program is 18 proefpersone lukraak in ‘n eksperimentele- en 
kontrolegroep ingedeel.  Die eksperimentele groep het elf persone bevat, terwyl 
daar sewe persone in the kontrole groep was.  Hierdie proefpersone moes 32 
oefensessies, van ‘n uur elk, in ‘n 10-week periode voltooi.  Die eksperimentele 
groep se oefenprogram is so aangepas dat geen gespesialiseerde toerusting 
gebruik is nie, terwyl die kontrole groep in ‘n goed-toegeruste oefen- en 
rehabilitasiesentrum geoefen het.   Al die proefpersone is aan dieselfde evaluasie 
voor en na die intervensieprogram onderwerp.  In die primêre program is 
beduidende verbeterings gevind in die internis se evaluasie van persone se 
algemene gesondheidstoestand (p < 0.0001), omvang van asemnood (p < 0.05), 
oefeningskapasiteit (p < 0.000001) en gesondheidsverwante lewenskwaliteit (p < 
0.001).   Geen beduidende verskille is gevind in longfunksies en liggaamsmassa-
indeks nie.  In die aangepaste program was daar beduidended verbeterings in die 
internis se evaluasie van persone se algemene gesondheidstoestand (p < 
0.000001), omvang van asemnood (p < 0.0001), oefeningskapasiteit (p < 
 v
0.000001) en gesondheidsverwante lewenskwaliteit (p < 0.001).  Soos met die 
primêre program, was daar geen beduidende verskille in longfunksie en 
liggaamsmassa-indeks nie.  Daar was geen beduidende verskille tussen die 
eksperimentele en kontrole groepe in die internis se evaluasie van persone se 
algemene gesondheidstoestand (p = 0.96), omvang van asemnood (p = 0.99), 
oefeningskapasiteit (p = 0.30), gesondheidsverwante lewenskwaliteit (p = 0.50), 
longfunksie en liggaamsmassa-indeks (p = 0.23) nie.    Die gevolgtrekking van 
hierdie studie is dat ‘n 12-week oefenprogram, wat aerobies- en 
versterkingsoefeninge insluit, beduidende verbeterings in die algemene 
gesondheidstoestand, omvang van asemnood, oefeningskapasiteit en 
gesondheidsverwante lewenskwaliteit van persone met KOLS tot gevolg het.  
Soortgelyke voordele kan verkry word deur ‘n goedkoper oefenprogram wat geen 
gespesialiseerde toerusting vereis nie.  Die implementasie van sulke koste-
effektiewe oefenprogramme hou groot potensiële voordele in vir persone met 
KOLS in Suid-Afrika.   
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Chronic Obstructive Pulmonary Disease (COPD), which encompasses both 
chronic bronchitis and emphysema, is one of the leading causes of death and 
disability in both the developed and developing world (Jindah et al., 2006; Bateman 
et al., 2004; Pinto-Plata et al., 2004; Mannino, 2002; Pauwels et al., 2001; Hurd, 
2000; Petty & Weinmann, 1997; Curtis et al., 1994).  COPD poses an enormous 
burden to society both in terms of direct cost to healthcare services and indirect 
costs to society through loss of productivity (Mannino, 2002; Hurd, 2000).  “COPD 
is a common, costly and preventable disease that has implications for the global 
health, of the public and the individual” (Petty & Weinmann, 1997).  Reasons for 
the major impact that COPD has on public health include the high mortality rates, 
large affected populations, the increase in prevalence and the impact that it has on 
daily living (Toshima et al., 1990).   
 
The information available on COPD is limited by various factors.  It is difficult to 
differentiate between COPD and chronic severe asthma and patients with mild to 
moderate disease may not be identified as suffering from COPD (Lundback et al., 
2003).  Various sources advise that statistics on COPD should be interpreted with 
caution because of underestimation (Chan-Yeung et al., 2004; Cerveri et al., 2001; 
Hurd, 2000; Mannino et al., 2000; American Thoracic Society (ATS), 1995; Isoaho 
et al., 1994; Bakke et al., 1991).  Furthermore, most information concerning COPD 
comes from developed countries and limited data is available for developing 
countries (Jindah et al., 2006).   
 
Various risk factors have been identified that contribute to the development of 
COPD.  Tobacco smoking is regarded as the most important risk factor in the 
development of chronic respiratory disorders (Behrendt, 2005; Bateman et al., 
2004; Croxton et al., 2002; Senior & Anthonisen, 1998; British Thoracic Society 
(BTS), 1997; ATS, 1995).  A family history of COPD seems to be another 
significant risk factor, although insufficient evidence exists to determine whether 
this relationship is as a result of genetic or environmental factors, or a combination 
of both (Behrendt, 2005; Senior & Anthonisen, 1998; BTS, 1997; Petty & 
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Weinmann, 1997; ATS, 1995).  According to Ehrlich and associates (2004), 
although tobacco smoking is a risk factor that cannot be overlooked in South 
Africa, the high prevalence of tuberculosis has “emerged as a powerful predictor of 
chronic bronchitis, much stronger than smoking”. 
 
Despite the high prevalence and enormous cost to healthcare and society, COPD 
has received scant attention in comparison to other respiratory conditions such as 
asthma and lung cancer.  This is due to the fact that COPD is thought of as a self-
inflicted disease with few effective treatments.  Furthermore, it mainly affects the 
more elderly and therefore less vocal population.  COPD is not an obvious killer 
such as lung cancer and therefore receives a less emotive response (O’Donnell et 
al., 2002).  According to MacNee (1997), the following statement had already been 
made in 1923 and is still true today: 
 
“The trite observation that familiarity breeds contempt is essentially true with 
regard to the outlook of chronic bronchitis; those afflicted are inclined to 
accept the complaint as inevitable…those called upon to treat it do not find it 
sufficiently interesting to study it closely.” 
 
Respiratory physicians around the world now believe that the attitude that “little can 
be done for this self inflicted disease” is not justifiable.  Attempts have been made 
to redress this deficit with the recent introduction of guidelines in the management 
and care of patients with COPD (O’Donnell et al., 2002).  COPD is not only a 
frustrating disease for patients, but for physicians as well.  This is due to the fact 
that medical treatment can only partially alleviate symptoms and functional 
improvements are limited (Clark, 1995:527). 
 
COPD is one of the most widespread lung diseases in the world and the major 
reason for the development of pulmonary rehabilitation programmes 
(ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel, 1997).  Today, 
pulmonary rehabilitation is seen as an integral part of the clinical management of 
patients with chronic respiratory conditions.  The improvement of quality of life and 
functional ability, through the management of symptoms and the increase in 
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participation in physical and social activities, are the basis on which pulmonary 
rehabilitation was established.  Pulmonary rehabilitation deals with problems that 
might not be adequately addressed by conventional medical treatment.  These 
problems include deconditioning, social isolation, psychological symptoms, muscle 
wasting and weight loss.  The complex interaction between these problems is 
illustrated in figure 1.1.  A positive intervention in any one of these problems would 
translate into positive gains in the other aspects (Global Initiative for Chronic 
Obstructive Lung Disease (GOLD), 2006).     
 
 
Lack of fitness 
COPD Dyspnoea Immobility 
Depression Social isolation 
Figure 1.1 The cycle of physical, social and psychosocial consequences of 
COPD (GOLD, 2006). 
 
Well-structured programmes consists of various components that all contribute to 
the achievement of treatment goals.  Although exercise training is seen as the 
cornerstone of pulmonary rehabilitation, other components include education of 
family members and patients, psychosocial intervention and various forms of 
symptom and co-morbidity management (Morgan, 2003; BTS, 2001; McArdle et 
al., 2001:953; ATS, 1999; Carrieri-Kohlman et al., 1996; Belman, 1993; Holden et 
al., 1990). 
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The positive outcomes of pulmonary rehabilitation in combination with medical 
treatment are well documented.  These benefits include improved health status 
and functionality, a decrease in dyspnoea and a reduction in health care costs and 
hospitalisations (Bauldoff et al., 2002; McArdle et al., 2001:953; Guell et al., 2000; 
Troosters et al., 2000; Strijbos et al., 1996; ATS, 1995; Celli, 1995; Reardon et al., 
1994; Cox et al., 1993; Holden et al., 1990; Busch & McClements, 1988).   
 
Initially, physicians adopted a very conservative approach to exercise for COPD 
patients.  In most cases exercise was limited or discouraged (Belman, 1993).  
Exercise was then later regarded as a last effort to manage these patients with little 
hope for success (ATS, 1999).  A conjoined report by the American College of 
Chest Physicians (ACCV) and the American Association of Cardiovascular and 
Pulmonary Rehabilitation (AAVCPR) recommended that exercise training should 
be included as a standard treatment modality in the rehabilitation of COPD patients 
(ACCV/AACVPR Pulmonary Rehabilitation Guidelines Panel, 1997).  This report 
was later supported by the ATS and the BTS (BTS, 2001; ATS, 1999).  At the 
present time, exercise is promoted for the improvement of quality of life and forms 
an integral part in the management of patients with respiratory disease (Nici et al., 
2006; Rochester, 2003; ATS, 1999; Ries et al., 1995; Belman, 1993).     
 
Controversy still exists regarding the optimal use of exercise training for COPD 
patients.  A wide range of exercise programmes exist with vast differences 
regarding training mode, frequency and intensity (American College of Sports 
Medicine (ACSM), 2000:343; Maltais et al., 1997; ATS, 1995; Celli, 1995; Belman, 
1993).  Despite the wide variety in exercise programmes, the fact that patients who 
adhere to these programmes are more committed to maintaining their own health 
and are more independent, remains constant (Ries et al., 1995). 
 
Research on the success of low-cost programmes is limited.  According to Belman 
(1993) programmes without the benefit of complex testing and training methods, 
have previously been successfully implemented.  
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 This study therefore aimed to contribute to the existing literature on the effects of 
exercise training on COPD patients, but with the focus on a South African setting.  
Furthermore, this study hoped to improve the accessibility of pulmonary 
rehabilitation to a broader community, by focusing on the feasibility of a low-cost 
programme.   
 
Motivation for the study 
 
• To assess the improvement of functional ability of COPD patients through 
exercise. 
• To determine if the same results can be obtained through a less costly 
adapted rehabilitation programme. 
 
Problem Statement and Objectives 
 
1. Research Statement 
 
There should be a significant difference between the following pre- and post test 
scores: 
• Six minute walk test for distance (6MWT) 
• St. Georges Respiratory Questionnaire (SGRQ) 
• Baseline Dyspnoea Index (BDI)  and Transitional Dyspnoea Index (TDI) 
• Physician’s Global Evaluation 
• Forced Expiratory Volume in one second (FEV1) 
• Forced Inspiratory Volume in one second (FIV1) 
• Body Mass Index (BMI) 
• Number of acute exacerbations 
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In the second part of the study, the results obtained (as measured by the variables 
stated above) by the modified programme (MP) and the Primary Programme (PP) 
should statistically be equivalent. 
 
2. Objectives 
 
• The aim of the study is to create exercise programmes that can be used 
successfully by all levels of health care professionals and COPD patients 
alike. 
• The study aims to design an adapted model for the rehabilitation of COPD 
patients that is less expensive than the conventional method, but ultimately 
produces the same results.   
• The study aims to use the results of the 6MWT for the prescription of 
exercise intensity of each individual subject. 
• COPD patients will be encouraged to continue such a programme at home. 
• This study will concentrate on exercise training, independent of other 
pulmonary rehabilitation components, such as education and psychological 
intervention.   
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Chronic obstructive pulmonary disease (COPD) is defined as a progressive, 
irreversible disease, characterised by partly reversible airflow obstruction and 
essentially encompasses two closely related respiratory disorders, namely chronic 
bronchitis and emphysema.  An abnormal inflammatory response to noxious 
particles or gases is usually associated with COPD (Behrendt, 2005; Croxton et al., 
2002; Eisner et al., 2002; Wouters, 2002; Pauwels et al., 2001; Senior & 
Anthonisen, 1998; Petty & Weinmann, 1997; ATS, 1995).  Although this definition 
was widely accepted for many years, the recent report of the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) revised this definition to:  
 
“Chronic Obstructive Pulmonary Disease (COPD) is a preventable and 
treatable disease with some significant extrapulmonary effects that may 
contribute to the severity in individual patients.  Its pulmonary component is 
characterised by airflow limitation that is not fully reversible.  The airflow 
limitation is usually progressive and associated with an abnormal 
inflammatory response of the lung to noxious particles or gases.”  
 
The majority of COPD patients are current or former smokers; although the 
disease is not limited to smokers (GOLD, 2006; Behrendt, 2005; Croxton et al., 
2002; Eisner et al., 2002; Wouters, 2002; Pauwels et al., 2001; Senior & 
Anthonisen, 1998; Petty & Weinmann, 1997; ATS, 1995).  Although the current 
working definition of the GOLD report does not include FEV1 characteristics of 
COPD, FEV1 is still central to the diagnosis and grading of COPD (see table 2.1).   
 
Chronic bronchitis is clinically defined, whereas emphysema is defined in terms of 
anatomical pathology.  A diagnosis of chronic bronchitis is based on two major 
symptoms, namely a chronic cough and sputum production.  Chronic bronchitis is 
defined as a long-standing inflammation of the airways with the presence of a 
productive cough for at least three months a year for two consecutive years.  All 
other causes of a chronic cough must be ruled out before the diagnosis can be 
made (Bateman et al., 2004; McArdle et al., 2001:950; Fishman, 1998:683; ATS, 
1995).  Chronic bronchitis is generally characterised by obstruction of the small 
airways (Wouters, 2002). 
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 Emphysema is defined as a morbid condition of the lungs, where there is 
permanent abnormal enlargement of the airspaces distal to the terminal 
bronchioles, with destruction and reduced elastic recoil of the alveolar walls.  It is 
accompanied by a lack of uniformity in the pattern of airspace enlargement without 
evident fibrosis (Bateman et al., 2004; Wouters, 2002; McArdle et al., 2001:951; 
Fishman, 1998:684; Senior & Anthonisen, 1998; ATS, 1995; Calverley & Pride, 
1995:14; Dorland’s Illustrated Medical Dictionary, 1967:481).  Emphysema and 
chronic bronchitis do not form part of the GOLD definition of COPD.  According to 
the most recent GOLD report, emphysema only describes one of several structural 
abnormalities present in COPD patients.  Although chronic bronchitis is seen as a 
clinically and epidemiologically useful term, it does not reflect the major impact of 
airflow limitation on the morbidity and mortality of COPD patients.  This report 
further emphasised that chronic cough and sputum production, that form the 
essential part of the definition of chronic bronchitis, may be present without airflow 
limitation or airflow limitation may be present without being preceded by a chronic 
cough or sputum production.   
 
In the past, asthma formed part of the COPD complex.  Due to the reversibility and 
participation of cellular and chemical mediators in the inflammation process, it has 
been separated from COPD.  It is important to note that COPD has in many cases, 
a large reversibility component and an asthmatic may develop an irreversible 
airflow obstruction that is not distinguishable from COPD (Petty & Weinmann, 
1997; ATS, 1995).  Asthma may coexist with COPD and it is not always easy to 
distinguish between the two diseases (GOLD, 2006).   
 
Staging or grading of COPD severity is vital to standardise the categorisation of 
this population and to optimise management.  Disease severity should ideally be 
based on the interrelationship between the sensation of breathlessness, 
impairment in airflow and derangement in gas exchange.  There is however, no 
data available to quantify this interrelationship and the widely accepted system for 
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classification of COPD is in terms of FEV1 (Pauwels et al., 2001; Berry et al., 1999; 
ATS, 1995).  The GOLD guidelines advised that the use of a staging system 
should be limited to educational purposes and as a general indication of the 
approach to initial management (GOLD, 2006).  Various staging systems grade 
COPD severity based on FEV1.  Differences in these systems impede comparisons 
between different studies (Weiss et al., 2003).   
 
The most widely accepted staging system is the GOLD criteria for classification of 
COPD severity.  COPD classification according to the GOLD criteria is summarised 
in table 2.1 (GOLD, 2006).  This system is based on post-bronchodilator FEV1.  
Although the cut-off points for the different stages are not clinically validated, these 
cut-off points are used for simplicity purposes.  The use of a fixed ratio for 
FEV1/FVC was based on a study by Johannessen and co-workers (2006), who 
found that the FEV1/FVC ratio exceeds 0.70 in healthy adults of all age groups.   
 
The previous GOLD guidelines (Pauwels et al., 2001) included a “Stage 0: At 
Risk”, which identified individuals who are at risk for the development of COPD 
based on symptoms and risk factors.  This stage was, however, not included in the 
revised guidelines, because of insufficient evidence to suggest that all individuals 
that are at risk would progress into Stage I (GOLD, 2006).   
 
Stage I COPD is characterised by mild airflow limitation.  Individuals with Stage I 
COPD may not be aware of their lung function impairment and it usually has no 
effect on their quality of life.  Chronic cough and sputum production may be present 
in these patients, but it is not always the case.  Patients generally seek medical 
attention when the disease progresses to Stage II, due to the worsening of airflow 
limitation and chronic symptoms.  Patients diagnosed with Stage III COPD 
experience severe impairment of quality of life, increased fatigue, a decrease in 
exercise capacity and an increase in dyspnoea and exacerbations (GOLD, 2006; 
Pauwels et al., 2001).  Stage IV COPD is characterised by severe airflow limitation 
and severely impaired quality of life.  Exacerbations experienced by these patients 
 13
are often life threatening.  According to Antonelli-Incalzi and co-workers (2003), 
this classification correlates with differences in health status. 
 
Table 2.1 Classification of COPD severity according to the GOLD criteria. 
Stage Characteristics 
I:   Mild COPD FEV1/FVC < 0.70 
FEV1 ≥ 80% predicted 
 
II:  Moderate COPD FEV1/FVC < 0.70 
50% ≤ FEV1 <  80% predicted 
 
III: Severe COPD FEV1/FVC < 0.70 
30% ≤ FEV1 <  50% predicted 
 
IV:  Very Severe COPD FEV1/FVC < 0.70 
FEV1 <  30% predicted or FEV1 < 50% predicted plus chronic 
respiratory failure* 
 
* Respiratory failure:  PaO2 < 8.0 kPa (60 mmHg) with of without PaCO2 > 6.7 kPa (50 mmHg) while 
breathing air at sea level. 
 
According to the classification system proposed by the American Thoracic Society 
(1995), Stage I COPD is where FEV1 is greater or equal to 50% of the predicted 
value, Stage II COPD is where FEV1 is between 35 and 49% of the predicted value 
and Stage III COPD is where FEV1 is less than 35% of the predicted value.  
Patients with Stage I COPD rarely experience severe hypoxaemia and arterial 
blood gas measurements are not required.  The majority of COPD patients would 
classify as having Stage I of the disease.  These patients generally have minimal 
impact on their health-related quality of life (HRQL) and rarely experience severe 
dyspnoea.  The smallest group of patients are those with Stage II and Stage III 
COPD, respectively.  In these patients, the oxygen and carbon dioxide tensions, in 
addition to arterial blood gas measurements, should be stated.  Patients with Stage 
II COPD experience a significant impact on their HRQL, whereas HRQL is severely 
impacted in patients with Stage III COPD (ATS, 1995).   
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 The criteria defined by the British Thoracic Society correlates with the GOLD 
criteria (BTS, 1997), but does not include FEV1 criteria.  According to Lundback 
and co-workers (2003), the ATS criteria are not as distinct as the GOLD, BTS and 
European Respiratory Society (ERS) criteria.   
 
The staging system defined by the South African Thoracic Society (SATS) is 
similar to the GOLD criteria, but with differences in the cut-off points.  Apart from 
FEV1 criteria, the staging system of the SATS includes dyspnoea or functional 
impairment, six minute walk test distances (6MWD) and BMI (Bateman et al., 
2004).   
 
Epidemiology 
 
Due to its origin in early Europe, COPD was known as the “British Disease”.  One 
possible explanation for the high prevalence of COPD in the United Kingdom the 
past 30 years is high pollution levels.  The prevalence of COPD was at least twice 
as high in the United Kingdom than any other country with the same tobacco 
smoking habits (Pride & Soriano, 2002).   
 
According to the American Thoracic Society (1995), the available statistics with 
regards to the prevalence of COPD are incomplete and only estimations can be 
given.  Varying age distributions, extensive use of the term COPD and the fact that 
it encompasses different conditions are among the reasons for misclassification 
and omission from statistics.  Therefore, data on the prevalence and mortality of 
COPD must be interpreted with caution (Chan-Yeung et al., 2004; Cerveri et al., 
2001; Hurd, 2000; Mannino et al., 2000; Isoaho et al., 1994; Bakke et al., 1991).  
Celli and co-workers (2003) illustrated that variation in measurement approaches 
could alter prevalence estimations of COPD by 200%.  According to Jindah and co-
workers (2006), statistics on the prevalence of COPD are vastly underestimated.  
Furthermore, the majority of data available on the prevalence of COPD originates 
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from developed countries and little is known about the extent of the disease in 
developing countries (Pauwels et al., 2001).  According to Lomas (2002), there is a 
rise in COPD in developing countries such as India, Mexico, Cuba, Egypt, China 
and South Africa.  This could be attributed to increasing tobacco export to and local 
tobacco production in these countries and consequently, an increase in tobacco 
consumption (Lomas, 2002).  Furthermore, due to the rise in litigation in 
industrialised countries, tobacco companies are now focusing on less litigious 
countries.  Mortality statistics of COPD can be improved by creating greater 
awareness of the disease, improvement of early diagnosis and rectifying biases 
toward COPD (Jensen et al., 2006; Mannino et al., 1997).   
 
According to Lundback and co-workers (2003), the prevalence of COPD correlates 
strongly with smoking habits and advancement in age.  In the western world, 
COPD is probably the fourth most common cause of death in middle aged to 
elderly men after ischemic heart disease, lung cancer and cerebrovascular disease 
(GOLD, 2003; Lundback et al., 2003; Pauwels et al., 2001; Hurd, 2000; 
ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel, 1997).  According to 
statistics produced by the American Lung Association, 15 million Americans suffer 
from COPD and it claimed the lives of 87,000 Americans in 1992 (Mak, n.d.).  
According to the ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel 
(1997), four to six percent of white adult males and one to three percent of white 
adult females in the United States suffers from COPD.  The prevalence increases 
to 15% in adults older than 55 years.   
 
According to Mak (n.d.), the prevalence of COPD in the United Kingdom is 
estimated at 18% for males and 14% for females aged 40-68 years.  In the U.S.A., 
13.6% of males and 11.8% of females aged 65 to 74 years are thought to have 
COPD.  Feenstra and co-workers (2001) developed a population model to illustrate 
the projected increase of COPD in the Netherlands from 1994 to 2015.  According 
to this model the prevalence of COPD in the Netherlands will increase by 40% 
among males and 140% among females (Feenstra et al., 2001). 
 16
 In the United Kingdom, the prevalence of COPD was higher in women than in men 
from 1990 to 1997 (De Torres et al., 2005).  In non-smokers, the prevalence of 
COPD is greater among women than men till the age of 60, where after the 
prevalence is the same for male and female non-smokers (Behrendt, 2005).  
McAllister (2002) attributed the rise in COPD among men after the age of 60 to 
smoking habits of the last 40 years.  In the last 40 years, smoking was more 
popular among men than women and those smoking patterns now manifest in an 
increase in COPD among men after the age of 60.  The rise in the prevalence of 
COPD among western women could be attributed to the increase in the popularity 
of smoking among these women (Lomas, 2002).   
 
In a recent systematic review on the global prevalence of COPD, Halbert and co-
workers (2006) illustrated that nine to ten percent of adults, 40 years and older, are 
diagnosed with COPD as defined by airflow limitation.  These findings were 
consistent with an earlier qualitative review by Halbert and co-workers (2003) who 
reported the global prevalence of COPD as between four and ten percent.  The 
World Health Organization (WHO) (2002) reported that the global prevalence of 
COPD in 2001 was between 1013 and 1206 for every 100 000 men and 810 for 
every 100 000 women.  This estimation, however, includes all age groups and 
therefore totally underestimates the true prevalence.   
 
A study by Cerveri and co-workers (2001) investigated the prevalence of chronic 
bronchitis in young adults aged 20 to 44.  Data from 16 countries (13 European 
countries, USA, Australia and New Zealand) were analysed for this study.  These 
authors found chronic bronchitis to be a significant health problem in young adults.  
The average prevalence of this disease was 2.6% in all the countries analysed, 
with the prevalence in individual countries ranging from 0.7 to 9.7%.   
 
Statistics on the prevalence of COPD in South Africa are not readily available.  
According to Halbert and co-workers (2006), no spirometric studies exist on the 
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prevalence of COPD in any African country.  A household survey done by Ehrlich 
and co-workers (2004) provided cross-sectional data on the prevalence of chronic 
bronchitis on a representative sample of the non-institutionalised South African 
population.  This study indicated that the overall prevalence of chronic bronchitis is 
2.3% in men and 2.8% in women (Ehrlich et al., 2004).  These figures are 
misleading due to the fact that adults between the ages of 15 and 44 years were 
included in the sample.  COPD usually develops in the fifth decade of life (Bateman 
et al., 2004; McArdle et al., 2001:948); therefore, inclusion of such a young age 
group will result in a low prevalence percentage.  Furthermore, patient-reported 
diagnoses generally underestimated disease prevalence (Halbert et al., 2006). 
 
1. Mortality 
 
COPD has developed into an important cause of morbidity and mortality 
(Calverley, 2001; ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel, 
1997; Curtis et al., 1994).  In 1996, COPD was the fourth leading cause of death in 
the U.S.A. and accounted for 4% of all deaths.  At that time the mortality rates for 
men and women were the same up to age 55, whereafter the mortality rates for 
men rose sharply (Hurd, 2000; Petty & Weinmann, 1997; ATS, 1995).  According 
to De Torres and co-workers (2005), there was a fivefold increase in the mortality 
rate of women with COPD from 1971 to 2000.    
 
According to Statistics South Africa (2002), respiratory disease accounted for 4% 
of all deaths in South Africa in 2001.  This figure increases to 6% in the Cape Town 
area for the same period (South African Medical Research Council, 2003). 
 
Economic impact 
 
It is estimated that by the year 2020, COPD will be under the top five conditions 
that bear the highest health burden on worldwide society (Hurd, 2000).  Although 
only about five percent of people in the working population (age 18 to 64) will 
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develop COPD, it is still a costly disease (Eisner et al., 2002).  In 1985 COPD 
accounted for 5% of visits to physicians and more than 13% of hospitalisations in 
the United States (ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel, 
1997). 
 
Costs of COPD can be divided into primary and secondary care.  Primary care 
involves consultations, prescriptions and oxygen, whereas secondary care 
encompasses hospital admissions and absenteeism from work (Pride & Soriano, 
2002).  COPD is responsible for severe impairment of health status and work 
disability (Eisner et al., 2002).  In the United Kingdom, respiratory conditions are 
the third most common cause of chronic disease in working people aged 45-64 
years and are the most common cause of respiratory related death and COPD 
accounts for 56% of days of certified incapacity due to respiratory conditions in 
males.  Hospital admissions account for the largest cost of COPD.  In the United 
Kingdom, this cost is estimated at £2.5 billion per year (Morgan, 2003).  In 1989, 
an estimated $7 billion was spent on provision of care for patients with COPD in 
the USA, with a further cost of $8 billion due to the loss of productivity (O’Donnell 
et al., 2002; Petty & Weinmann, 1997).  The total cost of COPD has increased 
sharply in 1999, in the USA, to more than $14 billion (Hurd, 2000).  Table 2.2 
illustrates the relative economic burden of COPD in four developed countries; 
unfortunately, no such data is available for developing countries (Pauwels et al., 
2001).   
 
Table 2.2 Direct and indirect costs of COPD. 
Country Year Direct costs (US$ 
millions) 
Indirect costs 
(US$ millions) 
Total (US$ 
millions) 
U.K. 1996 778 3 312 4 090 
Netherlands 1993 256 Not available Not available 
Sweden 1991 179 281 460 
U.S. 1993 14 700 9 200 23 900 
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Pathology of COPD 
 
According to McAllister (2002), an overlap exists between the disease processes of 
chronic bronchitis, emphysema and chronic asthma.  The airflow limitation 
experienced by COPD patients is the result of small airway disease (obstructive 
bronchiolitis) and destruction of the lung parenchyma (emphysema), of which the 
degree of contribution varies between individuals (figure 2.2) (GOLD, 2006).  
Inflammation leads to structural changes, narrowing of the small airways and 
destruction of lung parenchyma.   
 
Typical structural changes include fibrosis, epithelial disruption, thickening of 
basement membrane, smooth muscle hypertrophy and mucus hypersecretion.  
The destruction of lung parenchyma leads to the loss of alveolar attachments to 
the small airways and the loss of elastic recoil of the lung.  This leads to impaired 
gas exchange, because of the diminished ability of the airways to remain open 
during expiration and insufficient alveolar surface.  Chronic gas exchange 
abnormalities can lead to respiratory failure (GOLD, 2006; McAllister, 2002; ATS, 
1995). 
 
 
AIRFLOW LIMITATION
Parenchymal destruction 
  Loss of alveolar attachments 
  Decrease of elastic recoil 
Small airway disease 
  Airway inflammation 
  Airway remodelling 
INFLAMMATION 
Figure 2.2 Mechanisms underlying airflow limitation in COPD (GOLD, 2006). 
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The inflammatory process in the respiratory bronchioles is mainly lymphocyte and 
polymorph mediated.  Membranous bronchioles less than 2mm in diameter are 
important sites for airflow obstruction.  This obstruction includes varying degrees of 
plugging with mucus, goblet-cell metaplasia, inflammation, increased smooth 
muscle and distortion due to fibrosis.  The cross-sectional area of these 
bronchioles is decreased due to these changes together with the loss of alveolar 
attachments from the destructive process of emphysema.  Bronchoconstriction is 
another mechanism that could explain airflow obstruction in the COPD patient.  
This is however, reversible in one third of patients by the administering of an 
inhaled beta-adrenergic agonist (ATS, 1995).    
 
1. Emphysema 
 
In emphysema, the lung parenchyma is affected by destruction of the alveolar 
walls.  This destruction causes permanent enlargement of the distal airspaces and 
contributes to narrowing of the small airways through disruption of the alveolar 
attachments.  The collapsing of the small airways leads to air trapping and 
consequent hyperinflation.   
 
Due to the fact that emphysema is classified in terms of structural or anatomical 
pathology, three pathological changes should be considered when making a 
diagnosis.  The first consideration is the size of the airspaces, which is also the 
primary consideration for classifying disease severity and identifying subtypes.  
Secondly, there should be evidence of destruction, which can be detected in early 
stages of the disease, before other pathological changes occur.  Lastly, fibrosis 
should be minimal, which is important for the exclusion of other pathological 
conditions (Calverley & Pride, 1995:14).  As a result of alveolar wall destruction, 
the main characteristics of emphysema include the loss of lung elasticity and 
elastic recoil pressure (ACSM, 1998a:317).   
 
 21
There are three types of emphysema described in the literature, centriacinar 
emphysema, panacinar emphysema and distal acinar emphysema (Fishman, 
1998:684; ATS, 1995).  It is important to note that in most patients it is impossible 
to distinguish the type of emphysema, since it is common for all three types to be 
present in one patient.  Centriacinar emphysema starts in the respiratory 
bronchioles and spreads peripherally.  There are two types of centriacinar 
emphysema, namely centrilobular emphysema and focal emphysema.  
Centrilobular emphysema tends to occur in the upper lobes, is usually associated 
with cigarette smoking and is commonly associated with dilatation and destruction 
of respiratory bronchioles.  Focal emphysema is more widely distributed compared 
to centrilobular emphysema and is less severe.  This type of centriacinar 
emphysema occurs in coal workers’ pneumoconiosis (Hogg & Senior, 2002; 
Fishman, 1998:684; ATS, 1995).   
 
Panacinar emphysema tends to occur in the lower lobes of the lungs and the entire 
alveolus is involved uniformly.  It is difficult to differentiate between healthy lungs 
and lungs with mild panacinar emphysema and it only become significant in severe 
stages of this emphysema.  This type of emphysema is associated with smoking 
and homozygous alpha-1 antitrypsin (AAT) deficiency (Hogg & Senior, 2002; 
Fishman, 1998:684; ATS, 1995).   
 
Distal acinar emphysema is also known as paraseptal emphysema and involves 
distal airway structures, alveolar ducts and alveoli.  Airflow is often well preserved 
in this type of emphysema, but because the process is localised adjacent to the 
fibrous septa or pleura, apical bullae may cause spontaneous pneumothorax 
(Fishman, 1998:684; ATS, 1995).   
 
McLeod’s syndrome or unilateral emphysema is caused by severe childhood 
infection as a result of rubella or adenovirus.  Newborn babies can be affected by 
congenital lobar emphysema, which is a developmental abnormality.  The term 
irregular emphysema is used for emphysema without any special distribution 
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pattern and emphysematous spaces form around the margins of scars (Hogg & 
Senior, 2002; Calverley & Pride, 1995:15). 
 
 1.1 Pathophysiological sequelae of cigarette smoking 
 
Cigarette smoking directly and indirectly imposes oxidative stress on the lungs.  
Reactive species in cigarette smoke are directly responsible for oxidative damage 
in the lungs, while oxidative stress can indirectly increase through the activation of 
inflammatory cells (Croxton et al., 2002; Wouters, 2002).  Oxidants are released 
from inflammatory leukocytes and alter the oxidant/antioxidant balance (Fishman, 
1998:678).  If the oxidant/antioxidant balance is shifted in favour of oxidants, 
through the presence of an excess of oxidants or a depletion of antioxidants, 
oxidative stress occurs.  The effects of oxidative stress on the lungs include the 
activation of inflammatory genes, inactivation of antiproteases, stimulation of 
mucus secretion and increased plasma exudation (GOLD, 2006).   
 
The pathogenesis of emphysema is commonly explained by the proteinase-
antiproteinase hypothesis.  According to this hypothesis proteinase activity is 
responsible for destruction of the alveolar walls (Hogg & Senior, 2002).   
 
Neutrophils release the proteolytic enzyme neutrophil elastase, which is the major 
(not the only) proteinase involved in emphysema.  Smoking results in an increase 
in neutrophils in the lung capillary bed, which will increase the concentration of 
neutrophil elastase.  Adding to the pathology, cigarette smoke has been found to 
elicit an inflammatory response in the lungs and stimulates the release of elastase 
from these cells (Hogg & Senior, 2002; Wouters, 2002; Betsuyaku et al., 1995; 
Bates, 1989:152).  Elastase breaks down elastin, a normal structural component of 
lung tissue.  Neutrophils are not the only inflammatory cells responsible for 
pathogenesis of lung destruction.  Hogg and Senior (2002) implicated 
macrophages, T-lymphocytes and eosinophils as part of this process, as well.   
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In healthy individuals, the lung is protected from the destructive effect of elastase 
by an inhibitor, AAT.  This protective action of AAT is however, inactivated by 
cigarette smoke, which results in destruction of the alveolar walls due to proteinase 
activity (Hogg & Senior, 2002; Fishman, 1998:699).  Contrary to the majority of 
studies, Bates (1989:152) stated that AAT levels are not affected by cigarette 
smoke.   
 
2. Chronic bronchitis 
 
Chronic bronchitis is clinically defined in terms of sputum production and cough 
(ACSM, 1998a:315; Calverley & Pride, 1995:13).  Pathological features of chronic 
bronchitis include enlargement of mucus-secreting glands in the airways, an 
increase in mucus glands in relation to serous glands, accumulation of mucus in 
the airways, narrowing of small airways, diverticula in the airways and colonisation 
by Streptococcus pneumoniae and Haemophilus influenzae (George et al., 
1990:174).   
 
Hypersecretion of mucus is the result of an increase in the mass of submucosal 
glands and an increase in goblet cells in the surface epithelium (Calverley & Pride, 
1995:13).  Dilation of the ducts of submucosal glands further contributes to 
hypersecretion of mucus (Murray et al., 2000:1203; George et al., 1990:174).  The 
increase in the volume of submucosal glands is the result of cigarette smoke and 
other irritants (it may also be present in asthma), while the increase in goblet cells 
may occur due to chemical stimuli.  In healthy individuals, goblet cells are 
predominantly found in the proximal airways.  In smokers, goblet cells are found in 
the peripheral airways and may increase or decrease in the proximal regions 
(Calverley & Pride, 1995:13).  Smoking cessation leads to decreased sputum 
production (McAllister, 2002).  
 
Increased smooth muscle, inflammation and the loss of alveolar attachments 
further contribute to increased mucus in the airways (Murray et al., 2000:1203).  
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Mucus hypersecretion is accompanied by inflammatory changes, which results in 
scarring, fibrosis and distortion of peripheral airways (McAllister, 2002).  Diverticula 
in the walls of the airways are predominantly found in the larger airways (George et 
al., 1990:175). 
 
Pathophysiology of COPD 
 
Pathophysiology describes the physiological impact of pathological changes 
(Dorland’s Illustrated Medical Dictionary, 1967:1112).  In terms of COPD, it 
describes the distorted physiological characteristics of the disease that emanate 
from pathological changes in the lungs.  These pathological changes include 
airflow limitation, mucus hypersecretion, ciliary dysfunction, pulmonary 
hyperinflation, gas exchange abnormalities, pulmonary hypertension, cor 
pulmonale (Pauwels et al., 2001) and ventilation-perfusion mismatching (Fishman, 
1998:663).    
 
The airflow during forced expiration is the result of the interaction between elastic 
recoil and airway resistance.  Elastic recoil promotes airflow, whereas airway 
resistance limits airflow (Fishman, 1998:662).  The primary physiological change of 
COPD is expiratory airflow obstruction, which is the result of airway obstruction and 
consequently the increase in airway resistance and loss in elastic recoil.  The 
destruction of alveolar attachments contributes to expiratory airflow obstruction, but 
is secondary to airway obstruction, airway resistance and elastic recoil 
abnormalities (Pauwels et al., 2001; Fishman, 1998:662-663).  The reduction in 
FEV1 experienced by patients with COPD is primarily the result of inflammation, 
fibrosis and luminal exudates in the small airways (GOLD, 2006).    
 
The pathological origin of chronic cough and sputum, both key symptoms of 
COPD, is mucus hypersecretion and ciliary dysfunction (Pauwels et al., 2001).  In 
hyperinflation, the relaxation volume of the respiratory system (Vr) is raised above 
the functional residual capacity (FRC) due to changes in the elastic properties of 
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the lungs and chest walls (Gibson, 1996).  The elastic recoil pressure increases as 
the lung volume increases to preserve maximum expiratory airflow.  This causes 
an increase in the work of breathing and a decrease in ventilatory efficiency, which 
will contribute to dyspnoea (Fishman, 1998:664).   
 
Abnormalities in gas exchange are the result of peripheral airway obstruction, 
parenchymal destruction and pulmonary vascular abnormalities.  These 
abnormalities will lead to hypoxaemia and hypercapnia (Pauwels et al., 2001).  
Hypercapnia and hypoxaemia can induce renal and hormonal abnormalities, which 
can lead to oedema (McAllister, 2002).   
 
Various studies suggested that chronic low oxygen levels would cause 
vasoconstriction of the pulmonary arterioles, which results in pulmonary 
hypertension (McAllister, 2002; Pierson, 2000; Fishman, 1998:663).  Eventually, 
pulmonary hypertension can result in structural changes such as intimal 
hyperplasia and smooth muscle hypertrophy (GOLD, 2006).  Since these structural 
changes of the pulmonary arteries are seen in patients without hypoxaemia, this 
traditional view have been challenged.  Other studies proposed that various 
inflammatory proteins play an important role in the regulation of pulmonary artery 
pressure (Joppa et al., 2006; Wright et al., 2005; Barbera et al., 2003; Peinado et 
al., 1999; Barbera et al., 1994; Stevens et al., 1992).  Joppa and co-workers (2006) 
proposed that apart from chronic local inflammation in the airways and lung 
parenchyma, systemic inflammation could also play a role in the pathogenesis of 
pulmonary hypertension.  Further studies are needed to address this in more 
detail.    
 
Pulmonary hypertension can lead to cor pulmonale and right ventricular failure 
(McAllister, 2002; Pierson, 2000; Fishman, 1998:663).  Cor pulmonale refers to 
“alterations in the structure and function of the right ventricle” consequent upon 
increased pressure, which results from disease of the lungs (Pierson, 2000).  This 
is only evident in patients with a FEV1 that is 25% or less of the predicted value or 
 26
during chronic hypoxaemia (marked by PaO2 less than 55 mmHg).  It is common for 
patients with mild COPD to experience a slight increase in pulmonary pressure 
during exercise (Fishman, 1998:663).  An inverse relationship exists between 
pulmonary hypertension and the prognosis of COPD patients.  Therefore, an 
increase in pulmonary hypertension results in a poorer prognosis (Pierson, 2000). 
 
Ventilation-perfusion (VA/Q) mismatching is common pathology in COPD and 
affects the airways and lung parenchyma (Fishman, 1998:663; Scharf, 1992:309).  
Two distinct VA/Q profiles of COPD patients have been identified.  Type A patients 
(“pink puffers”) are characterised by a VA/Q profile where a “substantial amount of 
ventilation is distributed to high VA/Q regions”.  Type B patients (“blue bloaters”) 
are characterised by a substantial amount of pulmonary blood flow perfusion in the 
low VA/Q regions.  Most patients cannot be classified into one of these profiles 
because they have both high and low VA/Q regions (Fishman, 1998:663).  Type B 
patients usually suffer from hypoxaemia, which can be easily corrected by oxygen 
administration (Pierson, 2000).  VA/Q abnormalities generally arise from disease in 
the small airways and would therefore not be reflected in lung function tests.  The 
translation of VA/Q inequalities into hypoxaemia depends on cardiac output 
(Scharf, 1992:311).   
 
Cooper (2001b) describes the pathophysiology of COPD as “highly complex”, due 
to interdependence of the pulmonary, cardiovascular and musculoskeletal 
systems.  This interdependence is illustrated in figure 2.3.   
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Figure 2.3 An illustration of the complex pathophysiology of COPD (Cooper, 
1995).   
 
Chronic hypoxia will increase mortality regardless of the degree of airflow 
obstruction.  Hypoxia can result in increased ventilation, which can be perceived as 
dyspnoea.  Hypercapnia can lead to alveolar hypoventilation, which will contribute 
to hypoxaemia.  Hypoxaemia may increase the severity of dyspnoea, but results 
are variable (Pierson, 2000).     
 
1. Ventilation and pulmonary mechanics 
 
Abnormalities of ventilation and pulmonary mechanics are some of the primary 
limits to exercise performance (Rochester, 2003; Haccoun et al., 2002; Belman, 
1993; Casaburi et al., 1991).  Obstruction of expiratory flow due to alveolar wall 
destruction and bronchiolar narrowing and the consequent increase in airway 
resistance place a significant limitation on exercise performance (Rochester, 2003; 
Belman, 1993).   
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Deconditioning and peripheral muscle dysfunction can cause ventilation of COPD 
patients to be higher than expected.  This is due to increased dead space 
ventilation, impaired gas exchange and increased ventilatory demands.     
 
Airflow limitation can be severe enough to result in a maximal expiratory flow equal 
to resting expiratory flow (Murariu et al., 1998; Belman, 1993).  Prolonged 
expiration, together with an increased breathing frequency, lead to hyperinflation.  
A reduction in FEV1 leads to an increased end expiratory lung volume (Nici et al., 
2006; Rochester, 2003; O’Donnell et al., 2001; Gallagher, 1994; Belman, 1993).  
Hyperinflation can be static or dynamic.  Static hyperinflation is caused by loss of 
elastic recoil pressure, while dynamic hyperinflation is the result of air trapping and 
increased inspiratory muscle activity during expiration (Gosselink, 2003).  Dynamic 
hyperinflation is one of the most significant factors that cause exercise intolerance 
(O’Donnell et al., 2002).  Dynamic hyperinflation can be defined as an abnormal 
lung volume at the end of tidal expiration (Murariu et al., 1998; Gibson, 1996).   
 
Dynamic hyperinflation can also lead to Intrinsic Positive End-Expiratory Pressure 
(PEEPi).  PEEPi is identified when alveolar pressure is positive at the end of tidal 
volume expiration, because of expiratory flow limitation.  Because of dynamic 
hyperinflation, there is insufficient time for complete expiration to the resting 
volume, before the next inspiration.  Alveolar pressure will not reach atmospheric 
pressure, which will result in positive pressure throughout expiration.  As a result, 
intrathoracic pressure may increase high enough to impair venous return, limit 
cardiac output and lead to hypotension, barotrauma and pneumothorax (Fitting, 
2001; Dueck, 2000).   
 
Moderate hyperinflation is defined as the ratio between functional residual capacity 
(FRC) and total lung capacity (TLC) exceeding 0.6 and/or a residual volume 
(RV)/TLC ratio exceeding 0.5.  Severe hyperinflation is characterised by a 
FRC/TLC ratio above 0.8 (200% of the predicted value) and/or a RV/TLC ratio 
above 0.7 (180% of the predicted value) (Dueck et al., 1999; Gelb et al., 1996a).   
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 Hyperinflation limits tidal volume, increases elastic load of inspiratory muscles and 
forces inspiratory muscles into a shortened position (especially the diaphragm) 
(Rochester, 2003; Fitting, 2001; Mador et al., 2000b; Fishman, 1998:664).  
Hyperinflation can be detected radiographically by the presence of a depressed 
diaphragm without its normal curvature and enlargement of the retrosternal 
airspace.  The consequence of hyperinflation includes an abnormal distribution of 
resting tidal breathing between the rib cage and abdominal compartments, 
distortions of the chest wall motion and a reduced mechanical advantage of the 
diaphragm and the inspiratory muscles (Fishman, 1998:664; Gibson, 1996).  The 
flattening of the diaphragm places it in a mechanically disadvantaged position and 
results in what is known as Hoover’s sign.  Hoover’s sign is the constriction of the 
lower rib cage due to the abnormal pressure exerted by the flattened diaphragm, 
particularly during inspiration (Scharf, 1992:278).  According to Gibson (1996), 
Hoover’s sign is the best recognised distortion of the rib margin.   
 
Dynamic hyperinflation is one of the main consequences of expiratory flow 
limitation and has a three-way effect on inspiratory loading.  Firstly, inspiratory 
workload is increased through a decrease in static compliance, because patients 
breathe along the shallower portion of the pressure-volume curve.  Secondly, the 
inspiratory threshold load is increased.  Inspiration can only occur after respiratory 
muscles have generated enough force to overcome the elastic recoil pressure.  
Lastly, there is a greater dependence on breathing frequency, rather than 
breathing volume (O’Donnell et al., 2001; Bauerle et al., 1998; Eltayara et al., 
1996; Belman, 1993).     
 
According to Belman (1993), dynamic hyperinflation is “a necessary evil for without 
it the patients with COPD would not be able to increase ventilation to meet the 
demands of exercise”.  Ventilation is increased by the increase in end-expiratory 
lung volume.  An increase in end expiratory lung volume results in patients that 
demonstrate breathing along the higher portion of the expiratory flow-volume curve 
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and an increase in maximum expiratory airflow (figure 2.4).  This adaptive 
response does however, put the respiratory muscles at a mechanical disadvantage 
(Fishman, 1998:664; Carter, et al., 1993).   
 
 
Figure 2.4 Tidal and maximal flow-volume loops at rest and during exercise of a 
healthy individual and a typical COPD patient (McConnell & Romer, 
2004). 
 
To generate the added force to overcome the elastic recoil pressure of a 
hyperinflated chest, patients recruit abdominal and expiratory muscles of the rib 
cage during expiration.  However, expiration becomes an active action, rather than 
a passive action, which increases oxygen utilisation during this, usually passive, 
breathing phase.  This results in a reduction of breathing efficiency (Belman, 1993).  
According to Casaburi and co-workers (1991), if the ventilatory requirements for a 
certain work rate can be reduced, exercise tolerance will increase.   
 
Lung function can also limit exercise performance of COPD patients (Gosselink et 
al., 1996).  They reported that FEV1 and the transfer factor for carbon monoxide 
were determining factors for exercise performance.  Murariu and co-workers (1998) 
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found that lung function, based on resting inspiratory capacity (IC), contributes 
significantly to exercise intolerance of COPD patients.   
 
2. Impaired gas exchange 
 
Impaired gas exchange during exercise is the result of an increased physiologic 
dead space, ventilation-perfusion mismatch and reduced diffusing capacity.  An 
increase in the physiologic dead space results in an increase in ventilatory demand 
(Rochester, 2003; Gallagher, 1994).   
 
Hypoxaemia is a common feature of COPD and is especially significant during 
exercise.  Desaturation during exercise can largely be attributed to a reduction in 
mixed venous PO2 and hypoventilation.  Reduced alveolar ventilation results in an 
increase in total minute ventilation to maintain efficient carbon dioxide output 
(Gallagher, 1994; Belman, 1993).  High CO2 levels in the blood have been 
implicated as a factor affecting exercise tolerance (Carter et al., 1993).  Arterial 
hypoxaemia has an influence on exercise tolerance, because of impaired oxygen 
delivery to working muscles.  Hypoxaemia can also indirectly influence exercise 
tolerance because ventilatory limitation is experienced at an increasingly lower 
work rate (Gallagher, 1994).  According to Mak and co-workers (1993), oxygen 
desaturation during exercise is not a determining factor for submaximal exercise 
capacity.   
 
VE in patients with COPD is higher during exercise compared to healthy 
individuals.  This increase is, however, seldom enough to compensate for the 
increased physiological dead space to VT ratio, resulting in higher PaCO2 during 
exercise.  Increased PaCO2 limits exercise performance by impairing 
hyperventilation when metabolic acidosis develops (Gallagher, 1994).   
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3. Hypoxaemia and hypoxia 
 
According to Pierson (2000) no explicit definitions exist for hypoxaemia and 
hypoxia and that, an interrelationship exists between the two conditions.  The 
Dorland’s Illustrated Medical Dictionary (1967:717) defines hypoxaemia as a 
“deficient oxygenation of the blood”.  Hypoxaemia is usually the result of 
ventilation/perfusion mismatching.  Hypoxaemia results in an increase in ventilatory 
drive, dilatation of the vascular bed, tachycardia, vasoconstriction of pulmonary 
vasculature and an increase in cardiac output.  As heart rate, cardiac output and 
oxygen use by contracting muscles increase during exercise, the transit time of the 
blood through the capillary bed decreases.  This will accentuate the hypoxaemic 
abnormalities, which will result in reduced exercise capacity (Soo Hoo, 2003; 
Okubadejo et al., 1996).  Hypoxaemic patients’ exercise capacity is directly limited 
by the reduced oxygen delivery to the working muscles (Gallagher, 1994).  Another 
possible explanation for the relationship between hypoxaemia and reduced 
exercise capacity is the fact that chronic hypoxaemia results in muscle wasting 
(Degache et al., 2003).   
 
Hypoxia is a decrease in the oxygen supplied to the tissue (Dorland’s Illustrated 
Medical Dictionary, 1967:717).  Hypoxia results in impaired cardiac function by 
decreasing myocardial contractility and maximum cardiac output, which will 
translate into reduced exercise tolerance (Pierson, 2000).  When subjected to 
chronic hypoxia, adaptations occur in the skeletal muscles.  These adaptive 
responses result in vulnerability towards oxidative stress, which causes 
malfunction in adenosine triphosphate (ATP) generation.  This malfunction impairs 
exercise capacity (ATS & ERS, 1999). 
 
4. Hypercapnia and acidosis 
 
Lactic acid production during incremental exercise is dependant on circulatory 
function and fitness level (Belman, 1993).  A build-up of lactic acid occurs when the 
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production of lactate exceeds the oxidation in the muscle cells and energy 
requirements cannot be met aerobically (McArdle et al, 2001:160).  It was 
previously thought that COPD patients could not exercise at sufficient levels to 
elicit a lactic acid response (Belman, 1986; Hughes & Davison, 1983; Belman & 
Kendregan, 1981).  However, other studies (Maltais et al., 1996b; Casaburi et al., 
1991; Sue et al., 1988) did record lactic acidosis at low work rate levels.  It has 
been reported that COPD patients develop lactic acidosis at lower work rate levels 
than healthy individuals (Casaburi et al., 1991; Gallagher, 1994).  Casaburi and co-
workers (1991) attribute this phenomenon to two factors, reduced oxygen supply to 
working muscles and a sedentary lifestyle.  Maltais and co-workers (1996b) 
demonstrated that there is an excessive increase in lactic acid in COPD patients.  
This was attributed to altered skeletal muscle oxidative capacity.  They also found 
a relationship between increased lactic acid and impaired activity of mitochondrial 
enzymes.  The decrease in enzyme activity is the result of a decrease in the 
number of mitochondria due to a reduction in muscle mass.   
 
Respiratory acidosis develops as a result of carbon dioxide retention (Dorland’s 
Illustrated Medical Dictionary, 1967:27).  Increased carbon dioxide will decrease 
the serum pH, which is known as respiratory acidosis.  Respiratory and metabolic 
acidosis stimulate ventilation because of the fall in arterial pH.  Ventilation can also 
be indirectly stimulated by acidosis through an increase in CO2 production (Maltais 
et al., 1996b; Gallagher, 1994).   
 
As with healthy individuals, the lactic acid threshold (the point at which the level of 
lactic acid rises) in COPD patients is preceded by an increase in minute ventilation 
(Belman, 1993).  According to McArdle and co-workers (2001:291), exercise 
performance is influenced by the onset of blood lactate accumulation.  The same is 
true for COPD patients (Rochester, 2003).   
 
Peak lactate levels in COPD patients will be reduced because of their overall 
reduction in exercise capacity.  A rise in lactic acid levels in these patients is as a 
 34
result of working limb muscles and not respiratory muscles.  This is illustrated by 
the fact that low lactic acid levels are present in patients with severe obstruction 
and consequently high respiratory muscle work rates (Belman, 1993).    
 
Hypercapnia is defined as excessive carbon dioxide in the blood (Dorland’s 
Illustrated Medical Dictionary, 1967:700).  The degree of hypercapnia is 
determined by abnormalities in minute ventilation (VE), physiologic dead space and 
CO2 output.  Hyperinflation (resting and dynamic) contributes to hypercapnia 
through its influence on breathing patterns, inspiratory muscle function and 
neuroregulatory control (O’Donnell et al., 2002).  Hypercapnia at rest has been 
associated with poor survival (Hogdkin, 1990).  The impact of hypercapnia on 
respiratory muscle function is still unclear.  A recent study found that hypercapnia 
and consequent respiratory acidosis, could contribute to diaphragmatic fatigue 
(Jonville et al., 2002).  Mador and co-workers (1997) found that acute, moderate 
hypercapnia results in a decrease in the contractibility of limb muscle, which will 
impact exercise capacity.  Hypercapnia did not have any impact on diaphragmatic 
contractibility (Mador et al., 1997).  Another study illustrated that exercise capacity 
is not affected by hypercapnia, although hypercapnic patients achieved lower 
ventilation during exercise.  Furthermore, it was found that hypercapnia is the 
result of the lung’s inability to increase ventilation and could not be attributed to 
respiratory muscle weakness or dysfunction (Montes de Oca & Celli, 2000).   
 
5. Malnutrition 
 
According to the American Thoracic Society (1995), 60% of patients that are 
critically ill with COPD are malnourished.  Malnutrition varies according to the 
grade of pulmonary limitation.  Typically, the incidence of malnutrition increases 
with an increase in the severity of pulmonary limitation (ATS, 1995; Donahoe et al., 
1989).   
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One of the adverse effects of malnutrition is that it is associated with muscle 
wasting, which leads to weakness of respiratory muscles (Franssen, 2003; Marquis 
et al., 2002; ATS, 1995; Schols et al., 1991; Farber & Mannix, 1989).  Malnutrition 
can result in a reduction of diaphragmatic mass due to the loss of cross sectional 
area of the muscle fibres (Schols et al., 1991).  Engelen and co-workers (1994) 
reported a significant loss in skeletal and respiratory muscle strength in patients 
that suffered from depletion of fat-free body mass.  Efthimiou and co-workers 
(1988) showed a loss in muscle strength and an increase in fatigability of the 
sternomastoid muscle in underweight COPD patients.  These changes were 
explained by a decrease in local energy stores.  Donahoe and co-workers (1989) 
found an increase in oxygen consumption of the ventilatory muscles as patients’ 
body weight reduced.  Depletion of fat-free body mass is only significant in physical 
performance when this mass reduces significantly (Baarends et al., 1997; Schols 
et al., 1991).  Wilson and co-workers (1989) found a linear relationship between 
body weight and exercise tolerance.    
 
It is not just underweight COPD patients who are at risk, Schols and co-workers 
(1993) reported that depletion of fat-free body mass and muscle wasting could 
occur in normal weight COPD patients.  Body weight is not necessarily influenced 
by changes in body composition and may remain unchanged or even increase 
despite the presence of muscle wasting (Schols et al., 1993).  Body weight is 
therefore not a reliable indicator of nutritional status (Mador, 2002).  Obese 
patients and patients with fluid retention are especially susceptible to this 
phenomenon (Marquis et al., 2002).    
 
Malnutrition influences exercise tolerance in three ways.  Firstly, the atrophy of fast 
twitch fibres predisposes the diaphragm to fatigue.  Secondly, the decrease in local 
energy stores of the peripheral muscles, results in an increase in muscle 
fatigability.  Lastly, the increase in oxygen consumption of the ventilatory muscles 
decreases the total available oxygen for the exercising muscles (Schols et al., 
1991).   
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 Efthimiou and co-workers (1988) reported that increased dietary intake in COPD 
patients, results in improved respiratory muscle strength, handgrip strength, 
dyspnoea and distance on the six-minute-walk test (6MWT).   
 
Clinical features of COPD 
 
The natural course and clinical features of COPD is not the same in all patients.  It 
is a progressive disease and symptom manifestation in patients may vary greatly 
(GOLD, 2006).   
 
1. Patient history  
 
Most importantly when assessing a patient’s history, is the consideration of 
exposure to COPD risk factors (Pauwels et al., 2001).  Patients with COPD usually 
have a history of smoking 20 or more cigarettes per day for 20 or more years.  
When symptoms develop, they typically present with a productive cough or an 
acute chest illness (ATS, 1995).   
 
Primary symptoms that should be considered are a chronic cough with sputum 
production, wheezing and dyspnoea (Mahler, 1990:12).  Sputum production is 
initially only in the morning and only becomes purulent with an exacerbation.  A 
history of wheezing and dyspnoea can lead to the incorrect diagnosis of asthma 
(ATS, 1995).  It is important to consider that COPD is not a stable condition and 
symptoms and functionality may vary from day to day (Morgan, 2003).  As the 
disease progresses, acute exacerbations become more frequent and at later 
stages may lead to hypoxaemia with cyanosis.  Morning headaches suggest 
hypercapnia which may lead, together with hypoxaemia, to cor pulmonale with right 
heart failure and oedema.  Haemoptysis may be due to carcinoma, but usually is 
an indication of mucosal erosion (ATS, 1995).   
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2. Physical examination 
 
A physical examination is not considered a very effective diagnostic tool for COPD 
(Pauwels et al., 2001).  Slow expiration and wheezing with forced expiration may 
be the only findings in the initial chest examination (ATS, 1995).  Pursed-lip 
breathing is usually a sign of hyperinflation and an impaired FEV1 (McAllister, 
2002; Calverley & Pride, 1995:313).  As the disease progress findings will include 
limited motion of the diaphragm, an increase in breathing frequency, a decrease in 
breath sounds, prolonged expiration, distant heart sounds, coarse crackles at the 
lung bases and frequent wheezes.  An increased anteroposterior diameter of the 
chest or a barrel shaped chest may be a further indication of hyperinflation 
(McAllister, 2002; ATS, 1995).  Some patients increase their breathing frequency to 
compensate for the reduction in oxygen levels.  Although these patients experience 
severe dyspnoea, cyanosis is not present, hence they are classified as “pink 
puffers” (Type A).  Generally, these patients are able to maintain oxygen levels late 
into the disease process.  Patients that are not breathless, but appear blue are 
classified as “blue bloaters” (Type B) (McAllister, 2002).  Blunted hypoxic drives 
explain the lack of dyspnoea in type B patients (Pierson, 2000).  These patients are 
not able to increase breathing frequency to compensate for falling oxygen levels 
and have to rely on very low oxygen levels to maintain respiratory drive (McAllister, 
2002).  Type B patients might develop cor pulmonale earlier than type A patients 
(Pierson, 2000). 
 
Findings during end-stage COPD will include pursed-lip expiration, cyanosis, full 
use of accessory respiratory muscles of the neck and shoulder (especially the 
sternomastoid muscles) and neck vein distension.  An enlarged, tender liver may 
indicate right heart failure and asterixis may be seen with severe hypercapnia 
(ATS, 1995).  Other clinical signs of right heart or respiratory failure include central 
cyanosis, swelling of the ankles and increased jugular vein pressure (McAllister, 
2002; Pauwels et al., 2001).   
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Diagnostics 
 
Several objective measures are widely used for the diagnosis of COPD and other 
respiratory diseases.  These include spirometry (flow and volume tests), chest 
imaging and cytologic and haematologic tests (McArdle et al., 2001:953).  Chronic 
bronchitis usually does not have physiologic or radiographic evidence of 
hyperinflation and diffusion tests are generally normal.  Emphysema is 
characterised by abnormal diffusion tests and radiographic and pulmonary 
measures show evidence of hyperinflation (Petty & Weinmann, 1997).   
 
1. Spirometry 
 
Spirometry plays a key role in the diagnosis and management of patients with 
COPD.  It is useful in the assessment of severity and monitoring of the progression 
of COPD (Van Schalkwyk et al., 2004; ATS, 1999; ATS, 1995).  Pauwels and co-
workers (2001) suggest that spirometry should be performed on patients with a 
chronic productive cough and a history of exposure to risk factors, even if 
dyspnoea cannot be detected.   
 
Flow volume measurement is the foundation of spirometry and plays a vital role in 
the management of expiratory flow limitations (Dueck, 2000).  Pulmonary function 
tests should include FEV1, FVC and the ratio between the two (Pauwels et al., 
2001).  The degree of partially reversible or irreversible airflow obstruction forms an 
integral part in the diagnosis of COPD.  Therefore, most studies use FEV1 and lung 
function tests as patient population descriptors, rather than outcome measures 
(ATS, 1999; ATS, 1995).   
 
COPD patients experience a reduction in ventilatory capacity because of airflow 
obstruction.  In advanced stages of the disease, patients adjust their pulmonary 
mechanics to compensate for this reduced ventilatory capacity (Carter et al., 1993).  
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Carter and co-workers (1993) also found that even patients with mild COPD 
experience ventilatory limitations.     
 
 1.1 Forced expiratory volume in one second (FEV1) 
 
FEV1 reflects the airflow obstruction and is defined as the volume of air expired in 
the first second.  A degree of airflow limitation is usually used to predict morbidity 
and mortality (Celli et al., 2004; Pinto-Plata et al., 2004; Nishimura et al., 2002; 
BTS, 1997; Petty & Weinmann, 1997).   
 
Irreversible airflow obstruction is diagnosed when the post-bronchodilator FEV1 is 
less than 80% of the predicted value, together with a FEV1/FVC ratio of less than 
70% (Pauwels et al., 2001).  FEV1 does not describe all the negative attributes and 
systemic manifestations of COPD (Celli et al., 2004; Pinto-Plata et al., 2004; 
Nishimura et al., 2002).  The benefits of using FEV1 includes, that it has little 
variability, is easily measured and can be accurately predicted according to age, 
gender and height.  FEV1 cannot however, distinguish between emphysema and 
chronic bronchitis (ATS, 1995).  The value of FEV1 is specific for the diagnosis of 
an existing airflow limitation and has little value for early diagnosis (Petty & 
Weinmann, 1997).     
 
In non-smokers without respiratory disease, FEV1 begins to decline at the age of 
35 at a rate of 25 to 30ml per year.  In smokers that are susceptible to cigarette 
smoke, this decline is more severe and the heavier the smoking the more severe 
the decline (Scanlon et al., 2000; Senior & Anthonisen, 1998; ATS, 1995).  These 
smokers experience a decline twice as fast as non-smokers (50 to 60ml per year).  
However, the average decline that smokers experience is not significant enough to 
cause symptomatic airflow obstruction, until FEV1 reaches a level below 50% of its 
predicted value.  This leads to the conclusion that the decline in FEV1 which COPD 
patients experience, is significantly larger compared to the average smoker.  There 
is a direct relationship between the initial FEV1 level and the slope of FEV1 decline.  
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In men, there is a stronger relationship between FEV1/FVC and declining FEV1.  
Age, smoking history and number of cigarettes currently smoked are all factors that 
would contribute to a more rapid decline in FEV1.  After smoking cessation, the 
FEV1 decline returns to that of a non-smoker, although actual FEV1 does not return 
to that of a non-smoker (Senior & Anthonisen, 1998; ATS, 1995).   
 
 1.2 Forced vital capacity (FVC) 
 
FVC is the maximum volume of air that can be forcefully exhaled after maximal 
inspiration.  For a successful test, complete exhalation is required (Stewart, 
n.d.:24).  In COPD patients, FVC can be reduced.  FVC is typically assessed in 
conjunction with FEV1 and expressed as a ratio of these two measurements 
(FEV1/FVC).  A positive diagnosis for COPD requires a reduced FEV1 in 
combination with the FEV1/FVC ratio reduced below 70%.  FEV1/FVC is a more 
sensitive measure for airflow obstruction and measurements below 70% can be 
measured before FEV1 is reduced to a significant level.  Due to this, FEV1/FVC has 
immense value in early detection of COPD (Pauwels et al., 2001; O’Brien et al., 
2000).    
 
 1.3 Maximum voluntary ventilation (MVV) 
 
MVV differs from other dynamic lung function tests in that it assesses maximal 
effort throughout a preset interval (12 seconds), whereas most other tests focus on 
a single manoeuvre.  Important information obtained from this test includes, “an 
overall assessment of effort, coordination and the elastic and flow-resistive 
properties of the respiratory system” (Fishman, 1998:547).  Some patients cannot 
perform this test, due to the effort necessary to continue maximal ventilation for 12 
seconds.  A normal MVV test rules out moderate to severe COPD and restrictive 
disease (Fishman, 1998:547).  According to Efremidis and co-workers (2005), MVV 
is a good predictor of peak VO2 or exercise tolerance in COPD patients.   
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Exercise tolerance is determined by expressing VE as a fraction of MVV.  A 
limitation to this method is that MVV varies according to VT and end-expiratory lung 
volume.  Therefore, there will be a considerable difference between MVV at rest 
and MVV during exercise.  Another factor to consider is that the pattern of 
respiratory muscle activation differs from rest to exercise.  Another limitation is that 
MVV during exercise may be underestimated due to bronchodilatation during 
exercise.  Therefore, MVV values of individual patients vary according to different 
situations (Gallagher, 1994).   
 
The ratio between MVV and VEmax is diagnostically more useful than MVV alone.  
This ratio can contribute to distinguishing between COPD and restrictive lung 
disease (Gallagher, 1994).   
 
1.4 Peak expiratory flow (PEF) 
 
PEF measurements are useful for assessment of the impact of different factors on 
the airways.  This test is easy to perform, inexpensive and well tolerated by 
patients.  PEF measurements are useful when a series of measurements are 
needed for a particular patient (Bellia et al., 2003; BTS, 1997).  
 
FEV1 and PEF are similar in that both require a forced expiratory manoeuvre.  PEF 
differs from FEV1 in that it is “measured on the first effort-dependent portion of the 
forced expiratory manoeuvre”, while FEV1 “reflects airway resistance at different 
sites in the airways” (Bellia et al., 2003).  PEF measurements cannot distinguish 
between obstructive and restrictive disease and tend to underestimate airflow 
obstruction in COPD patients (BTS, 1997). 
 
1.5 Inspiratory capacity (IC) 
 
Recent studies determine that resting IC measures could be used to predict 
exercise capacity in COPD patients (Diaz et al., 2000b; Murariu et al., 1998).  IC 
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can also be used to determine the extent of dynamic hyperinflation and therefore, 
give an indication of disease progression (Marin et al., 2001; Murariu et al., 1998).  
According to Diaz and co-workers (2000b), FEV1/FVC is the best predictor of 
exercise capacity in patients without airflow limitation; however, this test gives little 
insight into exercise capacity of patients with airflow limitation.  Their study 
demonstrated that IC is the best predictor of exercise capacity in patients with 
airflow limitation.   
 
Albuquerque and co-workers (2006) argued that IC measurements alone do not 
give sufficient information about actual elastic load during exercise.  Casanova and 
co-workers (2005) reported that static hyperinflation, as expressed by IC as a ratio 
of total lung capacity (TLC) (named “inspiratory fraction”), is an independent 
mortality predictor in patients with moderate and severe COPD.  Albuquerque and 
co-workers (2006) found post-bronchodilator inspiratory fraction to be an 
independent predictor of maximal exercise capacity in COPD patients.  According 
to these authors, inspiratory fraction gives a better indication of the impact of air 
trapping combined with hyperinflation.  Furthermore, they found a correlation 
between inspiratory fraction and BMI, which could be a possible explanation for the 
relationship between low BMI and mortality.   
 
 1.6 Lung volumes  
 
The measurements of total lung capacity (TLC) should be considered for patients 
with a FVC less than 80% of the predicted value.  TLC can rule out restrictive 
disease and assess the severity of hyperinflation (Dueck, 2000).  If elastic recoil is 
decreased, TLC will be increased.  Residual volume (RV) can also be increased 
due to airway closure at higher volumes.  An increase in RV subsequently results 
in a decrease in FVC and IC.  The RV/TLC ratio is also useful as a predictor of 
airway obstruction, which is frequently found in COPD patients (Murray et al., 
2000:1191).   
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2. Chest radiography  
 
Chest radiography is the most extensive used pulmonary assessment technique.  
The value of chest radiography includes screening for abnormalities; provides a 
baseline for future assessments and monitors disease progression (McArdle et al., 
2001:952).  Chest radiographs are only accurate in severe emphysema cases and 
are not reliable for the diagnosis of mild emphysema (ATS, 1995).  Chest 
radiographs are however, valuable in the exclusion of other causes of dyspnoea 
(Pauwels et al., 2001).   
 
Radiographic images provide the best indication of the presence of emphysema.  
Evidence of the presence of emphysema on a posteroanterior (PA) and lateral 
chest radiograph includes a low, flat diaphragm, increased retrosternal airspace, a 
long narrow heart shadow and rapid tapering of the vascular shadows, 
accompanied by hypertransradiancy of the lungs.  Right ventricular hypertrophy 
and pulmonary hypertension cause the hilar vascular shadows to be prominent and 
the heart shadow to interrupt the retrosternal space (ATS, 1995).   
 
3. Computed Tomography (CT) 
 
CT scans are more sensitive in the diagnosis of emphysema than chest 
radiography.  These scans can be used to identify the specific anatomic type of 
emphysema, as well as the assessment of the size of emphysematous bullae.  The 
knowledge of the specific type of emphysema has no effect on therapy and thus 
limits the value of CT in the routine care of the COPD patient.  It is, however, useful 
for the diagnosis of complicating bronchiectasis and to predict the benefit of 
pulmonary resection for giant bullous disease (Pauwels et al., 2001; ATS, 1995).  
 
 44
4. Magnetic resonance imaging (MRI) 
 
Although MRI scans are sometimes used in the management of COPD patients, 
the value of these scans are limited, this is due to the fact that large sections of the 
lungs have insufficient density to create a clear MRI image (McArdle et al., 
1996:693).   
 
5. Sputum examination 
 
If chronic bronchitis is stable, sputum is mucoid with occasional macrophages, as 
opposed to an exacerbation where sputum becomes purulent with neutrophils.  
Gram’s stain would reveal an increased number of organisms.  The most frequent 
pathogens cultured from sputum are Steptococcus pneumoniae and Haemophilus 
influenzae.  Causes of exacerbations include viral infections or other 
oropharyngeal flora, such as Moraxella catarrhalis (ATS, 1995).   
 
6. Arterial blood gas analysis 
 
Arterial blood gas analysis has little value in the early stages of COPD, because 
PaO2 usually remains unchanged until FEV1 reaches a level below 50% of the 
predicted value.  PaCO2 is expected to stay normal until FEV1 reaches a level below 
25% of the predicted value (Fishman, 1998:663).  Blood gas abnormalities will 
however, occur before cyanosis manifests (McAllister, 2002).  In the early stages of 
COPD, the analysis of arterial blood gasses can be beneficial to detect mild 
hypoxaemia, particularly after exercise (Murray et al., 2000).   
 
This diagnostic tool is, however, of importance in advanced stages of COPD and is 
indicated when FEV1 reduces below 40% of the predicted value or if respiratory or 
right heart failure is suspected.  “Respiratory failure is indicated by PaO2 < 8.0 kPa 
(60 mm HG) with or without PaCO2 > 6.0 kPa (45 mm Hg) while breathing at sea 
level” (Pauwels et al., 2001).   
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 7. Other 
 
Additional investigations for patients with moderate or severe COPD may have 
added value.  Pauwels and co-workers (2001) suggested that bronchodilator 
reversibility testing is important to exclude asthma as a diagnosis, to establish a 
patient’s best attainable lung function, to determine prognosis and to guide 
treatment decisions.  However, according to the revised GOLD guidelines, 
although “post-bronchodilator FEV1/FVC and FEV1 measurements are 
recommended for the diagnosis and assessment of severity of COPD, the degree 
of reversibility of airflow limitation…is no longer recommended for diagnosis, 
differential diagnosis from asthma, or predicting the response to long-term 
treatment with bronchodilators or glucocorticosteroids (GOLD, 2006).” 
 
Alpha-1 Antitrypsin (AAT) deficiency screening may be indicated in patients who 
develop COPD before 45-years of age.  This screening can also be useful for 
families with a strong history of COPD (Pauwels et al., 2001). 
 
Aetiology    
 
1. Risk factors 
 
The identification of risk factors is essential for the prevention and management of 
any disease (GOLD, 2006).  In most countries, tobacco smoking is regarded as the 
most important risk factor in the development of COPD (Behrendt, 2005; Croxton 
et al., 2002; Senior & Anthonisen, 1998; BTS, 1997; ATS, 1995).  Research 
suggests that contributing risk factors cannot explain the fact that not all smokers 
develop COPD.  A family history of COPD seems to be the most significant risk 
factor, although insufficient evidence exists to determine whether this relationship 
is as a result of genetic or environmental factors, or a combination of both 
(Behrendt, 2005; Senior & Anthonisen, 1998; BTS, 1997; Petty & Weinmann, 1997; 
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ATS, 1995).  In a survey done by Ehrlich and co-workers (2004) it was determined 
that in South Africa a history of tuberculosis holds a greater risk for COPD than 
tobacco smoke.  Other important contributing risk factors for South Africa are 
ambient air pollution (i.e. domestic use of biomass fuel) and occupational factors 
(i.e. industrial and mining dust) (South African Medical Research Council, 2002; 
Hnizdo et al., 2000). 
 
 1.1 Tobacco smoke 
 
Tobacco smoking accounts for 80 to 90% of the risk for developing COPD (Jindah 
et al., 2006; McAllister, 2002; ATS, 1995).  The risk for developing COPD is five 
times higher for smokers compared to non-smokers and 50% of elderly smokers 
develop COPD (Jindah et al., 2006).    
 
According to the World Health Organisation (WHO) (1999:65), the current global 
smoking trends will result in an increase in mortality from tobacco use, from four 
millions deaths in 1998 to 10 million deaths in 2030.  Half of these deaths will occur 
in productive individuals between the ages of 35 and 69, and 75% will be as a 
result of chronic bronchitis and emphysema (WHO, 1999:66).  In South Africa, 
smoking contributes to one in 10 adult deaths; most of these deaths are a result of 
respiratory disease (Leeman, 2006).   
 
In many countries, COPD was an uncommon disease before tobacco smoking 
became popular.  The incidence of tobacco smoking in the United Kingdom was at 
its highest between 1940 and 1970.  During this time, it was reported that 70% of 
adult males were regular smokers.  A decrease in the popularity of tobacco 
smoking resulted in a decline in cigarette consumption after 1970.  In 1970, 44% of 
adult women in the United Kingdom were regular smokers, after which there was a 
decline in the prevalence.  Generally, men have larger average cigarette 
consumption than women (Pride & Soriano, 2002).  Although the incidence of 
smoking is relatively low in Africa, tobacco consumption is growing at an alarming 
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rate.  Tobacco consumption in Africa increased by 3.2% in 2000, while 
consumption only increased by 2.7% in other developing countries (Chan-Yeung et 
al., 2004).  A household survey in South Africa established that 42.3% of men and 
10.7% of women smoked in 1998 (Department of Health & Medical Research 
Council, 1998).   
 
Cigarette smoke is associated with higher death rates from chronic bronchitis and 
emphysema, a higher prevalence of spirometry abnormalities and respiratory 
symptoms.  A greater annual decline in FEV1 is probably one of the most significant 
effects of tobacco smoke (Pauwels et al., 2001; Petty & Weinmann, 1997; ATS, 
1995; Bates, 1989:152 & 157).  The effect of aging and tobacco smoke on FEV1 is 
illustrated in figure 2.5.  The maximal expiratory flow volume (MEFV) curve is 
thought to be the most sensitive reflection of the respiratory abnormalities in 
smokers.  Respiratory abnormalities can be detected on the MEFV curve before 
changes in FEV1 are observed (Bates, 1989:155-156).  According to Bates 
(1989:77), smoking results in impaired tracheal clearance; this is most likely due to 
the loss of organised ciliary function.  This impairment is partly reversible and 
mucociliary clearance will improve after three months in the event of smoking 
cessation.  In some smokers, there is a permanent increase in residual volume 
(Bates, 1989:158).  As a result of this increase in residual volume increased 
closing volumes can be measured.  This increase in closing volume can occur 
before any FEV1 abnormalities are detected (Bates, 1989:160).  Conflicting 
evidence exists regarding the loss of elastic recoil of lung tissue in smokers.  
According to Bates (1989:160-161) some studies found a decrease in elastic recoil 
as a result of smoking, where other studies reported normal lung recoil pressures.  
Smoking has a significant effect on airway reactivity, as shown by a reduced FEF25-
75%VC in smokers (Bates, 1989:161).   
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Figure 2.5 Decline in FEV1 with age (adapted from Fletcher and Peto, 1977). 
 
Pipe and cigar smoking are not as big a risk for COPD than cigarette smoking, 
although there is still an increased risk for the development of COPD when 
compared to non-smokers (Pauwels et al., 2001; ATS, 1995).   
 
Not all people who smoke, however, develop COPD; and not all patients with 
COPD are smokers or have smoked in the past.  Genetic factors (Pauwels et al., 
2001) and occupational exposures (Bergdahl et al., 2004) have been implicated for 
this inconsistency.  According to previous studies (Barnes, 2003; Scanlon et al., 
2000; ATS, 1995), only 15% of smokers develop clinically significant COPD.  
According to a study by Lundback and co-workers (2003), 50% of smokers may 
develop COPD and not 15 to 20%, as previously believed.  These authors 
attributed the differences in prevalence to different diagnostic criteria.  In the United 
States, the prevalence of a chronic cough is reported by 24% of smokers, 4.7% of 
ex-smokers and 4.0% of people who never smoked (Jindah et al., 2006).  Watson 
and co-workers (2002) found that individuals with a smoking history of ten pack 
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years or more, combined with a low dietary intake of fruit and vegetables are at 
greater risk for the development of COPD.  These authors suggested that low fruit 
and vegetable intake might be a possible explanation for the inconsistency in the 
development of COPD.   
 
There seems to be a varying susceptibility to lung damage due to cigarette smoke 
within the general population.  Only a proportion of smokers show a decline in lung 
function that is enough to result in severe impairment.  Susceptible subjects have 
an accelerated rate of decline of lung function (50-90ml of FEV1 per year compared 
with 20-30ml of FEV1 per year after the age of 30 in non-smokers), as illustrated in 
figure 2.5 (BTS, 1997).  According to the GOLD guidelines, not all individuals 
experience the decline in FEV1, as illustrated in figure 2.5 (GOLD, 2006).  
Lundback and co-workers (2003) found that the prevalence of COPD in female 
smokers, aged 61 to 62 is higher than in male smokers of the same age.  Recent 
studies suggest that women are more susceptible to the effects of cigarette smoke 
than men (Petty & Weinmann, 1997; Xu et al., 1994). 
 
According to Bates (1989:163) some pathologies caused by smoking are partly 
reversible after cessation.  As mentioned previously, an improvement in tracheal 
mucus velocity can be measured three months after cessation.  A significant 
improvement in FEV1 and VC has been reported five months after cessation.  The 
rate of disease progression is slowed down by half after smoking cessation, 
compared to the progression seen in smokers (Hoogendoorn et al., 2005; Petty & 
Weinmann, 1997).  The rate of FEV1 decline can return to normal after smoking 
cessation, although normal lung function is not regained (McAllister, 2002; BTS, 
1997).  The British Thoracic Society (1997) reported that 90% of smokers would 
experience a cessation of excessive sputum production after smoking cessation.   
 
Diverse acute effects of cigarette smoking have been reported.  These acute 
effects include a small increase in airway resistance, an increase in residual 
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volume, flow becomes more dependent on gas density and an increase in tidal 
volume (due to stimulation of irritant receptors) (Bates, 1989:154).   
 
Factors affecting the degree of the risk involved with tobacco smoke include the 
quantity of smoking, age of starting, total pack-years and current smoking status 
(ATS, 1995).  According to the British Thoracic Society (1997), most COPD 
patients have a smoking history of between 10 and 20 pack years.  One pack-year 
equals 20 cigarettes, one joint of cannabis or 15g or pipe tobacco per day, for one 
year (Bateman et al., 2004).    
 
1.1.1 Environmental Tobacco Smoke (ETS) 
 
ETS is an important risk factor for all non-smokers (Jindah et al., 2006).  ETS may 
contribute to the development of respiratory symptoms and COPD (GOLD, 2006).  
Children of parents who smoke are at the greatest risk to ETS and these children 
are more likely to take up smoking at some stage in their life.  These children have 
a higher prevalence of respiratory symptoms and disease as well as measurable 
spirometry deficiencies (Jindah et al., 2006; Steyn et al., 2000; ATS, 1995).  In 
South Africa, urban, coloured children are at the highest risk for exposure to ETS 
(Steyn et al., 2000).    
 
 1.2 Tuberculosis (TB) 
 
Tuberculosis (TB) is a contagious, infectious disease caused by the airborne 
mycobacterium, Mycobacterium tuberculosis.  Other mycobacteria that have been 
implicated in the development of TB are Mycobacterium bovis and Mycobacterium 
africanum.  An individual diagnosed with TB has a five percent chance to develop 
an active infection within one to two years.  This risk increases substantially, if an 
individual contracts the AIDS-virus and becomes infected with TB (Merck Manual, 
2003).  
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According to the Health Systems Trust (2006) the prevalence of TB in South Africa 
increased from 411 individuals per 100 000 in 1990 to 670 individuals per 100 000 
in 2004.  In developing countries, TB is more prevalent in younger individuals, 
whereas in developed countries, TB is predominantly diagnosed amongst older 
individuals.  Eight million new cases of symptomatic TB are reported world wide 
each year (Merck Manual, 2003).  Due to the high occurrence of TB in South 
Africa, a large population of South Africans who suffer from TB are at risk of 
developing COPD (Hnizdo et al., 2000).  
 
TB generally affects the lungs, although any other organ can be involved (Merck 
Manual, 2003).  Damage to lung tissue after TB treatment includes fibrosis, 
bronchovascular distortion, emphysema and bronchiectasis.  Pulmonary TB results 
in chronic impairment of pulmonary function.  This adverse relationship between 
pulmonary TB and COPD has already between described in a study in South Africa 
in 1989 (Willcox & Ferguson, 1989).  According to Hnizdo and co-workers (2000), 
recurrent TB episodes result in escalating lung function impairment.  In their study, 
18% of subjects with one TB episode, 27% of subjects with two TB episodes and 
35% of subjects with three TB episodes, developed chronic lung function 
impairment (Hnizdo et al., 2000).  According to the WHO (1999:66), TB’s mortality 
figures are doubled in smokers, compared to non-smokers.   
 
The GOLD guidelines advised that in countries where the prevalence of TB is high, 
a diagnosis of TB should always be considered in patients with COPD symptoms 
(GOLD, 2006).   
 
 1.3 Genetic factors 
 
A well established risk factor is the deficiency of the protective protease inhibitor, 
AAT (Pauwels et al., 2001; Fishman, 1998:662; ATS, 1995).  This inherited 
autosomal recessive disorder is rare in the general gene pool.  The AAT deficiency 
gene increases the risk for the development of COPD 40 times (Chan-Yeung et al., 
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2004).  Despite significantly increasing the risk for COPD, AAT deficiency accounts 
for less than 1% of all cases of COPD (BTS, 1997; ATS, 1995). 
 
AAT is a serum protein that is produced by the liver and usually found in the lungs 
(ATS, 1995).  AAT protects the alveoli against destruction of structural proteins due 
to the actions of elastase.  Destruction of the alveoli eventually develops into 
emphysema (ACSM, 1998a:317; ATS, 1995).  
 
Emphysema is the result of proteolytic activity due to insufficient levels of AAT.  
Patients with AAT deficiency may not develop emphysema, but AAT deficient 
individuals who smoke have a greatly increased risk of developing emphysema, 
especially at an early age (Hogg & Senior, 2002).   
 
 1.4 Ambient air pollution  
 
Ambient air pollution is considered another risk factor for COPD.  However, the 
exact role of high levels of urban air pollution is not known.  When compared to 
tobacco smoke, the risk seems small (Pauwels et al., 2001; ATS, 1995).  
According to Jindah and co-workers (2006), ambient air pollution is an important 
factor in chronic respiratory morbidity.  Air pollution has been associated with 
increased exacerbations and cardiovascular and respiratory mortality (McAllister, 
2002). 
 
Indoor air pollution has been implicated as a risk factor for developing COPD.  The 
burning of biomass fuel in ill ventilated dwellings, poses a great risk for persons 
that are continuously exposed (Pauwels et al., 2001).  Grobelaar and Bateman 
(1991) studied women in rural areas of South Africa.  Their study found a 
relationship between COPD and biomass fuels, particularly cow dung and grinding 
procedures (resulting in mixed dust pneumoconiosis) used in ill ventilated houses.   
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 1.5 Chest infections 
 
Reduced lung function and respiratory symptoms have been associated with 
severe childhood respiratory infections (Tager et al., 1988).  According to Barnes 
and Godfrey (1997:3), there is an association between chest infections in the first 
year of life and the development of COPD at a later stage.      
 
In COPD patients, an exacerbation is defined as “sustained worsening of the 
patient's condition from the stable state and beyond normal day-to-day variations 
that is acute in onset and may warrant additional treatment in a patient with 
underlying COPD” (Burge & Wedzicha, 2003).  Senior & Anthonisen (1998) 
reported that acute exacerbations have no long-term effect on the decline rate of 
FEV1.  The belief that recurring chest infections can lead to COPD is described as 
the “British hypothesis”.  This hypothesis has been refuted by Fletcher and 
colleagues (1976) who reported that repetitive chest infections had no long-term 
effects on the rate of FEV1 decline.  Additionally, a study by Seemungal and co-
workers (1998) found that exacerbations have a negative effect on the quality of 
life of patients with COPD.  This study further found that previous exacerbations 
increase the risk for future exacerbations in COPD patients.  Patients with a 
productive cough may also be more susceptible to chest infections and 
environmental risk factors (Seemungal et al., 1998).  Repeated chest infections 
may also contribute to the pathogenesis and progression of COPD (GOLD, 2006).   
 
 1.6 Occupational factors 
 
There are certain occupational factors that can increase a person’s risk for 
developing COPD.  Mine, textile and cement workers are especially at risk for 
exposure to coal, silica, cotton and heavy metals (especially cadmium).  Constant 
exposure to these substances is associated with an increase in the prevalence of 
COPD (especially emphysema), increased rates in FEV1 decline and higher 
mortality rates (McAllister, 2002; ATS, 1995).  Exposure to dust is considered more 
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hazardous than exposure to gas or fumes (McAllister, 2002).  Hazardous airborne 
substances cause an increase in airway responsiveness and promote the 
destructive effects of cigarette smoke (McAllister, 2002; ATS, 1995).  Bergdahl and 
co-workers (2004) showed that one out of every ten deaths, attributable to COPD, 
can be prevented through the reduction of exposure to inorganic dusts alone.  
Trupin and co-workers (2003) found that occupational exposures can increase the 
risk for the development of COPD by more than 100%, even after tobacco 
consumption is taken into account.  Although the mechanisms through which dust 
exposure increases the risk for COPD remain unclear, scarring or fibrosis of the 
smaller airways and parenchyma could be a possible explanation (Bergdahl et al., 
2004).   
 
 1.7 Gender and race 
 
Generally, it is believed that men, compared to women, are more at risk of 
developing COPD (Fishman, 1998:662; Petty & Weinmann, 1997; ATS, 1995).  
The fact that tobacco use is higher among men is responsible for this 
misconception.  According to Senior and Anthonisen (1998), women are more 
prone to airway reactivity and rapid decline of FEV1, which increase their risk for 
the development of COPD.  Recent studies have shown that females are more 
likely to experience respiratory symptoms than males (Dales et al., 2006; De 
Torres et al., 2005).  Furthermore, females are more likely to be diagnosed with 
chronic airway disease and respiratory medication is more frequently prescribed.  
A possible explanation for gender differences in COPD diagnoses, is the fact that 
females might express their experience of respiratory symptoms as more severe, 
compared to males.  This might result in unintentional gender-related biases by 
physicians (Dales et al., 2006).  According to De Torres and co-workers (1995), 
women develop significant airflow obstruction at a younger age with a lower 
smoking history, compared to men.  These authors also found that women have 
more exacerbations than men.  Although symptoms experienced by women might 
be more severe, women with COPD tend to have better survival rates than men.  A 
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possible explanation for this is the fact that women have higher PaO2 and lower 
PaCO2 levels than men with similar FEV1 values.   
 
Mortality rates are higher among white females compared to other races.  The 
difference between white males and other races is smaller (ATS, 1995).  
 
 1.8 Socio-economic status 
 
It appears that there is a decline in the prevalence of COPD with an increase in 
socio-economic status.  This difference may however, be attributed to higher 
exposure to air pollutants, crowding and poor nutrition in lower socio-economic 
classes (McAllister, 2002; Pauwels et al., 2001; ATS, 1995).  Cooking in ill 
ventilated kitchens or single room houses may contribute to indoor air pollution and 
result in a significant increase in risk for the development of respiratory disease 
(Jindah et al., 2006).  Other factors that can cause the apparent correlation 
between low socio-economic status and the risk for COPD, is poor housing, 
exposure to secondary smoke, popularity of active smoking, increased lower 
respiratory tract infections during childhood and occupational exposures 
(McAllister, 2002).   
 
 1.9 Acquired Immune Deficiency Syndrome (AIDS) 
 
Limited studies exist on the relationship between COPD and HIV (Human 
Immunodeficiency Virus) or AIDS.  A number of HIV-seropositive individuals 
experience respiratory symptoms, such as dyspnoea, coughing and sputum 
production, which cannot be explained by AIDS-related pulmonary complications.  
Evidence exists to suggest that HIV infection can contribute to the damaging 
effects of tobacco smoking and consequently increases the risk for the 
development of COPD (Diaz et al., 2003).  Diaz and co-workers (2000a) reported 
that HIV infection is associated with an increased rate in the onset of smoking-
related emphysema.  
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 1.10 Reactivity of  airways 
 
One possibility to account for differences in the susceptibility to develop COPD, is 
that there is a genetically determined predisposition to develop allergy and 
bronchial hyperresponsiveness, the "Dutch Hypothesis" (Pauwels et al., 2001; 
Scanlon et al., 2000; ATS, 1995).  According to this hypothesis, asthma, 
emphysema and chronic bronchitis are different manifestations of a single disease 
process.  Whether an individual develops asthma, bronchitis or emphysema, is a 
result of genetic and environmental factors that are modulated by age and gender.  
An alternative school of thought is the "Two-type Hypothesis", which includes a 
Dutch-type limb termed "Chronic Asthmatic Bronchitis" or "Overlap Syndrome" and 
a more insidious form which leads to chronic bronchitis and emphysema.  Both 
schools of thought, however, emphasise the interrelationship between bronchial 
hyperreactivity, infection and smoking.  Recently, the focus was placed on 
identifying the population most at risk of developing COPD (Fishman, 1998:662). 
 
Non-specific airway reactivity might be a risk factor for COPD.  Reactivity is 
inversely related to FEV1 and may be predictive of an accelerated rate of decline of 
spirometry in smokers.  The specific role that it plays in the development of COPD 
is unclear and might be attributable to inflammation (Senior & Anthonisen, 1998; 
Petty & Weinmann, 1997; ATS, 1995).  Airway reactivity is more common in 
women than in men and the rate of decline in FEV1 is also more severe in women 
(Senior & Anthonisen, 1998; Tashkin et al., 1992).  In some cases there is a 
relationship between exposure to tobacco smoke or other noxious particles and 
gases and hyperresponsiveness of the airways (Pauwels et al., 2001).   
 
2. Symptoms 
 
COPD patients experience various symptoms, some of which could be attributed to 
co-morbidities (ATS, 1999).  Generally, symptoms only occur late in the disease 
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process (once patients have lost more than 50% of their lung function).  Chronic 
coughing, excessive sputum production, dyspnoea and functional impairment are 
among the most frequent complaints (McAllister, 2002; Murariu et al., 1998; 
O’Donnell et al, 1995).  Other common symptoms include weight loss, sleep 
disturbance, depression and anxiety (McAllister, 2002).  This section will 
concentrate on dyspnoea, functional impairment and weight loss; other symptoms 
will be discussed elsewhere.   
 
2.1 Dyspnoea   
 
Dyspnoea is defined as an uncomfortable awareness of breathing or an increase in 
respiratory effort that is regarded as abnormal by the patient and can lead to 
functional impairment (Lareau et al., 1994; Mahler, et al., 1984).  Dyspnoea is a 
common symptom of patients with COPD and can be distressing and disabling 
despite optimal medical therapy.  Increased intrinsic mechanical loading of 
inspiratory muscles, increased mechanical restriction of the chest wall, functional 
weakness of inspiratory muscles, increased ventilatory demand, gas exchange 
abnormalities, cardiovascular limitations and dynamic hyperinflation are 
contributing factors to exertional dyspnoea (Franssen, 2003; Gosselink, 2003; 
Marin et al., 2001; ATS, 1999; Carrieri-Kohlman et al., 1996; Lareau et al., 1994).  
Other factors that contribute to dyspnoea include hypercapnia, hypoxaemia 
(Fishman, 1998:665), loss of alveolar tissue and skeletal muscle weakness 
(Franssen, 2003).  According to Nishimura and co-workers (2002), dyspnoea 
classification is a better indicator of mortality than FEV1. 
 
It is important to quantify the impact of dyspnoea on patients to evaluate medical 
therapy and for successful individualisation of rehabilitation programmes (ATS, 
1999; Lareau et al., 1994).  Dyspnoea can be assessed through psychophysical 
methods and clinical scales (Mahler et al., 1984).  Instruments for the 
measurement of the effect of dyspnoea on functional status and daily activities 
include the Medical Research Council dyspnoea questionnaire, the Baseline and 
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Transitional Dyspnoea Indexes (BDI and TDI) and the Pulmonary Functional 
Status and Dyspnoea Questionnaire (PFSDQ).  Mahler and co-workers (1984) 
found dyspnoea ratings to be effective in assessing and quantifying 
breathlessness, although no correlation was found between dyspnoea ratings and 
pulmonary function.  Various scales and questionnaires exist for the measurement 
of exertional dyspnoea.  Most commonly used are the Borg scale of perceived 
exertion (Borg RPE scale) (Appendix A) and the visual analogue scale (VAS) 
(ATS, 1999; Carter et al., 1993; Borg, 1982). 
 
Dyspnoea leads to impaired functional capacity, a decline in the ability to perform 
daily tasks and consequently, impaired quality of life (Boueri et al., 2001).  The 
impact of dyspnoea may vary.  Dyspnoea may only be associated with activities; it 
can limit activities or activities may be eliminated altogether (ATS, 1999).  Patients 
with mild COPD do not typically complain of dyspnoea, probably due to the body’s 
ability to adapt to minor reductions in pulmonary function.  However, the daily 
function of these patients may be impaired (Carter et al., 1993).  Dyspnoea often 
results in lack of confidence to perform physical activities.  This causes patients to 
refrain from physical activities that they are physically capable of performing (Wigal 
et al., 1991). 
 
Pulmonary rehabilitation programmes are essential to improve exercise tolerance 
(Boueri et al., 2001).  Programmes that focus on education and exercise training 
play a vital role in assisting patients to manage dyspnoea (Scherer & Schmieder, 
1997). 
 
2.2 Impairment of functional capacity 
 
Dyspnoea and impaired functional capacity are interrelated (Franssen, 2003; 
Carter et al., 1993).  As dyspnoea increases, patients tend to develop sedentary 
lifestyles, which in turn will contribute to impaired functional capacity (Carter et al., 
1993).   
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 Assessment of functional capacity in COPD patients is vital to management and 
understanding the impact of the disease.  The 6MWT, that was adapted from the 
12-minute walk test, is most frequently used for this purpose (Pinto-Plata et al. 
2004; Carter et al., 2003).   
 
Generally, the use of the 6MWT is limited to the assessment of the functional 
status of patients living with COPD.  The 6MWT is normally influenced by two main 
physiological factors, namely the degree of airflow limitation (FEV1) and the single 
breath carbon monoxide diffusion capacity (Marin et al., 2001).  Benefits in using 
the 6MWT are that it is simple to administer, requires no specialised equipment, 
has been standardised and reflects the capacity to perform day-to-day activities 
(Carter et al., 2003; Enright et al., 2003).  
 
Pinto-Plata and co-workers (2004) illustrated that the 6MWT is a better indicator of 
mortality than FEV1 and BMI.  This study also found that a decline in 6MWDs 
occurs independently of changes in lung function.   
 
2.3 Weight loss 
 
It is widely accepted that COPD is accompanied by weight loss (Wilson et al., 
1989).  According to Engelen and co-workers (1994), between 20% and 70% of 
COPD patients, are estimated to be underweight.  Weight loss and a low body 
weight are associated with increased morbidity and a poor diagnosis for COPD 
patients (Farber & Mannix, 2000; Engelen et al., 1994).  According to Wouters 
(2002), a loss of more than 40% of metabolising tissue, will result in death.  This 
was confirmed by other retrospective survival studies that reported that low body 
weight is associated with higher mortality rates (Schols et al., 1998; Gray-Donald et 
al., 1996; Wilson et al., 1989).  According to Gray-Donald and co-workers (1996), 
body mass index (BMI) is a strong predictor of mortality.  Baarends and co-workers 
(1997) indicated that BMI is not sensitive to changes in muscle mass and therefore 
 60
not suitable for mortality prediction or indication of exercise capacity.  Weight loss 
in COPD patients can be attributed to the loss of muscle mass and not fat, as in 
the case of starvation (Mador, 2002).  According to Marquis and co-workers 
(2002), muscle wasting is the actual indicator of mortality and not weight loss per 
se.  Muscle wasting can occur in the absence of weight loss and therefore body 
weight might be a false reassurance of survival.  The correlation between muscle 
wasting and mortality is explained by the presence of important amino acids in 
muscle tissue.  Depletion of these amino acids impairs vital physiological functions, 
such as immune defence and tissue regeneration (Kotler, 2000).   
 
Due to the increased energy requirements of the respiratory muscles, COPD 
patients have increased resting energy requirements.  It is of vital importance that 
patients with COPD are educated on good dietary habits.  Well-balanced dietary 
habits are essential to maintain an ideal body weight (Schols et al., 1998; ATS, 
1995).  Several studies have shown that the implementation of good dietary habits 
in malnourished COPD patients, lead to an increase in body weight, fat-free body 
mass, respiratory muscle function, and subsequently higher survival rates 
(Rochester, 2003; Schols et al., 1998; Schols et al., 1995; Rogers et al., 1992; 
Whittaker et al., 1990; Efthimiou et al., 1988).   
 
Treatment 
 
The three most important goals in the treatment of COPD patients, according to the 
American Thoracic Society (1995), are to lessen airflow limitation, to prevent and 
treat secondary medical complications and to improve quality of life by decreasing 
respiratory symptoms.  Pauwels and co-workers (2001) summarised the goals for 
treatment of COPD patients as: “(1) prevent disease progression, (2) relieve 
symptoms, (3) improve exercise tolerance, (4) improve health status, (5) prevent 
and treat complications, (6) prevent and treat exacerbations and (7) reduce 
mortality”.  Petty and Weinmann (1997) also emphasised the importance of the 
alteration of disease progression and alleviation of symptoms. 
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 Currently medical treatment for COPD has only partial success when it comes to 
reduction of symptoms and the improvement of functional capacity (Calverley & 
Pride, 1995:528).  Management of patients with COPD should therefore include a 
wide range of treatment modalities; these include patient education, preventive 
care, smoking cessation, pharmacological and oxygen therapy, ventilatory muscle 
training and exercise rehabilitation (Pinto-Plata et al., 2004; Guyatt et al., 1984).  
Figure 2.6 illustrates the approach to the management of COPD according to the 
American Thoracic Society (1995).  
 
It is important to note that patients respond differently to different treatment 
modalities and certain treatments may result in benefits in more than one area.  
Therefore, treatment goals need to be adjusted according to a patient’s specific 
needs and responses (Pauwels et al., 2001). 
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Figure 2.6 Management of COPD (ATS, 1995). 
 
1. Drug and inhaler treatments 
 
According to the American Thoracic Society (1995), there is no evidence to 
suggest that early regular use of pharmacotherapy can alter the progress of 
COPD.   
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 1.1 Bronchodilators 
 
Most COPD patients respond to bronchodilator therapy (Petty & Weinmann, 1997).  
Bronchodilators are effective in reducing dyspnoea, coughing intensity and 
wheezing (Calverley, 2001).  The use of a bronchodilator results in a significant 
increase in FEV1 in most patients with COPD (Senior & Anthonisen, 1998).  
According to O’Brien and co-workers (2000), bronchodilators can reduce 
pulmonary hyperinflation even if no change in FEV1 is observed.  Both short- and 
long-acting beta2-agonists and anticholinergic agents are generally effective 
(Calverley, 2001; Petty & Weinmann, 1997).  Szafranski and co-workers (2003) 
found that the use of budesonide/formoterol was effective for the management of 
moderate to severe COPD.  In their study, the use of this long-acting beta-
antagonists reduced exacerbations, improved lung function, symptoms and HRQL 
(Szafranski et al., 2003).  Because COPD patients are typically, older patients it is 
important to bear in mind that they may have less tolerance to sympathomimetic-
induced tremors and cardiac side effects.  Due to fewer side effects, slower onset 
and longer action, a long-acting anticholinergic agent might be more effective than 
a long-acting beta2-agonist (ATS, 1995).  Calverley and co-workers (2007) found 
that the use of combination therapy, with a long-acting beta-
antagonist/corticosteroid combination, was effective in reducing exacerbations and 
improved health status and lung function.  No statistically significant improvement 
in mortality was documented (Calverley et al., 2007).  According to Senior and 
Anthonisen (1998) although bronchodilators have short-term benefits for COPD 
patients, insufficient evidence exists to conclude that this therapy will alter the long-
term course of the disease.   
 
Despite theophylline’s potential for toxicity, it still has a vital role to play in the 
treatment of COPD patients, if careful dosing is applied.  It has the most value in 
the patient who cannot use aerosol therapy optimally.  Due to its long-acting 
nature, theophylline can be taken once or twice a day (ATS, 1995).  It improves 
respiratory muscle function, improves cardiac output, reduces pulmonary vascular 
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resistance and improves perfusion of ischemic myocardial muscle (Petty & 
Weinmann, 1997; ATS, 1995).  
 
Tantucci and co-workers (1998) found that salbutamol significantly reduced FRC 
and increased inspiratory capacity.  This improvement originates from a reduction 
in hyperinflation.   
 
 1.2 Anti-inflammatory therapy 
 
COPD is characterised by constant airway inflammation.  In advanced stages of 
this disease the number of neutrophils in the alveolar structures increase, which 
warrants anti-inflammatory therapy, in the form of either oral or inhaled 
corticosteroids (Calverley, 2001).  According to the American Thoracic Society 
(1995), the role of anti-inflammatory treatment in the COPD patient is unclear.  This 
society proposed that insufficient evidence exists to suggest that anti-inflammatory 
agents will have added benefits for the COPD patient already on a regular 
bronchodilator.  Other studies reported that inhaled corticosteroids had no effect on 
the decline of FEV1 (Burge et al., 2000; The Lung Health Study Research Group, 
2000; Vestbo et al., 1999).  According to the GOLD report, the use of 
corticosteroids should be considered in patients with a FEV1 less than 50% of the 
predicted value if they experience at least one exacerbation per year.  Inhaled 
corticosteroids will reduce the frequency of exacerbations and improve health 
status in this population (GOLD, 2006; Pauwels et al., 2001).   
 
In the event of an acute exacerbation, a short course of oral corticosteroids is 
mandatory (GOLD, 2006; Petty & Weinmann, 1997; ATS, 1995).  Side effects of 
systemic corticosteroids in the older population include skin damage, cataracts, 
diabetes, osteoporosis and secondary infection; therefore, long-term use is not 
recommended (GOLD, 2006; ATS, 1995).   
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 1.3 Antibiotics 
 
The use of a broad spectrum antibiotic for the treatment of acute exacerbations is 
widely accepted (Petty & Weinmann, 1997; ATS, 1995).  According to the 
guidelines of the South African Thoracic Society, antibiotics “should be prescribed 
where there is clear evidence or strong suspicion of an infection (marked sputum 
purulence and/or fever)” (Bateman et al., 2004).  The presence of Streptococcus 
pneumoniae, Haemophilus influenzae and Moraxella catarrhalis (organisms 
commonly involved in infection) could be confirmed by sputum Gram stain, but is 
not essential.  Resistance to macrolides and doxycycline should be kept in mind 
when prescribing an antibiotic.  Alternative agents include amoxycillin/clavulanate, 
cefuroxima or quinolones (Bateman et al., 2004).  According to Petty and 
Weinmann (1997), sputum cultures may be misleading and broad spectrum 
antibiotics should be given on an empiric basis (Petty & Weinmann, 1997).  There 
is no evidence to suggest that antibiotics have any benefits in the prevention or 
treatment of COPD exacerbations due to the fact that the cause of these 
exacerbations is unknown.  However, symptoms of an infection, such as fever and 
changes in the chest radiograph, will justify a course of antibiotics (Senior & 
Anthonisen, 1998; ATS, 1995).  In the case of severely ill patients, or recurrent 
infections, treatment should be continued for 10 to 14 days (Bateman et al., 2004).  
The benefits provided by flu vaccines suggest that exacerbations are partly due to 
airway infections.  Antibiotics can also be useful in the treatment of recurrent 
infections (Senior & Anthonisen, 1998; ATS, 1995).   
 
 1.4 Other pharmacologic agents 
 
In younger, non-smoking patients with a severe AAT deficiency, with associated 
emphysema, AAT augmentation therapy may be justified (ATS, 1995).  
Immunisations with pneumococcal and influenza vaccines are recommended to 
prevent exacerbations and infections of the respiratory tract (Calverley, 2001; ATS, 
1995).  
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  1.5 Adjustment of therapy 
 
 Vital to the success of pharmacologic therapy is a dynamic relationship between 
the physician and the patient.  Patients must be educated on therapy possibilities 
and become actively involved in treatment (ATS, 1995).   
 
2. Oxygen therapy 
 
Supplemental oxygen could be life preserving for COPD patients.  Oxygen is 
administered to correct or prevent hypoxaemia (Soo Hoo, 2003; Petty & 
Weinmann, 1997; ATS, 1995).  Oxygen therapy has a positive affect on mortality 
and the more continuous the therapy, the larger the effect (Soo Hoo, 2003; Senior 
& Anthonisen, 1998).  Figure 2.7 illustrates how oxygen therapy increased survival 
in a study conducted by the Medical Research Council Working Party (1981). 
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Figure 2.7 Results of British trials of home oxygen therapy in hypoxemic chronic 
obstructive pulmonary disease.  Survival is plotted against time of 
follow-up.   
 
 2.1 Benefits of oxygen therapy 
 
 Long-term oxygen therapy holds various benefits for the hypoxaemic patient.  
Physiological benefits include reversal of secondary polycythemia, alleviation of 
right heart failure (caused by cor pulmonale), strengthening of cardiac function and 
improvement of pulmonary hypertension and enhancement of neuropsychological 
function.  Other benefits for the patient include an increase in body weight, a 
decrease in hospitalisations, an improvement in exercise ability and improved 
quality of life.  It was furthermore found that long-term, continuous oxygen therapy 
improves the survival of hypoxaemic COPD patients and reduces overall mortality 
(Fujimoto et al., 2002; ATS, 1995).  Other benefits of supplemental oxygen during 
exercise is summarised in table 2.3. 
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 Table 2.3 Benefits of supplemental oxygen for COPD patients during exercise 
(Soo Hoo, 2003). 
Treatment Mechanism of benefit 
Oxygen Prevents oxygen desaturation 
 Decreases pulmonary artery pressure 
 Improves right ventricular function 
 Decreases minute ventilation 
 Decreases dyspnoea 
 Decreases or delays diaphragmatic fatigue 
 Decreases diaphragmatic work 
 Increases exercise endurance 
 Decreases serum lactate levels 
 Decreases tachycardia 
 Reverses hypoxia-induced bronchoconstriction  
Hyperoxia All of the above (probably dose-related effect) 
 Decreases ventilatory drive 
 Slows respiratory rate 
 Decreases dynamic hyperinflation 
 
Most studies concerned with oxygen therapy focused on COPD patients with 
severe hypoxaemia, due to the belief that oxygen therapy would have little effect 
on mild hypoxaemia (Fujimoto et al., 2002).  A study by O’Donnell and colleagues 
(1997) found that patients with mild hypoxaemia, at rest, could experience 
improved exercise tolerance and dyspnoea during exercise with supplemental 
oxygen.  Fujimoto and colleagues (2002) further documented significant 
improvements in exercise performance of COPD patients who experienced mild 
hypoxaemia at rest.  The factor that determines the extent of the improvement of 
exercise performance during oxygen inhalation is the degree of airflow obstruction 
and not the degree of hypoxaemia (Fujimoto et al., 2002).    
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 2.2 Mechanisms of improvement 
 
The mechanisms in the reduction of the mortality of COPD patients by the 
administration of long-term oxygen therapy, are not yet fully understood.  It may be 
explained by the reduction in pulmonary arterial pressures.  The pulmonary arterial 
pressures tend to increase in chronic hypoxaemic patients and oxygen therapy 
causes a reduction in these pressures.  However, these pressures are not lowered 
to normal levels, but the reduction is enough to improve cardiac output and tissue 
oxygen delivery. 
 
Oxygen inhalation can improve pulmonary hypertension in patients with moderate 
to severe airflow obstruction.  The mechanism of this improvement is related to the 
inhibition of hypoxic vasoconstriction and a reduction in pulmonary artery occlusion 
pressure (Fujimoto et al., 2002).   
 
2.3 Oxygen therapy during exercise 
 
Activity or exercise is encouraged in COPD patients.  Some hypoxaemic patients 
experience an increase in hypoxaemia during exercise and others, who are not 
hypoxaemic during rest, develop it during exercise.  Although it is not supported by 
research, home supplemental oxygen is often prescribed for patients who are 
hypoxaemic only during exertion.  Immediate benefits of oxygen during exercise 
include the reduction of dyspnoea and improvement in exercise tolerance and 
minute ventilation during submaximal workloads (Fujimoto et al., 2002; ATS, 1995).   
 
2.4 Hazards of oxygen 
 
Generally, oxygen therapy is considered safe.  There are, however, some dangers 
that should be taken into account when prescribing oxygen therapy.  These include 
oxygen toxicity, CO2 retention and physical hazards (ATS, 1995). 
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2.4.1 CO2 retention 
 
CO2 retention is not a common risk in low-flow oxygen therapy.  Supplemental 
oxygen may suppress the ventilatory drive which can lead to aggravation of 
hypercapnia, respiratory acidosis and CO2 narcosis (McAllister, 2002; ATS, 1995).  
Patients with an intact renal system will be able to tolerate CO2 retention (ATS, 
1995).   
 
2.4.2 Physical hazards 
 
Fires and explosions are the major physical risks of oxygen therapy.  Smoking 
during oxygen therapy is, in most cases, the cause of these fires.  Explosions could 
occur if an oxygen canister is knocked over.  These fires and explosions are rare 
and with proper education of patients, family and caregivers, can be avoided (ATS, 
1995).   
 
3. Surgical treatments 
 
Due to an increased risk for mortality and morbidity in surgical treatment of the 
COPD patient, it is important to assess the risk-benefit ratio prior to surgery to 
assure that the benefits outweigh the risks.  Pulmonary function studies are 
important to assess physiological operability prior to surgery (ATS, 1995).   
 
 3.1 Lung transplantation 
 
Lung transplantation can be lifesaving for some patients and has shown to improve 
quality of life and functional capacity of patients with severe COPD (Pauwels et al., 
2001; ATS, 1995).  According to Pauwels and co-workers (2001) patients should 
be considered for lung transplantation when their FEV1 lowers to below 35% of the 
predicted value, their PaO2 lowers to 7.3 to 8.0 kPa (55 to 60 mm Hg), their PaCO2 
rises above 6.7 kPa (50 mm Hg) and secondary pulmonary hypertension is 
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diagnosed.  However, this procedure is impeded by high costs, donor availability 
and requires lifelong immunosuppression (ATS, 1995).   
 
 3.2 Lung volume reduction surgery 
 
As a result of the loss of elastic recoil, the conducting airways may collapse.  
Collapsed airways will lead to severe expiratory flow limitation, dynamic 
hyperinflation and intrinsic positive end-expiratory pressure (PEEPi) (Dueck, 2000).   
 
Lung volume reduction surgery (LVRS) is a surgical procedure in which parts of the 
lung are resected to reduce hyperinflation.  This improves mechanical efficiency of 
the respiratory muscles by improving the effectiveness of pressure generation (as 
measured by length/tension relationship, curvature or diaphragm and area of 
apposition).  LVRS can significantly improve the elastic recoil, which will increase 
the diameter of the collapsed airways, and therefore improves expiratory flow rates 
(GOLD, 2006; Gelb et al., 1996b).   
 
According to Hamacher and co-workers (2002), apart from improvements in 
dyspnoea, walking distance and pulmonary measures, LVRS is associated with 
significant improvements in quality of life.  Furthermore, their study indicated that 
quality of life improvements are maintained for at least two years.   
 
However, insufficient evidence exists to fully understand the role and benefits of 
LVRS and the high cost involved limits this procedure to a small population (GOLD, 
2006; Pauwels et al., 2001).   
 
 3.3 Resection of large bullae 
 
In the patient where large bullae are compressing normal tissue, this surgery can 
relieve dysfunction and dyspnoea (Pauwels et al., 2001; ATS, 1995).  Computed 
tomography is generally used to differentiate between large bullae and non-
 72
compressive destructive emphysema (ATS, 1995).  CT scans, together with arterial 
blood gas analyses and comprehensive respiratory function tests, are essential for 
determining a patient’s suitability for surgery (Pauwels et al., 2001).    
 
4. Smoking cessation 
 
Smoking cessation is one of the key elements in the treatment of patients with not 
just COPD, but all lung conditions (Willemse et al., 2004; Buist, 2003).  According 
to Senior and Anthonisen (1998), smoking cessation is the best way to change the 
disease process of COPD.  The success rate of cessation is as low as 27% and 
multiple interventions are sometimes necessary for successful smoking cessation.  
Table 2.4 summarise the elements of successful smoking cessation (ATS, 1995).  
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Table 2.4 Protocol for smoking cessation (ATS, 1995). 
 
1 Initiation Physician or health care worker should initiate quitting, explaining risks 
of cigarette smoking for the individual and including strong admonition.  
Encourage establishment of a definite quit date.  Offer referral for self-
help or group programme. 
 
2 Early follow-up Telephone patient within three to five days after quit date.  Review 
progress and counsel regarding recruitment of support person.  Call 
again one to two weeks after quit date.  Repeat as needed. 
 
3 Continuing 
reinforcement 
Further follow-up should be arranged by physician or health care 
worker.  Next regular visit should be less than two months after initiating 
cessation programme; assess progress with expired air and/or cotinine 
in urine, blood or saliva.  If absent, review and reward success and 
reinforce prior warnings.  May follow up by phone monthly until next 
visit; continue follow-up at increasing intervals for 12 months after quit 
date. 
 
4 Failure  If a patient fails to achieve abstinence or does so but relapses, 
physician or health care worker should review programme with patient, 
emphasising elements of success and identifying circumstances of 
failure; explore alternatives.  Nicotine replacement may be used to 
control withdrawal symptoms; infrequently other pharmacologic therapy, 
such as clonidine of buspirone, may be discussed.  Hypnosis may be 
considered, but is of little value when applied as a single-session 
recourse.  Acupuncture is not recommended.  
Despite the emphasis from all parties concerned to promote smoking cessation, 
26% of COPD patients have never been advised to quit smoking (Sherman et al., 
2003). 
   
 4.1 Factors influencing cessation  
 
Factors that influence the success rate negatively include the addictive potential of 
nicotine, conditioned response, depression, poor education, low income and 
forceful promotional campaigns by the tobacco industry (ATS, 1995).  The latter 
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will not be considered in the South African setting, due to the tobacco laws.  
Sherman and co-workers (2003) found equal success rates for smoking cessation 
in COPD and non-COPD patients, despite the fact the COPD patients are more 
often referred to smoking cessation programmes.  Factors contributing to 
unsuccessful cessation in COPD patients include depression, poor education and 
the perception among COPD patients that it is more difficult for them to quit than 
for the average person (Sherman et al., 2003).   
 
 4.2 Pharmacotherapy 
 
Today there are numerous pharmacotherapies available to assist patients in 
smoking cessation.  Research has shown that any form of nicotine replacement 
therapy is effective for smoking cessation and long-term abstinence (Calverley, 
2001; Lancaster et al., 2000).  Other pharmacotherapies that have shown success 
are antidepressants and the antihypertensive drug clonidine.  Clonidine is 
associated with various side effects that limit its usefulness (Lancaster et al., 
2000).  Antidepressants with dopamine agonist properties (e.g. bupropion), have 
been highly successful in assisting in smoking cessation (Calverley, 2001).  These 
agents are however, only of value if smokers are adequately motivated to 
discontinue their habit. 
 
 4.3 The effects of cessation on lung function 
 
A study by Scanlon and co-workers (2000) investigated the effects of smoking 
cessation on the lung function of 5 887 COPD patients with mild to moderate 
airflow obstruction.  One of their key findings was that the annual FEV1 decline in 
patients, who quit smoking, was half that of patients that continued smoking, over a 
four year period.  Patients who continued smoking had an average decline of 62ml 
per year, compared to the 31ml per year in quitters.  According to this study, the 
factors that influence the improvement or stabilisation of FEV1 include baseline 
pulmonary measures, baseline bronchodilator responsiveness, race and age.  
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Factors that are responsible for a greater improvement, during the first year of 
cessation, include greater airway responsiveness, lower initial lung function, 
younger age, heavy smoking and the female gender.  Importantly, women who 
continued smoking had a greater loss of lung function compared to men with 
similar smoking rates (Scanlon et al., 2000).  This could be explained by the fact 
that women are more susceptible to the harmful effects of cigarette smoking (Petty 
& Weinmann, 1997; Xu et al., 1994).  Willemse and co-workers (2004) 
demonstrated that smoking cessation improves airway hyperresponsiveness.   
 
5. Pulmonary rehabilitation 
 
Rehabilitation is defined by the British Thoracic Society (BTS) (1997) as “the 
restoration of the individual to the fullest medical, mental, emotional, social and 
vocational potential of which he/she is capable”.  The American College of Chest 
Physicians (ACCP) defines pulmonary rehabilitation as “an art of medical practice 
wherein an individually tailored, multidisciplinary programme is formulated, which 
through accurate diagnosis, therapy, emotional support and education, stabilizes or 
reverses both the physiology and psychopathology of pulmonary diseases and 
attempts to return the patient to the highest possible functional capacity allowed by 
this pulmonary handicap and overall life situation” (ACCP/AACVPR Pulmonary 
Rehabilitation Guidelines Panel, 1997).   
 
The most recent definition adopted by the ATS and ERS is:  
“Pulmonary rehabilitation is an evidence-based, multidisciplinary and 
comprehensive intervention for patients with chronic respiratory diseases 
who are symptomatic and often have decreased daily life activities.  
Integrated into the individualized treatment of the patient, pulmonary 
rehabilitation is designed to reduce symptoms, optimize functional status, 
increase participation and reduce health care costs through stabilizing or 
reversing systemic manifestations of the disease” (Nici et al., 2006).   
 
The use of pulmonary rehabilitation to enhance standard therapy of patients with 
COPD, is well documented and widely accepted.  It also forms an essential part of 
the clinical management and health maintenance of these patients (Nici et al., 
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2006; Rochester, 2003; ATS, 1999; American Association of Cardiovascular and 
Pulmonary Rehabilitation (AACVPR), 1998; Fishman, 1998; ACCP/AACVPR 
Pulmonary Rehabilitation Guidelines Panel, 1997; Celli 1995; Ries et al., 1995; 
Curtis et al., 1994; Cox et al., 1993).  According to Mahler (1998), several factors 
played a role in the renewed interest in pulmonary rehabilitation that was 
experienced in recent years.  The key factors, according to this author, were the 
marked increase in the prevalence of COPD and a greater awareness of the 
deconditioning of these patients (Mahler, 1998).  The ATS and ERS attribute the 
rise in interest towards pulmonary rehabilitation to an increase in the number of 
patients referred to programmes and the support of well-designed clinical trials, 
which provided a scientific basis for the implementation of these programmes.  
Improved understanding of the pathophysiology of chronic respiratory diseases, 
further contributes to possibilities and applicability of pulmonary rehabilitation   (Nici 
et al., 2006). 
 
The main aim of pulmonary rehabilitation is to reduce respiratory symptoms, 
decrease disability and improve health status, functional capacity, independence 
and overall quality of life, while diminishing health care costs (Nici et al., 2006; 
BTS, 2001; McArdle et al., 2001:953; ATS, 1999; Mahler, 1998; Gosselink et al., 
1997; Petty & Weinmann, 1997; Ries et al., 1995; Belman, 1993; Jones et al., 
1992).  Apart from the financial implications of hospital admissions, frequent 
admissions contribute to inactivity and dependence on others.  Therefore, the 
prevention of hospital admissions and management of risk factors for admissions 
should be an essential treatment goal when treating COPD patients.  Risk factors 
for hospital admissions include previous admissions, a low FEV1, hypoxaemia and 
inactivity (Morgan, 2003; Osman et al., 1997; Ries et al., 1995).   
 
Pulmonary rehabilitation programmes may include an array of therapeutic 
modalities.  These include education of the patient and family members, treatment 
of bronchospasm and bronchial infection, treatment of congestive heart failure, 
oxygen therapy, physical and occupational therapy, breathing technique training, 
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psychosocial therapy and exercise training (Nici et al., 2006; Morgan, 2003; BTS, 
2001; McArdle et al., 2001:953; ATS, 1999; Belman, 1993; Holden et al., 1990).  
Exercise training is seen as the foundation of pulmonary rehabilitation (ATS, 1999; 
Bernard et al., 1999; Berry et al., 1999; Make, 1986; ATS, 1981).  These 
intervention strategies collaborate into the lifelong management of patients with 
chronic respiratory disease (Nici et al., 2006).  According to Ries and co-workers 
(1988), education alone is not as effective as a programme that includes exercise 
training.  This was confirmed by Carrieri-Kohlman and co-workers (1996) who 
stated: “Exercise is the key to improvement…” 
 
According to Morgan (2003) only about three percent of COPD patients are 
referred for pulmonary rehabilitation, while only 14% of this three percent actually 
receive it.  Another fact of concern is that pulmonary rehabilitation is usually 
prescribed when patients are in an advanced stage of the disease.  Most patients 
that end in programmes could be classified as having moderate COPD.  Patients 
with mild COPD are rarely encountered in pulmonary rehabilitation, despite the fact 
that these patients already experience a significant loss in functionality and quality 
of life.  Although the impairment that patients with mild COPD experience, is not as 
debilitating as with moderate and severe COPD, these patients can still benefit 
from these programmes and physical function and HRQL can be improved.  This 
was established by Berry and co-workers (1999), who found that there is no 
significant difference in the benefits obtained from participating in a pulmonary 
rehabilitation programme through all stages of COPD (Berry et al., 1999).  Figure 
2.8 illustrates the cycle of disabling symptoms experienced by COPD patients and 
the importance of pulmonary rehabilitation in the management of these symptoms.   
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Figure 2.8 A diagram to illustrate the cycles of COPD with and without exercise 
orientated pulmonary rehabilitation (Cooper, 2001b). 
 
 5.1 Collaborative self-management 
 
Collaborative self-management is the education of patients and family members to 
become actively involved in their treatment and to assume charge of their own 
care.  Education plays a key role in order for patients to understand their disease, 
recognise symptoms and learn practical ways to cope with and treat these 
symptoms.  It is important that the educational component of a rehabilitation 
programme be tailored to the needs of each individual patient (ATS, 1995).  A 
randomised, controlled study by Monninkhof and co-workers (2003) found that a 
comprehensive self-management programme had no effect on the quality of life, 
walking distance, symptoms or exacerbation frequency of COPD patients.  These 
authors suggest that in order for self-management programmes to succeed, an 
exercise component needs to be incorporated.  Based on previous literature, these 
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authors, furthermore, concluded that a self-management programme would be 
more effective in patients with severe COPD.   
 
 5.2 Exercise training  
 
Initially, physicians adopted a very conservative approach to exercise for COPD 
patients.  In most cases exercise was limited or discouraged (Belman, 1993).  
Exercise was then later regarded as a last effort to manage these patients with little 
hope for success (ATS, 1999).  A conjoined report by the American College of 
Chest Physicians (ACCV) and the American Association of Cardiovascular and 
Pulmonary Rehabilitation (AAVCPR) recommended that exercise training should 
be included as a standard treatment modality in the rehabilitation of COPD patients 
(ACCV/AACVPR Pulmonary Rehabilitation Guidelines Panel, 1997).  This report 
was later supported by the ATS and the BTS (BTS, 2001; ATS, 1999).  At the 
present time, exercise is promoted for the improvement of quality of life and forms 
an integral part of the management of patients with respiratory disease (Rochester, 
2003; ATS, 1999; Ries et al., 1995; Belman, 1993).     
 
Dyspnoea is usually one of the foremost reasons for the decrease in physical 
activity amongst COPD patients.  Inactivity results in deconditioning, which 
aggravates dyspnoea at ever lower work levels (Steiner & Morgan, 2001; Celli, 
1995; Folgering & van Herwaarden, 1994).  Deconditioning further contributes to 
inability to perform daily tasks, which will lead to social isolation, depression and 
dependence on others.  Improvement of physical capacity is therefore important to 
prevent this vicious cycle (Steiner & Morgan, 2001).   
 
The success of exercise training can be attributed to the fact that most of the 
disabilities experienced by these patients result from secondary morbidities that 
are often treatable.  Exercise training does not improve the degree of obstruction or 
hyperinflation of COPD patients, but the muscle conditioning together with pacing, 
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enable patients to walk further with less breathlessness (ATS, 1999).  Secondary 
consequences of respiratory disease are summarised in Table 2.5. 
 
Table 2.5 Consequences of respiratory disease (ATS, 1999).  
Types of secondary 
morbidity 
Mechanism(s) 
Peripheral muscle 
dysfunction 
Deconditioning, steroid myopathy, ICU neuropathy, malnutrition, 
decreased lean body mass, fatigue, effects of hypoxaemia, acid-
base disturbance, electrolyte abnormalities 
 
Respiratory muscle 
dysfunction 
Mechanical disadvantage secondary to hyperinflation, malnutrition, 
diaphragmatic fatigue, steroid myopathy, electrolyte abnormalities 
 
Nutritional abnormality Obesity, cachexia, decreased lean body mass 
 
Cardiac impairment Deconditioning, cor pulmonale 
 
Skeletal disease Osteoporosis, kyphoscoliosis 
 
Sensory deficits (impaired 
vision, hearing, etc.) 
Medications (e.g., steroids, diuretics, antibiotics) 
Psychosocial Anxiety, depression, guilt, panic, dependency, cognitive deficit, 
sleep disturbance, sexual dysfunction 
  
Contrary to prior belief (Belman, 1986), COPD patients can exercise at a sufficient 
intensity to instigate physiological adaptations (Maltais et al., 1996a).  Due to the 
wide range of exercise tolerance experienced by COPD patients, outcome 
objectives have been diversified.  The first refers to patients that are able to train at 
a sufficient intensity to produce physiological adaptations.  The second refers to 
patients that are limited by dyspnoea and other symptoms.  These patients cannot 
sustain exercise intensities sufficient to produce physiological adaptations.  
Therefore, the objective for these patients would be to improve mobility within 
these constraints.  To address the needs of all patients, it is of vital importance to 
individualise exercise programmes (Clark et al., 1996).   
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Table 2.6 Evidence-based guidelines for exercise training in COPD (Rochester, 
2003). 
Training / Candidacy BTS ATS ACCP/AACVPR 
Lower extremity 
training 
Endurance and 
strength training 
recommended: 
• 20-30 min 
• 3-5 times per 
week 
• Intensity of 60-
70% of 
VO2max 
where 
possible 
• Maintain O2 
saturation 
above 90% 
 
 
Endurance and 
strength training 
recommended: 
• 20-30 min 
• 2-5 times per 
week 
• Intensity of 
60% of 
VO2max 
where 
possible 
Recommended as part 
of pulmonary 
rehabilitation:  optimal 
specific prescription 
not defined 
Upper extremity 
training 
Strength and 
endurance training 
may be included 
 
 
Strength and 
endurance training 
recommended 
Strength and 
endurance training 
recommended 
Ventilatory muscle 
training 
Non-essential  Role unclear Evidence does not 
support routine use.  
May be considered in 
some patients with 
decreased respiratory 
muscle strength and 
dyspnoea 
 
The basic principles for exercise prescription apply for both healthy individuals and 
COPD patients, namely mode, frequency, intensity and duration (ACSM, 2000:343; 
ATS, 1995; Celli, 1995).  These principles greatly influence the degree of the 
training effect experienced (Celli, 1999:195).  Table 2.6 summarises the clinical 
guidelines for exercise training according the BTS, ATS and the ACCP/AACVPR 
(BTS, 2001; ATS, 1999; ACCP/AACVPR Pulmonary Rehabilitation Guidelines 
Panel, 1997). 
 
5.2.1 Training intensity 
 
Training intensity ascertains that improvement or a training effect will only be 
observed if a load higher than the baseline is induced (Celli, 1995).  Athletes 
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usually train at the maximum tolerated intensity to achieve maximum benefits from 
a session.  Adjustment to exercise intensity to suit individual needs are, however, 
common practice in exercise prescription (Celli, 1999:195).   
 
The recommended exercise intensity for healthy individuals is 60 to 90% of the 
predicted maximal heart rate or 50 to 80% of the maximal oxygen uptake (McArdle 
et al., 2001:954; ACSM, 2000:145; ATS, 1999; ACSM, 1998b; ACSM, 1990).  Until 
recently, it was thought that COPD patients cannot exercise at these intensities 
and the prescribed intensities were between 30 and 50% of the predicted maximal 
heart rate.  However, these intensities are below the anaerobic threshold and 
beneficial physiologic adaptations are minimal.  Today it is accepted practice to 
exercise respiratory patients at 60 to 75% of maximal work rate (ATS, 1999; 
Coppoolse et al., 1999; Folgering & van Herwaarden, 1994).  A recent study by 
Probst and co-workers (2006) confirmed that COPD patients could easily exercise 
within the prescribed intensities for healthy individuals.   
 
For patients who cannot sustain the prescribed intensity for a prolonged period, 
interval training is recommended.  Interval training consists of several high intensity 
exercise bouts that are alternated with rest periods (ATS, 1999).  An added benefit 
of interval training is that it correlates better to daily activities than continuous 
training.  The effectiveness of interval training for COPD patients has been 
confirmed (Vogiatzis et al., 2004; Vogiatzis et al., 2002; Coppoolse et al., 1999).  
Vogiatzis and co-workers (2002) reported that interval training could improve 
quality of life and exercise tolerance.  One of the important benefits of interval 
training is that patients can exercise at their maximal intensity with a significant 
decrease in their perception of dyspnoea (Vogiatzis et al., 2002).   
 
Casaburi and co-workers (1991) confirmed that COPD patients that trained at a 
higher intensity, demonstrated a significantly lower cardiac frequency after two 
months of aerobic training, compared to patients that trained at a lower intensity.  
In contrast, Clack and co-workers (1996) established that low intensity training 
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could improve exercise tolerance and dyspnoea in COPD patients.  Ries and co-
workers (1995) recorded an improvement in treadmill endurance with low intensity 
training, despite the absence of VO2max improvement.  In a study by Maltais and 
co-workers (1997), 88% of subjects could not tolerate high intensity training.  
However, they did show an improvement in exercise capacity with low intensity 
training.  These authors recommend low intensity training for patients with 
moderate to severe COPD and higher intensities for patients with mild COPD.  
According to Celli (1999:196), any exercise intensity above 50% of maximal work 
rate can instigate a training effect, after which intensity can be increased as 
exercise tolerance improves.  Table 2.7 illustrates the criteria that should be taken 
into account when prescribing exercise intensity to COPD patients (Cooper, 
2001a).   
 
Table 2.7 Intensity criteria for aerobic exercise prescription. 
Criteria Definition 
Target Minimum intensity necessary to produce a clinically meaningful response 
Range Span of training intensity from the target to maximum intensity safely tolerated 
by subject 
Progression Maintenance of the intensity stimulus in the face of training adaptations 
 
It is important to note that predicted heart rate is not always the best indicator to 
use when determining exercise intensity for these patients.  Peak exercise levels 
can be reached well below prescribed work rates due to ventilatory limitation (ATS, 
1999; Horowitz et al., 1996; Belman et al., 1991; Casaburi et al., 1991).  
Controversy still exists as to what the best approach is; suggested alternatives are 
dyspnoea ratings or the Borg RPE scale (Appendix A) (ATS, 1999; Glass et al., 
1992; Belman et al., 1991; ACSM, 1990).  The Borg RPE scale is the preferred 
method of exercise prescription, but should be paired with heart rate readings 
(Cooper, 2001a; ACSM, 1990).  Two studies (Mejia et al., 1999; Horowitz et al., 
1996) have found that dyspnoea ratings are effective in the prescription of exercise 
intensity in COPD patients.  The pitfall of this method according to Cooper (2001a) 
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is that patients may not exercise at sufficient intensities due to the fact that 
dyspnoea will decrease with training.   
 
It is important to note that any exercise is better than none.  Even if patients can 
only tolerate low intensity exercise, benefits can still be observed when compared 
to doing no exercise at all (ZuWallack et al., 1991).   
 
5.2.2 Training frequency and duration 
 
Training frequency and duration prescribed for healthy individuals are 30 to 45 
minutes per day, three to five times per week.  In order for a training programme to 
elicit a physiological response, the programme must be continued for five to eight 
weeks (ACSM, 1990; Yerg et al., 1985; Seals et al., 1984).  Casaburi and co-
workers (1991) argued that the same principles apply to COPD patients.  
Guidelines according to the ATS (1999) and BTS (2001) recommend 20 to 30 
minute sessions, two to five times per week over an eight to 12 week period.  Clark 
(1994) acknowledged that significant improvements can be observed after six 
weeks of exercise training, but suggests that the minimum programme duration for 
COPD patients should be 12 weeks.  An extended programme could ensure 
adherence to exercise after the programme is completed (Clark, 1994).    
 
The recommended exercise prescription for COPD patients according to McArdle 
and co-workers (2001:954) is three times per week, with each session lasting 20 
minutes.  If exercise duration needs to be reduced, frequency needs to be 
increased, e.g. if sessions are five to 15 minutes, frequency should be adapted to 
five to seven days a week.  Cooper (2001a) recommends 30 minutes of aerobic 
exercise, at least three days per week for six to eight consecutive weeks.   
 
According to Cooper (2001a), the greater the frequency and duration of exercise 
training, the greater the benefits will be.  The minimum frequency and duration for 
COPD patients to obtain benefits, in terms of exercise capacity, is not known.  
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Ringbaek and co-workers (2000) concluded that exercise sessions twice a week 
are not sufficient to produce a significant improvement in six-minute-walk-test 
distances.  It is generally accepted that three exercise sessions weekly, are the 
required minimum (BTS, 2001; Ringbaek et al., 2000).  Green and co-workers 
(2001) found that a seven week rehabilitation programme is more effective than a 
four week rehabilitation programme.  The seven week programme showed greater 
improvements in health status and exercise assessments (Green et al., 2001).  
Rossi and co-workers (2005) compared the effectiveness of 10 and 20 exercise 
sessions, respectively.  This study found that 20 exercise sessions are more 
effective in improving exercise tolerance, symptoms and HRQL in mild-to-moderate 
COPD patients.      
 
5.2.3 Training specificity 
 
Specificity of training is the physiological principle that refers to improvement only 
in the exercise or skill practised (Celli, 1995) and training is only beneficial to the 
muscle or muscle group being trained (Celli, 1999:195).  It is important that the 
exercises included in the exercise programme closely relate to the individual’s daily 
activities (Bernard et al., 1999; ATS, 1995). 
 
5.2.4 Reversibility of training 
 
Reversibility of training refers to the phenomenon that once training is suspended, 
the training effect will disappear.  The majority of research does not focus on the 
long-term effect of exercise training in COPD patients and therefore existing 
evidence is inconclusive (Celli, 1995).  However, Ries and co-workers (1988) 
demonstrated that aerobic benefits obtained through treadmill walking, persisted 
up to 16 months after the programme was completed.  A more recent study by 
Cambach and co-workers (1997) confirmed these results.  In this randomised 
controlled study, 99 subjects exercised 90 minutes, three times a week, over a 
three month period.  Subjects were evaluated after three and six months.  
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Improvements in exercise tolerance and quality of life were documented after three 
and six months.   
  
5.2.5 Pre-exercise evaluation and outcome assessments  
 
Most COPD patients have a history of smoking.  This, together with the fact that 
these patients are generally older patients, puts them at risk for cardiovascular 
disease.  One of the main reasons for conducting pre-exercise evaluation is to 
exclude any cardiovascular disease (ATS, 1995).  Furthermore, pre-exercise 
evaluations give an objective assessment of the impact of the disease on 
functionality of the patients (Johnson, 2004).   
 
Pre-exercise evaluations also assist in the formulation of clear exercise goals for 
each individual.  Important to formulation of these goals, is the assessment of the 
severity of respiratory impairment.  To determine respiratory impairment, a physical 
examination is conducted and clinical history and spirometry records are reviewed 
(ATS, 1999).  This evaluation should include a cardiac stress test and spirometry to 
ensure the safety of the patients (ATS, 1995).   
 
The determination of baseline exercise capacity is important for various reasons.  
Firstly, it is important to assist in exercise prescription to determine the optimal 
exercise intensity for each individual.  Secondly, exercise induced hypoxaemia and 
other abnormal responses can be evaluated, and proper precautions can be taken.  
Thirdly, the cardiac response to exercise can be evaluated and abnormalities can 
be detected.  It is furthermore important to assess the VO2-work rate relationship.  
Psychological limitations and the impact that it has on exercise training, can also 
be assessed (Gallagher, 1994; ATS, 1999).   
 
Outcome assessments are vital to determine the overall effectiveness of an 
exercise programme and serve as a motivational tool.  Exercise tests play a vital 
role in the outcome assessment of an exercise programme.  Various tests are used 
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for this purpose, of which the six-minute walk test is probably the most frequently 
used in pulmonary rehabilitation (Turner et al., 2004; ATS, 1999).   
 
Dyspnoea is a common symptom of COPD and therefore an important variable to 
measure in an outcome assessment.  Various scales and questionnaires can be 
used for this purpose; these include the Borg RPE scale (Appendix A), the 
Baseline and Transitional Dyspnoea Indexes (BDI and TDI) and the Pulmonary 
Functional Status and Dyspnoea Questionnaire (ATS, 1999).   
 
The measurement of HRQL of life has two vital applications in the pulmonary 
rehabilitation context.  Firstly, it is an important instrument in determining the 
benefits and effectiveness of various programmes and secondly, it is valuable in 
evaluating new methodologies (ATS, 1999).   
 
Supplemental to the measurement of HRQL is the measurement of respiratory-
specific functional status.  Functional status can be described as the interaction 
between what a patient is capable of doing (capacity), what a patient is actually 
doing (performance), the difference between capacity and performance (reserve) 
and capacity utilisation.  Rehabilitation should focus on increasing a patient’s 
reserve and motivating patients to utilise this added ability (ATS, 1999).   
 
Evaluation of functional status of the respiratory patient should focus on how well a 
patient can perform daily activities.  Daily activities should be divided into basic and 
instrumental activities.  Basic activities include eating, bathing and dressing, 
whereas instrumental activities are the activities needed to adapt to the 
environment.  Instrumental activities are closely related to a patient’s 
independence and include shopping and walking outdoors (ATS, 1999).   
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5.2.6 Aerobic training 
 
It is accepted that aerobic capacity will decline with age as a result of the natural 
aging process.  In COPD patients, this decline is aggravated by physical inactivity 
and deconditioning.  As exercise capacity declines and the patient advances in 
age, so does the potential of improvement of the absolute work capacity (Cooper, 
2001a).  A decline in exercise capacity of a COPD patient, is accompanied by a 
decline in airway function (Palange et al., 2000; Fletcher & Peto, 1977).  Lacasse 
and co-workers (1996) did a meta-analysis of 11 studies concerned with aerobic 
training of COPD patients.  They found an improvement in exercise capacity after 
endurance training.  Therefore, aerobic or endurance training is fundamental to any 
exercise programme prescribed to COPD patients (Cooper, 2001a; O’Donnell et 
al., 1995).   
 
An aerobic exercise training programme will improve the exercise endurance of 
COPD patients, although the mechanism of improvement is not fully understood 
(BTS, 2001; ATS, 1999; ACCP/AACVPR Pulmonary Rehabilitation Guidelines 
Panel, 1997; Strijbos et al., 1996; Celli, 1995; O’Donnell et al., 1995; Ries et al., 
1995; Wijkstra et al., 1994; Toshima et al., 1990).  Belman and Kendregan (1981) 
suggested that endurance is improved because of desensitisation towards 
dyspnoea.  This study found no changes in the oxidative enzyme content of trained 
muscles after six weeks of exercise training, despite a significant improvement in 
aerobic endurance.  In contrast, Casaburi and co-workers (1991) showed a 
reduction in exercise lactic acidosis and ventilation following eight weeks of 
exercise training, which suggests that physiological adaptations occurred.  Maltais 
and co-workers (1997) suggested that the improvement in endurance is the result 
of an accumulation of several factors, namely better motivation, desensitisation 
towards dyspnoea, improvement in mechanical skill and enhanced respiratory 
muscle function.  O’Donnell and co-workers (1995) reported significant 
improvements in dyspnoea, after endurance exercise training, which far exceeded 
improvements recorded by any other therapeutic intervention.  Possible 
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explanations for their findings include a reduction in ventilatory demand, improved 
ventilatory muscle strength, improved mechanical efficiency and psychological 
improvements.  Another important finding was an increase in resting IC, which was 
explained by an increase in inspiratory muscle strength (O’Donnell et al., 1995).  A 
study by Porszasz and co-workers (2005) found a 300% increase in aerobic 
capacity after seven weeks of endurance training, which was ascribed to a 
decrease in dynamic hyperinflation.  Cooper (2001a) argued that due to the 
effectiveness and the backing of numerous studies, aerobic training should occupy 
most of the time allocated to a pulmonary rehabilitation programme.   
 
A wide array of programmes has been studied through the years with varied 
success.  Consensus is still to be reached regarding the most advantageous 
exercise frequency, intensity, duration and mode.  Uncomplicated, low activity 
programmes have been successfully implemented and successful exercise 
programmes have varied anything from two to six sessions a week, with session 
duration varying from one to three hours (ATS, 1999; O’Donnell et al., 1995; 
Belman, 1993).  Table 2.8 summarise the guidelines for endurance training 
according to Clark (1994).   
 
Table 2.8 Guidelines for endurance training. 
Frequency Minimum of three times weekly 
Duration Minimum of 20 minutes 
Intensity No less than two thirds of the exercise intensity achievable without lung 
disease. 
Timescale Minimum of six weeks. 
 
With reference to functional capacity, upper-extremity endurance training is not as 
effective as lower-extremity endurance training (Lake et al., 1990).  Walking or 
treadmill walking is the most preferred mode of endurance exercise, because it 
translates best to daily activities (Cooper, 2001a).  Other authors also promote 
walking as an exercise modality on the basis that it resembles daily activities 
(Gosselink et al., 1997; Maltais et al., 1997).  Celli (1999:199) promotes treadmill 
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walking as an exercise modality on the basis that it produces a higher oxygen 
uptake.  Some patients with arthritis, joint deformities and obesity may prefer 
stationary cycling to walking, due to the added stress on the joints during walking 
(Cooper, 2001a).  Gosselink and co-workers (1997) demonstrated that stationary 
cycling can improve walking distances and therefore, can be beneficial to activities 
of daily living.   
 
Casaburi and co-workers (1991) ascribe the lack of physiological adaptations 
recorded by various pulmonary rehabilitation programmes to discrepancies in 
training frequency, duration and intensity.  Traditionally, patients with severe COPD 
are not referred for exercise training.  The typical patient in these programmes has 
mild to moderate COPD.  Previous studies did, however, show that exercise 
training can be beneficial for patients with severe COPD (Bernard et al., 1999; 
Niederman et al., 1991; ZuWallack et al., 1991).    
 
5.2.7 Strength training 
 
According to Wouters (2002), the loss of muscle strength is a common problem 
experienced by COPD patients.  Hamilton and co-workers (1995) found that the 
average muscle strength of COPD patients is only 81% of that of healthy, age-
matched controls.  Strength training will result in an increase in myofibrils in muscle 
fibres (Celli, 1999:195).  The aim of strength training for the COPD patient should 
be “to reduce the effects of major skeletal muscle deconditioning and the loss of 
function due to enforced inactivity and poor nutritional status” (Clark, 1994).  COPD 
patients will obtain the same improvement in muscle strength from strength training 
as healthy individuals (Mador et al., 2004).  Strength- or resistance training is 
especially important for individuals who present with specific muscle weaknesses, 
since muscle weakness contributes to exercise limitation.  In individuals who do not 
demonstrate muscle weakness, strength training is still important to maintain 
muscle strength (Spruit et al., 2002; ATS, 1999; ATS, 1995; Simpson et al., 1992).  
According to Belman (1993), a structured strength training programme can improve 
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cycle endurance and quality of life of COPD patients.  This was confirmed by other 
studies (Clark et al., 1996; Simpson et al., 1992).  Clark and co-workers (1996) 
subjected 32 subjects to a 12-week exercise programme that focused on 
conditioning of peripheral skeletal muscles.  They found a significant improvement 
in the treadmill walking endurance, despite the fact that the programme only 
focused on peripheral muscle conditioning and that maximal cardiorespiratory 
fitness remained unchanged.  In a study by Clark and co-workers (2000), muscle 
function and treadmill endurance improved after a programme that only included 
weight training of the upper- and lower extremities.  Patients included in this study 
suffered from mild COPD and the programme demonstrated to be effective for 
patients with impaired isokinetic muscle function prior to training (Clark et al., 
2000).  Spruit and co-workers also found a cross-over effect between endurance 
and resistance training.  These authors found that endurance training could result 
in significant increases in peripheral muscle force, while resistance training 
resulted in an increase in 6MWD and peak workload.  Contrary to these findings, 
other studies found that apart from improving muscle strength, strength training 
has no added benefits, in terms of quality of life and exercise endurance, for COPD 
patients above a structured endurance programme (Bernard et al., 1999; Mador et 
al., 2004).   
 
Strength training is safe and well-tolerated by COPD patients and does not inhibit 
endurance training (Mador et al., 2004).  Benefits for including strength training 
exercises in an exercise programme for COPD patients, include the fact that 
dyspnoea is limited during these exercises, which results in improved exercise 
tolerance (Bernard et al., 1999; Clark et al., 1996; Simpson et al., 1992).  
Furthermore, cardiopulmonary stress during strength training is significantly lower 
compared to walking, cycling and stair climbing (Probst et al., 2006).  According to 
Dekhuijzen and Decramer (1992), a well structured strength training programme is 
vital for COPD patients being treated with corticosteroids to prevent steroid-
induced myopathy to some extent.  The variety of strength training exercises 
provides for an interesting exercise programme that adds to motivation of patients.  
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Another added benefit is that strength training helps to combat osteoporosis and 
promotes bone density (Bernard et al., 1999; Clark et al., 1996; Simpson et al., 
1992).   
 
Decramer and co-workers (1997) explored another potential benefit of strength 
training, when their research showed a correlation between peripheral muscle 
weakness and health care costs.  This relationship can possibly be explained by 
the fact that health care utilisation and muscles weakness are indicators of disease 
severity.  Muscle weakness could also be associated with recurrent complaints, 
which can result in hospitalisations that are more frequent.  A final possible 
explanation is that there is an interrelationship between health care utilisation and 
muscle weakness.  Frequent hospitalisations and subsequent bed rest, combined 
with more frequent treatment with corticosteroids and subsequent steroid-induced 
myopathy, may result in muscles weakness.  It could then be proposed that an 
improvement in muscle weakness will not only result in improved exercise 
tolerance and functional status, but also lead to reduced health care costs 
(Decramer et al., 1997).   
 
In a systematic review of strength training in COPD patients, O’Shea and co-
workers (2004) concluded that strength training is both safe and appropriate for 
these patients.  It is however, of vital importance to thoroughly screen patients 
before prescribing a strength training programme due to the possibility of co-
morbidities.  A possible limitation to the feasibility of strength training for COPD 
patients, is the availability and access to equipment.  According to O’Shea and co-
workers (2004), only one study evaluated the use of free weights and resistance 
bands as a simple alternative to expensive equipment.  Further research is 
required into more cost-effective strength training methods (O’Shea et al., 2004).   
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5.2.7.1 Lower extremity training 
 
Several studies have shown that lower extremity exercises are beneficial for COPD 
patients (Mahler, 1998; Ries et al., 1995; Wijkstra et al., 1994; Hughes & Davison, 
1983; Moser et al., 1980; Christie, 1968; Paez et al., 1967).  According to Bernard 
and co-workers (1999), lower extremity aerobic training improves exercise 
tolerance in COPD patients, but has no effect on muscle weakness and muscle 
atrophy.  This supports the use of lower extremity strength training.  An increase in 
muscle strength will result in an improvement of exercise tolerance.   
 
The perception of muscle fatigue can be reduced by increasing the strength of the 
quadriceps femoris muscles.  Strength training in healthy, older, individuals results 
in an increase of the skeletal muscle’s oxidative capacity, improved peripheral 
muscle strength and an increase in muscle volume and muscle cross-sectional 
area (McArdle et al., 2001:535 & 882; Bernard et al., 1999).  The same benefits 
can be obtained in patients with moderate to severe COPD.  Muscle hypertrophy 
and improved neural recruitment can explain the increase in muscle strength after 
a strength training programme, for healthy individuals as well as COPD patients 
(Bernard et al., 1999).   
 
   5.2.7.2 Upper extremity training 
 
Various upper extremity muscles or muscle groups have both respiratory and 
postural functions.  These include the upper and lower trapezius, latissimus dorsi, 
serratus anterior, subclavius, pectoralis major and pectoralis minor.  With severe 
COPD, the diaphragm’s ability to generate force diminishes and the above-
mentioned muscles become increasingly important in the generation of inspiratory 
pressures (Celli, 1999:200; Lareau et al., 1992).    
 
Dyspnoea associated with upper extremity activities, at lower intensities than with 
lower extremity activities, are common among COPD patients.  Upper extremity 
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work is associated with a higher ventilatory demand compared to the same 
workload for the lower extremities (Fishman, 1998:714; Mahler, 1998; ATS, 1995; 
Belman, 1993; Couser et al., 1993; Ries et al., 1988).  This can be explained by 
the stabilising role that the muscles of the shoulder girdle have during respiration.  
Upper extremity exercises may cause dyssynchronous breathing because of the 
loss of this stabilising effect (Celli, 1999:200; Clark, 1995:529).  Certain upper 
extremity actions elicit more dyspnoea than others do.  These actions include 
activities that require sustained, unsupported arm extension (i.e. washing hair) and 
activities that restrict diaphragmatic movement (i.e. forward bending) (Lareau et al., 
1992).  Exercise benefits are specific to the muscle group involved in training, 
therefore the inclusion of upper extremity exercises in an exercise programme is 
vital for the alleviation of these symptoms (ATS, 1995; Belman, 1993; Ries et al., 
1988).   
 
According to Celli (1999:200), during arm exercises, pressure generation is shifted 
from the inspiratory muscles to the diaphragm and abdominal muscles.  Regular 
upper extremity exercises result in a decrease in metabolic and ventilatory demand 
for these exercises (Celli, 1999:200; ATS, 1995; Belman, 1993; Couser et al., 
1993).  Therefore, a patient’s capacity to perform these exercises should increase 
(Celli, 1999:200).  This was confirmed by Couser and co-workers (1993) who 
illustrated that metabolic and ventilatory demand for arm elevation decreases after 
an eight week rehabilitation programme that includes upper extremity training.  The 
14 subjects recruited for their study reported a decrease in dyspnoea after an eight 
week training programme.  According to the American Thoracic Society (1999), 
training of the upper extremities should not only focus on strength, but in addition, 
should have an endurance component.  Mahler (1998) noted that patients should 
be instructed on proper breathing techniques during upper body movements.  
Coordination of movement and breathing could facilitate breathing.  Expiration 
should occur during the part of the movement that requires the most effort, which 
generally is the extension of the arms.   
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Previous studies concluded that upper extremity training alone does not improve 
performance in arm activities used in daily living.  Furthermore, quality of life 
benefits are only observed during a combination of upper and lower extremity 
training (Lake et al., 1990; Ries et al., 1988).  Improved performance from upper 
extremity training is task specific; activities of daily living therefore play an integral 
part in the exercise prescription process (Celli, 1995).  Contrary to previous 
studies, Hamilton and co-workers (1995) found a relationship between upper body 
and thoracic muscle strength and maximal exercise capacity.  This was confirmed 
by a recent study that reported that the strength of the thoracic muscles is a 
predictor of functional capacity, as determined by the 6MWT (Dourado et al., 
2006).   
 
  5.2.8 Pursed-lip breathing 
  
The goal of pursed-lip breathing is to relieve or control dyspnoea and to counteract 
hyperinflation.  It is often unconsciously used by patients to enhance exercise 
tolerance (Gosselink, 2003; ATS, 1999; ATS, 1995). 
 
The aim of pursed-lip breathing is to alter the breathing patterns of symptomatic 
patients (Celli, 1995).  This is achieved by slowing the respiratory rate, decreasing 
minute ventilation and carbon dioxide level, increasing tidal volume and oxygen 
saturation, preventing dynamic airway compression, improving respiratory 
synchrony of abdominal and thoracic musculature and improvement of gas 
exchange (ATS, 1999; ATS, 1995).  It is still unclear whether pursed-lip breathing 
actually alleviates dyspnoea, despite the physiological improvements (ATS, 1999).   
 
Instructions for pursed-lip breathing according to the American Thoracic Society 
(1995) are as follows:  “Breathe in slowly and deeply through the nose; purse the 
lips lightly, as if to whistle; then breathe out slowly through the pursed lips, taking 
twice as long to exhale as to inhale.”   
 
 96
Diaphragmatic breathing is another technique sometimes taught to COPD patients 
to optimise ventilatory function (Rochester, 2003).  During this technique, patients 
are told to move the abdominal wall during inspiration, while limiting upper rib cage 
movement.  The aim of diaphragmatic breathing is to “improve chest wall motion 
and the distribution of ventilation, decrease the energy cost of breathing, the 
contribution of rib cage muscles and dyspnoea and improve exercise performance” 
(Gosselink, 2003).  According to Gosselink and co-workers (1995), diaphragmatic 
breathing can increase inspiratory loading and dyspnoea in some COPD patients.  
Rochester (2003) noted that patients with a low tidal volume (VT) and rapid 
breathing rate could benefit from this technique.   
 
5.2.9 Ventilatory muscle training 
 
Inspiratory muscles are affected by COPD and there is a relationship between the 
condition of these muscles and quality of life and mortality (Senior & Anthonisen, 
1998).  Ventilatory muscle weakness can contribute to fatigue, dyspnoea, exercise 
limitation, hypercapnia and even respiratory failure (Rochester, 2003; ATS, 1999; 
ATS, 1995a).  The aim of ventilatory muscle training is to improve gas exchange 
and ventilation, improve respiratory muscle function, decrease dyspnoea, increase 
exercise tolerance and ultimately improve quality of life (Gosselink, 2003).  
Controversy still exists as to whether weakened inspiratory muscles should be 
strengthened through exercise, or rested; assuming weakness is as a result of 
fatigue (Senior & Anthonisen, 1998).   
 
Training of these weakened inspiratory muscles will result in a training response, 
which will translate into improved respiratory muscle function (McConnell & Romer, 
2004; Celli, 1995).  Scherer and co-workers (2000) found that respiratory muscle 
training improved respiratory muscle endurance, exercise performance, HRQL and 
dyspnoea.  This study found that respiratory muscle training had no effect on 
pulmonary function.  Weiner and co-workers (1992 & 2004) found that an exercise 
programme that includes inspiratory threshold loading training, showed significantly 
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better results than a programme that focuses on general exercise training alone.  
Results included improved inspiratory muscle strength and endurance and an 
increase in exercise tolerance.  Hart and co-workers (2002) emphasised that 
attention should be given to respiratory muscle endurance and not just respiratory 
muscle strength.  In the study by Scherer and co-workers (2000), there was a 
258% improvement in respiratory muscle endurance after respiratory muscle 
training.   
 
Respiratory muscle strength can be improved through high-intensity, low-frequency 
stimuli.  This is achieved through increasing inspiratory pressures by inspiring 
against a closed glottis or shutter.  Inspiratory muscle strength will also improve 
through endurance training for the inspiratory muscles (Celli, 1995).  Hill and co-
workers (2006) established that high-intensity inspiratory muscle training improved 
inspiratory muscle strength and endurance, dyspnoea and exercise capacity.   
 
Respiratory muscle endurance is improved by low-intensity, high-frequency stimuli 
(Celli, 1995).  Methods of training inspiratory muscles include resistive loading, 
threshold loading, voluntary isocapnic hyperventilation or controlled breathing 
strategy (Gosselink, 2003; Rochester, 2003; ATS, 1999; ATS, 1995a; Celli, 1995).  
In resistive loading, the load is increased by narrowing of the inspiratory hole size, 
provided the frequency, tidal volume and inspiratory time remain unchanged.  
Threshold loading training is independent of inspiratory flow rate (Celli, 1995).  The 
benefits of threshold loading include that it is easily quantified and training load can 
be adjusted (Rochester, 2003).  In voluntary isocapnic hyperpnoea, high levels of 
ventilation are maintained for 15 minutes, two to three times a day (Celli, 1995).  
These techniques improve inspiratory muscle strength and endurance in COPD 
patients, but it is unclear whether these improvements result in alleviation of 
symptoms (ATS, 1999).  Insufficient research exists to fully understand the role of 
respiratory muscle training and the benefits it holds for COPD patients.   
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Weiner and co-workers (2004) emphasised the importance of a maintenance 
programme after a short-term ventilatory muscle training programme.  These 
authors found that the benefits obtained through ventilatory muscle training, 
gradually decline over 12 months in the absence of a maintenance programme.  
Studies concerned with resting ventilatory muscles found that this is very 
impractical and difficult to achieve and that no significant benefits are attained 
(Senior & Anthonisen, 1998; Albert, 1997).   
 
 5.3 Exercise tolerance 
 
Exercise tolerance and its prediction are of vital importance when it comes to 
training individuals with COPD (Rochester, 2003; Pauwels et al., 2001; Gosselink 
et al., 1997; Gallagher, 1994; Decramer, 1992).  Killian and co-workers (1992) 
studied exercise limiting symptoms in 97 COPD patients and compared it to the 
response of 320 healthy individuals.  An important finding of this study was that 
both the average COPD patient and healthy individual, stopped exercising when 
leg effort or dyspnoea reached an intensity of 7 (very severe) on the revised Borg 
RPE scale.  The difference between the COPD patients and the control group was 
that the COPD patients reached the mentioned intensity at a much lower workload.   
 
According to a study by Efremidis and co-workers (2005) exercise tolerance, as 
expressed by peak VO2, can be accurately predicted through resting pulmonary 
measurements.  The most consistent predictors of peak VO2 were expiratory 
airflow limitation and inspiratory-expiratory strength measures (Efremidis et al., 
2005).  The prediction of exercise tolerance in COPD patients is important for 
disability evaluations and to establish the cause of exertional symptoms and 
limitations (Efremidis et al., 2005; Pauwels et al., 2001).   
 
Various pathologies are implicated in the limitation of exercise performance of 
COPD patients.  These pathologies include abnormalities of ventilatory mechanics, 
respiratory muscles, alveolar gas exchange and cardiac function, as well as leg 
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fatigue, dyspnoea and chronic deconditioning (O’Donnell et al., 2002; Etnier et al., 
1999; Bauerle et al., 1998; Gosselink et al., 1996; Hamilton et al., 1995).  
According to the ATS and ERS, the primary symptoms that limit exercise 
performance are dyspnoea and fatigue.  Dyspnoea and fatigue may result from the 
other pathologies mentioned (Nici et al., 2006).  According to Foglio and co-
workers (2000), the most important predictors of exercise capacity are pulmonary 
hyperinflation, dyspnoea and age.  It was previously thought that FEV1 is the 
primary cause or indication of exercise intolerance.  However, patients with similar 
FEV1 values display a wide range in exercise capacity (Maltais et al., 1996b).  
According to Montes de Oca and Celli (2000), the exact impact of deconditioning, 
hypoxaemia, hyperinflation, muscle weakness and haemodynamic compromise 
has on exercise tolerance remains unclear. 
 
Treatment aimed at reducing these limitations will improve exercise performance 
(Rochester, 2003; Aliverti & Macklem, 2001; Belman, 1993; Carter et al., 1993; 
Killian et al., 1992).  It is important to note that physiological factors that limit one 
form of exercise (i.e. incremental work loads) may not necessarily limit other forms 
of exercise training (i.e. constant work load) (Gallagher, 1994). 
 
Due to the complex interaction between the different variables that limit exercise 
performance, it is often difficult to isolate these variables.  For example, 
deconditioning would result in peripheral muscle fatigue and peripheral muscle 
fatigue could contribute to deconditioning (Nici et al., 2006).  The variables that 
contribute to exercise intolerance are discussed separately.  The interrelationship 
between these factors will also be addressed. 
 
5.3.1 Respiratory muscle dysfunction 
 
COPD patients often exhibit weakness of the respiratory muscles.  Weakness in 
the skeletal muscles of COPD patients can often be explained by deconditioning.  
However, because the respiratory muscles of COPD patients are under constant 
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mechanical loading, other factors than deconditioning are responsible (Orozco-
Levi, 2003).   
 
Extrinsic and intrinsic factors result in muscle weakness in COPD patients.  
Extrinsic factors include hypoxia, hypercapnia, malnutrition, electrolyte 
disturbances, steroid myopathy and dynamic hyperinflation (Orozco-Levi, 2003; 
Rochester, 2003; Fitting, 2001; Gibson, 1996; Folgering & van Herwaarden, 1994; 
Belman, 1993).  Intrinsic factors include changes in fibre size, sarcomere length, 
muscle mass and muscle metabolism (Orozco-Levi, 2003).   
 
Dynamic hyperinflation shortens the diaphragm fibre sarcomere and reduces the 
zone of apposition, which results in weakened diaphragmatic function.  The 
diaphragm can shorten sufficiently to eliminate the zone of apposition altogether 
(Scharf, 1992:278).  Upper body actions place further limitations on diaphragmatic 
function, due to the fact that the stabilising effect of the shoulder girdle on the 
thorax is lost during these movements.  This restriction on the diaphragm results in 
a decrease in exercise capacity and an earlier onset of dyspnoea (Rochester, 
2003; Fitting, 2001; Gibson, 1996; Folgering & van Herwaarden, 1994; Belman, 
1993).  Clinical signs of diaphragmatic dysfunction include dyspnoea, which is 
aggravated in a supine position, elevation of the diaphragm and abnormalities in 
the chest wall motion (Scarf, 1992:285).  Weakness of respiratory muscles is 
assessed by measuring the pressures, expiratory flows and lung volumes during 
the MVV test (Scharf, 1992:286).   
 
O’Donnell and co-workers (1995) reported that ventilatory muscle weakness would 
limit exercise performance.  They suggested that a six-week exercise training 
programme that trains at near maximal ventilation levels, should improve 
ventilatory muscle strength and endurance, which will translate into improved 
exercise performance.  Contrary to these findings, Belman (1993) reported that the 
effect, if any, that ventilatory muscle training has on exercise performance, is 
insignificant (Belman, 1993).     
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 5.3.2 Respiratory muscle fatigue 
 
Muscle fatigue is defined as “an exertion-induced, reversible decrease in muscle 
strength or in the force exerted by the muscles in response to a given stimulus or 
load” (Scharf, 1992:283).  According to Belman (1993), the role of respiratory 
muscle fatigue in the toleration of exercise in the COPD patient is unclear.  
Insufficient evidence exists to suggest that the respiratory muscles are fatigued in 
COPD patients after prolonged exercise.  Rochester (1991) emphasises that 
inspiratory muscle weakness plays a more significant role than muscle fatigue.  
According to Wijkstra and co-workers (1994), inspiratory muscle strength can limit 
exercise performance.  Respiratory muscle weakness can lead to hypercapnia, 
which can further limit performance (Begin & Grassino, 1991).  Contrary to 
Rochester’s (1991) findings, Hart and co-workers (2002) emphasised the role of 
inspiratory muscle endurance.  According to Gallagher (1994), the susceptibility to 
fatigue varies between different respiratory muscles.  Therefore, recorded fatigue 
in a specific respiratory muscle cannot necessarily be transferred to other 
respiratory muscles.   
 
According to Mador and co-workers (2000b), COPD patients are predisposed to 
respiratory muscle fatigue during exercise.  These authors attribute this 
predisposition to the imbalance between inspiratory load and capacity during 
exercise (Mador et al., 2000b; Belman, 1993).  Mador and co-workers (2000b) 
studied diaphragmatic fatigue and found that some COPD patients experience 
fatigue during high-intensity, constant load cycle exercise.  They hypothesised that 
dynamic hyperinflation may have been the determining factor.  Important to their 
findings was that the majority of their subjects did not experience any 
diaphragmatic fatigue.   
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5.3.3 Peripheral muscle dysfunction and fatigue 
 
Exercise tolerance cannot be explained by ventilatory limitations alone.  Therefore, 
other possible factors have been explored, including peripheral muscle dysfunction 
(Storer, 2001).  The relationship between exercise tolerance and the condition of 
the skeletal muscles has recently received considerable attention (Haccoun et al., 
2002; Casaburi, 2001; Gea et al., 2001; Storer, 2001; Clark et al., 2000; Mador et 
al., 2000a; Murariu et al., 1998; Gosselink et al., 1996; Maltais et al., 1996b; 
Casaburi et al., 1991).  Previous studies demonstrated that the determining factor 
in exercise tolerance is leg effort and not dyspnoea, as expected (O’Donnell et al., 
1995; Killian et al., 1992).  Physiological attributes of peripheral and respiratory 
muscles are identical and they show the same decrements in strength (Carter et 
al., 2003; Aliverti & Macklem, 2001; Bernard et al., 1999; O’Donnell et al., 1995; 
Belman, 1993; Killian et al., 1992).  According to Franssen (2003), muscle 
dysfunction experienced by COPD patients is not homogeneously distributed over 
different muscle groups.  Mador and co-workers (2000a) found that contractile 
fatigue is specific to the exercising muscles and that muscle fatigue contributes 
significantly to exercise intolerance. 
 
Various factors contribute to the dysfunction of skeletal muscles of COPD patients.  
Muscle mass, strength and endurance will decrease as a result of inactivity, aging, 
hypoxaemia, hypercapnia, malnutrition, steroid myopathy, atrophy of type I and 
type IIa muscle fibres, reduction in muscle fibre capillarisation, reduced oxidative 
enzyme capacity and impaired muscle metabolism (Franssen, 2003; Casaburi, 
2001; Gea et al., 2001; Mador et al., 2000a; ATS & European Respiratory Society 
(ERS), 1999; Baarends et al., 1997; Maltais et al., 1996b; Jakobsson & Jorfeldt, 
1995; Engelen et al., 1994).  Decrease in muscle mass is also associated with an 
increase in mortality (Schols et al., 1998; Gray-Donald et al., 1996).  Peripheral 
muscle dysfunction leads to increased ventilatory demand and excessive muscle 
fatigue (Gosselink et al., 1996; Hamilton et al., 1995).   
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The cause of muscle dysfunction in COPD patients is not fully understood.  
Possible causes for dysfunction include systemic inflammation, low anabolic 
hormone levels, reactive oxygen species, deconditioning, malnutrition, ageing, 
hypoxia (Wouters et al., 2002; Debigare et al., 2001; ATS & ERS, 1999) and 
steroid myopathy (Rochester, 2003).  Muscle wasting is also the result of an 
increased proteolytic/antiproteolytic ratio.  Proteolytic activity can increase due to 
inactivity and proinflammatory cytokines (Debigare et al., 2001).  The continual 
reduction in the availability of oxygen at cellular level can also contribute to skeletal 
muscle dysfunction (Maltais et al., 1996b).  A study done on healthy individuals 
also found that constant exposure to hypoxaemia is detrimental to the oxidative 
capacity of skeletal muscle cells (Howald et al., 1990).  According to Graham and 
co-workers (1980), respiratory acidosis may also contribute to impaired muscle 
oxidative capacity. 
 
Exercise tolerance can be improved by a structured, lower extremity aerobic and 
strength training programme (Rochester, 2003; Bernard et al., 1999; Celli, 1995).  
Belman (1993) also emphasised the importance of nutritional status on both 
peripheral and respiratory muscles.   
 
  5.3.4 Cardiovascular function 
 
Restriction of exercise performance as a result of cardiovascular limitation is 
frequently observed in COPD patients (O’Donnell et al., 2001; Sietsema, 2001).  
Thickening of the intimae, narrowing of the lumens of arteries and arterioles, 
emphysematous destruction of vascular bed, alveolar hypoxia, increased alveolar 
pressure, increased haematocrit and acidosis result in an increase in pulmonary 
vascular resistance and pulmonary artery pressures (O’Donnell et al., 2001; 
Sietsema, 2001; Gallagher, 1994; Belman, 1993).  Cardiac output may be further 
limited by the decrease in right ventricular preload.  This decrease is related to 
hyperinflation, which impairs the stroke volume of the right ventricle.  The decrease 
in cardiac output will result in a decrease in exercise tolerance (O’Donnell et al., 
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2001; Sietsema, 2001; Gallagher, 1994).  There may also be an increase in the 
heart rate/VO2 ratio, which means that estimation of exercise intensity by means of 
heart rate can be inaccurate (Gallagher, 1994; Belman, 1993).   
   
5.3.5 Deconditioning 
 
Chronic inactivity in COPD patients is an aggravating factor for exercise 
intolerance (Belman, 1993).  The level of obstruction is not the only factor that 
influences the extent of dyspnoea, as varying levels of dyspnoea have been 
observed in patients with similar airway obstruction (O’Donnell & Webb, 1992).  
Impaired pulmonary function can only account for part of the reduced exercise 
capacity experienced by COPD patients.  Carter and co-workers (1993) implicated 
deconditioning as another contributing factor.   
 
Prolonged periods of bed rest and inactivity are common amongst COPD patients.  
This prolonged inactivity and disuse result in deconditioning and consequent 
impaired muscle strength and endurance (Franssen, 2003; ATS & ERS, 1999).   
 
  5.3.6 Steroid-induced myopathy 
 
One of the well-known side effects of continuous use of corticosteroids is steroid-
induced myopathy and muscle atrophy (Dekhuijzen & Decramer, 1992).  Cardiac 
decompensation, malnutrition, electrolyte imbalances and blood gas abnormalities 
all contribute to muscle weakness in COPD patients.  Due to already weakened 
muscles, COPD patients may be more susceptible to steroid-induced myopathy 
(Decramer et al., 1996).  Steroid-induced myopathy may also affect the diaphragm.  
Diaphragm function of the COPD patient may already be limited by the effects of 
hyperinflation, hypoxaemia, hypercapnia, malnutrition and inactivity, increasing the 
susceptibility for steroid-induced myopathy (Dekhuijzen & Decramer, 1992).   
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Decramer and co-workers (1996) confirmed that steroid-induced myopathy 
contributes to peripheral as well as respiratory muscle weakness, which in turn will 
result in aggravation of dyspnoea.  In that study, patients with steroid-induced 
myopathy had a reduced BMI and increased mortality rates.   
  
5.3.7 Psychological factors  
 
Depression, anxiety and fear of exercise are very important factors to consider 
when exercise tolerance is addressed in COPD patients.  Patients’ perception and 
reaction to dyspnoea varies widely and must be taken into account (Nici et al., 
2006; Rochester, 2003; Belman, 1993; Belman et al., 1991).  Poor motivation 
should also be considered an important factor of exercise intolerance (Nici et al., 
2006).   
  
5.3.8 Other 
 
In addition to the factors mentioned above, Rochester (2003) includes optimisation 
of medical therapy, breathing strategies and oxygen therapy as factors that can 
improve exercise tolerance.   
 
 5.4 Mechanisms of improvement  
 
According to Belman (1993), there is to date no conclusive evidence to indicate the 
main mechanism of improved exercise performance in COPD patients.  It has 
however, been proven by numerous studies, that exercise has no influence on 
pulmonary mechanics and gas exchange (McArdle et al., 2001:953; ATS, 1995a; 
Casaburi et al., 1991; Busch & McClements, 1988; Belman, 1986; Belman & 
Wasserman, 1981).  Strijbos and co-workers (1996) suggested that possible 
mechanisms of improvement in exercise capacity include physiological changes, 
improved efficiency, better co-ordination of neuromuscular activity and 
desensitisation to dyspnoea.    
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 5.4.1 Improved aerobic capacity 
 
In healthy individuals, an improvement in endurance capabilities can be ascribed to 
physiological and metabolic adaptations.  These adaptations included an increase 
in mitochondrial density (size and number), an increase in the activity and 
concentration of aerobic enzymes, an increase in capillary density and enhanced 
oxidation of lipids and carbohydrates.  Functional adaptations included a decrease 
in exercise and resting heart rate and enhanced stroke volume and cardiac output 
(Rochester, 2003; McArdle et al., 2001:467-468; Belman, 1993; Casaburi et al., 
1991; Belman & Kendregan, 1981).   
 
In a study done by Belman and Kendregan (1981) 15 patients showed an 
improvement in overall exercise endurance after six weeks of exercise training, but 
no changes in muscle oxidative enzyme activity and cardiac frequency were 
recorded.  Due to the fact that these changes are not observed in COPD patients, 
it is concluded that exercise intensities during the training of these patients are not 
enough to attain a true aerobic response (Belman, 1993).  Bernard and co-workers 
(1999) recorded a reduction in cardiac frequency, VE and blood lactate 
concentration for a specific workload, after a 12-week exercise programme for 
COPD patients that included aerobic and strength training.  O’Donnell and co-
workers (1995) reported that increased aerobic capacity could be attributed to 
reduced ventilatory demand.   
 
5.4.2 Increased motivation 
 
Belman (1993) found that an increase in maximal VE or heart rate could indicate an 
increase in a patient’s motivation.  However, improvements in these variables are 
not consistent.  The importance of motivation amplifies during submaximal steady 
state exercise tests (Belman, 1993).  McGavin and co-workers (1977) regarded 
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patient motivation and the enthusiasm of health care providers a vital aspect of 
improved performance.   
 
5.4.3 Reduction in dyspnoea 
 
The perceived reduction in dyspnoea after regular exercise training can be the 
result of various factors.  The measurement of the intensity of dyspnoea is an 
integral part of pulmonary rehabilitation.  Due to the subjective nature of available 
scales and questionnaires, there is a strong correlation between improvements in 
wellbeing and reduction in dyspnoea (Belman, 1993; Belman et al., 1991; Belman 
and Kendregan, 1981).  According to Scherer and Schmieder (1997), there is 
enough evidence to conclude that a patient’s perception towards dyspnoea will 
influence physical endurance.  According to Fishman (1994), patients’ perceptions 
of the intensity of dyspnoea may change without any physiological changes.  In a 
study by Reardon and co-workers (1994), 30 patients experienced a reduction in 
dyspnoea that could not be explained by an improvement in exercise efficiency 
alone.  They concluded that the improvement in dyspnoea was a result of altered 
perceptions of dyspnoea and increased motivation, which enabled patients to 
improve their exercise endurance more than expected.   
 
Another factor responsible for the reduction of this symptom is desensitisation to 
dyspnoea (Mahler, 1998; Reardon et al., 1994; Belman, 1993; Belman et al., 1991; 
Belman and Kendregan, 1981).  Therefore, a decrease in dyspnoea may be the 
result of repeated exposure to this symptom.  Improved exercise performance 
results in more efficient movement and a decrease in ventilation, which will 
influence the perception of dyspnoea (Scherer & Schmieder, 1997; Carrieri-
Kohlman et al., 1996; O’Donnell et al., 1995; Holden et al., 1990; Cockcroft et al., 
1981; Moser et al., 1980).  A study by Belman and co-workers (1991) found an 
improvement in dyspnoea after just 10 days of exercising.  This improvement in 
dyspnoea was explained by desensitisation towards dyspnoea, because minute 
ventilation and oxygen consumption remained unchanged.   
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 A study by O’Donnell and co-workers (1995) unexpectedly reported an 
improvement in lung function.  They established that an increase in inspiratory 
reserve volume or a decrease in end-inspiratory lung volumes would translate into 
reduced exertional dyspnoea.   
 
Cox and co-workers (1993) ascribe the improvement in dyspnoea to reliable intake 
of medication, development of better coping strategies and a decrease in smoking 
habits.  When patients exercise under supervision of health professionals, they 
may experience more confidence in their abilities, which will improve their 
perception of dyspnoea (Make, 1990; McGavin et al., 1977).   
 
5.4.4 Improved mechanical skill 
 
Early studies identified improved mechanical skill as a means of improving 
performance (McGavin et al., 1977).  Paez and co-workers (1967) attributed this 
improvement to better neuromuscular co-ordination.  Improvement of mechanical 
skill improves the efficiency of oxygen utilisation and ventilatory requirements.  
Although improvement of mechanical skill will have an effect on exercise 
endurance, there is no benefit with regards to pulmonary function and gas 
exchange (Belman, 1993; ATS, 1987).   
 
Improvement of mechanical skill has frequently been associated with treadmill 
exercise.  However, Casaburi and co-workers (1991) have illustrated that 
physiological response plays a greater role in improvement than “learning” the skill 
of efficient treadmill walking.   
 
 5.5 Benefits of pulmonary rehabilitation 
 The benefits of pulmonary rehabilitation include improved health status, a 
decrease in dyspnoea and a reduction in health care costs.  Although pulmonary 
rehabilitation consists of various important components, exercise training was 
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found to be the “cornerstone” of benefits obtained (BTS, 2001; Carrieri-Kohlman et 
al., 1996). 
The benefits of regular exercise training for healthy individuals have been studied 
extensively.  These benefits include an increased maximal oxygen uptake, an 
increase in muscular strength and endurance, improved muscle co-ordination, 
positive changes to body composition and an improved sense of wellbeing (Celli, 
1999:195; O’Donnell et al., 1995; Ries et al., 1995; Goldstein et al., 1994; Casaburi 
et al., 1991).   
 
Significant evidence exists to validate the use of exercise training to have 
physiological and psychological benefits for the COPD patient (ATS, 1995a).  
Patients with mild to moderate COPD respond similarly to exercise as healthy 
individuals.  Patients with severe airflow obstruction will have a limited 
improvement in maximal oxygen uptake (Celli, 1999:195).  Various studies have 
reported on the improvement of exercise endurance after pulmonary rehabilitation 
(Niederman et al., 1991; ZuWallack et al., 1991; Ries et al., 1988; Belman, 1986; 
Cockcroft et al., 1981).  Exercise training in conjunction with medical therapy has 
had great success in improving the quality of life and functional capacity of COPD 
patients.  Exercise training is not aimed at reversing symptoms, but at minimising 
disability and dependence and increasing involvement in physical and social 
activities (ATS, 1999; Berry et al., 1999; ACCP/AACVPR Pulmonary Rehabilitation 
Guidelines Panel, 1997; Wijkstra et al., 1994; Niederman et al., 1991; ZuWallack et 
al., 1991).   
 
Physiological benefits of exercise training for the COPD patient include an 
increased capacity for physical activity and exercise performance; even though 
changes in conventional pulmonary function are seldom documented (Bauldoff et 
al., 2002; McArdle et al., 2001:953; Guell et al., 2000; Troosters et al., 2000; 
Strijbos et al., 1996; ATS, 1995a; Celli, 1995; Reardon et al., 1994; Cox et al., 
1993; Holden et al., 1990; Busch & McClements, 1988).  Belman & Kendregan 
(1982) demonstrated that exercise has no influence on ventilatory muscle function.  
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McGavin and co-workers (1977) reported, after reviewing early studies on 
exercise, that improvement in exercise tolerance is a universal conclusion when 
COPD patients are subjected to exercise.  In addition to improving exercise 
tolerance, pulmonary rehabilitation is beneficial for improving dyspnoea and HRQL 
(Rochester, 2003; Guell et al., 2000; Troosters et al., 2000; ATS, 1999; O’Donnell 
et al., 1995; Ries et al., 1995; Wijkstra et al., 1995; Goldstein et al., 1994; Reardon 
et al., 1994).  In several studies, patients have noted an improvement in quality of 
life variables (sense of wellbeing, self-esteem and self-efficiency), a functional 
improvement in respiratory muscle function, less coughing and a decrease in 
sputum.  A decrease in dyspnoea is an essential benefit of exercise training for 
these patients (Boueri et al., 2001; BTS, 2001; McArdle et al., 2001:953; ATS, 
1999; Foglio et al., 1999; ACCP/AACPR Pulmonary Rehabilitation Guidelines 
Panel, 1997; Benstrup et al., 1997; Scherer & Schmieder, 1997; Lacasse et al., 
1996).  An increase in oxidative enzyme activity and a decrease in lactic acid 
production have also been recorded (Celli, 1999:195; Maltais et al., 1996a; 
Casaburi et al., 1991).  A study by Coppoolse and co-workers (1999) found a 
decrease in leg pain and an increase in maximal inspiratory pressure after 
pulmonary rehabilitation.  Cardiovascular benefits of exercise training in COPD 
patients have been reported by Costes and co-workers (2004).  Increased survival 
rates have been reported by Bowen and co-workers (2000) as a result of improved 
functional status.  Ries and co-workers (1995) recorded a decrease in mortality 
rates after pulmonary rehabilitation.  Holden and co-workers (1990) reported that 
the increased attention by different health care providers during pulmonary 
rehabilitation, could bestow functional benefits on COPD patients.  Make (1990) 
suggested that the increased attention by health care providers improves patients’ 
confidence in their abilities, which reflects as an increase in exercise capacity. 
 
The decrease in the number of hospitalisations and the number of hospital days 
after pulmonary rehabilitation, has been documented by several studies (McArdle 
et al., 2001:953; Griffiths et al., 2000; ATS, 1999; AACVPR, 1998; Fishman, 1998; 
Bendstrup et al., 1997; Celli, 1995; Cox et al., 1993).  This decrease in 
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hospitalisations, combined with the decrease in medical costs, result in 
considerable savings in total healthcare (Decramer et al., 1997; ATS, 1995a).  This 
was confirmed by Cox and co-workers (1993) who reported that the number of 
working days increased after 12 weeks of pulmonary rehabilitation.  In this study, 
the 44 patients in the experimental group’s working days increased from 2.1 ± 0.4 
to 3.4 ± 0.4 days per week, whereas the working days of the control group 
decreased.  According to Griffiths and co-workers (2000), pulmonary rehabilitation 
does not only decrease the number of hospital admissions, but decreases the 
length of hospital stay.  A randomised controlled study by Guell and co-workers 
(2000) found a decrease in the number of exacerbations after a pulmonary 
rehabilitation programme, which contributed significantly to savings in health care 
costs.  Celli (1995) noted that more scientific research is needed to determine 
exactly what the effect of pulmonary rehabilitation is in terms of healthcare savings.   
 
According to Brooks and co-workers (2002), benefits obtained through pulmonary 
rehabilitation are irrespective of the type of programme used.  The same benefits 
can be obtained through inpatient, outpatient and community-based programmes.  
In contrast, Strijbos and co-workers (1996) found that exercise maintenance is 
better with home-based exercise programmes, compared to outpatient 
programmes.  Wijkstra and co-workers (1995) also obtained positive results with 
home-based rehabilitation sessions.  In their study, the quality of life benefits 
obtained through the home-based programme were sustained for 18 months.  This 
was supported by Hernandez and co-workers (2000) who found significant 
improvements in quality of life, exercise tolerance and dyspnoea after a simple, 12-
week, home-based exercise programme. 
 
One of the main concerns regarding the effectiveness of pulmonary rehabilitation is 
the limited duration of benefits achieved (Rochester, 2003; Ries et al., 1995).  
Various studies showed that quality of life benefits obtained through pulmonary 
rehabilitation are retained for months after completion of the programme (Cambach 
et al., 1997; Wijkstra et al., 1995; Cox et al., 1993; Vale et al., 1993).  Ketelaars 
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and co-workers (1997) reported that HRQL benefits decline nine months after 
completion of a programme.  Other studies confirmed the presence of training 
benefits up to two years after completion of a training programme (Verrill et al., 
2005; Ries et al., 2003; Guell et al., 2000; Troosters et al., 2000; Foglio et al., 
1999; Ries et al., 1995).  Toshima and co-workers (1990) recorded improved 
exercise endurance six months after completion of a training programme.  
Cockcroft and co-workers (1981) found that improvements in functional capacity, 
as measured by the 12-minute walk test, were sustained for seven months after 
completion of pulmonary rehabilitation.  In a long-term study by Casanova and co-
workers (2007), they found that the average annual decline of walking distance, 
measured by the 6MWT, is only 12.5m.  According to these authors, the largest 
decline in functional capacity is found among patients with severe COPD 
(Casanova et al., 2007).  Vale and co-workers (1993) found that even though 
improvements in quality of life and exercise endurance significantly reduced after 
11 months, the follow-up measurements were still higher than the baseline values.  
Cox and co-workers (1993) attribute this to the positive effect that pulmonary 
rehabilitation has on patients’ lifestyles.  According to these authors, the patients in 
their study engaged more frequently in leisure activities and made other positive 
lifestyle changes.  It is important to note that even in healthy individuals the 
benefits obtained through an exercise programme decline once exercise is 
discontinued (ACSM, 1998b).   
 
5.6 Cost involved in pulmonary rehabilitation 
 
Despite the established benefits of exercise for COPD patients, the use of exercise 
as a treatment modality for these patients has been challenged by Albert (1997).  
According to Albert (1997), exercise rehabilitation is not cost effective and 
undoubtedly the most expensive component of pulmonary rehabilitation.  In 
contrast, Griffiths and co-workers (2001) illustrated that pulmonary rehabilitation is 
cost effective when considering health care utilisation of patients not engaged in a 
programme.  Senior and Anthonisen (1998) reported that a need exists for the 
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development of an inexpensive alternative to conventional pulmonary 
rehabilitation.   
 
 5.7 Adherence after pulmonary rehabilitation 
 
Due to poor self-management and self-discipline and a lack of adherence to 
treatment protocols, the benefits obtained through a pulmonary rehabilitation 
programme tend to diminish after completion of the programme (Griffiths et al., 
2000; Celli, 1999:196).  Benefits gained from pulmonary rehabilitation tend to last 
for 18 months after completion of a programme, after which improvements decline.  
These declines are evident despite follow-up programmes to promote adherence.  
Patients with lower pre-rehabilitation walking distances seem to experience greater 
declines compared to other patients (Brooks et al., 2002; Ketelaars et al., 1997).   
 
Greater adherence is seen in programmes where patients perform supervised 
exercise routines, compared to behaviourally-orientated programmes where the 
focus is on education.  Other factors that may influence adherence include age, 
socio-economic status, anxiety, duration and difficulty of exercises, type of 
exercises and social support.  Adherence tends to be better with exercises that 
patients can easily incorporate into their daily routine (Norweg et al., 2005; Brooks 
et al., 2002).  Gosselink (2002) added motivation, logistics of living environment 
and disease stability to the above mentioned factors that influence exercise 
adherence.  Disease stability is considered the most important factor in 
determination of exercise adherence.  Frequent exacerbations impede exercise 
continuation and lead to a decline in functional capacity.  A significant obstacle, for 
patients and clinicians alike, is how to maintain exercise performance despite 
frequent exacerbations (Gosselink, 2002).  Foglio and co-workers (2001) raised the 
question whether severity and frequency of exacerbations has an influence on the 
long-term outcomes of pulmonary rehabilitation.  Their research established that 
patients admitted to pulmonary rehabilitation on a yearly basis experienced 
repeated improvements in exercise tolerance and a reduction in exacerbations.  
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Improvements in exercise tolerance had, however, the same duration after 
completion of each programme and repeated pulmonary rehabilitation did not 
result in extension of benefits (Foglio et al., 2001).  
 
Several studies addressed the effectiveness of a maintenance programme after 
completion of a pulmonary rehabilitation programme (Ries et al., 2003; Bauldoff et 
al., 2002; Brooks et al., 2002; Ketelaars et al., 1997; Wijkstra et al., 1995; Vale et 
al., 1993).  The results of the effectiveness of maintenance programmes are 
inconsistent.  In general, these programmes are valuable in promoting exercise 
adherence for the duration of the maintenance programme (usually 12 months), 
where after adherence is equivalent to patients not engaged in such a programme 
(Rochester, 2003).  Ketelaars and co-workers (1997) reported that patient selection 
for maintenance programmes is important.  According to these authors, not all 
patients need to follow a maintenance programme after completion of pulmonary 
rehabilitation.  Patients who have shown little improvement or those with poor 
baseline values will probably not benefit from a maintenance programme 
(Ketelaars et al., 1997).  Bauldoff and co-workers (2002) found that the use of 
distractive stimuli, in the form of music, could result in increased success of 
maintenance programmes. 
 
Ries and co-workers (2003) addressed possible factors responsible for the modest 
effects of maintenance programmes.  They found that it is unlikely that the 
weakness of outcome measures could be responsible.  Another possible 
explanation is that maintenance intervention is not sufficient to produce long-term 
change.  The effectiveness of maintenance programmes depends on how well it 
can equip patients with coping strategies.  They found that due to the unstable 
nature of the health status of COPD patients, it is very difficult to sufficiently adapt 
maintenance programmes to the complex behaviour changes of these patients.  
Therefore, ineffectiveness of maintenance programmes can be a key factor 
responsible for the relative low success rates of these programmes.  Finally, it is 
important to remember that COPD is a progressive disorder and that disease 
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progression may play a major role in a patient’s decline, despite the level of 
adherence after completion of a pulmonary rehabilitation programme (Ries et al., 
2003; Brooks et al., 2002).   
 
Healthy related quality of life (HRQL) 
 
While the improvement of survival time is still an important treatment goal, health 
care providers have shifted their focus from quantity of life to quality of life in the 
treatment process of COPD patients.  The term HRQL is preferred when referring 
to chronic diseases, since quality of life can be influenced by factors other than 
health status (i.e. financial status, social status, employment) (Curtis & Patrick, 
2003; Curtis et al., 1994).  The term “functional status” is often used alongside 
HRQL.  There is, however, a clear distinction between the two.  Functional status 
refers to a person’s ability to perform tasks of daily living, whereas HRQL refers to 
a person’s subjective experience of the impact that disease has on one’s quality of 
life (Ketelaars et al., 1996; Curtis et al., 1994; Lareau et al., 1994).  According to 
Lareau and co-workers (1994), functional status is in some settings regarded 
“synonymous with physiologic measures of airway obstruction”.  COPD generally 
affects older individuals that usually consider the ability to enjoy life (i.e. HRQL) 
more important than task performance (i.e. functional status).  Although HRQL is a 
subjective measure, it is of vital importance to optimise treatment and management 
of COPD patients (Curtis et al., 1994). 
  
It is important to note that improvements in physiological measures, such as FEV1 
and oxygen saturation, do not necessarily translate to improvements in HRQL 
(Ketelaars et al., 1996; Curtis et al., 1994).  The opposite is also true; improvement 
in HRQL does not necessarily reflect an improvement in physiological measures 
(Curtis et al., 1994).  According to Ketelaars and co-workers (1996), HRQL 
consists of four components, namely “symptoms”, “activities”, “impacts” and 
“wellbeing”, as developed in the St. George’s Respiratory Questionnaire (SGRQ).  
According to these authors, improvements in pulmonary function have little effect 
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on the HRQL of the COPD patient.  A good correlation was found between 
exercise performance and HRQL, although it did not account for all the variability in 
HRQL (Ketelaars et al., 1996; Okubadejo et al., 1996). 
 
Many physiological factors influence the quality of life of patients with COPD.  
According to Okubadejo and co-workers (1996), the quality of life of COPD patients 
will be impacted by hypoxaemia.  A good correlation was found between PaO2 and 
quality of life.  Osman and co-workers (1997) found a significant correlation 
between poor quality of life and hospital re-admission.  Shoup and co-workers 
(1997) found that both high and low body weight was associated with poor HRQL.  
Furthermore, this study reported a significant correlation between dyspnoea and 
HRQL as measured by the baseline dyspnoea index (BDI) and the SGRQ, 
respectively.  Mahler and co-workers (1992) also found dyspnoea to be the most 
important predictor of HRQL.  Exacerbations are another important factor that 
influences quality of life.  Seemungal and co-workers (1998) found that an 
increased occurrence of exacerbations resulted in a decrease in HRQL.  Spencer 
and co-workers (2004), who found that exacerbations had a cumulative effect on 
health status, confirmed this.  Another study reported that an increase in quality of 
life is associated with an increase in survival rate (Bowen et al., 2000).   
 
Apart from this obvious impact that COPD has on HRQL, other less obvious 
issues, such as depression, anxiety and sleep deprivation, are sometimes 
overlooked.  The interdependence between these issues and HRQL are apparent 
(Curtis et al., 1994).  According to Okubadejo and co-workers (1996) depression 
and anxiety correlates with HRQL as indicated by the SGRQ.  Furthermore, they 
found anxiety and depression to be better indicators of HRQL than physiological 
measurements.   
 
It is vital to assess the impact of interventions on the quality of life of patients with 
COPD (Boueri et al., 2001).  Various scales and questionnaires have been 
developed to assess the impact of disease on the HRQL of patients (Osman et al., 
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1997; Okubadejo et al., 1996).  According to Okubadejo and co-workers (1996), 
disease-specific questionnaires that are specifically developed for patients with 
airflow obstruction, have a higher sensitivity than general health measures.  The 
most popular questionnaires used for COPD patients include the Chronic 
Respiratory Questionnaire (CRQ) and the SGRQ.  These questionnaires focus on 
a patient’s subjective experience of symptoms, the impact of symptoms on a 
patient’s life and the level of distress and anxiety caused by the disease.  Although 
these questionnaires do not correlate well with physiological measures, they are 
important, because quality of life is central to the management of these patients 
(Osman et al., 1997).   
 
The SGRQ includes three subscales, namely symptoms, impacts and activities.  
According to Osman and co-workers (1997), female COPD patients experience 
greater limitation in activities and greater levels of distress than male patients do.  
These authors also demonstrated that younger patients experienced a greater 
psychological impact due to their illness, compared to older patients.   
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Ethical approval 
 
This study was an extension of a similar study by J.L. Brown (Stellenbosch 
University).  The Ethics Committee of Human Research of the Faculty of Health 
Sciences of Stellenbosch University was informed of the extension and initially no 
further approval was needed as approval for the initial study was obtained, 
reference number 2002/C076.  An adjustment to the protocol necessitated further 
approval.  The adjusted protocol gained consent from the Ethics Committee and 
was added to the original approval as an amendment.   
 
The eight subjects that comprised the study of J.L. Brown were also reported on in 
the current study.  The decision to include those subjects was made on the basis 
that not all the variables included in the current study were reported on in the study 
by J.L. Brown.  The current researcher was also involved in the testing and 
evaluation of those patients and additional evaluations were added to the original 
protocol.    
 
Subject selection 
 
According to the American Thoracic Society (1999), exercise as part of the 
management of COPD patients is indicated for patients, who despite optimal 
medical treatment, experience a restriction in daily activities and exercise 
capability.  Indications for referral is summarised in Table 3.9. 
 
Table 3.9 Common indications for referral for pulmonary rehabilitation (ATS, 
1999). 
 
Respiratory disease resulting in: 
• Anxiety engaging in activities 
• Breathlessness with activities 
• Limitations with social and leisure activities, indoor and/or outdoor chores, basic or 
instrumental activities or daily living 
• Loss of independence 
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 Subjects mainly came from the Helderberg, Tygerberg and Oostenberg municipal 
areas.  The study was advertised in local newspapers, pharmacies and through 
radio interviews.  General practitioners and physicians were informed of the study 
and asked to refer appropriate patients for screening by a physician.  A total of 25 
subjects were identified as suitable for the primary programme (PP) of the study, 
according to the inclusion and exclusion criteria.  Three of these subjects did not 
complete the study.  A further 21 subjects were identified by a physician for the 
extension of the study according to the inclusion and exclusion criteria.  These 
patients were randomly divided into an experimental and control group.  The ten 
subjects in the control group followed the same protocol as in the PP, whereas the 
eleven subjects in the experimental group followed the MP.  Three subjects in the 
control group did not complete the study.  Reasons for non-completion will be 
discussed later in this chapter.  Figure 3.9 illustrates how subjects were divided 
into different groups. 
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Subjects who did not 
complete the study 
n = 3 
Experimental group 
n = 11 
Control group 
n = 10 
Subjects who did not 
complete the study 
n = 3 
n = 21 
Modified programme 
n = 25 
Primary programme 
n = 46
Subjects included in 
the study 
Figure 3.9 Subjects included in the study. 
 
Subjects were encouraged to continue other forms of treatment and medication.  
All subjects had to be correctly medicated before the date of initial testing.  Current 
medication was assessed by a senior physician and optimised where necessary.  
Subjects were encouraged to maintain daily routines and disruptions were to be 
avoided for the duration of the study.  General practitioners and physicians were 
informed if one of their patients enrolled in the study and of any modification to 
their medication.   
 
As with similar studies (Berry et al., 1999, Foglio et al., 1999, Scherer & 
Schmieder, 1997; Couser et al., 1993, Holden et al., 1990) no control group was 
used for the initial part of the study.  The decision not to include a control group 
was made on ethical grounds.  Numerous studies have illustrated the benefits of 
exercise training for COPD patients (Rochester, 2003; Bauldoff et al., 2002; Boueri 
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et al., 2001; BTS, 2001; Griffiths et al., 2000; Guell et al., 2000; Troosters et al., 
2000; Celli, 1999:195; Foglio et al., 1999; AACVPR, 1998; Fishman, 1998; 
ACCP/AACPR Pulmonary Rehabilitation Guidelines Panel, 1997; Benstrup et al., 
1997; Scherer & Schmieder, 1997; Carrieri-Kohlman et al., 1996; Lacasse et al., 
1996; Strijbos et al., 1996; Celli, 1995; O’Donnell et al., 1995; Ries et al., 1995; 
Wijkstra et al., 1995; Goldstein et al., 1994; Reardon et al., 1994; Cox et al., 1993; 
Casaburi et al., 1991; Niederman et al., 1991; ZuWallack et al., 1991; Holden et al., 
1990; Busch & McClements, 1988; Ries et al., 1988; Belman, 1986; Cockcroft et 
al., 1981).  Adding a control group would have denied beneficial treatment to 
patients that are also in desperate need of help.  Therefore, each subject served as 
his or her own control.   
 
In the MP, the group that followed the same programme as the PP represented the 
control group.  No placebo group was included based on the same reasons that no 
control group was included in the PP. 
  
1. Inclusion Criteria 
 
 Subjects are diagnosed with COPD according to the GOLD criteria 
 
According to the GOLD criteria, COPD can be diagnosed if the FEV1 is less than 
80% of the predicted value in combination with a FEV1/FVC ratio of less than 70%, 
which is not reversible by the use of a bronchodilator.  Reversibility is defined as an 
increase in FEV1 exceeding 12% or an absolute increase of 200ml after the 
inhalation of a bronchodilator (Pauwels et al., 2001:1257; Berry et al., 1999).   
 
 Subjects are mobile and can walk unaided  
 
Since one of the primary aims of the study was to assess functional capacity, the 
6MWT represented an essential part of the assessments.  Furthermore, walking 
was the main cardiovascular component of the exercise programmes.  For the 
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study to be successful, it was important that subjects exercised at an intensity that 
was sufficient to elicit a physiological response.  Therefore, the inability to walk 
unaided would have prevented subjects obtaining the full benefits of the exercise 
intervention.    
 
 Subjects must own telephonic communication 
 
It was important to be able to communicate with the subjects throughout the 
intervention programme.  Telephonic communication was especially important in 
the event of absenteeism.  Subjects knew that they were likely to be called if they 
missed a session, so sessions were only missed for essential reasons.  
Furthermore, it was important to be able to reach patients for rescheduling of 
sessions or reporting of any complaints or illness.  Subjects that did not own a 
personal telephone, but had access to a reliable neighbour or family member’s 
telephone were allowed to participate in the study.   
 
 Subjects must be willing to follow a 10-week rehabilitation programme 
 
Subjects in the initial part of the study had to exercise three times a week for 12 
weeks.  Subjects who missed more than six sessions were excluded from the 
study.  In the MP, subjects had to complete 32 exercise sessions in a 10-week 
period.  To encourage adherence to the programme, subjects were allowed to 
schedule sessions around their daily programme.  It was each subject’s 
responsibility to ensure that they have sufficient time to complete the prescribed 
sessions in the allowed time.  Subjects who could not commit to the 10-week 
programme, due to travel or business engagements, were excluded from the study.   
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 Age of 45 years and older 
 
An age specification was included to homogenise subjects.  COPD is generally 
diagnosed in the fifth or sixth decade of life (Weiss et al., 2003; WHO, 1999); 
therefore, subjects were unlikely to be excluded based on their age.       
 
 Consent and support of the subjects’ personal physician 
 
Since a physician was part of the study, consent from the subjects’ personal 
physician was essential for ethical reasons.  It was vital that physicians had a 
positive impression of the study and did not feel that patients were taken away 
from their practices.  Physicians were well informed of the study protocol and 
feedback was given when necessary.  Consent from personal physicians was also 
required to promote adherence.  It was thought that subjects would have more 
confidence in the programme if it was recommended or supported by their personal 
physician.   
 
 Completion and signature of an informed consent document  
 
Subjects were informed about the study protocol and what was expected of them 
by a physician.  Subjects were allowed time to study the patient-information-and-
consent documents thoroughly (Appendix D).  Subjects that agreed to participate 
had to sign the consent form before the initial evaluation.  One of the signed copies 
was given to the subject, while a second signed copy was kept by the researchers 
in the subject’s file.    
 
 126
2. Exclusion Criteria 
 
 Serious illnesses or co-morbidities  
 
Subjects with serious illnesses or co-morbidities, such as cancer, chronic arthritis, 
uncontrolled hypertension, congestive cardiac failure or uncontrolled angina, were 
excluded from the study to ensure that the results reflect the impact of the 
intervention programme on COPD status.  Furthermore, certain co-morbidities 
could prevent subjects from completing the exercise programme, i.e. painful 
arthritic joints may prevent weight bearing exercises.   
 
 Serious psychological disorders  
 
Patients with serious psychological disorders that would have interfered with the 
rehabilitation process, for example an inability to learn, severe depression or 
disruptive behaviour, were excluded from the study.  Although the exercise 
programme was easy to understand and subjects exercised under constant 
personal supervision, a certain level of motivation and intellectual capacity were 
required from the subject.  Although depression is common among COPD patients 
(Rochester, 2003; Curtis et al., 1994; Belman, 1993; Belman et al., 1991), severe, 
untreated depression could have affected a subject’s ability to participate and/or 
complete the study.  Serious psychological disorders may have impaired a 
subject’s ability to understand the study protocol completely.  Psychologically 
unstable or disruptive subjects may have hindered other subjects from completing 
exercise sessions or would not have been able to complete sessions in the allowed 
time. 
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 Known or suspected cases of ischemic heart disease and right or left 
heart failure 
 
Serious cardiac conditions can place a patient at unnecessary risk during exercise 
training (ATS, 1999).  Although exercise training can be beneficial for these 
conditions, a cardiac rehabilitation programme would be better suited for these 
patients to minimise their risk for complications.   
 
 One year or less post – Tuberculosis 
 
Current tuberculosis would have obscured the results of the study, since changes 
in health status could possibly be attributed to TB medication and not the exercise 
intervention.  To ensure homogeneity among subjects, these patients were 
excluded.   
 
 Smokers of less than 8 pack years 
 
Smoking history is important, although not essential, in COPD diagnosis.  COPD 
patients without a smoking history were excluded to ensure homogeneity among 
subjects. 
 
 Any known alcohol or drug addictions 
 
Alcohol and drug addictions would have interfered with the exercise programme.  
Addictions could have prevented subjects from attending all exercise sessions or 
from exercising optimally.  Furthermore, subjects had to be as healthy as possible 
prior to the initial evaluation to ensure that evaluations were not obscured by other 
conditions.   
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 Subjects who are in respiratory failure or desaturated to below 80% 
during the pulmonary evaluation 
 
Oxygen saturation levels were continuously monitored during the initial 6MWT.  In 
the initial part of the study, subjects who desaturated below 85% were given 
supplemental oxygen while completing the test.  Supplemental oxygen was given 
to these subjects during the exercise intervention.  In the MP, subjects who 
desaturated below 80% were excluded from the study.  This was because it was 
thought that supplemental oxygen would not be readily available to the broader 
community of South Africa and would therefore not be realistic for the modified 
programme.  It would also not be feasible to supply oxygen to participants who 
underwent their exercise training outside of the confines of the formal rehabilitation 
area.   
 
Research timeline  
 
The data collection for the PP started in September 2002 and the last patient was 
admitted to the study during July 2004.  Patients were evaluated and underwent a 
12-week intervention programme.  The post-intervention assessment was repeated 
after six months. 
 
The data collection for the MP started May 2005 and the last subject was admitted 
to the study during October 2006.  The pre- and post-intervention assessments 
were separated by eight to ten weeks of exercise training.  No follow-up 
assessment was included in this part of the study.   
 
Pre-intervention assessment procedure 
 
In the MP, a pre-evaluation was included to ensure that only candidates suitable 
for the study underwent the pre-intervention assessment.  Suitable subjects 
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identified at the local Stellenbosch regional hospital were invited to attend the first 
meeting at the senior physician’s practice.   
 
 All subsequent screening and testing took place at an independent practice of a 
senior physician.  Contact numbers of this practice was supplied in all 
advertisements and interested individuals contacted the practice directly.  Other 
possible subjects were referred to the practice by their personal physicians.  
Interested individuals were screened on appointment at the practice and were 
given more information on the study and what was to be expected.    
 
On arrival, the study protocol and what was required of the subjects, were 
explained to interested individuals by a physician.  Before commencing the 
screening process, possible subjects were issued with patient-information-and-
consent documents (Appendix D).  Time was allowed for individuals to study these 
documents and any questions or uncertainties were addressed.  Subjects that 
agreed to participate had to sign the consent form before the screening began.  
Copies of these signed documents were kept on file and one signed copy was 
handed to each of the subjects.   
 
All subjects that signed the consent forms were then clinically screened.  
Screening included documentation of the subject’s history, a medical screening 
and an examination.  After the initial screening, the BDI and physician’s global 
evaluation were completed.   
 
All subjects received four inhalations of Combivent (480μg salbutamol and 80μg 
Atrovent) prior to spirometry.  A clinical technologist advised the subject on the 
correct use of an inhaler and made sure that the bronchodilator was administered 
correctly.  A minimum of ten minutes were allowed for the bronchodilator to take 
effect before testing lung function.  Next, the subject’s height and weight were 
measured and recorded by a clinical technologist using a standard Paramedic 2m 
stadiometer and a Soehnle Certified-150kg scale (serial number: 6176).  Lung 
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function testing procedures (including the Borg-RPE-scale) were thoroughly 
explained to the subject by a clinical technologist.  Three correct lung function tests 
were performed and the best effort was recorded.  A Jaeger Master Lab system 
(serial number: 700707-02A250046) was used to measure lung function.  The 
system was calibrated prior to the tests using a three litre syringe.  After lung 
function testing, a resting ECG was recorded, using a Cardio Perfect MD ECG 
machine (serial number: 015219).  Subjects with normal resting ECG were 
required to perform the 6MWT.  The procedure of the 6MWT was thoroughly 
explained to the subject by a clinical technologist and any questions were 
addressed.  Since the 6MWT was performed on a StarTrac treadmill (model: ST 
2005-EZ; serial number: 206759), subjects were allowed time to familiarise 
themselves with the machine.  When the subject was comfortable walking on the 
treadmill, the subject was rested till cardiovascular parameters (heart rate, blood 
pressure and breathing rate) returned to normal.  The subject was guided through 
the test by the clinical technologist, who encouraged the subject throughout 
according to the ATS standards.  The walking distance and time was measured by 
the treadmill.  Oxygen saturation levels were monitored throughout the test with a 
BCI Oxi Pulse oximeter (catalogue number: 3301; serial number: 320014739).  In 
the PP, subjects who desaturated below 85% during the first 6MWT were given 
supplemental oxygen.  Subjects in the MP who desaturated below 80% were 
excluded from the study.  Blood pressure and heart rate were measured and 
recorded after the test.  Blood pressure was measured using a standard Surgifix 
mercury sphygmomanometer.  Two tests were initially performed.  If the distances 
in each test differed by more than 10%, a third test was performed.  The best 
distance was recorded.  Subjects were rested between tests till cardiovascular 
parameters returned to normal and they felt that their legs were well rested.  After 
the test, a clinical technologist again explained the Borg-RPE-scale to the subject 
and recorded their Borg rating on the Modified Borg-RPE-scale after each test.  
After the subject was well rested, the investigator explained the SGRQ to the 
subject.  The subject completed the SGRQ without help from the investigator.   
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Subjects who did not meet the inclusion and exclusion criteria during the initial 
evaluation process, were treated or referred to conform to the criteria, for possible 
inclusion at a later stage.  Subjects that were current smokers were allowed into 
the PP, but were advised on how to quit.  Since the benefits obtained in the PP 
were significantly less for current smokers, smokers were excluded from the MP 
until they successfully quit smoking.   
 
After the evaluation, an appointment was made to begin the exercise programme 
at the Stellenbosch Biokinetics Centre (Department of Sport Science, Stellenbosch 
University, South Africa).   
 
Intervention programme 
 
1. Primary programme 
 
The invention programme was staged over 12-weeks and subjects had to attend 
three, hour long exercise sessions per week.  Subjects were not allowed to miss 
more than six sessions during the entire programme.  The exercise programme 
was conducted at a fully equipped exercise- and rehabilitation centre.  Subjects 
exercised under constant, one-to-one supervision of a Biokineticist or student-
Biokineticist.   
 
The exercise programme (Appendix B) included an aerobic component as well as 
upper and lower body strength training exercises.  Programmes were 
individualised by adjusting the intensity and repetitions according to each subject’s 
ability, but no changes to the type of exercises were allowed.  The same 
programme was followed at every session and subjects had to complete all 
exercises at every session.   
 
Subjects were advised to use their bronchodilator ten minutes prior to arrival for 
each exercise session.  On arrival, subjects were fitted with Polar® heart rate 
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monitors and allowed to sit and rest for five to ten minutes before blood pressure 
was measured.  Blood pressure and heart rate readings were recorded prior to and 
after each exercise session.  If an abnormal blood pressure reading was obtained, 
the subject was instructed to sit and relax for a further five minutes until a normal 
reading could be obtained.  If the blood pressure did not reach a safe level for 
exercise, the subject was advised to reschedule his/her appointment.  In the event 
of repeated abnormal blood pressure readings, the subjects were referred to their 
physician or doctor for exercise clearance.  
 
The aerobic component of the exercise session consisted of 20 minutes of 
treadmill walking (ten minutes in the beginning of the session and ten minutes at 
the end).  Treadmill walking was used because it reflects the metabolic and 
ventilatory requirements of daily activities (Palange et al., 2000).  The intensity of 
the aerobic exercise was determined by using a percentage of the maximum heart 
rate, according to the Karvonen formula (Appendix E), in combination with the 
Borg-RPE-scale.  The target intensity for subjects was 60 to 75% as described in 
previous literature (ATS, 1999; Coppoolse et al., 1999; Maltais et al., 1997; 
Folgering & van Herwaarden, 1994).  A Borg rating of five (severe), was prescribed 
on the modified Borg scale (Appendix A).  Horowitz and co-workers (1996) 
demonstrated the use of subjective rating scales to be effective in prescribing 
exercise intensity for COPD patients.  Subjects had to exercise, for ten minutes, at 
which ever intensity they reached first.  Some subjects reached their target heart 
rate before they considered the exercise as “severe”, while others could not reach 
their target heart rate, but exercised at a “severe” intensity on the Borg scale.  
Some subjects could not continuously walk for ten minutes.  Subjects were allowed 
to rest and continue with the remainder of the prescribed minutes, if possible.  For 
these subjects, the duration of their treadmill walks were gradually increased until 
they were able to walk continuously for ten minutes.  As the subjects’ exercise 
capacity increased, the treadmill speed was adjusted to ensure that the prescribed 
intensity was achieved at each session.   
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After each treadmill walk, stretching of the large muscle groups of the legs was 
done.  Subjects were assisted in these stretches to ensure maximal mobility and 
range of motion was retained throughout the intervention programme.   
 
Stretches were followed by a combination of upper and lower body resistance 
training.  Resistance exercises focused on the main muscle groups of the body and 
used a combination of free weights, gym equipment and own body weight as 
resistance.  The aim was to complete three sets of ten repetitions for each of the 
prescribed exercises.  Initially, some subjects were not able to complete all the 
sets, but gradually improved to the prescribed programme.  As described by 
Horowitz and co-workers (1996) RPE-ratings were used to determine the 
heaviness of the weights.  Resistance was prescribed as five (severe) on the 
modified Borg-RPE-scale.  Resistance was continuously adjusted to reach the 
prescribed intensity.  Heart rate and RPE-ratings were documented after each 
exercise for future reference.   
 
2. Modified programme 
 
In the MP subjects had to complete 32, hour long exercise sessions over an eight 
to ten week period.  Subjects were allowed to schedule sessions three or four 
times a week, depending on their daily programmes.  The investigator assisted 
subjects in the scheduling of sessions and ensured that the subjects completed the 
prescribed sessions in the allowed time.  The control group exercised in a fully 
equipped exercise- and rehabilitation centre and followed the same exercise 
protocol as in the PP.  The experimental group’s exercise programme was adapted 
to be more cost-effective and accessible to individuals of all socio-economic 
backgrounds.  The programme was designed in such a way that no specialised 
equipment was needed and that it could be easily implemented anywhere in South 
Africa.   
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Similar to the PP, the MP (Appendix B) included an aerobic component as well as 
upper and lower body strength training exercises.  Subjects were also advised to 
use their bronchodilator ten minutes prior to arrival for each exercise session.   
 
Although heart rate monitors are not affordable for the majority of South Africans, 
both the experimental and control groups wore Polar® heart rate monitors 
throughout the exercise sessions.  Heart rate monitors were used for research and 
safety purposes, but are not essential to achieve successful results in an adapted 
programme.  The same blood pressure and heart rate protocol was used as in the 
PP.   
 
The protocol for the MP consisted of the same components as in the PP and the 
same supervising and monitoring principles applied.  Similar to the PP, the 
intensity of each session was determined using heart rate and the Borg-RPE-scale.   
 
For the experimental group, treadmill walking was replaced by walking on a flat 
surface.  When the weather permitted it, walking was done outside, otherwise 
subjects walked inside a hall.  Because the pre- and post-walk test assessments 
were done on a treadmill, a treadmill walk was brought into the experimental 
group’s exercise programme every two weeks.  This was done to ensure that the 
control group did not have any advantage regarding familiarity to a treadmill.  
Stretching of large muscle groups was done in the same way as in the PP.  
Resistance exercises mainly used body weight, sandbags and free weights.  
Similar to the PP, heart and RPE-ratings were documented after each exercise for 
future reference.   
 
Safety measures 
 
The following criteria for termination of the exercise test were used as a guideline 
to ensure that subjects were not placed under unnecessary risk during the 6MWT 
(ACSM, 2000:104).  
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 Absolute indications: 
1. Onset of moderate-to-severe angina (chest pain)  
2. Drop in systolic blood pressure below standing resting pressure or drop in 
systolic blood pressure with increasing workload accompanied by signs of 
ischemia 
3. Signs of poor perfusion (circulation or blood flow), including pallor (pale 
appearance of the skin), cyanosis (bluish discoloration), or cold and clammy 
skin  
4. Severe or unusual shortness of breath  
5. Central nervous system symptoms e.g., ataxia (failure of muscular 
coordination), vertigo (an illusion of dizzying movement), visual or gait 
(pattern of walking or running) problems, confusion  
6. Patient's request (to stop)  
 
Relative indications: 
1. Drop in systolic blood pressure below standing resting pressure or drop in 
systolic blood pressure with increasing workload without signs of ischemia 
2. An increase in chest pain 
3. Physical or verbal manifestations of shortness of breath or severe fatigue  
4. Wheezing  
5. Leg cramps or intermittent claudication (grade 3 on a 4-point scale)  
6. Hypertensive response (systolic blood pressure >260 mm Hg; diastolic 
blood pressure >115 mm Hg)  
7. Less serious arrhythmias (abnormal heart rhythms) such as supraventricular 
tachycardia 
 
All personnel involved in the exercise training of the subjects were trained in 
cardio-pulmonary resuscitation (CPR) and first aid.  Emergency contact numbers 
were kept beside the telephone.  A physician or general practitioner, from the 
Stellenbosch University Student Health Services, was always on standby during 
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the exercise sessions.  If any abnormalities in heart rate or blood pressure were 
detected during exercise, the physician or general practitioner was contacted.  
Since heart rate and RPE-ratings were documented after each exercise, during 
every session, severe changes could easily be detected. 
 
Contraindications to exercise, according to the ACSM (2000:167), were used to 
further ensure the subjects safety. 
1. Unstable angina 
2. Resting systolic blood pressure of more than 200mmHg or resting 
diastolic blood pressure of more than 100mmHg had to be evaluated on 
a case-by-case basis 
3. Orthostatic blood pressure drop of more that 20mmHg with symptoms 
4. Acute systemic illness or fever 
5. Uncontrolled systemic atrial or ventricular arrhythmias 
6. Uncontrolled tachycardia (more than 120 beats per minute) 
7. Uncontrolled diabetes 
8. Severe, acute orthopaedic conditions that would prohibit exercise 
 
Facilities and equipment 
 
Pre- and post rehabilitation assessments of subjects took place at a physician’s 
practice in Stellenbosch using available facilities and testing equipment.  Exercise 
sessions took place at the Stellenbosch Biokinetics Centre (Stellenbosch 
University), using their facilities and equipment.  Equipment needed for the 
conventional programme included a sphygmomanometer, Polar® heart rate 
monitors, free weights, multigym equipment, stepping benches and treadmills.  
Equipment used in the adapted programme included a sphygmomanometer, 
Polar® heart rate monitors, free weights, chairs and sandbags. 
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Measurements 
 
1. Six minute walk test for distance (6MWT) 
 
 1.1 Aim 
 
A treadmill 6MWT was used to assess the exercise capacity of the subjects in this 
study.  The 6MWT is considered a safe, effective, simple and inexpensive 
measurement of exercise capacity to assess the functional status of patients living 
with COPD.  It is also used to assess the effectiveness of different treatment 
modalities (Johnson, 2004; Marin et al., 2001; Stevens et al., 1999; Redelmeier et 
al., 1997).  According to Casanova and co-workers (2005), the 6MWT correlates 
well with dyspnoea, airflow obstruction and hyperinflation. 
 
1.2 Description 
 
The 6MWT can be performed on a treadmill or in a corridor.  In the current study, a 
treadmill was used due to limited space at the evaluation centres.  The use of a 
treadmill also facilitates the monitoring of subjects and the administration of oxygen 
during the test.  During the 6MWT, patients are instructed to walk as far as 
possible in the allowed six minutes.  Patients are allowed to stop and rest during 
the test, but rest periods form part of the six minute period (Redelmeier et al., 
1997).  Most protocols (ATS, 2002) do not allow for the use of a treadmill, due to 
underestimation of exercise ability.  Stevens and co-workers (1999) found that 
when using a treadmill, walking distance was shorter by a mean of 14%, compared 
to corridor distances.  However, Johnson (2004) argued that the use of a treadmill 
is more versatile and gives a better indication of functional improvements.  
According to the American Thoracic Society (2002), treadmill tests are not 
interchangeable with corridor tests.   
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The 6MWT was performed after spirometric measures were completed.  The 
clinical technologists that administered the tests were experienced in performing 
treadmill 6MWTs.  The procedure of the 6MWT was thoroughly explained to the 
subject by a clinical technologist and any questions were addressed.  If subjects 
were unfamiliar with a treadmill, time was given to adjust to walking on a treadmill.  
Subjects were seated before testing began.  This time was used to document 
resting heart rate, blood pressure and oxygen saturation.  The technologist 
adjusted the treadmill speed on the request of the subject (faster or slower).  
Verbal encouragement was given throughout the test.  After completion of the test, 
blood pressure, heart rate and oxygen saturation were documented while subjects 
were still standing.  Subjects were seated on a chair to rest, while their Borg rating 
[on the modified Borg scale (Appendix A)] was obtained.   
 
A pulse oximeter was used to record oxygen saturation throughout the test.  If 
patients (PP only) desaturated below 85%, supplemental oxygen was supplied 
during subsequent testing and exercise training.  During the MP, patients that 
desaturated below 85% during the 6MWT were excluded from the study. 
 
A minimum of two tests were performed per evaluation, with sufficient rest in 
between.  If results of the two tests were not within 10% of each other, the test was 
repeated until results were within 10%.  The longest distance of the completed 
tests was recorded.  A threshold of 54m is considered as a significant improvement 
in functional status (Enright et al., 2003; ATS, 1999; Redelmeier et al., 1997; 
Guyatt et al., 1984). 
 
1.3 Reliability and validity 
 
The 6MWT is considered reliable and valid for the assessment of functional 
capacity in COPD patients (Carter et al., 2003; Mak et al., 1993; Knox et al., 1988).  
The 6MWT can be used in all patients, regardless of age, gender or level of literacy 
(Guyatt et al., 1984).   
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  1.4 Limitations 
 
Carter and co-workers (2003) investigated the effect of body height and weight on 
the 6MWT.  They concluded that body height might affect stride length, which in 
turn can influence the distance covered and the ambulatory efficiency.  
Furthermore, a direct correlation exists between body weight and energy 
expenditure.  The heavier a person’s body weight, the higher energy expenditure 
will be, which will have an influence on the distance covered in the walk test.  A 
further limitation is that it does not allow for the assessment of maximal exercise 
capacity, which may be important in certain patients (Gallagher, 1994).  Other 
limitations include that the 6MWT measures global function and gives no 
information on the cause of limitation.  Furthermore, patients with mild disease will 
not be able to demonstrate their full exercise capability while walking on a flat 
surface.  Improvement is the result of increased walking speed, which might limit 
some patients, since many patients have difficulty walking faster due to mechanical 
limitations (Johnson, 2004).  The repeatability of the 6MWT when conducted by 
different supervisors is an issue which could influence the distance achieved.  This 
issue was addressed in the MP by including an independent 6MWT at the post-
intervention assessment (See “Post-intervention assessment”). 
 
2. Modified Borg RPE scale 
 
 2.1 Aim 
 
The modified Borg RPE scale was used in this study to rate the effort of the 6MWT 
and to prescribe exercise intensity during the intervention programme.  According 
to Belman and colleagues (1991), the Borg RPE scale is an effective and 
reproducible method to evaluate dyspnoea and determine exercise intensity for 
COPD patients, provided patients exercise at a high intensity or close to VO2max.   
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 2.2 Description 
 
The Modified Borg scale (Appendix A) was used throughout this study to document 
subjects’ perceived exertion.  Subjects were shown the scale and asked to rate 
exertion on a scale from zero to ten.  To limit being influenced by the tester, the 
instructions described in Appendix A were given to the subject.  Subjects had to 
identify a single number; a range (i.e. a five to a six) was not acceptable.   
 
 2.3 Validity and reliability 
 
Glass and co-workers (1992) demonstrated the validity and clinical application of 
the Borg-RPE-scale in prescribing exercise intensity.  There is a high correlation 
between exertion ratings, heart rate and workload (ACSM, 2000:78). 
 
3. St. George’s Respiratory Questionnaire (SGRQ) 
 
 3.1 Aim 
 
The SGRQ was used in this study to assess health related quality of life of the 
subjects.  The aim of the SGRQ is to provide a standardised measurement of the 
limitations that respiratory disease place on a patient’s daily life.  This 
questionnaire was proven sensitive in patients with airflow obstruction (Okubadejo 
et al., 1996). 
 
3.2 Description 
 
The SGRQ (Appendix F) is a self-administrated questionnaire that contains 50 
items, with 76 weighted responses, that measures frequency of symptoms, 
activities that cause or are limited by dyspnoea and impact on daily life 
(employment, panic, disturbance and medication) (Wedzicha et al., 1998; Curtis et 
al., 1994).  This questionnaire produces three component scores, which range from 
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0 to 100 and a total score.  Scores are converted to a percentage where 100 
indicates maximum disability.  A difference of 4% is considered significant for any 
of the components or the total score (Jones, 2002; Wedzicha et al., 1998; Osman 
et al., 1997; Okubadejo et al., 1996; Jones et al., 1991).  According to Okubadejo 
and co-workers (1996), the SGRQ can distinguish between mild, moderate and 
severe COPD.  
 
The SGRQ was explained to the subject by the investigator and questions were 
addressed.  The subject was left alone in a quiet room to complete the 
questionnaire.  Any further questions were addressed after completion of the 
questionnaire to limit the influence of the investigator on the subject’s responses.  
The questionnaires were available in English and Afrikaans.    
 
After completion, the scores were calculated using the method described in 
Appendix F.   
 
3.3 Validity and reliability 
 
The SGRQ is reproducible, valid and responsive and correlates well with a range 
of established measures of disease activity (Jones et al., 1992).  The SGRQ is a 
standardised questionnaire, which allows for comparison between different studies 
and interventions (Curtis & Patrick, 2003; Finnerty et al., 2006).     
 
 3.4 Limitations 
 
Although this questionnaire is comprehensive, it cannot address all possible 
disturbances (Okubadejo et al., 1996). 
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4. Baseline Dyspnoea Index (BDI) and Transitional Dyspnoea Index (TDI) 
 
4.1 Aim 
 
In this study, the BDI and TDI (Appendix G) were used to assess breathlessness 
and the impact it has on quality of life.  The BDI and TDI are dyspnoea 
measurement instruments designed by Mahler and co-workers (1984).  The aim of 
the BDI and TDI is to measure the degree of dyspnoea and the impact it has on an 
individual’s life (Curtis et al., 1994).   
 
4.2 Description 
 
The BDI is the initial assessment, whereas the TDI is related to the BDI, but 
assesses changes after an intervention programme.  These indexes include three 
scales of measurement, namely functional impairment (the degree to which 
activities of daily living are impaired), magnitude of task needed to evoke dyspnoea 
(the intensity of activity) and magnitude of effort needed to evoke dyspnoea (the 
overall effort exerted to perform activities) (Mahler et al., 1984).  According to a 
patient’s history, an interviewer rates the patients in each category.  Ratings of 
each category are combined to obtain a central BDI or TDI score.  The total score 
of the BDI is 12.  Four points per scale of measurement can be obtained, where 
zero is considered a very severe impairment and four is considered no impairment.  
Therefore, the higher the score, the less the impact of dyspnoea is.  The TDI is 
measured after the intervention programme and can receive three positive or 
negative points per scale of measurement.  Plus three is considered a major 
improvement, while minus three is considered a major deterioration.  Therefore, 
the TDI score can range from minus nine to plus nine.  A change of one unit from 
the BDI to the TDI score is considered a clinically significant change (Witek & 
Mahler, 2003).  The BDI and TDI were measured by a senior physician during the 
pre- and post-intervention assessments.   
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4.3 Validity and reliability 
 
The BDI and TDI are valid and reliable for the assessment of dyspnoea amongst 
COPD patients; it correlates well with pulmonary function measures and is 
sensitive to treatment effects (Mahler et al., 1992; Mahler et al., 1987; Mahler et al., 
1989; Mahler et al., 1984). 
 
5. Flow-volume spirometry 
 
5.1 Aim 
 
Flow-volume spirometry was used in this study to measure FVC, FEV1, FEV1 
predicted and FIV1.  A Jaeger Master Lab system was used to perform spirometry.   
 
5.2 Description 
 
The variables mentioned above were tested using a maximal test according to the 
ATS/ERS standards (Miller et al., 2005).  Maximum effort by the subject was 
essential for a valid test.  A clinical technologist explained and demonstrated the 
testing procedure to the subject and any questions were addressed.  The subject 
was seated in front of the system and a nose clip was used to prevent air from 
escaping through the nose.  The test started with a period of quiet breathing (tidal 
volume), followed by a rapid breath in (forced inspiration), after which the subject 
had to exhale as hard as possible for as long as possible.  The test was ended with 
a rapid inhalation.  The subjects were continuously and loudly encouraged 
throughout the manoeuvre.   
 
The test was repeated three times and the best result was recorded.  If the results 
of the three tests differed by more than 5% or 100 to 150ml, the test was repeated 
until the results were satisfactory.  The results of the test were compared to the 
predicted values that are calculated based on age, gender and height. 
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 5.3 Validity and reliability 
 
Flow-volume spirometry is considered essential in the diagnosis and assessment 
of disease severity in COPD patients (Dueck, 2000; ATS, 1999; ATS, 1995a).  It is 
essential that the test be performed by adequately trained persons using a 
regularly calibrated spirometer of approved standard and quality (Van Schalkwyk et 
al., 2004). 
 
5.4 Limitations 
 
Flow-volume spirometry is highly dependent on the subject’s cooperation and 
effort.  Since results are dependent on patient cooperation, results can only be 
underestimated, never overestimated (Lalloo et al., 1991). 
 
6. Body mass index (BMI) 
 
6.1 Aim 
 
In this study, BMI was used to assess the subjects’ weight and any weight 
changes.  BMI is an expression of weight relative to height.  Since there is a strong 
correlation between weight loss, mortality and exercise tolerance in COPD 
patients, the evaluation of weight changes are essential (Farber & Mannix, 2000; 
Gray-Donald et al., 1996; Engelen et al., 1994).   
 
6.2 Description 
 
BMI is calculated by dividing body mass (kilograms) by height (metres) squared.    
 
BMI (kg/m2) = body mass (kg) / height (m)2   
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Standing height was measured in metres, to the nearest millimetre with the use of 
a stadiometer.  Height was taken without shoes.  Subjects were instructed to stand 
erect with their arms hanging to their sides.  The subjects’ head was adjusted into 
the Frankfort Plane.  (Frankfort Plane is achieved by aligning the lower edge of the 
eye socket in the same horizontal plane as the notch superior to the tragus of the 
ear.)  Subjects were instructed to look straight ahead while taking a deep breath.  
At the end of inhalation, the clinical technologist measured the highest point on the 
skull. 
 
Body weight was measured with a Soehnle Certified-150kg scale to the nearest 
0.5kg.  Body weight was measured without shoes, while subjects were wearing 
light clothing. 
 
6.3 Validity and reliability 
 
BMI assessment is commonly used by researchers and clinicians (McArdle et al., 
2001:755).  BMI is considered a reliable measure providing that the same scale is 
used for every measurement (ACSM, 2000:63).    
 
6.4 Limitations 
 
BMI gives no indication of body composition and has a large standard error of 
estimating percentage body fat (± 5%).  The standard error of BMI increases in 
individuals that are grossly over- or underweight (McArdle et al., 2001:758; ACSM, 
2000:63).  
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7. Physician’s global evaluation 
 
7.1 Aim 
 
This study used the physician’s global evaluation to assess the overall condition of 
the subjects.   
 
7.2 Description 
 
The same physician evaluated the subjects at the pre- and post-intervention 
assessments and recorded a physician’s global score for each subject (Appendix 
H).  This score ranged from one to eight, with one falling into the poor category and 
eight falling into the excellent category.  This score was based on the physician’s 
evaluation of the subject’s concomitant therapy, number and severity of 
exacerbations, severity of cough, ability to exercise and amount of wheezing since 
the last visit.   
 
7.3 Validity and reliability 
 
The physician’s global evaluation is frequently used in chronic disease research 
and by physicians and pulmonologists.  Numerous published studies and drug 
trials have used this evaluation with success (Donohue, 2005).  A study by Falcone 
and co-workers (2005) reported a good inter-observer agreement in the physician's 
global assessment of patients with juvenile idiopathic arthritis.   
 
 Limitations 
 
Although this evaluation provides important information regarding disease severity 
and prognosis, further investigation is needed into the elements that influence 
severity and the predictive validity (Kroenke et al., 2006).   
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8. Exacerbations 
 
Although the measurement of the number of acute exacerbations was not included 
in the study protocol, a secondary analysis was conducted on the number of acute 
exacerbations.  For this purpose, an exacerbation was defined as an increase in 
pulmonary symptoms that was severe enough to prevent a subject from attending 
an exercise session.  Furthermore, exacerbations reported by subjects in the 
SGRQ were also analysed, by evaluating the subjects’ response to Question 5 in 
Part 1: “Over the last 3 months, how many severe or very severe unpleasant 
attacks of chest trouble have you had?” 
 
Post-intervention assessment 
 
The same protocols and procedures were followed at the post-intervention 
assessments.  In the MP, an additional 6MWT assessment was included to confirm 
repeatability of this test when conducted by independent supervisors.  After 
completion of the intervention programme, a 6MWT was performed at the 
Stellenbosch Biokinetics Centre (SBC), using the same protocol as in the pre-
intervention assessment at the physician’s practice.  The clinical technologist, who 
administered the 6MWT at the post-intervention assessment, was not informed of 
the results obtained at the SBC 6MWT.  After completion of the post-intervention 
assessment, subjects received feedback on their results.  Subjects were educated 
on exercise adherence.  Some subjects chose to continue exercising at the current 
facility at their own expense, while others joined gymnasiums or exercised at 
home.  For subjects included in the PP an appointment was made for a six month 
follow-up assessment.  After six months, the subjects in the PP were evaluated 
again, using the same protocol and procedures as in the post-intervention 
assessment.   
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Absenteeism and complications 
 
As with previous studies (Troosters et al., 2000; Cambach et al., 1997; Goldstein et 
al., 1994; Busch & McClements, 1988), a number of patients who met the inclusion 
criteria did not finish the programme.  Three female subjects dropped out of the PP 
and three male subjects dropped out of the MP (all three were in the control 
group).   
 
Two of the female subjects developed depression and lacked motivation.  Despite 
various attempts to keep them motivated, they eventually ceased to attend the 
exercise sessions.  The third female subject suffered from several prolonged 
exacerbations that forced her to withdraw from the study.  Attempts were made to 
keep her in the study, but due to the exacerbations, she was restricted to four 
weeks of bed rest.  This would have negatively influenced the results of the 
intervention programme.  Although she was excluded from the study, the 
researchers allowed her to continue to exercise at the facility when possible.   
 
One of the male subjects that did not finish the study was a farm worker at a wine 
farm.  Due to harvesting, he was not able to attend sessions for three months.  The 
second male subject developed TB and had to be excluded from the study.  The 
third male subject was initially motivated to exercise, but did not receive any 
support from his family.  His spouse was convinced that the exercise would not be 
beneficial to him and he eventually withdrew from the study.   
 
Other subjects missed sessions, but continued to be motivated and completed the 
programme without missing more than six sessions or within the allowed time.  
Reasons for absenteeism included business and travel engagements, holiday 
arrangements, acute exacerbations and hypertension.   
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Data analysis 
 
The Centre of Statistical Consultation (Stellenbosch University) assisted in 
analysing the data.  The Statistica 7.1 software was used.  Repeated measures 
ANOVA and correlations were used to analyse the data.  The significance was set 
at 5%.   
 
The repeated measures ANOVA was used to test if the mean measurements of the 
different groups and/or different evaluations were equal to each other.  In cases 
where this hypothesis was rejected, the Bonferroni correction was used to 
distinguish which means differed from each other.   
 
For the correlations, the p-values were reported.  The r-values (to indicate how 
strong the relationship between two variables was) were insignificant, due to the 
small number of subjects included in the study. 
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 Subject Demographics 
 
A total of 22 subjects completed the PP, 15 males and seven females.  Although all 
subjects were encouraged to quit smoking, five subjects continued smoking 
despite advice to the contrary.  Three of the subjects were black and 19 were 
caucasian.  Four subjects exercised with supplemental oxygen.  According to the 
GOLD criteria, three subjects were classified with very severe COPD, 11 with 
severe COPD and eight with moderate COPD. 
 
A total of 18 subjects completed the MP, nine males and nine females.  Of the 
seven subjects in the control group, three were male and four were female.  Of the 
eleven subjects in the experimental group, six were male and five were female.  
Smokers were excluded from the MP.  Five of the subjects in the experimental 
group were black and six were caucasian.  One subject in the control group was 
black and six were caucasian.  Four subjects in the experimental group and three 
in the control group had severe COPD.  Seven subjects in the experimental group 
and four in the control group had moderate COPD.  Classification was also done 
according to the GOLD criteria (See Chapter II).   
 
See Appendix I.   
 
Results 
 
Frequency histograms are included for the baseline values of the variables tested.  
These histograms illustrate the overall frequency distribution of the variables for all 
the subjects at baseline level.  These graphs give further insight in the subjects’ 
demographics at baseline level.  ANOVA graphs are included for all the variables 
to illustrate the statistical difference between the baseline, three month and six 
month evaluations (where applicable).  In these graphs, the means of the data are 
illustrated by a small circle (°).  The vertical bars on either side of these circles 
illustrate the confidence intervals.  Correlations are calculated between certain 
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variables.  Box plots are included for certain variables.  Medians, 25th and 75th 
percentiles, ranges and outliers can be identified on these plots.  Medians are 
indicated by a small square (□).  The bottom and top lines of the large square 
indicate the 25th and 75th percentiles, respectively.  The vertical bars (whiskers) on 
either sides of the square indicate the range of the data.  Outliers are represented 
by a small circle (°).  The results of the different parts of the study will be discussed 
separately. 
 
1. Primary programme 
 
1.1 Frequency histograms of baseline data 
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Figure 4.10 A frequency histogram of the subjects’ baseline distances on the 
6MWT. 
 
There was a marked variability in the physical capability of the subjects at the 
baseline evaluation.  This is clearly illustrated in figure 4.10.  The shortest distance 
covered in six minutes was 120m and the longest distance was 620m. 
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  1.1.2 Baseline dyspnoea index 
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Figure 4.11 A frequency histogram of the subjects’ BDI values. 
 
Again, there was a very wide distribution for the BDI scores at the baseline 
evaluation.  The scores were converted to a percentage.  The lowest score was 
25% and the highest score was 75%. 
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  1.1.3 St. George’s Respiratory Questionnaire 
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Figure 4.12 A frequency histogram of the subjects’ baseline scores on the SGRQ. 
 
The same pattern is seen with the SGRQ.  Again there was a wide distribution, the 
lowest score (least impaired) was 24.87 and the highest score (most impaired) was 
82.49. 
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  1.1.4 Lung function variables 
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Figure 4.13 A frequency histogram of the subjects’ baseline FEV1. 
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Figure 4.14 A frequency histogram of the subjects’ baseline FEV1 percentage of 
their predicted scores. 
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Due to the wide variety of subjects tested, it was expected that the FEV1 scores 
and subsequently, the percentage of the predicted FEV1 scores would vary greatly.  
The lowest FEV1 was 0.59 l and the highest was 2.52 l.  According to GOLD 
criteria (see Chapter II), no subjects with mild COPD were included in this part of 
the study, 36.36% of the subjects were classified as having moderate COPD and 
63.63% had severe or very severe COPD.  (The criteria from the SATS were not 
used because the GOLD criteria were more recently updated.) 
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Figure 4.15 A frequency histogram of the subjects’ baseline FIV1 values. 
 
Again, there was a wide distribution between these scores, although most of the 
scores were at the lower half of the histogram.  The highest FIV1 was 4.63 l and 
the lowest was 1.62 l.   
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1.1.5 Physician’s global index 
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Figure 4.16 A frequency histogram of the subjects’ baseline scores for the 
physician’s global evaluation. 
 
Figure 4.16 illustrates the distribution of the physician’s global scores.  The lowest 
score was two and the highest score was six out of a possible eight.  
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  1.1.6 Body mass index 
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Figure 4.17 A frequency histogram of the subjects’ baseline BMI’s. 
 
BMI scores are illustrated in figure 4.17.  The encouraging finding here is that most 
of the scores are between 24 kg/m2 and 26 kg/m2 which are still an acceptable 
BMI.  The lowest score was an alarming 13.19kg/m2 and the highest score was 
34.31kg/m2. 
 
Important questions raised by the frequency histograms presented were whether 
the highest and lowest scores were continuously obtained by the same subjects.  
When comparing the BDI-scores and the baseline FEV1-values of the subjects, the 
subject that scored the highest (slight dyspnoea) on the BDI had one of the lowest 
FEV1’s, whereas the subject who scored the lowest (very severe dyspnoea) on the 
BDI had a baseline FEV1 of 2.52 l, which was also the highest FEV1 tested.  This 
was consistent with the finding of Mahler et al. (1992) who found that although 
patients who experience severe breathlessness have lower pulmonary function 
measures, this generalisation could not be uniformly applied to individual patients.  
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The subject that achieved the highest (most impaired) score on the SGRQ had a 
FEV1 of 1.98 l and a BDI-score of 50%.  The subject that scored the lowest (least 
impaired) on the SGRQ had a FEV1 of 0.95 l, and a BDI-score of 25%.  This was 
consistent with previous studies that found that pulmonary function has a small 
effect on HRQL (Ketelaars et al., 1996; Curtis et al., 1994).  Previous studies found 
a good correlation between exercise performance and HRQL (Ketelaars et al.1996; 
Okubadejo et al., 1996).  When looking at the frequency distribution of the 6MWDs 
and HRQL, the subject that demonstrated the best exercise performance, also 
scored fairly well on the SGRQ.  The subjects with poor exercise performance 
demonstrated poor HRQL.  Although the tendency was similar to previous studies, 
these subjects were not the outliers on the SGRQ. 
 
 1.2 Changes from the first to the third evaluation 
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Figure 4.18 An ANOVA graph to illustrate the subjects’ differences in the mean 
distance walked in the 6MWT in all three evaluations. 
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The repeated measures ANOVA test illustrated that there was a significant 
improvement in the six minute walking distance (6MWD) the subjects obtained 
from first to the second evaluation (p < 0.000001).  There was a slight decline in 
6MWD at the third evaluation, but the improvement was still significant if, 
compared to the baseline values (p < 0.00001).  The mean 6MWD at the first 
evaluation was 381.42m (SD ± 137.20m; SE ± 36.40m), which improved to 
523.21m (SD ± 101.56m; SE ± 28.66) at the second evaluation.  The 6MWD at the 
third evaluation was 495.71m (SD ± 98.58m; SE ± 26.35m), which is not 
statistically lower than the mean distance of evaluation 2 (p = 0.42).  The mean 
improvement from the first to the second evaluation was 142m (SD ± 69.37m).  
The mean improvement from the first to the third evaluation was 114.29m (SD ± 
74.70m).  Both these improvements are higher than the threshold of 54m that is 
necessary for an intervention to be significant (Enright et al., 2003; ATS, 1999; 
Redelmeier et al., 1997; Guyatt et al., 1984). 
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Figure 4.19 An ANOVA graph to illustrate the mean difference in 6MWD between 
males and females from first to the third evaluation.   
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The mean distance for the men at the first evaluation was 401.82m (SD ± 
129.17m) and for the women it was 306.67m (SD ± 140.22m).  These mean 
distances improved to 540m (SD ± 98.30) for the men and 461.67 (SD ± 85.46m) 
for the women from the first to the second evaluation.  The mean distance for men 
at the third evaluation was 514.55m (SD ± 102.41m) and for women 426.67m (SD 
± 40.41).  Although the female subjects covered noticeably shorter distances on 
the 6MWT, there was no statistically significant difference between the 
performance of the two gender groups (p = 0.23).   
 
1.2.2 Baseline and Transitional Dyspnoea Index 
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Figure 4.20 An ANOVA graph to illustrate the subjects’ mean BDI-scores at the 
first evaluation and the mean TDI-scores at the second and third 
evaluations. 
 
The TDI is the measure of change from the BDI.  A repeated measures ANOVA 
test was used to analyse the BDI and TDI.  The mean BDI-score at the first 
evaluation was 45.67% (SD ± 16.13%; SE ± 6.19%), which improved to 54.54% 
(SD ± 17.84; SE ± 8.78%).  The mean TDI-score at the third evaluation was 
54.36% (SD ± 18.93%; SE ± 7.31%).  Figure 4.20 illustrates the significant 
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improvement from the first to the second evaluation (p < 0.05).  Although the mean 
TDI-score was lower at evaluation 3, it was not statistically significant (p = 1.00). 
 
1.2.3 St. George’s Respiratory Questionnaire 
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Figure 4.21 An ANOVA graph to illustrate the subjects’ differences in mean 
scores on the SGRQ. 
A repeated measure ANOVA test was used to analyse the scores the subjects 
obtained in the SGRQ.  A high score indicates a low quality of life and a low score 
indicates a high quality of life.  The mean score at the first evaluation was 52.94 
(SD ± 15.21; SE ± 4.05) which lowered to 36.30 (SD ± 18.46; SE ± 2.93) at the 
second evaluation.  This difference was statistically significant (p < 0.001).  At the 
third evaluation the mean SGRQ-score increased to 41.81 (SD ± 14.65; SE ± 
4.14).  Although this increase was not statistically significant (p = 0.48), it was 
clinically significant as it exceeds four units, as determined by Jones (2002).  
Despite this clinically significant decrease in HRQL from the second to the third 
evaluation, the improvement from the first to the third evaluation remained 
statistically significant (p = 0.02).   
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1.2.4 Lung function variables 
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Figure 4.22 An ANOVA graph to illustrate the subjects’ differences in mean FEV1 
from the first to the third evaluation. 
 
A repeated measures ANOVA test was used to analyse the subjects’ FEV1-scores.  
There was no change in the subjects’ mean FEV1 (p = 0.97).  As figure 4.22 
illustrates and as previously noted, there was a wide range in FEV1 throughout the 
evaluations.  The mean FEV1 at the first evaluation was 1.36 l (SD ± 0.54 l; SE ± 
0.15 l) which changed to 1.37 l (SD ± 0.51 l; SE ± 0.16 l) at the second evaluation.  
At the third evaluation, the mean FEV1 was 1.36 l (SD ± 0.53 l; SE ± 0.15 l).   
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Figure 4.23 An ANOVA graph to illustrate the subjects’ differences in mean 
percentage of predicted FEV1 from the first to the third evaluation. 
 
A repeated measures ANOVA test was used to analyse the subjects’ percentage of 
predicted FEV1’s.  There was no change in the subjects’ mean percentage of 
predicted FEV1 (p = 0.85).  The mean predicted percentage at the first evaluation 
was 46.55% (SD ± 17.65%; SE ± 4.40%), which changed to 47.23% (SD ± 
15.78%; SE ± 4.90%) at the second evaluation.  At the third evaluation, the mean 
predicted percentage was 47.59% (SD ± 17.03%; SE ± 4.72%).   
 165
Evaluation 1 Evaluation 2 Evaluation 3
2.4
2.5
2.6
2.7
2.8
2.9
3.0
3.1
3.2
3.3
3.4
3.5
3.6
FV
C
 (l)
 
Figure 4.24 An ANOVA graph to illustrate the subjects’ differences in mean FVC-
values from the first to the third evaluation. 
 
A repeated measures ANOVA test was used to analyse the subjects’ FVC-values.  
There was no statistically significant change in the mean FVC from the first to the 
third evaluation (p = 0.65).  The mean FVC at the first evaluation and second 
evaluation was 3.03 l (SD ± 0.99 l & 0.96 l; SE ± 0.20 l).  At the third evaluation, 
the mean FVC was 3.03 l (SD ± 0.99 l; SE ± 0.20 l).   
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Figure 4.25 An ANOVA graph to illustrate the subjects’ differences in mean FIV1 
from the first to the third evaluation. 
 
A repeated measures ANOVA test was used to analyse the subjects’ FIV1’s.  There 
was no statistically significant change in the mean FIV1 from the first to the third 
evaluation (p = 0.67).  As seen with FEV1, once again there was a very wide range 
in the subjects’ scores throughout the evaluations.  The mean FIV1 at the first 
evaluation was 6.53 l (SD ± 6.06 l; SE ± 1.32 l), which changed to 7.21 l (SD ± 
6.06 l; SE ± 1.31 l) at the second evaluation.  At the third evaluation, the mean 
FIV1 was 7.16 l (SD ± 6.22 l; SE ± 1.66 l).   
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1.2.5 Physician’s Global Evaluation 
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Figure 4.26 An ANOVA graph to illustrate the subjects’ differences in mean 
scores in the physician’s global evaluation. 
 
As illustrated in the figure 4.26, there was a statistically significant improvement in 
the physician’s global evaluation of subjects from the first to the second evaluation 
(p < 0.0001).  Again there was a decrease in the mean scores from the second to 
the third evaluation, but this decrease was not statistically significant (p = 1.00).  
The overall improvement from the first to the third evaluation was statistically 
significant (p < 0.0001).  The mean score at the first evaluation was 3.93 (SD ± 
1.22; SE ± 0.40), which changed to 5.64 (SD ± 1.14; SE ± 0.31) at the second 
evaluation.  At the third evaluation, the mean physician’s global score was 5.43 
(SD ± 1.34; SE ± 0.33).   
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1.2.6 Body Mass Index 
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Figure 4.27 An ANOVA graph to illustrate the subjects’ differences in mean BMI 
from the first to the third evaluation. 
 
There was no statistically significant difference in the BMI values of the subjects 
from the first to the third evaluation (p = 0.84).  A significant decrease in BMI can 
be linked to mortality (Gray-Donald et al., 1996).  The mean BMI-scores at the first, 
second and third evaluations was 25.43kg/m2 (SD ± 4.64kg/m2; SE ± 1.41kg/m2), 
25.31kg/m2 (SD ± 4.74kg/m2; SE ± 1.39kg/m2) and 25.29kg/m2 (SD ± 4.58kg/m2; 
SE ± 1.35kg/m2), respectively.   
 
1.2.7 Exacerbations 
 
Exacerbations were assessed through the number of sessions missed due to acute 
pulmonary infections and through self-reported exacerbations as reported in the 
SGRQ.   
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Figure 4.28 A box plot illustrating the exercise sessions missed by subjects due 
to acute exacerbations. 
 
In the PP, subjects missed an average of 1.33 sessions (SD ± 1.57) due to acute 
exacerbations.  One subject missed a total of six sessions.  At the first evaluation 
the average of self-reported exacerbations was 2.14 (SD ± 1.59), which lowered to 
0.62 (SD ± 0.97).  This decrease in exacerbations was significantly lower at the 
second evaluation (p < 0.001).  
 
To analyse the data based on the extent of dyspnoea experienced by the subjects 
at the first evaluation; the group was divided into two, based on their BDI-scores.  
Subjects who scored less than four on the BDI were in one group and subjects that 
scored four or more were included in the other.  Although the less dyspnoeic group 
was expected to score better in the other evaluations, none of these analyses 
delivered significant results (see Appendix M). 
      
The major findings of the PP were that this programme was successful in 
instigating positive changes in 6MWD, HRQL, dyspnoea and the physician’s global 
evaluation.  Furthermore, these positive changes remained significant at the six 
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month follow-up evaluation.  Consistent with previous studies (Bauldoff et al., 2002; 
Brooks et al., 2002; McArdle et al., 2001:953; Guell et al., 2000; Boueri et al., 2001; 
Troosters et al., 2000; Benstrup et al., 1997; Strijbos et al., 1996; ATS, 1995a; 
Celli, 1995; Reardon et al., 1994; Cox et al., 1993; Holden et al., 1990; Busch & 
McClements, 1988), no significant changes occurred in lung function variables and 
BMI. 
      
1.3 Correlations 
 
1.3.1 Relationship between FEV1 and 6MWD 
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Figure 4.29 A scatter plot illustrating the correlation between 6MWD and FEV1 at 
the first evaluation. 
 
Contrary to previous studies (Brooks et al., 2002; Boueri et al., 2001; Benstrup et 
al., 1997; Jones, 1991; Swinburn et al., 1985; McGavin et al., 1976), a strong 
correlation was found between 6MWD and FEV1 at the first evaluation (p < 0.001).   
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Figure 4.30 A scatter plot illustrating the correlation between 6MWD and FEV1 at 
the second evaluation. 
 
Consistent with the first evaluation, there was a very strong correlation between 
FEV1 and 6MWD at the second evaluation (p < 0.0001). 
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Figure 4.31 A scatter plot illustrating the correlation between 6MWD and FEV1 at 
the third evaluation. 
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 As illustrated in figure 4.31, a correlation was found between FEV1 and 6MWD at 
the third evaluation.  This correlation was the strongest at the second evaluation (p 
= 0.000007) and slightly weaker at the first (p = 0.0005) and third evaluations (p = 
0.0007).   
 
Table 4.10 Correlations calculated that did not deliver any significant results. 
Variables Evaluation p-value 
6MWT and SGRQ 1 0.06 
 2 0.13 
Physician’s global evaluation and SGRQ 1 0.11 
 2 0.19 
Physician’s global evaluation and BDI 1 0.43 
BDI and SGRQ 1 0.42 
TDI and SGRQ 2 0.08 
6MWT and BDI 1 0.82 
6MWT and TDI 2 0.10 
Physician’s global evaluation and 6MWT 1 0.44 
 2 0.09 
FEV1 and SGRQ 1 0.32 
 2 0.10 
FEV1 and BMI 2 0.08 
 
Since no significant changes were recorded during the third evaluation for any of 
the variables, no correlations were calculated between variables of the third 
evaluation.  
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2. Modified programme 
 
2.1 Frequency histograms of baseline data 
 
2.1.1 Six minute walk test 
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Figure 4.32 A frequency histogram illustrating subjects’ 6MWDs at the first 
evaluation. 
 
There was a wide variation in the baseline 6MWDs of both groups.  The shortest 
distance covered by the experimental group was 280m and the longest distance 
was 530m.  The shortest distance covered by the control group was 220m and the 
longest distance was 500m. 
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2.1.2 Baseline dyspnoea index 
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Figure 4.33 A frequency histogram illustrating the subjects’ BDI scores at the first 
evaluation. 
 
BDI scores were converted to a percentage; the lower the score, the more severe 
the impact of dyspnoea is.  The majority of the subjects had scores of less than 
50%, or six out of 12.  The lowest BDI score recorded for both groups was three 
out of 12.  The highest BDI score recorded for experimental group was nine out of 
12 and the highest score recorded for the control group was eight out of 12. 
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2.1.3 St. George’s respiratory questionnaire 
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Figure 4.34 A frequency histogram illustrating the subjects’ SGRQ scores at the 
first evaluation. 
 
A high score on the SGRQ represents a severely impaired quality of life, whereas a 
low score indicates that the impact that the disease has on the subject’s quality of 
life is minimal.  The lowest SGRQ score recorded was 21.49 for the experimental 
group and 29.25 for the control group.  The highest SGRQ score recorded was 
69.79 for the experimental group and 82.07 for the control group. 
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2.1.4 Lung function variables 
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Figure 4.35 A frequency histogram illustrating the subjects’ FEV1’s at the first 
evaluation. 
 
The control group had a wider variation in FEV1 scores at the first evaluation, 
compared to the experimental group.  The lowest FEV1 recorded for the 
experimental and control group was 0.92 l and 0.66 l, respectively.  The highest 
FEV1 recorded for the experimental and control group was 1.78 l and 1.91 l, 
respectively.   
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Figure 4.36 A frequency histogram illustrating the subjects’ FEV1 percentage of 
their predicted values at the first evaluation. 
 
The lowest FEV1 percentage of the predicted value recorded for the experimental 
and control groups was 32.62% and 32.88%, respectively.  The highest FEV1 
percentage of the predicted value recorded for the experimental and control groups 
was 59.64% and 67.36%, respectively.  According to GOLD criteria (see Chapter 
II), no subjects with mild or very severe COPD were included in this part of the 
study.  In the experimental group, 63.63% of the subjects were classified as having 
moderate COPD and 36.36% had severe COPD.  In the control group, 57.14% of 
the subjects were classified as having moderate COPD and 42.86% had severe 
COPD. 
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Figure 4.37 A frequency histogram illustrating the subjects FIV1’s at the first 
evaluation. 
 
There was a wide distribution in the FIV1 scores of the subjects in both groups.  
The lowest FIV1 score recorded for the experimental and control groups at the 
baseline evaluation was 1.71 l and 1.84 l, respectively.  The highest FIV1 score 
recorded for the experimental and control groups at the baseline evaluation was 
3.85 l and 4.05 l, respectively.   
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2.1.5 Physician’s global evaluation 
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Figure 4.38 A frequency histogram illustrating the physician’s global scores of the 
subjects at the first evaluation.   
 
The lowest physician’s global score recorded for the control group was two and for 
the experimental group the lowest score recorded was three.  The highest scores 
recorded were six for the experimental group and five for the control group. 
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2.1.6 Body mass index 
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Figure 4.39 A frequency histogram illustrating the subject’s BMI’s at the first 
evaluation. 
 
The lowest BMI recorded for the experimental and control group was 18.16 kg/m2 
and 19.92 kg/m2, respectively.  The highest BMI recorded for the experimental and 
control group was 31.67 kg/m2 and 31.63 kg/m2, respectively. 
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2.2 Changes from the first to the second evaluation 
 
2.2.1 Six minute walk test 
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Figure 4.40 An ANOVA graph illustrating the improvement in mean 6MWD of the 
experimental and control group from the first to the second 
evaluation.   
 
The mean distances covered by the experimental and control group at the first 
evaluation was 410.91m (SD ± 101.14m; SE ± 30.60m) and 342.86m (SD ± 
101.93m; SE ± 38.36m), respectively.  The mean distances covered by the 
experimental and control group at the second evaluation were 510.00m (SD ± 
108.44m; SE ± 29.51m) and 481.43m (SD ± 77.12m; SE ± 36.99m), respectively.  
Although it seemed as if the control group was more impaired in terms of exercise 
capacity, there was no statistically significant difference between the mean 
distances covered at both evaluations (p = 0.30).  The improvement of both groups 
from the first to the second evaluation was highly significant (p < 0.000001).  The 
mean improvement from the first to the second evaluation for the experimental and 
control group was 99.09m (SD ± 46.14) and 138.57m (SD ± 88.21m).  Both these 
improvements are higher than the threshold of 54m that is necessary for an 
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intervention to be significant (Enright et al., 2003; ATS, 1999; Redelmeier et al., 
1997; Guyatt et al., 1984). 
 
To confirm repeatability of the 6MWT when conducted by independent supervisors, 
a second test was included.  This 6MWT was performed at the Stellenbosch 
Biokinetics Centre (SBC), using the same protocol as in the pre-intervention 
assessment at the physician’s practice.  The clinical technologist, who 
administered the 6MWT at the physician’s practice, was not informed of the results 
obtained at the SBC 6MWT.  The results obtained in the two 6MWTs are presented 
in figure 4.41.  In figure 4.41, 6MWT 1 refers to the test conducted at the SBC, 
whereas 6MWT 2 refers to the test conducted at the physician’s practice.   
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Figure 4.41 An ANOVA graph illustrating the two 6MWTs conducted by 
independent supervisors. 
 
As illustrated by figure 4.41, there was no statically significant difference in the 
results obtained in the two 6MWTs of the experimental or control groups (p = 0.33).   
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2.2.2 Baseline and transitional dyspnoea index 
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Figure 4.42 An ANOVA graph illustrating the improvement in mean BDI/TDI 
scores of the experimental and control group from the first to the 
second evaluation.   
 
The repeated measures ANOVA indicated a significant improvement in BDI/TDI 
scores of both groups, from the first to the second evaluation (p < 0.0001).  The 
mean score for the experimental and control groups at the first evaluation was 
44.69% (SD ± 14.56%; SE ± 4.47m) and 41.67% (SD ± 15.22%; SE ± 5.60%), 
respectively.  The mean score for the experimental and control groups at the 
second evaluation was 74.75% (SD ± 19.30%; SE ± 5.18) and 77.78% (SD ± 
12.83%; SE ± 6.49%), respectively.  There was no statistically significant difference 
between the mean scores of the two groups at the first or second evaluation (p = 
0.99).   
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2.2.3 St. George’s respiratory questionnaire 
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Figure 4.43 An ANOVA graph illustrating the improvement in mean SGRQ scores 
of the experimental and control group from the first to the second 
evaluation. 
 
The repeated measures ANOVA indicated a significant improvement in the mean 
SGRQ scores of both groups, from the first to the second evaluation (p < 0.001).  
The mean score for the experimental and control groups at the first evaluation was 
47.60 (SD ± 15.93; SE ± 5.58) and 52.47 (SD ± 19.78; SE ± 6.67), respectively.  
The mean score for the experimental and control groups at the second evaluation 
was 28.44 (SD ± 13.10; SE ± 5.08) and 33.71 (SD ± 19.70; SE ± 6.07), 
respectively.  Although there was no statistically significant difference between the 
mean scores of the two groups at the first or second evaluation (p = 0.50), the 
difference was more than four percent or four units (Jones, 2002) and therefore 
this difference was clinically significant.   
 
No significant correlation was found between the BDI/TDI and SGRQ for the 
experimental group at the first (p = 0.79) or second evaluation (p = 0.37).  No 
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significant correlation was found between the BDI/TDI and SGRQ for the control 
group at the first (p = 0.11) or second evaluation (p = 0.54).   
 
2.2.4 Lung function variables 
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Figure 4.44 An ANOVA graph illustrating the changes in mean FEV1 scores of the 
experimental and control group from the first to the second 
evaluation.  
 
The repeated measures ANOVA indicated that there was no statistically significant 
difference between the mean FEV1’s of the two groups at both evaluations (p = 
0.94).  There was also no statistically significant change in the FEV1 scores of 
either group from the first to the second evaluation (p = 0.66).  The mean FEV1 for 
the experimental and control groups at the first evaluation was 1.29 l (SD ± 0.24 l; 
SE ± 0.10 l) and 1.22 l (SD ± 0.45 l; SE ± 0.13 l), respectively.  The mean score for 
the experimental and control groups at the second evaluation was 1.25 l (SD ± 
0.27 l; SE ± 0.12 l) and 1.29 l (SD ± 0.52 l; SE ± 0.15 l), respectively.   
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Figure 4.45 An ANOVA graph illustrating the subjects’ mean FEV1 percentage of 
their predicted values at the first and the second evaluation. 
 
The repeated measures ANOVA indicated that there was no statistically significant 
difference between the mean predicted FEV1’s of the two groups at both 
evaluations (p = 0.60).  There was also no statistically significant change in the 
predicted FEV1 scores of either group from the first to the second evaluation (p = 
0.50).  The mean predicted FEV1 for the experimental and control groups at the 
first evaluation was 50.24% (SD ± 8.93%; SE ± 3.11%) and 51.17% (SD ± 12.30%; 
SE ± 3.9%), respectively.  The mean prediction for the experimental and control 
groups at the second evaluation was 49.15% (SD ± 11.01%; SE ± 3.84%) and 
54.04% (SD ± 15.18%; SE ± 4.81%), respectively.  Although not statistically 
significant, there was an improvement in the mean predicted percentage FEV1 of 
the control group, as indicated by figure 4.45.   
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Figure 4.46 An ANOVA graph illustrating the subjects’ mean FVC values at the 
first and the second evaluation. 
 
The repeated measures ANOVA indicated that there was no statistically significant 
difference between the mean FVC scores of the two groups at both evaluations (p 
= 0.71).  There was also no statistically significant change in the FVC scores of 
either group from the first to the second evaluation (p = 0.92).  The mean FVC for 
the experimental and control groups at the first evaluation was 2.97 l (SD ± 0.62 l; 
SE ± 0.27 l) and 2.76 l (SD ± 0.84 l; SE ± 0.34 l), respectively.  The mean score for 
the experimental and control groups at the second evaluation was 3.06 l (SD ± 
0.74 l; SE ± 0.26 l) and 2.69 l (SD ± 0.75 l; SE ± 0.33 l), respectively.   
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Figure 4.47 An ANOVA graph illustrating the subjects’ mean FIV1 values at the 
first and the second evaluation. 
 
The repeated measures ANOVA indicated that there was no statistically significant 
difference between the mean FIV1 scores of the two groups at both evaluations (p 
= 0.67).  There was also no statistically significant change in the FIV1 scores of 
either group from the first to the second evaluation (p = 0.76).  The mean FIV1 for 
the experimental and control groups at the first evaluation was 2.83 l (SD ± 0.64 l; 
SE ± 0.23 l) and 2.68 l (SD ± 0.09 l; SE ± 0.28 l), respectively.  The mean score for 
the experimental and control groups at the second evaluation was 2.87 l (SD ± 
0.77 l; SE ± 0.25 l) and 2.69 l (SD ± 0.95 l; SE ± 0.32 l), respectively.   
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2.2.5 Physician global evaluation 
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Figure 4.48 An ANOVA graph illustrating the physician’s global evaluation for the 
subjects at the first and second evaluations. 
 
The repeated measures ANOVA indicated a significant improvement in the mean 
physician’s global scores of both groups, from the first to the second evaluation (p 
< 0.000001).  The mean score for the experimental and control groups at the first 
evaluation was 4.36 (SD ± 1.12; SE ± 0.35) and 4.14 (SD ± 1.21; SE ± 0.44), 
respectively.  The mean score for the experimental and control groups at the 
second evaluation was 6.45 (SD ± 0.52; SE ± 0.19) and 6.71 (SD ± 0.76; SE ± 
0.23), respectively.  There was no statistically significant difference between the 
mean scores of the two groups at the first or second evaluation (p = 0.96). 
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2.2.6 Body mass index 
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Figure 4.49 An ANOVA graph illustrating the subjects’ mean BMI values at the 
first and second evaluation. 
 
The repeated measures ANOVA indicated that there was no statistically significant 
difference between the two groups at either evaluation (p = 0.73).  There was also 
no statistically significant change in the mean BMI values of the two groups from 
the first to the second evaluation (p = 0.23).  The mean BMI for the experimental 
and control groups at the first evaluation was 26.28 kg/m2 (SD ± 4.39; SE ± 1.23) 
and 25.27 kg/m2 (SD ± 4.39; SE ± 1.66), respectively.  The mean BMI for the 
experimental and control groups at the second evaluation was 26.47 kg/m2 (SD ± 
4.43; SE ± 1.30) and 26.02 kg/m2 (SD ± 4.19; SE ± 1.64), respectively. 
 
2.2.7 Exacerbations 
 
As in the PP, exacerbations were assessed by the number of sessions missed due 
to acute exacerbations and by self-reported exacerbations as reported in the 
SGRQ.   
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Figure 4.50 A box plot illustrating the exercise sessions missed due to acute 
exacerbations. 
 
In the MP, acute exacerbations caused the experimental and control group to miss 
an average of 1.64 (SD ± 2.01) and 0.71 (SD ± 0.95) sessions, respectively.  There 
was no statistically significant difference between the sessions missed by the two 
groups (p = 0.28). 
 
At the baseline evaluation, the experimental and control groups reported an 
average of 1.87 (SD ± 1.77) and 1.36 (SD ± 1.29) exacerbations, respectively.  At 
the second evaluation the experimental group’s average reported exacerbations 
lowered to 0.18 (SD ± 0.40), while the control group’s lowered to 1.29 (SD ± 1.50).  
This decrease in the number of exacerbations was statistically significant for the 
experimental group (p < 0.01), but not for the control group (p = 0.41).  There was 
no statistically significant difference in the number of reported exacerbations by two 
groups at the first evaluation (p = 0.50).  However, at the second evaluation the 
experimental group reported significantly less exacerbations, compared to the 
control group (p < 0.05). 
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2.3 Correlations 
 
2.3.1 Relationship between FEV1 and 6MWD 
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Figure 4.51 A scatter plot illustrating the correlation between the mean 6MWD 
and mean FEV1 for the control group at the first evaluation. 
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Figure 4.52 A scatter plot illustrating the correlation between the mean 6MWD 
and mean FEV1 for the experimental group at the first evaluation. 
 
Although the correlation between 6MWD and FEV1 was not as strong as in the PP, 
the correlation between these variables was significant at the 5% level for the 
experimental and control groups at the first evaluation (p < 0.05).   
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Table 4.11 Correlations calculated that did not deliver any significant results. 
Variables Group Evaluation p-value 
6MWT and SGRQ experimental 1 0.57 
 experimental 2 0.16 
 control 1 0.31 
 control 2 0.16 
6MWT and BDI/TDI experimental 1 0.46 
 experimental 2 0.85 
 control 1 0.82 
 control 2 0.91 
SGRQ and FEV1 experimental 1 0.98 
 experimental 2 0.96 
 control 2 0.12 
Physician’s global evaluation and SGRQ experimental 1 0.59 
 experimental 2 0.72 
Physician’s global evaluation and BDI/TDI experimental 1 0.70 
 experimental 2 0.91 
 control 2 0.68 
 
Correlations that did not deliver significant results, when comparing the changes in 
variables from the first to the second evaluation, are presented in Appendix J. 
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Primary programme 
 
The PP found that a structured, 12-week exercise programme improves the 
exercise capacity, quality of life, dyspnoea and a physician’s assessment of overall 
condition in subjects with COPD (as assessed by the 6MWT, SGRQ, BDI/TDI and 
the physician’s global evaluation, respectively).  Even though there was a slight 
decrease in the benefits obtained six months after completion of the intervention 
programme, this decrease was not statistically significant.  This was consistent with 
previous studies executed in industrialised countries (Cambach et al., 1997; 
Wijkstra et al., 1995; Cox et al., 1993; Vale et al., 1993).  This study confirmed that 
an exercise programme fails to instigate any statistically significant changes in lung 
function variables and BMI in subjects with COPD.  This finding was also 
consistent with previous authors (Bauldoff et al., 2002; McArdle et al., 2001:953; 
Guell et al., 2000; Troosters et al., 2000; Bendstrup et al., 1997; Strijbos et al., 
1996; ATS, 1995a; Celli, 1995; Reardon et al., 1994; Cox et al., 1993; Holden et 
al., 1990; Busch & McClements, 1988).  
 
Three subjects included in the PP had very severe COPD, 11 had severe COPD 
and eight were classified as moderate COPD.  There was no statistically significant 
difference between the results obtained by these two groups (p > 0.05).  This was 
consistent with a study by Berry and co-workers (1999).  Since such a small 
number of subjects were classified with severe COPD, the relevance of this finding 
is questionable.  No subjects with mild COPD were included in this study.  
Although Berry and co-workers (1999) illustrated that the benefits obtained through 
exercise training do not differ significantly in the different stages (even with mild 
COPD), previous reports have criticised the inclusion of subjects with mild COPD 
on the basis that these subjects would be expected to benefit more from exercise 
training (Albert, 1997).  Differentiating between the results obtained by subjects in 
different stages of COPD, was not one of the key aims of this study, therefore 
these findings were considered circumstantial.   
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Contrary to the findings of De Torres and co-workers (2005), there was no 
statistically significant difference between the 6MWDs achieved by the men and 
women at all three evaluations.  This could be explained by the small number of 
women included in the PP.  Only seven of the subjects included in this group were 
women. 
 
Modified programme 
 
The MP found that the same benefits in exercise capacity, quality of life, dyspnoea 
and overall condition could be obtained through a less expensive, adapted 
exercise programme (as assessed through the 6MWT, SGRQ, BDI/TDI and the 
physician’s global evaluation).  Consistent with the PP, no changes in pulmonary 
function measurements or BMI were observed in the experimental or control group.   
 
In the MP, a significant difference was found between men and women for 6MWD, 
absolute FEV1 values and SGRQ scores.  The women were more impaired in all 
these areas (p < 0.05).  No significant gender differences were found in the 
percentage predicted FEV1, BMI, BDI, FIV1 and the physician’s global evaluation.  
These findings were consistent with the findings by De Torres and co-workers 
(2005).  A difference noted in the findings was that De Torres and co-workers 
(2005) documented significantly lower BMI-values for the women included in their 
study.    
 
In the MP, two independent 6MWTs were conducted at the post-intervention 
assessment.  The two tests were conducted within two days of each other, at two 
different locations, by independent supervisors.  An important finding was that 
there was no statistically significant difference between the results obtained in 
these two tests.  This adds to the validity of the test and indicates that subjects 
performed at their best.  Furthermore, this shows that if supervisors are adequately 
trained, the 6MWT can successfully be conducted by different supervisors.  To my 
knowledge, it is the first time that the 6MWT has been validated with regards to its 
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repeatability when conducted by separate supervisors in South Africa.  According 
to the American Thoracic Society (2002), one other study found a mean difference 
of 7% in 6MWDs when comparing the data of two different testing centres.   
 
Exacerbations 
 
Although not included in the protocol, the impact of exercise training on the 
frequency of exacerbations and the impact of exacerbations on the outcome 
measures of the programme were evaluated.  As mentioned previously, 
exacerbations were firstly defined as an increase in pulmonary symptoms that was 
severe enough to prevent a subject from attending an exercise session.  Sessions 
missed by subjects were carefully documented and these were assessed.  
Secondly, the subjects’ perception of exacerbations was assessed by analysing 
the number of reported exacerbations in the SGRQ.  Subjects reported the number 
of exacerbations they experienced in the time they were attending the programme.  
These exacerbations were described as “Over the last 3 months, how many severe 
or very severe unpleasant attacks of chest trouble have you had?”   
 
Previous studies on the effects of exercise training on the frequency of 
exacerbations were contradictory.  Some studies found that exercise training had 
no effect on the frequency of exacerbations (Benstrup et al., 1997; Ries et al., 
1995), while Guell and co-workers (2000) found a significant decrease.  All 
exacerbations that resulted in subjects missing exercise sessions were thoroughly 
documented.  The value of this data was, however restricted, since data on 
exacerbations prior to the study was not available for all subjects and 
exacerbations were defined differently from previous studies.  Assessment on 
possible changes in the frequency of exacerbations had to rely on self-reported 
incidents in the SGRQ.   
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1. Primary programme 
 
In the PP, there was a significant decrease in the number of reported 
exacerbations by the subjects from the first to the second evaluation.  Records 
were not available to assess the number of exacerbations from the second to the 
third evaluation.   
 
2. Modified programme 
 
An important finding was that the same decrease in the number of exacerbations 
was observed among the experimental group in the MP.  The small number of 
subjects in the control group could explain why the decrease in exacerbations 
observed in this group was not statistically significant.   
 
Correlations  
 
1. Primary programme 
 
A significant correlation was found between the FEV1 and 6MWD in the PP.  There 
was a significant improvement in 6MWD from the first to the third evaluation, but no 
significant change was noted in the FEV1 values.  The correlation between these 
variables was the strongest at the second evaluation and weaker at the first and 
third evaluation.   
 
Various previous studies have found no correlation between FEV1 and 6MWD 
(Brooks et al., 2002; Boueri et al., 2001; Benstrup et al., 1997; Jones, 1991; 
Swinburn et al., 1985; McGavin et al., 1976).  When comparing the baseline data 
of the current study with the baseline data of previous studies, this correlation 
could be attributed to a difference in mean baseline FEV1 values.  The mean 
baseline FEV1 of the current study is higher than that of most of the previous 
studies.  The mean FEV1 value of the study by Brooks and co-workers (2002) was 
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0.70 l  ± 0.03 l, which was significantly lower than the mean FEV1 (1.31 l  ± 0.43 l) 
of the current study.  Detailed information on the baseline values of other studies 
was not available.   
 
Previous studies have found significant correlations between the number of 
exacerbations and HRQL (Spencer et al., 2004; Seemungal et al., 1998).  Based 
on this literature, subjects that experienced the most number of exacerbations 
should score higher (more impaired HRQL) on the SGRQ.  This was true in the PP 
at the first evaluation, but not at the second evaluation.   
 
2. Modified programme 
 
A significant correlation was found between the FEV1 and 6MWD in the PP.  
Although the trend was similar in the MP, the correlation was not as strong as in 
the PP.  The fact that the correlation was not as strong in the MP was attributed to 
the smaller sample size.  As in the PP, there was a significant improvement in 
6MWD from the first to the second evaluation, but no significant change was noted 
in the FEV1 values.  In the PP, the correlation between these variables was the 
strongest at the second evaluation and weaker at the first and third evaluation.  In 
the MP, the correlation between these variables was absent at the second 
evaluation.  The fact that there was no change in the mean FEV1 of either group, 
while significant changes were observed in 6MWD, would explain the absence of 
this correlation at the second evaluation.   
 
The correlation between FEV1 and 6MWD was inconsistent when analysing the 
three groups at all the evaluations.  Therefore, the conclusion could be made that 
FEV1 is not a valuable predictor of functional capacity, as measured by the 6MWT.  
Furthermore, an improvement in FEV1 is not essential in the improvement of 
functional capacity.   
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According to previous studies (Ketelaars et al., 1996; Curtis et al., 1994), 
improvements in FEV1 do not necessarily translate into improvements in quality of 
life.  In the MP, a weak but significant correlation was found between FEV1 and the 
SGRQ scores of the control group at the first evaluation.  The absence of this 
correlation at the second evaluation can be explained by the fact that there was no 
significant change in FEV1 values, but a highly significant decrease in SGRQ 
scores and therefore an improvement of HRQL.  Consistent with a study by 
Ketelaars and co-workers (1996), this correlation was not present in the PP, or in 
the experimental group.  Patients with similar FEV1 values often display a wide 
range in exercise capabilities and overall health (Maltais et al., 1996b).  FEV1 is 
therefore not considered a good predictor of HRQL.  It could be argued that this 
correlation could be attributed to the fact that low FEV1 values are often associated 
with an increase in exacerbations (Pauwels et al., 2001).  The SGRQ has a large 
component for the assessment of the impact of exacerbations.  Therefore, this 
correlation could be attributed to a relationship between FEV1 and exacerbations 
and not HRQL per se.  However, after assessment of the correlation between FEV1 
and the number of exacerbations, no correlations were found (Appendix J).   
 
According to Gosselink (2002), frequent exacerbations during exercise 
intervention, would result in a decrease in the effectiveness of exercise training and 
subsequently reduce improvement in functional capacity.  Therefore, it was 
important to assess the impact of exacerbations on functional capacity.  Based on 
the findings of Gosselink (2002), it would be expected that the subjects that missed 
the most number of sessions due to exacerbations, would show the smallest 
improvement in functional capacity.  However, no correlations were found between 
the number of sessions missed due to exacerbations and the improvement in 
6MWD (Appendix J). 
 
In the MP, significant correlations were found between the number of 
exacerbations and HRQL at the first evaluation for the experimental group and at 
the second evaluation for the control group.  These correlations would be 
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expected, since the number of exacerbations was calculated from the SGRQ.  The 
fact that this correlation was not present at all evaluations could be explained by 
the fact that the SGRQ includes three sub-categories (Chapter III).  Exacerbations 
contribute to the symptom-category.  In the cases where this correlation was 
absent, it could be concluded that the impact- and activity-components had a 
greater influence on quality of life compared to symptoms.   
 
Contrary to previous studies (Ketelaars et al., 1996; Okubadejo et al., 1996), the 
present study found no significant correlations between exercise performance and 
HRQL.  This could possibly be attributed to the small sample size of this study.  
This was affirmed by the fact that when the results of the subjects in the PP were 
combined with the results of the control group, a significant correlation was found 
between 6MWD and SGRQ scores (Appendix K).   
 
Conclusion  
 
In conclusion, the benefits that a structured exercise programme has for patients 
with COPD have been clearly illustrated by these results.  One important benefit 
that should be emphasised is the improvement in quality of life that was 
experienced by all subjects included in this study.  The interaction between 
improved quality of life, psychological, physical and social wellbeing, highlights the 
importance that this holds for these patients.  The positive feedback received from 
all the subjects included in the study, further confirms the important role that an 
exercise programme could play in the successful management of patients with 
COPD.  The fact that similar results was obtained by a low-cost programme was 
another important finding.  This substantiates the fact that it is possible to make 
pulmonary rehabilitation accessible to all patients with COPD.   
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Numerous previous studies have focused on the benefits of exercise training on 
various aspects of COPD.  However, most of this research has focused on COPD 
in industrialised countries.  Recently a few studies on COPD in developing 
countries have emerged.  From this limited data, it is obvious that the challenges 
faced by developing countries are very different from those in industrialised 
nations.  Furthermore, little research exists on exercise training of the COPD 
patients in a South African setting.   
 
Although the challenges faced by industrialised and developing countries are very 
different, exercise training of COPD patients in developing countries could prove to 
be more beneficial.  COPD patients in developing countries have to rely more on 
physical fitness due to the absence of luxuries, such as transport and proper health 
care.  COPD is an incurable disease and therefore, the most important aim of 
therapy is the enhancement of the remaining life years.  Standard medical therapy 
is however, limited in this regard, due to complex interaction between physiological 
variables, functional status and quality of life.  Therefore, exercise training can 
enhance the benefits of standard medical therapy and provide the patient with a 
more comprehensive treatment strategy.   
 
One of the main challenges in South Africa remains the high prevalence of TB and 
HIV/AIDS.  This was illustrated in one subject with severe COPD that developed 
TB after inclusion in the programme.  Both these conditions contribute to the 
prevalence of COPD and add to the complexity of successful management of the 
disease process (Diaz et al., 2003; Hnizdo et al., 2000).  Although it will always be 
challenging to keep patients with TB or HIV/AIDS in an exercise routine, these 
patients should not be excluded from exercise programmes.  Exercise programmes 
can be successfully tailored or adapted to accommodate these patients.  This 
emphasises the importance of individualised programmes.   
 
All subjects included in the study were clinically diagnosed with COPD and 
conformed to the inclusion and exclusion criteria.  Despite this, a large baseline 
 205
scatter between subjects was observed for all variables.  This highlights the 
diversity of COPD patients and the complexity of the disease process.  An 
important finding was that despite the large diversity of the study group, all subjects 
benefited greatly from the intervention programme.  This demonstrates that an 
exercise programme can be successfully implemented in a diverse group of 
patients and that the benefits that can be obtained remain the same.  The diversity 
of COPD patients further necessitates the individualising of exercise programmes.  
It is important that exercise programmes should be tailored and adjusted to the 
specific needs of the patients.   
 
Few previous studies have documented similar improvements in 6MWD.  An 
earlier study (McGavin et al., 1978) suggested that an improvement greater than 
30m in the 6MWT could be considered a clinical improvement.  Although this 
benchmark is still used by some studies (Boueri et al., 2001), recently published 
studies showed that a clinical improvement could only be assumed when a change 
of 54m or more occurs (Enright et al., 2003; ATS, 1999; Redelmeier et al., 1997; 
Guyatt et al., 1984).  The mean improvements in the current study were 142m (SD 
± 69.37m) in the PP, 99.09m (SD ± 46.14) in the experimental group and 138.57 
(SD ± 88.21m) in the control group.  This indicates that 86.36% of the subjects 
included in the PP, 81.81% of the subjects in the experimental group and 85.71% 
of the subjects in the control group had clinically significant improvements in the 
6MWT from the first to the second evaluation.  Compared to recent literature, this 
outcome was considerably better than previous studies.  A study by Norweg and 
co-workers (2005) reported a 54m improvement in 6MWD after 15 exercise 
sessions that consisted mainly of aerobic exercise.  Other studies that incorporated 
both strength and endurance training into their exercise routines failed to achieve a 
mean improvement of more than 54m in the 6MWT (Boueri et al., 2001; Mador et 
al., 2004).  The primary difference between these studies and the current study 
was the duration of the intervention programme.  Ringbaek and co-workers (2000) 
found that eight weeks of exercise training is insufficient to obtain a significant 
change in 6MWD.  Another study with a similar design than the current study 
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reported a mean improvement of 113.1m (SD ± 17.8m) in the 6MWT after 12 
weeks of exercise training (Benstrup et al., 1997).  The success of the present 
study suggests that a 12-week exercise programme that focuses on both aerobic 
and strength training is probably more effective in obtaining health benefits for 
COPD patients than the studies quoted above.  Exercise programmes should also 
focus on educating COPD patients on safe exercise practices and techniques.   
 
Pulmonary rehabilitation is very limited in South Africa and is currently only 
available in Stellenbosch and Johannesburg.  Current programmes do not allow for 
training adequate numbers of professionals for pulmonary rehabilitation and is on 
average not accessible to the broader community.  An added benefit of the current 
study was that various Biokineticists-in-training were trained to assist with the 
intervention programmes.  This enables them to specialise in pulmonary 
rehabilitation and start their own pulmonary rehabilitation centres once they have 
finished their training.  The networks and co-operation agreements that were 
established during this study will further contribute to the training of Biokineticists 
wanting to specialise in pulmonary rehabilitation.  This would greatly benefit the 
accessibility of pulmonary rehabilitation in South Africa.   
 
High costs and specialised equipment are some of the important factors that limit 
the availability of pulmonary rehabilitation programmes.  This study showed that a 
more cost-effective programme could be successfully implemented with similar 
benefits than conventional programmes.  Feedback received from subjects that 
followed the modified programme was very positive.  Exercising outdoors was 
effective in eliciting an exercise response and subjects found it to be very 
enjoyable.   
  
Important to the success of low costs programmes, are comprehensive pre- and 
post-exercise assessments.  These evaluations are important to promote exercise 
adherence and to identify any co-morbidities that might place an individual at risk 
during exercise (ATS, 1995a).  During a pre-exercise assessment, patients get a 
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clear understanding of their limitations as well as their capabilities.  This 
assessment is vital in the formulation of clear exercise goals and to individualise 
exercise prescription (Johnson, 2004).  Post-exercise assessments provide an 
opportunity to evaluate the goals that were set at the pre-assessment and make 
adjustments where necessary.  Furthermore, it provides an opportunity for patients 
to quantify their progression and evaluate the effectiveness of the exercises, which 
is essential to exercise adherence (Turner et al., 2004).   
 
Another important factor that has been identified during the present study, is the 
scientific implementation of exercise programmes.  Pulmonary rehabilitation has 
developed in recent years from an art to a defined medical science 
(ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel, 1997).  Scientific 
implementation is important to maximise the benefits that the patient can obtain.  
Due to the wide range of physical impairments seen in COPD patients during 
similar stages of the disease, exercise programmes should be tailored to each 
individual’s capabilities and needs.   
 
An additional factor that contributed to the success of the current programme is the 
constant individual supervision that the subjects received.  Constant supervision is 
important to ensure that continuous feedback is given, high levels of motivation are 
maintained and necessary adjustments are made to exercises.  These 
programmes should be supervised by qualified clinicians that are specialised in 
pulmonary rehabilitation.  It is important that patients have confidence in these 
programmes and in the people that are administering it.   
 
Due to the risk involved when exercising these patients, constant contact with the 
patient’s medical doctor or physician is imperative.  Silent ischaemic heart disease 
can be present in COPD patients, which can be a limiting factor to exercise and an 
imminent danger if undiagnosed, particularly early in the rehabilitation process.  
Another factor contributing to the success of the programme is the early 
identification and treatment of acute chest infections.  If there is constant 
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interaction between the programme supervisors and the patients’ doctors or 
physicians, early identification and treatment of exacerbations is inevitable.   
 
Limitations 
 
The data collection process stretched over a period of more than four years.  
Despite extensive efforts to recruit subjects for the study, a relatively small number 
of subjects were included.  A major contributing factor, was the fact that the 
symptoms experienced by these patients fluctuate.  Therefore, subjects were 
primarily recruited during the winter months.  Typically, these patients are healthier 
during the warmer parts of the year and exacerbations are few.  In developed 
countries, COPD is diagnosed earlier and has a higher health status, compared to 
South Africa.  This contributes to the difficulties when studying this population in a 
developing country.  Furthermore, it seems that a considerable portion of this 
population remains ignorant as to the disease and its impact on quality of life.  
There is a need in South Africa for education of the broader community on the risk 
factors, symptoms and treatment of COPD.   
 
The small control group in the MP did limit data analyses.  This was unforeseen, 
since a number of subjects included in the control group withdrew from the study.  
Due to the randomisation, the study leaders could not supplement this group.  If a 
larger sample size is used in future research, this problem would be counteracted.   
 
The small number of subjects from previously disadvantaged communities could 
be criticised.  Although extensive recruitment campaigns were launched to recruit 
these individuals, there were a number of unforeseen factors that influenced the 
inclusion of these subjects, which should be addressed in future research.  
Typically, patients from previously disadvantaged communities continue working 
despite severe impairment, which makes it difficult for them to commit to a 12-week 
programme.  Although transportation was provided to patients in the vicinity of 
Stellenbosch, a number of patients without regular transport came from farms and 
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areas that were too far to include.  Unfavourable housing circumstances contribute 
to the frequency of exacerbations and the difficulty of exercising continuously.  A 
number of social difficulties were also encountered.  Although patients with known 
drug and alcohol addictions were excluded from the study, some subjects missed 
sessions due to alcohol misuse.  A small number of domestic problems were also 
encountered, which further contributed to the difficulty of exercise adherence.  In 
one subject new tuberculosis required withdrawal from the programme - another 
important problem to be faced when COPD rehabilitation is implemented among a 
population of low socio-economic status.   
 
Despite all these obstacles, the few subjects from previously disadvantaged 
communities that did finish the study, responded extremely well to the exercise 
training.  This population should definitely be considered for pulmonary 
rehabilitation and efforts are needed to improve the accessibility of programmes to 
this population.   
 
Contributing to the importance of pulmonary rehabilitation in previously 
disadvantaged communities is the fact that many of these patients have to rely on 
their physical fitness to obtain daily provisions, since proper transport is not always 
available.  Low-cost programmes that are readily accessible can greatly contribute 
to the inclusion of these patients in structured programmes.  This particular 
programme could easily be used to successfully implement pulmonary 
rehabilitation programmes in community centres or church halls.  In light of the 
challenges faced in previously disadvantaged communities, programmes should be 
designed to suit individual needs and must be flexible to accommodate external 
influences.  A programme design that for example, incorporates home-based 
sessions in addition to supervised sessions, could add to the accessibility and 
adherence to programmes for patients that continue to work or have other 
responsibilities.  Support of family members proved an obstacle in this study.  
Therefore, an information session with family members prior to commencing a 
programme, could further aid adherence.   
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 In the MP, neither the subjects nor the supervisors of the training programmes 
were blinded towards the group randomisation.  Biases could have existed towards 
a specific programme. 
 
Although patients that require supplemental oxygen were included with great 
success into the PP, these patients had to be excluded from the MP.  This was 
because of the assumption that supplemental oxygen is not readily available to the 
broader community, which implies that supplemental oxygen would fall beyond the 
borders of a cost-effective, community-orientated programme.  Therefore, the 
results of the MP cannot be readily extrapolated to patients with more severe 
COPD.  However, the PP showed that it is important to include severely impaired 
patients into these programmes.  The oxygen apparatuses that were used in the 
PP were kindly supplied by Vital Aire.  This kind of interaction needs to be 
expanded so that severely impaired patients from previously disadvantaged 
communities can benefit from pulmonary rehabilitation programmes. 
 
The exercise programme that was followed by the experimental group was 
designed to be easily implemented into a low-cost setting.  A possible limitation to 
the study design was that the pre- and post-walk tests were done on a treadmill.  
The decision to perform both the experimental and control group’s 6MWTs on a 
treadmill, were made to ensure that the results obtained from the two groups were 
comparable.  This could have put the experimental group at a disadvantage since 
the exercise programme did not include treadmill walking.  This problem was partly 
compensated for by including a treadmill walk into the experimental group’s 
training schedule every two weeks.  This may however, have influenced the 
differentiation between the two programmes.   
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Future research and recommendations  
 
Although it was not objectively measured, the casual observation was made that 
subjects from previously disadvantaged communities had better functional 
capabilities compared to other subjects with similar lung function impairment.  Due 
to the small number of subjects from previously disadvantaged communities 
included in this study, no statistical comparisons could be made.  This could be a 
potentially important opportunity for future research.   
 
The present study focused on making pulmonary rehabilitation more accessible to 
the broader community.  Further research is needed into the role and feasibility of 
home-based programmes in South Africa and the promotion of exercise 
adherence.   
 
According to Jindah and co-workers (2006), the lack of consensus around 
terminology of airway obstruction accounts for a variance of 200% in the estimation 
of the prevalence of COPD.  Research that is concerned with defining the 
characteristics of COPD is essential to completely understand the impact of this 
disease (Pauwels et al., 2001).  Very little data is available on the prevalence of 
COPD in South Africa.  A comprehensive study into the epidemiology of this 
disease is vital to fully understand its impact. 
 
Frequent exacerbations are one of the main obstacles to exercise adherence.  
Functional decline after exacerbations, due to exercise discontinuation, warrants 
further research into exercise maintenance despite recurring exacerbations 
(Gosselink, 2002; Foglio et al., 2001).   
 
One other important recommendation would be the inclusion of a mandatory 
community year for Biokineticists after the completion of their degree, similar to 
other medical and paramedical professions.  This would greatly benefit the 
implementation of pulmonary rehabilitation in previously disadvantaged 
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communities, since qualified clinicians would be available to implement these 
programmes.     
 
 
 213
REFERENCES 
__________________________________________________________ 
 
A .............................................................................................................  215 
B .............................................................................................................  216 
C .............................................................................................................  219 
D .............................................................................................................  222 
E .............................................................................................................  223 
F .............................................................................................................  224 
G .............................................................................................................  226 
H .............................................................................................................  228 
I .............................................................................................................  229 
J .............................................................................................................  229 
K .............................................................................................................  230 
L .............................................................................................................  231 
M .............................................................................................................  232 
N .............................................................................................................  236 
O .............................................................................................................  236 
P .............................................................................................................  237 
R .............................................................................................................  238 
S .............................................................................................................  239 
T .............................................................................................................  242 
V .............................................................................................................  243 
W .............................................................................................................  243 
X .............................................................................................................  245 
Y .............................................................................................................  245 
Z .............................................................................................................  245 
 
 214
ACCP/AACVPR PULMONARY REHABILITATION GUIDELINES PANEL (1997). 
Special report, pulmonary rehabilitation: Joint AACP/AACVPR evidence based 
guidelines.  Chest, 112(5):1363-1396. 
 
ALBERT, R.K. (1997).  Is pulmonary rehabilitation an effective treatment for 
chronic obstructive pulmonary disease?  No.  American Journal of Respiratory 
and Critical Care Medicine, 155:784-785. 
 
ALBUQUERQUE, A.L.P.; NERY, L.E.; VILLACA, D.S.; MACHADO, T.Y.S.; 
OLIVEIRA, C.C.; PAES, A.T. & NEDER, J.A. (2006).  Inspiratory fraction and 
exercise impairment in COPD patients GOLD stages II-III.  European 
Respiratory Journal, 28:939-944. 
 
ALIVERTI, A. & MACKLEM, P.T. (2001).  How and why exercise is impaired in 
COPD.  Respiration, 68:229-239. 
 
AMERICAN ASSOCIATION OF CARDIOVASCULAR AND PULMONARY 
REHABILITATION (ACVPR) (1998).  Guidelines for pulmonary rehabilitation 
programs.  2nd edition.  Human Kinetics: Champaign. 
 
AMERICAN COLLEGE OF SPORTS MEDICINE (2000).  ACSM’s guidelines for 
exercise testing and prescription.  Lippincott Williams & Wilkins: Baltimore. 
 
AMERICAN COLLEGE OF SPORTS MEDICINE (1998a).  ACSM’s resource 
manual for guidelines for exercise testing and prescription.  Lippincott Williams 
& Wilkins: Baltimore. 
 
AMERICAN COLLEGE OF SPORTS MEDICINE (1998b).  Position stand: The 
recommended quantity and quality of exercise for developing and maintaining 
cardiorespiratory and muscular fitness, and flexibility in healthy adults.  
Medicine and Science in Sports and Exercise, 30:975-991. 
 
AMERICAN COLLEGE OF SPORTS MEDICINE (1990).  Position stand: The 
recommended quantity and quality of exercise for developing and maintaining 
cardiorespiratory and muscular fitness, and flexibility in healthy adults.  
Medicine and Science in Sports and Exercise, 22:265-274.   
 
AMERICAN THORACIC SOCIETY (1981).  Pulmonary rehabilitation.  American 
Review of Respiratory Disease, 124:663-666. 
 
AMERICAN THORACIC SOCIETY (1987).  Standards for the diagnosis and care 
of patients of patients with chronic obstructive pulmonary disease (COPD) and 
asthma.  American Review of Respiratory Disease, 136:225-244. 
 
AMERICAN THORACIC SOCIETY (1995).  Standards for the diagnoses and care 
of patients with chronic obstructive pulmonary disease.  American Journal of 
Respiratory and Critical Respiratory Medicine,  152: s77-s120. 
 215
 
AMERICAN THORACIC SOCIETY (1999).  Pulmonary rehabilitation.  American 
Journal of Respiratory and Critical Respiratory Medicine, 159:1666-1682. 
 
AMERICAN THORACIC SOCIETY (2002).  ATS statement: Guidelines for the six-
minute walk test. American Journal of Respiratory and Critical Respiratory 
Medicine.  166(1):111-117. 
 
AMERICAN THORACIC SOCIETY AND EUROPEAN RESPIRATORY SOCIETY 
(1999).  Skeletal muscle dysfunction in chronic obstructive pulmonary disease.  
American Journal of Respiratory and Critical Care Medicine, 159(4):S2-S40. 
 
ANTONELLI-INCALZI, R.; IMPERIALE, C.; BELLIA, V.; CATALANO, F.; 
SCICHILONE, N.; PISTELLI, R.; RENGO, F. & THE SaRA INVESTIGATORS 
(2003).  Do GOLD stages of COPD severity really correspond to differences in 
health status?  European Respiratory Journal, 22:444-449. 
 
BAARENDS, E.M.; SCHOLS, A.M.W.J.; MOSTERT, R. & WOUTERS, E.F.M. 
(1997).  Peak exercise response in relation to tissue depletion in patients with 
chronic obstructive pulmonary disease.  European Respiratory Journal, 
10:2807-2813.  
 
BAKKE, P.S.; BASTE, V.; HANOA, R. & GULSVIK, A. (1991).  Prevalence of 
obstructive lung disease in a general population:  Relation to occupational title 
and exposure to some airborne agents.  Thorax, 46:863-870. 
 
BARBERA, J.A.; PEINADO, V.I. & SANTOS, S. (2003).  Pulmonary hypertension 
in chronic obstructive pulmonary disease.  European Respiratory Journal, 
21:892-905. 
 
BARBERA, J.A.; RIVEROLA, A.; ROCA, J.; RAMIREZ, J.; WAGNER, P.D.; ROS, 
D.; WIGGS, B.R. & RODRIGUEZ-ROISIN, R. (1994).  Pulmonary vascular 
abnormalities and ventilation-perfusion relationships in mild chronic obstructive 
pulmonary disease.  American Journal of Respiratory and Critical Care 
Medicine, 149:423-429. 
 
BARNES, P.J. (2003).  Therapy of chronic obstructive pulmonary disease.  
Pharmacology and Therapeutics, 97(1):87-94.   
 
BARNES, P.J. & GODFREY, S. (1997).  Chronic obstructive pulmonary disease.  
Martin Dunitz: London.   
 
BATEMAN, E.D.; FELDMAN, C.; O’BRIEN, J.; PLIT, M. & JOUBERT, J.R. (2004).  
Guideline for the management of chronic obstructive pulmonary disease 
(COPD): 2004 revision.  COPD Guideline working group of the South African 
Thoracic Society.  South African Thoracic Society, 94:559-575. 
 
 216
BATES, D.V. (1989).  Respiratory function in disease.  W.B. Saunders: 
Philadelphia.  
 
BAUERLE, O.; CHRUSCH, C.A. & YOUNES, M. (1998).  Mechanisms by which 
COPD affects exercise tolerance.  American Journal of Respiratory and Critical 
Care Medicine, 157:57-68. 
 
BAULDOFF, G.S.; HOFFMAN, L.A.; ZULLO, T.G. & SCIURBA, F.C. (2002).  
Exercise maintenance following pulmonary rehabilitation: Effect of distractive 
stimuli.  Chest, 122:948-954. 
 
BEGIN, P. & GRASSINO, A. (1991).  Inspiratory muscle dysfunction and chronic 
hypercapnia in chronic obstructive pulmonary disease.  American Review of 
Respiratory Disease, 143:905-912. 
 
BEHRENDT, C.E. (2005).  Mild and moderate-to-severe COPD in non-smokers:  
Distinct demographic profiles.  Chest, 128:1239-1244. 
 
BELLIA, V.; PISTELLI, F.; GIANNINI, D.; SCICHILONE, N.; CATALANO, F.; 
SPATAFORA, M.; HOPPS, R.; CARROZZI, L.; BALDACCI, S.; DI PEDE, F.; 
PAGGIARO, P. & VIEGI, G. (2003).  Questionnaires, spirometry and PEF 
monitoring in epidemiological studies on elderly respiratory patients.  European 
Respiratory Journal, 21:21S-27S. 
 
BELMAN, M.J. (1986).  Exercise in chronic obstructive pulmonary disease.  Clinics 
in Chest Medicine, 7:585-597. 
 
BELMAN, M.J. (1993).  Exercise in patients with chronic obstructive pulmonary 
disease.  Thorax, 48:936-946.   
 
BELMAN, M.J. & KENDREGAN, B.A. (1981).  Exercise training fails to increase 
skeletal muscle enzymes in patients with chronic obstructive pulmonary 
disease.  American Review of Respiratory Disease, 123:256-261. 
 
BELMAN, M.J. & KENDREGAN, B.A. (1982).  Physical training fails to improve 
ventilatory muscle endurance in patients with chronic obstructive pulmonary 
disease.  Chest, 81:440-443. 
 
BELMAN, M.J. & WASSERMAN, K. (1981).  Exercise training and testing in 
patients with chronic obstructive pulmonary disease.  Basics of Respiratory 
Disease, 10(2):1-6. 
 
BELMAN, M.J.; BROOKS, L.R.; ROSS, D.J. & MOHSENIFAR, Z. (1991).  
Variability of breathlessness measurement in patients with chronic obstructive 
pulmonary disease.  Chest, 99:566-571. 
 
 217
BENSTRUP, K.E.; INGEMANN JENSEN, J.; HOLM, S. & BENGTSSON, B. (1997).  
Out-patient rehabilitation improves activities of daily living, quality of life and 
exercise tolerance in chronic obstructive pulmonary disease.  European 
Respiratory Journal, 10:2801-2806. 
 
BERGDAHL, I.A.; TOREN, K.; ERIKSSON, K.; HEDLUND, U.; NILSSON, T.; 
FLODIN, R. & JARVHOLM, B. (2004).  Increased mortality in COPD among 
construction workers exposed to inorganic dust.  European Respiratory 
Journal, 23:402-406. 
 
BERNARD, S.; WHITTOM, F.; LeBLANC, P.; JOBIN, J.; BELLEAU, R.; BERUBE, 
C.; CARRIER, G. & MALTAIS, F. (1999).  Aerobic and strength training in 
patients with chronic obstructive pulmonary disease.  American Journal of 
Respiratory and Critical Care Medicine, 159:896-901.   
 
BERRY, M.J.; REJESKI, W.J.; ADAIR, N.E. & ZACCARO, D. (1999).  Exercise 
rehabilitation and chronic obstructive pulmonary disease stage.  American 
Journal of Respiratory and Critical Care Medicine, 160(4):1248-1253.   
 
BETSUYAKU, T.; YOSHIOKA, A.; NISHIMURA, M.; MIYAMOTO, K.; KONDO, T. & 
KAWAKAMI, Y. (1995).  Neutrophil elastase associated with alveolar 
macrophages from older volunteers.  American Journal of Respiratory and 
Critical Care Medicine, 151(2):436-442. 
 
BORG, G.A. (1982).  Psychological basis of physical exertion.  Medicine and 
Science in Sports and Exercise, 14:377. 
 
BOUERI, F.M.V.; BUCHER-BARTELSON, B.L.; GLENN, K.A. & MAKE, B.J. 
(2001).  Quality of life measured with a generic instrument (short form-36) 
improves following pulmonary rehabilitation in patients with COPD.  Chest, 
119(1):77-84. 
 
BOWEN, J.B.; VOTTO, J.J.; THRALL, R.S.; HAGGERTY, M.C.; STOCKDALE-
WOOLLEY, R.; BANDYOPADHYAY, T. & ZuWALLACK, R.L. (2000).  
Functional status and survival following pulmonary rehabilitation.  Chest, 
118(3):697-703. 
 
BRITISH THORACIC SOCIETY (1997).  British Thoracic Society guidelines for the 
diagnosis and management of stable COPD.  Thorax, 52(5):S12-S15. 
 
BRITISH THORACIC SOCIETY (2001).  Standards of care subcommittee on 
pulmonary rehabilitation:  Pulmonary rehabilitation.  Thorax, 56(11):827-834. 
 
BROOKS, D.; KRIP, B.; MANGOVSKI-ALZAMORA, S. & GOLDSTEIN, R.S. 
(2002).  The effect of post rehabilitation programmes among individuals with 
chronic obstructive pulmonary disease.  European Respiratory Journal, 20:20-
29. 
 218
 
BUIST, A.S. (2003).  Similarities and differences between asthma and chronic 
obstructive pulmonary disease: Treatment and early outcomes.  European 
Respiratory Journal, 21:30S-35S. 
 
BURGE, P.S.; CALVERLEY, P.M.; JONES, P.W.; SPENCER, S.; ANDERSON, 
J.A. & MASLEN, T.K. (2000).  Randomised, double blind, placebo controlled 
study of fluticasone propionate in patients with moderate to severe chronic 
obstructive pulmonary disease: The ISOLDE trial. British Medical Journal, 
320:1297-1303. 
 
BURGE, S. & WEDZICHA, J.A. (2003).  COPD exacerbations: Definitions and 
classifications.  European Respiratory Journal, 21:46S-53S. 
 
BUSCH, A. & McCLEMENTS, J.D. (1988).  Effects of a supervised home exercise 
program on patients with severe chronic obstructive pulmonary disease.  
Physical Therapy, 68(4):469-474. 
 
CALVERLEY, P.M.A. (2001).  Modern treatment of chronic obstructive pulmonary 
disease.  European Respiratory Journal, 18:60S-66S. 
 
CALVERLEY, P.M.A.; ANDERSON, J.A.; CELLI, B. & FERGUSON, G.T. (2007).  
Salmeterol and Fluticasone propionate and survival in chronic obstructive 
pulmonary disease.  New England Journal of Medicine, 356(8):775-789. 
 
CALVERLEY, P. & PRIDE, N. (1995).  Chronic obstructive pulmonary disease.  
Chapman & Hall: London. 
 
CAMBACH, W.; CHADWICK-STRAVER R.V.M.; WAGENAAR, R.C.; VAN 
KEIMPEMA, A.R.J. & KEMPER, H.C.G. (1997).  The effect of a community-
based pulmonary rehabilitation programme on exercise tolerance and quality 
of life: A randomized controlled trial.  European Respiratory Journal, 10:104-
113.  
 
CARRIERI-KOHLMAN, V.; GORMLEY, J.M.; DOUGLAS, M.K.; PAUL, S.M. & 
STULBARG, M.S. (1996).  Exercise training decreases dyspnea and the 
distress and anxiety associated with it:  Monitoring alone may be as effective 
as coaching.  Chest, 110:1526-1535. 
 
CARTER, R.; NICOTRA, B.; BLEVINS, W. & HOLIDAY, D.B. (1993).  Altered 
exercise gas exchange and cardiac function in patients with mild chronic 
obstructive pulmonary disease.  Chest, 103(3):745-750.  
 
CARTER, R.; HOLIDAY, D.B.; NWASURUBA, C.; STOCKS, J.; GROTHUES, C. & 
TIEP, B. (2003).  6-Minute walk work for assessment of functional capacity in 
patients with COPD.  Chest, 123:1408-1415. 
 
 219
CASABURI, R. (2001).  Skeletal muscle dysfunction in chronic obstructive 
pulmonary disease.  Medicine and Science in Sports and Exercise, 
33(7):S662-S670. 
 
CASABURI, R.; PATESSIO, A.; IOLI, F.; ZANABONI, S.; DONNER, C.F. & 
WASSERMAN, K. (1991).  Reductions in exercise lactic acidosis and 
ventilation as a result of exercise training in patients with obstructive lung 
disease.  American Review of Respiratory Disease, 143:9-18. 
 
CASANOVA, C.; COTE, C.G.; MARIN, J.M.; DE TORRES, J.P.; AGUIRRE-JAIME, 
A.; MENDEZ, R.; DORDELLY, L. & CELLI, B.R. (2007).  The 6-min walking 
distance: long-term follow up in patients with COPD.  European Respiratory 
Journal, 29:535-540.   
 
CASANOVA, C.; COTE, C.; TORRES, J.P.; AGUIRRE-JAIME, A.; MARIN, J.M.; 
PINTO-PLATA, V. & CELLI, B.R. (2005).  Inspiratory-to-total lung capacity 
ratio predicts mortality in patients with chronic obstructive pulmonary disease.  
American Journal of Respiratory and Critical Care Medicine, 171:591-597. 
 
CELLI, B.R. (1995).  Pulmonary rehabilitation in patients with COPD.  American 
Journal of Respiratory and Critical Care Medicine, 152:861-864. 
 
CELLI, B.R. (1999).  Respiratory disease.  In W.R. Frontera; D.M. Dawson & D.M. 
Slovik (Eds.), Exercise in rehabilitation medicine, (pp.193-207).  Human 
Kinetics: Champaign.   
 
CELLI, B.R.; COTE, C.G.; MARIN, J.M.; CASANOVA, C. (2004).  The body-mass 
index, airflow obstruction, dyspnea, and exercise capacity index in chronic 
obstructive pulmonary disease.  The New England Journal of Medicine, 
350(10):1005-1012. 
 
CELLI, B.R.; HALBERT, R.J.; ISONAKA, S. & SCHAU, B. (2003).  Population 
impact of different definitions of airway obstruction.  European Respiratory 
Journal, 22:268-273.  
 
CERVERI, I.; ACCORDINI, S.; VERLATO, G.; CORSICO, A.; ZOIA, M.C.; CASALI, 
L.; BURNEY, P. & DE MARCO, R. (2001).  Variations in the prevalence across 
countries of chronic bronchitis and smoking habits in young adults.  European 
Respiratory Journal, 18:85-92. 
 
CHAN-YEUNG, M.; AIT-KHALED, N.; WHITE, N.; IP, M.S. & TAN, W.C. (2004).  
The burden and impact of COPD in Asia and African.  International Journal of 
Tuberculosis and Lung Disease, 8(1):2-14. 
 
CHRISTIE, D. (1968).  Physical training in chronic obstructive lung disease.  British 
Medical Journal, 2:150-151. 
 
 220
CLARK, C.J. (1994).  Pulmonary rehabilitation in chronic respiratory insufficiency:  
Setting up a pulmonary rehabilitation programme.  Thorax, 49:270-278. 
 
CLARK, C.J. (1995).  Pulmonary rehabilitation.  In P. Calverley & N. Pride (Eds.), 
Chronic obstructive pulmonary disease (pp.527-533).  Chapman & Hall: 
London. 
 
CLARK, C.J.; COCHRANE, L. & MACKAY, E.  (1996) Low intensity peripheral 
muscle conditioning improves exercise tolerance and breathlessness in 
COPD.  European Respiratory Journal, 9:2590-2596. 
 
CLARK, C.J.; COCHRANE, L.; MACKAY, E. & PATON, B. (2000).  Skeletal muscle 
strength and endurance in patients with mild COPD and the effects of weight 
training.  European Respiratory Journal, 15:92-97. 
 
COCKCROFT, A.E.; SAUNDERS, M.I. & BERRY, G. (1981).  Randomized 
controlled trial of rehabilitation in chronic respiratory disability.  Thorax, 36:200-
236. 
 
COOPER, C.B. (1995).  Determining the role of exercise in chronic pulmonary 
disease.  Medicine and Science in Sports and Exercise, 27:147-157. 
 
COOPER, C.B. (2001a).  Exercise in chronic pulmonary disease: Aerobic exercise 
prescription.  Medicine and Science in Sports and Exercise, 33(7):S671-S679. 
 
COOPER, C.B. (2001b).  Exercise in chronic pulmonary disease: Limitations and 
rehabilitation.  Medicine and Science in Sports and Exercise, 33(7):S643-
S646. 
 
COPPOOLSE, R.; SCHOLS, A.M.W.J.; BAARENDS, E.M.; MOSTERT, R.; 
AKKERMANS, M.A.; JANSSEN, P.P. & WOUTERS, E.R.M. (1999).  Interval 
versus continuous training in patients with severe COPD: A randomized 
clinical trial.  European Respiratory Journal, 14:258-263. 
 
COSTES, F.; ROCHE, F.; PICHOT, V.; VERGNON, J.M.; GARET, M. & 
BARTHELEMY, J-C. (2004).  Influence of exercise training on cardiac 
baroreflex sensitivity in patients with COPD.  European Respiratory Journal, 
23:396-401. 
 
COUSER, J.I.; MARTINEZ, F.J. & CELLI, B.R. (1993).  Pulmonary rehabilitation 
that includes arm exercise reduces metabolic and ventilatory requirements.  
Chest, 103(1): 37-41. 
 
COX, N.J.M.; HENDRICKS, J.C.; BINKHORST, R.A. & VAN HERWAARDEN, 
C.L.A. (1993).  A pulmonary rehabilitation program for patients with asthma 
and mild chronic obstructive pulmonary disease.  Lung, 171:235-244. 
 
 221
CROXTON, T.L.; WEINMANN, G.G.; SENIOR, R.M. & HOIDAL, J.R. (2002).  
Future research directions in chronic obstructive pulmonary disease: 
Workshop summary.  American Journal of Respiratory and Critical Care 
Medicine, 165(6):838-844.  
 
CURTIS, J.R.; DEYO, R.A. & HUDSON, L.D. (1994).  Health related quality of life 
among patients with chronic obstructive pulmonary disease.  Thorax, 49:162-
170. 
 
CURTIS, J.R. & PATRICK, D.L. (2003).  The assessment of health status among 
patients with COPD.  European Respiratory Journal, 21:36S-45S. 
 
DALES, R.E.; MEHDIZADEH, A.; AARON, S.D.; VANDEMHEEN, K.L. & CLINCH, 
J. (2006).  Sex differences in the clinical presentation and management of 
airflow obstruction.  European Respiratory Journal, 28:319-322. 
 
DEBIGARE, R.; COTE, C.H. & MALTAIS, F. (2001).  Peripheral muscle wasting in 
chronic obstructive pulmonary disease.  American Journal of Respiratory and 
Critical Care Medicine, 164:1712-1717. 
 
DECRAMER, M. (1992).  Pulmonary rehabilitation.  Art or science.  European 
Respiratory Journal, 5:155-156. 
 
DECRAMER, M.; DE BOCK, V. & DOM, R. (1996).  Functional and histologic 
picture of steroid-induced myopathy in chronic obstructive pulmonary disease.  
American Journal of Respiratory and Critical Care Medicine, 153:1958-1964. 
 
DECRAMER, M.; GOSSELINK, R.; TROOSTERS, T.; VERSCHUEREN, M. & 
EVERS, G. (1997).  Muscle weakness is related to utilization of health care 
resources in COPD patients.  European Respiratory Journal, 10:417-423. 
 
DEGACHE, F.; COSTE, F.; CALMEL, P.; GARET, M.; BARTHELEMY, J.C. & 
ROCHE, F. (2003).  Determination of isokinetic muscle strength in chronic 
heart failure patients and in patients with chronic obstructive pulmonary 
disease.  Isokinetics and Exercise Science, 11:31-35. 
 
DEKHUIJZEN, P.M.R. & DECRAMER, M. (1992).  Steroid-induced myopathy and 
its significance to respiratory disease: A known disease rediscovered.  
European Respiratory Journal, 5:997-1003. 
 
DEPARTMENT OF HEALTH AND MEDICAL RESEARCH COUNCIL (1998).  
South African demographic and health survey, 1998: Full report.  Department 
of Health and Medical Research Council: Pretoria. 
 
DE TORRES, J.P.; CASANOVA, C.; HERNANDEZ, C.; ABREU, J.; AGUIRRE-
JAIME, A. & CELLI, B.R. (2005).  Gender and COPD in patients attending a 
pulmonary clinic.  Chest, 128:2012-2016. 
 222
 
DIAZ, P.T.; KING, M.A.; PACHT, E.R.; WEWERS, M.D.; GADEK, J.E.; 
NAGARAJA, H.N.; DRAKE, J. & CLANTON, T.L. (2000a).  Increased 
susceptibility to pulmonary emphysema among HIV-seropositive smokers.  
Annals of Internal Medicine, 132(5):369-372. 
 
DIAZ, O.; VILLAFRANCA, C.; GHEZZO, H.; BORZONE, G.; LEIVA, A.; MILIC-
EMIL, J. & LISBOA, C. (2000b).  Role of inspiratory capacity on exercise 
tolerance in COPD patients with and without tidal expiratory flow limitation at 
rest.  European Respiratory Journal, 16(2):269-275. 
 
DIAZ, P.T.; WEWERS, M.D.; PACHT, E.; DRAKE, J.; NAGARAJA, H.N. & 
CLANTON, T.L. (2003).  Respiratory symptoms among HIV-seropositive 
individuals.  Chest, 123:1977-1982. 
 
DONAHOE, M.; ROGERS, R.M.; WILSON, D.O. & PENNOCK, B.E. (1989).  
Oxygen consumption of the respiratory muscles in normal and in malnourished 
patients with chronic obstructive pulmonary disease.  American Review of 
Respiratory Disease, 140:385-391. 
 
DONOHUE, J.F. (2005).  Synopsis of discussions in session 5: Opportunities for 
combination therapy in COPD.  The Proceedings of the American Thoracic 
Society, 2:394-395. 
 
DORLAND’S ILLUSTRATED MEDICAL DICTIONARY, 24th edition (1967).  W.B. 
Saunders: Philadelphia.   
 
DOURADO, V.Z.; DE OLIVEIRA ANTUNES, L.C.; TANNI, S.E.; DE PAIVA, S.A.R.; 
PADOVANI, C.R. & GODOY, I. (2006).  Relationship of upper-limb and 
thoracic muscle strength to 6-min walk distance in COPD patients.  Chest, 
129(3):551-557. 
  
DUECK, R. (2000).  Assessment and monitoring of flow limitation and other 
parameters from flow/volume loops.  Journal of Clinical Monitoring and 
Computing, 16:425-432. 
 
DUECK, R.; COOPER, S.; COLT, H.; KAPELANSKI, D. & CLAUSEN, J. (1999).  A 
pilot study of expiratory flow limitation and lung volume reduction surgery.  
Chest, 116:1762-1771. 
 
EFREMIDIS, G.; TSIAMITA, M.; MANOLIS, A. & SPIROPOULOS, K. (2005).  
Accuracy of pulmonary function tests in predicted exercise capacity in COPD 
patients.  Respiratory Medicine, 99:609-614. 
 
 223
EFTHIMIOU, J.; FLEMING, J. GOMES, C. & SPIRO, S.G. (1988).  The effect of 
supplementary oral nutrition in poorly nourished patients with chronic 
obstructive pulmonary disease.  American Review of Respiratory Disease, 
137:1075-1082. 
 
EHRLICH, R.I.; WHITE, N.; NORMAN, R.; LAUBSCHER, R.; STEYN, K.; 
LOMBARD, C. & BRADSHAW, D. (2004).  Predictors of chronic bronchitis in 
South African adults.  International Journal of Tuberculosis and Lung Disease, 
8(3):369-376. 
 
EISNER, M.D.; YELIN, E.H.; TRUPIN, L. & BLANC, P.D. (2002).  The influence of 
chronic respiratory conditions on health status and work disability.  American 
Journal of Public Health, 92(9):1506-1513. 
 
ELTAYARA, L.; BECKLAKE, M.R.; VOLTA, C.A. & MILIC-EMILI, J. (1996).  
Relationship between chronic dyspnea and expiratory flow limitation in patients 
with chronic obstructive pulmonary disease.  American Journal of Respiratory 
and Critical Care Medicine, 154:1726-1734. 
 
ENGELEN, M.P.J.K.L.; SCHOLS, A.M.W.J.; BAKEN, W.C.; WESSELING, G.J. & 
WOUTERS, E.F.M. (1994).  Nutritional depletion in relation to respiratory 
function in out-patients with COPD.  European Respiratory Journal, 7:1793-
1797. 
 
ENRIGHT, P.L.; McBURNIE, M.A.; BITTNER, V.; TRACY, R.P.; McNAMARA, R.; 
ARNOLD, A. & NEWMAN, A.B. (2003).  The 6-min walk test: A quick measure 
of functional status in elderly adults.  Chest, 123:387-398. 
 
ETNIER, J.; JOHNSTON, R.; DAGENBACH, D.; POLLARD, R.J.; REJESKI, W.J. 
& BERRY, M. (1999).  The relationships among pulmonary function, aerobic 
fitness, and cognitive functioning in older COPD patients.  Chest, 116(4):953-
960. 
 
FALCONE, A.; CASSONE, R.; ROSSI, E.; PISTORIO, A.; MARTINI, A. & 
RAVELLI, A. (2005).  Inter-observer agreement of the physician’s global 
assessment of disease activity in children with juvenile idiopathic arthritis.  
Clinical Experimental Rheumatology, 23(1):113-116. 
 
FARBER, M.O. & MANNIX, E.T. (2000).  Tissue wasting in patients with chronic 
obstructive pulmonary disease, the acquired immune deficiency syndrome, 
and congestive heart failure.  Neurologic Clinics, 18(1):245-262. 
 
FEENSTRA, T.L.; VAN GENUGTEN, M.L.; HOOGENVEEN, R.T.; WOUTERS, 
E.F. & RUTTEN-VAN MOLKEN, M.P. (2001).  The impact of aging and 
smoking on the future burden of chronic obstructive pulmonary disease: A 
model analysis in the Netherlands.  American Journal of Respiratory and 
Critical Care Medicine, 164:590-596. 
 224
 
FINNERTY, J.P.; KEEPING, I.; BULLOUGH, I. & JONES, J. (2006).  The 
effectiveness of outpatient pulmonary rehabilitation in chronic lung disease: A 
randomized controlled trial.  Chest, 119(6):1705-1710. 
 
FISHMAN, A. (1998).  Fishman’s pulmonary diseases and disorders.  McGraw-Hill: 
New York. 
 
FISHMAN, A.P. (1994).  Pulmonary rehabilitation research.  American Journal of 
Respiratory and Critical Care Medicine, 149:825-833. 
 
FITTING, J.W. (2001).  Respiratory muscles in chronic obstructive pulmonary 
disease.  Swiss Medicine Weekly, 131:483-486. 
 
FLETCHER, C. & PETO, R. (1977).  The natural history of chronic airflow 
obstruction.  British Medical Journal, 25:1645-1648. 
 
FLETCHER, C.; PETO, R.; TINKER, C. & SPEIZER, F.E. (1976).  The natural 
history of chronic bronchitis and emphysema an eight-year study of early 
chronic obstructive lung disease in working men in London.  Oxford University 
Press: New York. 
 
FOGLIO, K.; BIANCHI, L. & AMBROSINO, N. (2001).  Is it really useful to repeat 
outpatient pulmonary rehabilitation programs in patients with chronic airway 
obstruction? A 2-year controlled study.  Chest, 119(6):1696-1704. 
 
FOGLIO, K.; BAINCHI, L.; BRULETTI, G.; BATTISTA, L.; PAGANI, M. & 
AMBROSINI, N. (1999).  Long term effectiveness of pulmonary rehabilitation in 
patients with chronic airway obstruction.  European Respiratory Journal, 
13(1):125-132. 
 
FOGLIO, K.; CARONE, M.; PAGANI, M.; BIANCHI, L.; JONES, P.W. & 
AMBROSINO, N. (2000).  Physiological and symptom determinants of 
exercise performance in patients with chronic airway obstruction.  Respiratory 
Medicine, 94:256-263. 
 
FOLGERING, H. & VAN HERWAARDEN, C. (1994).  Exercise limitations in 
patients with pulmonary diseases.  International Journal of Sports Medicine, 
15(3):107-111. 
 
FRANSSEN, F. (2003).  The influence of comorbid factors on muscle function, 
morphology and metabolism in COPD.  In F.F.M. Wouters & A.M.W.J. Schols 
(Eds.), European Respiratory Monograph – Nutrition and metabolism in 
chronic respiratory disease, 8(24):  no page numbers.  
 
 225
FUJIMOTO, K.; MATSUZAWA, Y.; YAMAGUCHI, S.; KOIZUMI, T. & KUBO, K. 
(2002).  Benefits of oxygen on exercise performance and pulmonary 
hemodynamics in patients with COPD with mild hypoxemia.  Chest, 122:457-
463. 
 
GALLAGHER, C.G. (1994).  Exercise limitation and clinical exercise testing in 
chronic obstructive pulmonary disease.  Clinics in Chest Medicine, 15(2):305-
326. 
 
GEA, J.G.; PASTO, M.; CARMONA, M.A.; OROZCO-LEVI, M.; PALOMEQUE, J. & 
BROQUETAS, J. (2001).  Metabolic characteristics of the deltoid muscle in 
patients with chronic obstructive pulmonary disease.  European Respiratory 
Journal, 17:939-945. 
 
GELB, A.F.; BRENNER, M.; McKENNA, R.J.; ZAMEL, N.; FISCHEL, R. & 
EPSTEIN, J.D. (1996a).  Lung function 12 months following emphysema 
resection.  Chest, 110:1407-1415. 
 
GELB, A.F.; McKENNA, R.J.; BRENNER, M.; FISCHEL, R.; BAYDUR, A. & 
ZAMEL, N. (1996b).  Contribution of lung and chest wall mechanics following 
emphysema resection.  Chest, 110:11-17. 
 
GEORGE, R.B.; LIGHT, R.W.; MATTHAY, M.A. & MATTHAY, R.A. (1990).  Chest 
medicine, essentials of pulmonary and critical care medicine.  2nd edition.  
Williams & Wilkins: Baltimore. 
 
GIBSON, G.J. (1996).  Pulmonary hyperinflation in a clinical overview.  European 
Respiratory Journal, 9:2640-2649. 
 
GLASS, S.C.; KNOWLTON, R.G. & BECQUE, M.D. (1992).  Accuracy of RPE from 
graded exercise to establish training intensity.  Medicine and Science in Sports 
and Exercise, 24:1303-1307. 
 
GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (2003).  
“Facts about COPD.”  GOLD workshop 2003. [Hyperlink 
http://www.goldcopd.com/slides/slide5.htm].  23 July 2004. 
 
GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (2006).  
Global strategy for the diagnosis, management, and prevention of chronic 
obstructive pulmonary disease.  [Hyperlink http://www.goldcopd.com].  3 
September 2007. 
 
GOLDSTEIN, R.S.; GORT, E.H.; STUBBING, D.; AVENDADO, M.A. & GUYATT, 
G.H. (1994).  Randomised controlled trial of respiratory rehabilitation.  Lancet, 
344:1394-1397. 
 
 226
GOSSELINK, R. (2002).  Respiratory rehabilitation: Improvement of short- and 
long-term outcome.  European Respiratory Journal, 20:4-5. 
 
GOSSELINK, R. (2003).  Controlled breathing and dyspnea in patients with chronic 
obstructive pulmonary disease (COPD).  Journal of Rehabilitation Research 
and Development, 40(5):25S-34S. 
 
GOSSELINK, R.; TROOSTERS, T. & DECRAMER, M. (1996).  Peripheral muscle 
weakness contributes to exercise limitation in COPD.  American Journal of 
Respiratory and Critical Care Medicine, 153:976-980. 
 
GOSSELINK, R.; TROOSTERS, T. & DECRAMER, M. (1997).  Exercise training in 
COPD patients:  The basic questions.  European Respiratory Journal, 
10:2884-2891.   
 
GOSSELINK, R.; WAGENAAR, R.C.; RIJSWIJK, H.; SARGEANT, A.J. 
&DECRAMER, M.L. (1995).  Diaphragmatic breathing decreases the efficiency 
of breathing in patients with COPD.  American Journal of Respiratory and 
Critical Care Medicine, 151:436-442. 
 
GRAHAM, T.; WILSON, B.A.; SAMPLE, M.; VAN DIJK, J. & BONEN, A. (1980).  
The effects of hypercapnia on metabolic responses to progressive exhaustive 
work.  Medicine and Science in Sports and Exercise, 12:278-284. 
 
GRAY-DONALD, K.; GIBBONS, L.; SHAPIRO, S.H.; MACKLEM, P.T. & MARTIN, 
J.G. (1996).  Nutritional status and mortality in chronic obstructive pulmonary 
disease.  American Journal of Respiratory and Critical Care Medicine, 
153:961-966. 
 
GREEN, R.H.; SINGH, S.J.; WILLIAMS, J. & MORGAN, M.D.L. (2001).  A 
randomised controlled trial of four weeks versus seven weeks of pulmonary 
rehabilitation in chronic obstructive pulmonary disease.  Thorax, 56(2):143-
145. 
 
GRIFFITHS, T.L.; BURR, M.L.; CAMPBELL, I.A.; LEWIS-JENKINS, V.; MULLINS, 
J.; SHIELDS, K.; TURNER-LAWLOR, P.J.; PAYNE, N.; NEWCOMBE, R.G.; 
LONESCU, A.A.; THOMAS, J. & TUNBRIDGE, J. (2000).  Results at 1 year of 
outpatient multidisciplinary pulmonary rehabilitation: A randomised controlled 
trail.  Lancet, 355:362-368. 
 
GRIFFITHS, T.L.; PHILLPS, C.J.; DAVIES, S.; BURR, M.L. & CAMPBELL, J.A. 
(2001).  Cost effectiveness of an outpatient multidisciplinary pulmonary 
rehabilitation programme.  Thorax, 56:779-784. 
 
GRIMBY, S. & SALTIN, B. (1983).  The ageing muscle.  Clinical Physiology, 3:209-
218. 
 
 227
GROBELAAR, J. & BATEMAN, E.D. (1991).  Hut lung: A domestically acquired 
pneumoconiosis of mixed aetiology in rural women.  Thorax, 46:334-340. 
 
GUELL, R.; CASAN, P.; BELDA, J.; SANGENIS, M.; MORANTE, F.; GUYATT, 
G.H. & SANCHIS, J. (2000).  Long-term effects of outpatient rehabilitation of 
COPD: A randomized trial.  Chest, 117(4):976-983. 
 
GUYATT, G.H.; PUGSLEY, S.O.; SULLIVAN, M.J.; THOMPSON, P.J.; BERMAN, 
L.B.; JONES, N.L.; FALLEN, E.L. & TAYLOR, D.W. (1984).  Effect of 
encouragement on walking test performance.  Thorax, 39:818-822. 
 
HACCOUN, C.; SMOUNTAS, A.A.; GIBBONS, W.J.; BOURBEAU, J. & LANDS, 
L.C. (2002).  Isokinetic muscle function in COPD.  Chest, 121:1079-1084. 
 
HALBERT, R.J.; ISONAKA, S.; GEORGE, D. & IQBAL, A. (2003).  Interpreting 
COPD prevalence estimates: What is the true burden of disease?  Chest, 
123:1684-1692. 
 
HALBERT, R.J.; NATOLI, J.L.; GANO, A.; BADAMGARAV, E.; BUIST, A.S. & 
MANNINO, D.M. (2006).  Global burden of COPD: Systematic review and 
meta-analysis.  European Respiratory Journal, 28:523-532. 
 
HAMACHER, J.; BUCHI, S.; GEORGESCU, C.L.; STAMMBERGER, U.; 
THURNHEER, R.; BLOCH, K.E.; WEDER, W. & RUSSI, E.W. (2002).  
Improved quality of life after lung volume reduction surgery.  European 
Respiratory Journal, 19:54-60. 
 
HAMILTON, A.L.; KILLIAN, K.J.; SUMMERS, E. & JONES, N.L. (1995).  Muscle 
strength, symptom intensity, and exercise capacity in patients with 
cardiorespiratory disorders.  American Journal of Respiratory and Critical Care 
Medicine, 152:2021-2031. 
 
HART, N.; HAWKINS, P.; HAMNEGARD, C-H.; GREEN, M.; MOXHAM, J. & 
POLKEY, M.I. (2002).  A novel clinical test of respiratory muscle endurance.  
European Respiratory Journal, 19:232-239. 
 
HEALTH SYSTEMS TRUST (2006).  “Tuberculosis prevalence rate per 100 000 
population.”  Health Statistics.  [Hyperlink  http://www.hst.org.za].  9 June 
2006. 
 
HERNADEZ, M.T.E.; RUIO, T.M.; RUIZ, F.O.; RIERA, H.S.; GIL, R.S. & GOMEZ, 
J.C. (2000).  Results of a home-based training program for patients with 
COPD.  Chest, 118(1):106-114. 
 
HILL, K.; JENKINS, S.C.; PHILIPPE, D.L.; CECINS, N.; SHEPERD, K.L.; GREEN, 
D.J.; HILLMAN, D.R. & EASTWOOD, P.R. (2006).  High-intensity inspiratory 
muscle training in COPD.  European Respiratory Journal, 27:1119-1128. 
 228
 
HNIZDO, E.; SINGH, T. & CHURCHYARD, G. (2000).  Chronic pulmonary function 
impairment caused by initial and recurrent pulmonary tuberculosis following 
treatment.  Thorax, 55(1):32-38. 
 
HOGG, J.C. & SENIOR, R.M. (2002).  Chronic obstructive pulmonary disease 2: 
Pathology and biochemistry of emphysema. Thorax, 57:830-834. 
 
HODGKIN, J. (1990).  Prognosis in chronic obstructive pulmonary disease.  Clinics 
in Chest Medicine, 11:555-569. 
 
HOLDEN, D.A.; STELMACH, K.D.; CURTIS, P.S.; BECK, G.J. & STOLLER, J.K. 
(1990).  The impact of a rehabilitation program on functional status of patients 
with chronic lung disease.  Respiratory Care, 35(4):332-341. 
 
HOOGENDOORN, M.; RUTTEN-VAN MöLKEN, M.P.M.H.; HOOGENVEEN, R.T.; 
VAN GENUGTEN, M.L.L.; BUIST, A.S.; WOUTERS, E.F.M. & FEENSTRA, 
T.L. (2005).  A dynamic population model of disease progression in COPD.  
European Respiratory Journal, 26:223-233. 
 
HOROWITZ, M.B.; LITTENBERG, B. & MAHLER, D.A. (1996).  Dyspnea ratings 
for prescribing exercise intensity in patients with COPD.  Chest, 109(5):1169-
1175. 
 
HOWALD, H.; PETTE, D.; SIMONEAU, A.; UBER, A.; HOPPELER, H. & 
CERRETELLI, P. (1990).  Effects of chronic hypoxia on muscle enzymes 
activities.  International Journal of Sports Medicine, 11:S10-S14. 
 
HUGHES, R.L. & DAVISON, R. (1983).  Limitations of exercise reconditioning in 
COPD.  Chest, 83:241-249. 
 
HURD, S. (2000).  The impact of COPD on lung health worldwide, epidemiology 
and incidence.  Chest, 117(2):1S-4S.   
 
ISOAHO, R.; PUOLIJOKA, H.; HUHTI, E.; KIVELA, S.L.; LAIPPALA, P. & TALA, E. 
(1994).  Prevalence of chronic obstructive pulmonary disease in elderly Finns.  
Respiratory Medicine, 88:571-580. 
 
JAKOBSSON, P. & JORFELDT, L. (1995).  Long-term oxygen therapy may 
improve skeletal muscle metabolism in advanced chronic obstructive 
pulmonary disease patients with chronic hypoxaemia.  Respiratory Medicine, 
89:471-476. 
 
JENSEN, H.H.; GODTFREDSEN, N.S.; LANGE, P. & VESTBO, J. (2006).  
Potential misclassification of causes of death from COPD.  European 
Respiratory Journal, 28:781-785. 
 
 229
JINDAH, S.K.; AFFARWAH, A.N.; CHAUDHRY, K.; CHHABRA, S.K.; D’SOUZA, 
G.A.; GUPTA, S.K.; KUMAR, R.; SHAH, B. & VIJAYAN, V.K. (2006).  A 
multicentric study on epidemiology of chronic obstructive pulmonary disease 
and its relationship with tobacco smoking and environmental tobacco smoke 
exposure.  The Indian Journal of Chest Diseases and Allied Sciences, 48:23-
29.   
 
JOHANNESSEN, A.; LEHMANN, S.; OMENAAS, E.R.; EIDE, G.E.; BAKKE, P.S. & 
GULSVIK, A. (2006).  Post-bronchodilator spirometry reference values in 
adults and implications for disease management.  American Journal of 
Respiratory and Critical Care Medicine, 173(12):1316-1325. 
 
JOHNSON, J.E. (2004).  Which exercise test should be used for patients with 
symptomatic COPD?  Chest, 126(3):668-670. 
 
JONES, P.W. (1991).  Quality of life measurement for patients with diseases of the 
airways.  Thorax, 46:676-682.   
 
JONES, P.W. (2002).  Interpreting thresholds for a clinically significant change in 
health status in asthma and COPD.  European Respiratory Journal, 19:398-
404.   
 
JONES, P.W.; QUIRK, F.H. & BAVEYSTOCK, C.M. (1991).  The St. George’s 
Respiratory Questionnaire.  Respiratory Medicine, 85:25-31. 
 
JONES, P.W.; QUIRK, F.H.; BAVEYSTOCK, C.M. & LITTLEJOHNS, P. (1992).  A 
self-complete measure of health status for chronic airflow limitation: The St. 
George’s Respiratory Questionnaire.  American Review of Respiratory 
Disease, 145: 1321-1327. 
 
JONVILLE, S.; DELPECH, N. & DENJEAN, A. (2002).  Contribution of respiratory 
acidosis to diaphragmatic fatigue at rest.  European Respiratory Journal, 
19:1079-1086. 
 
JOPPA, P.; PETRASOVA, D.; STANCAK, B.; TKACOVA, R. (2006).  Systemic 
inflammation in patients with COPD and pulmonary hypertension.  Chest, 
130(2):326-333. 
 
KETELAARS, C.A.J.; HUYER ABU-SAAD, H.; SCHLOSSER, M.A.G.; MOSTERT, 
R. & WOUTERS, E.F.M. (1997).  Long-term rehabilitation of pulmonary 
rehabilitation in patients with COPD.  Chest, 112(2):363-369. 
 
KETELAARS, C.A.J.; SCHLöSSER, M.A.G.; MOSTERT, R.; HUYER ABU-SAAD, 
H.; HALFENS, R.J.G. & WOUTERS, E.F.M. (1996).  Determinants of health-
related quality of life in patients with chronic obstructive pulmonary disease.  
Thorax, 51:39-43. 
 230
 
KILLIAN, K.J.; LeBLANC, R.; MARTIN, D.H.; SUMMERS, E.; JONES, N.L. & 
CAMPBELL, E.J. (1992).  Exercise capacity and ventilatory, circulatory, and 
symptom limitation in patients with chronic airflow limitation.  American Review 
of Respiratory Disease, 146:935-940. 
 
KNOX, A.J.; MORRISON, J.F.J. & MUERS, M.F. (1988).  Reproducibility of 
walking test results in chronic obstructive airways disease.  Thorax, 43:388-
392. 
 
KOTLER, D.P. (2000).  Cachexia.  Annals of Internal Medicine, 133:622-634. 
 
KROENKE, K.; WYRWICH, K.W.; TIERNEY, W.M.; BABU, A.N. & WOLINSKY, 
F.D. (2006).  Physician-estimated disease severity in patients with chronic 
heart or lung disease: A cross-sectional analysis.  Health and Quality of Life 
Outcomes, 4(60):  no page numbers. 
 
LACASSE, Y.; WONG, E.; GUYATT, G.H.; KING, D.; COOK, D.J. & GOLDSTEIN, 
R.S. (1996).  Meta-analysis of respiratory rehabilitation in chronic obstructive 
pulmonary disease.  Lancet, 348:1115-1119.   
 
LAKE, F.R.; HENDERSON, K.; BRIFFA, T.; OPENSHAW, J. & MUSK, A.W. 
(1990).  Upper-limb and lower-limb exercise training in patients with chronic 
airflow obstruction.  Chest, 97:1077-1082. 
 
LALLOO, U.G.; BECKLAKE, M.R. & GOLDSMITH (1991).  Effect of standing 
versus sitting position on spirometric indices in healthy subjects.  Respiration, 
58:122-125. 
 
LANCASTER, T.; STEAD, L.; SILAGY, C.; SOWDEN, A. (2000).  Effectiveness of 
interventions to help people stop smoking:  Findings from the Cochrane 
Library.  British Medical Journal, 321:355-358. 
 
LAREAU, S.C.; BRESLIN, E.H.; ANHOLM, J.D. & ROOS, P.J. (1992).  Reduction 
in arm activities in patients with severe obstructive pulmonary disease.  
American Review of Respiratory Disease, 145:A476. 
 
LAREAU, S.C.; CARRIERI-KOHLMAN, V.; JANSON-BJERKLIE, S. & ROOS, P.J. 
(1994).  Development and testing of the pulmonary functional status and 
dyspnea questionnaire.  Heart & Lung, 23:242-250. 
 
LEEMAN, P. (2006).  “Anti-smoking chews on fatal statistics.”  Health Systems 
Trust.  [Hyperlink http://new.hst.org.za ].  9 June 2006. 
 
LOMAS, D.A. (2002).  Chronic obstructive pulmonary disease – Introduction.  
Thorax, 57:735. 
 
 231
LUNDBACK, B.; LINDBERG, A.; LINDSTROM, M.; RONMARK, E.; JONSSON, 
A.C.; JONSSON, E.; LARSSON, L.G.; ANDERSSON, S.; SANDSTROM, T. & 
LARSSON, K.  (2003). Not 15 but 50% of smokers develop COPD?  – Report 
from the obstructive lung disease in Northern Sweden Studies.  Respiratory 
Medicine, 97:115-122. 
 
MACNEE, W. (1997).  “Oxidants and antioxidants in smoking induced lung 
disease.”  South African Respiratory Journal.  [Hyperlink 
http://www.pulmonology.co.za/journal/journal2/article2.htm].  17 Augustus 
2007. 
 
MADOR, M.J. (2002).  Muscle mass, not body weight, predicts outcome in patients 
with chronic obstructive pulmonary disease.  American Journal of Respiratory 
and Critical Care Medicine, 166(16):787-789. 
 
MADOR, M.J.; BOZKANAT, E.; AGGARWAL, A.; SHAFFER, M. & KUFEL, T.J. 
(2004).  Endurance and strength training in patients with COPD.  Chest, 
125(6):2036-2045. 
 
MADOR, M.J.; KUFEL, T.J. & PINEDA, L.A. (2000a).  Quadriceps fatigue after 
cycle exercise in patients with chronic obstructive pulmonary disease.  
American Journal of Respiratory and Critical Care Medicine, 161:447-453. 
 
MADOR, M.J.; KUFEL, T.J.; PINEDA, L.A. & SHARMA, G.K. (2000b).  
Diaphragmatic fatigue and high-intensity exercise in patients with chronic 
obstructive pulmonary disease.  American Journal of Respiratory and Critical 
Care Medicine, 161:118-123. 
 
MADOR, M.J.; WENDEL, T. & KUFEL, T.J. (1997).  Effect of acute hypercapnia on 
diaphragmatic and limb muscle contractility.  American Journal of Respiratory 
and Critical Care Medicine, 155(5):1590-1595.  
 
MAHLER, D.A. (1990).  Dyspnea.  Futura publishing: New York. 
 
MAHLER, D.A. (1998).  Pulmonary rehabilitation.  Chest, 113:S263-S268. 
 
MAHLER, D.A.; FARYNIARZ, K.; TOMLINSOM, D.; COLICE, G.L.; ROBINS, A.G.; 
OLMSTEAD, E.M.; O’CONNOR, G.T. (1992).  Impact of dyspnea and 
physiologic function on general health status in patients with chronic 
obstructive pulmonary disease.  Chest, 102(2):395-401. 
 
MAHLER, D.; HARVER, A.; ROSIELLO, R.A. & DAUBENSPECK, J.A. (1989).  
Measurement of respiratory sensation in interstitial lung disease:  Evaluation of 
clinical dyspnea ratings and magnitude scaling.  Chest, 96:767-771. 
 
 232
MAHLER, D.; ROSIELLO, R.; HARVER, A.; LENTINE, T.; McGOVERN, J. & 
DAUBENSPECK, J. (1987).  Comparison of clinical dyspnea ratings and 
psychophysical measurements of respiratory sensation in obstructive airway 
disease.  American Review of Respiratory Disease, 135:1229-1233. 
 
MAHLER, D.; WEINBER, D.; WELLS, C. & FEINSTEIN, A. (1984).  The 
measurement of dyspnea: Contents, interobserver agreement, and physiologic 
correlates of two new clinical indexes.  Chest, 85(6):751-758. 
 
MAK, V.H.F.; BUGLER, J.R.; ROBERTS, C.M. & SPIRO, S.G. (1993).  Effect of 
arterial oxygen desaturation on six minute walk distance, perceived effort, and 
perceived breathlessness in patients with airflow limitation.  Thorax, 48:33-38. 
 
MAK, V.H.F. (n.d.).  “Chronic obstructive pulmonary disease, the UK perspective.”  
Chest medicine online.  [Hyperlink http://www.priory.com/cmol/copd.htm].  24 
September 2004. 
 
MAKE, B.J. (1986).  Pulmonary rehabilitation:  Myth of reality?  Clinics in Chest 
Medicine, 7:519-540. 
 
MAKE, B. (1990).  Pulmonary rehabilitation: What are the outcomes?  Respiratory 
Care, 35:329-331. 
 
MALTAIS, F.; LeBLANC, P.; JOBIN, R.; BERUBE, C.; BREBEAU, J.; CARRIER, 
L.; BRETON, M.; FALARDEAU, G. & BELLEAU, R. (1997).  Intensity of 
training and physiologic adaptation in patients with chronic obstructive 
pulmonary disease.  American Journal of Respiratory and Critical Care 
Medicine, 155:555-561. 
 
MALTAIS, F.; LeBLANC, P.; SIMARD, C.; JOBIN, J.; BERUBE, C.; BRUNEAU, J.; 
CARRIER, L. & BELLEAU, R. (1996a).  Skeletal muscle adaptation to 
endurance training in patients with chronic obstructive pulmonary disease.  
American Journal of Respiratory and Critical Care Medicine, 154:442-447. 
 
MALTAIS, F.; SIMARD, A.A.; SIMARD, C.; JOBIN, J.; DESGAGNES, P. & 
LeBLANC, P. (1996b).  Oxidative capacity of the skeletal muscle and lactic 
acid kinetics during exercise in normal subjects and in patients with COPD.  
American Journal of Respiratory and Critical Care Medicine, 153:288-293.   
 
MANNINO, D.M. (2002).  COPD: Epidemiology, prevalence, morbidity, mortality, 
and disease heterogeneity.  Chest, 121:S121-S126.   
 
MANNINO, D.M.; BROWN, C. & GIOVINO, G.A. (1997).  Obstructive lung disease 
deaths in the United States from 1979 through 1993: An analysis using 
multiple-cause mortality data.  American Journal of Respiratory and Critical 
Care Medicine, 156:814-818. 
 
 233
MANNINO, D.M.; GAGNON, R.C.; PETTY, T.L. & LYDICK, E. (2000).  Obstructive 
lung disease and low lung function in adults in Unites States.  Data from the 
National Health and Nutrition Examination Survey, 1988-1994.  Archives of 
Internal Medicine, 160:1683-1689. 
 
MARIN, J.M.; CARRIZO, S.J.; GASCON, M.; SANCHEZ, A. & GALLEGO, B. 
(2001).  Inspiratory capacity, dynamic hyperinflation, breathlessness, and 
exercise performance during the 6-minute-walk test in chronic obstructive 
pulmonary disease.  American Journal of Respiratory and Critical Care 
Medicine, 163:1395-1399. 
 
MARQUIS, K.; DEBIGARE, R.; LACASSE, Y.; LeBLANC, P.; JOBIN, J.; CARRIER, 
G. & MALTAIS, F. (2002).  Midthigh muscle cross-sectional areas is a better 
predictor of mortality than body mass index in patients with chronic obstructive 
pulmonary disease.  American Journal of Respiratory and Critical Care 
Medicine, 166:809-813. 
 
McALLISTER, J. (2002).  Special focus on chronic obstructive pulmonary disease.  
Nursing Times, 98(35):41-44. 
 
McARDLE, W.D.; KATCH, F.I. & KATCH, V.L. (2001).  Exercise Physiology, 
Energy, Nutrition and Human Performance.  Baltimore: Williams & Wilkins. 
 
McARDLE, W.D.; KATCH, F.I. & KATCH, V.L. (1996).  Exercise Physiology, 
Energy, Nutrition and Human Performance.  Baltimore: Williams & Wilkins. 
 
McCONNELL, A.K.; ROMER, L.M. (2004).  Dyspnoea in health and obstructive 
pulmonary disease: The role of respiratory muscle function and training.  
Sports Medicine, 34(2):117-132. 
 
McGAVIN, C.R.; ARTVINLI, M.; NAOE, H. & McHARDY (1978).  Dyspnoea, 
disability, and distance walked: comparison of estimates of exercise 
performance in respiratory disease.  British Medical Journal, 2:241-243. 
 
McGAVIN, C.R.; GUPTAN, S.P.; LLOYD, E.L. & McHARDY, G.J.R. (1977).  
Physical rehabilitation for the chronic bronchitic: Results of a controlled trial of 
exercise in home.  Thorax, 32:307-311. 
 
McGAVIN, C.R.; GUPTA, S.P. & McHARDY, G.J.R. (1976).  Twelve minute 
walking test for assessing disability in chronic bronchitis.  British Medical 
Journal, i:822-823. 
 
MEDICAL RESEARCH COUNCIL WORKING PARTY (1981).  Long term 
domiciliary oxygen therapy in chronic cor pulmonale complicating chronic 
bronchitis and emphysema.  Lancet, 1:681-686. 
 
 234
MEJIA, R.; WARD, J.; LENTINE, T. & MAHLER, D.A. (1999).  Target dyspnea 
rating predict expected oxygen consumption as well as target heart rate 
values.  American Journal of Respiratory and Critical Care Medicine, 
159:1485-1489. 
 
MERCK MANUAL (2003).  “Tuberculosis.”  The Merck Manual – Home Edition.  
[Hyperlink http://www.merck.com].  30 June 2007. 
 
MILLER, M.R.; HANKINSON, J.; BRUSASCO, V.; BURGOS, F.; CASABURI, R.; 
COATES, A. CRAPO, R.; ENRIGHT, P.; VAN DER GRINTEN, C.P.M.; 
GUSTAFSSON, P.; JENSEN, R.; JOHNSON, D.C.; MACINTYRE, N.; McKAY, 
R.; NAVAJAS, D.; PEDERSEN, O.F.; PELLENGRINO, R.; VIEGI, G. & 
WANGER, J. (2005).  ATS/ERS Task force: Standardisation of lung function 
testing.  Standardisation of spirometry.  European Respiratory Journal, 26:319-
338. 
 
MONNINKHOF, E.; VAN DER VALK, P.; VAN DER PALEN, J.; VAN 
HERWAARDEN, C. & ZIELHUIS, G. (2003).  Effects of a comprehensive self-
management programme in patients with chronic obstructive pulmonary 
disease.  European Respiratory Journal, 22:815-820. 
 
MONTES DE OCA, M. & CELLI, B.R. (2000).  Respiratory muscle recruitment and 
exercise performance in eucapnic and hypercapnic severe chronic obstructive 
pulmonary disease.  American Journal of Respiratory and Critical Care 
Medicine, 161:880-885. 
 
MORGAN, M.D.L. (2003).  Preventing hospital admissions for COPD:  Role of 
physical activity.  Thorax, 58:95-96. 
 
MOSER, K.M.; BONKINSKY, G.E.; SAVAGE, R.G.; ARCHIBALD, C. & HANSEN, 
P.R. (1980).  Results of a comprehensive rehabilitation program.  Archives of 
Internal Medicine, 140(12):1596-1601. 
 
MURARIU, C.; GHEZZO, H.; MILIC-EMILI, J. & GAUTIER, H. (1998).  Exercise 
limitation in obstructive lung disease.  Chest, 114(4):965-968. 
 
MURRAY, J.F.; NADEL, J.A.; MASON, R.J. & BOUSHEY, H.A. (2000).  Textbook 
of respiratory medicine.  3rd edition, volume 2.  W.B. Saunders: Philadelphia. 
 
 235
NICI, L.; DONNER, C.; WOUTERS, E.; ZuWALLACK, R.; AMROSINO, N.; 
BOURBEAU, J.; CARONE, M.; CELLI, B.; ENGELEN, M.; FAHY, B.; 
GARVEY, C.; GOLDSTEIN, R.; GOSSELINK, R.; LAREAU, S.; MACINTYRE, 
N.; MALTAIS, F.; MORGAN, M.; O’DONNELL, D.; PREFAULT, C.; 
REARDON, J.; ROCHESTER, C.; SCHOLS, A.; SINGH, S. & TROOSTERS, 
T. (2006).  American Thoracic Society / European Respiratory Society 
statement on pulmonary rehabilitation.  American Journal of Respiratory and 
Critical Care Medicine, 173:1390-1413. 
 
NIEDERMAN, M.S.; CLEMENTE, P.H.; FEIN, A.M.; FEINSILVER, S.H.; 
ROBINSON, D.A.; JONATHAN, S.; ILOWITE, J.S. & BERNSTEIN, M.G. 
(1991).  Benefits of a multidisciplinary pulmonary rehabilitation program.  
Chest, 99(4):798-804. 
 
NISHIMURA, K.; IZUMI, T.; TSUKINO, M. & OGA, T. (2002).  Dyspnea is a better 
predictor of 5-year survival than airway obstruction in patients with COPD.  
Chest, 121(5):1434-1440. 
 
NORWEG, A.M.; WHITESON, J.; MALGADY, R.; MOLA, A. & REY, M. (2005).  
The effectiveness of different combinations of pulmonary rehabilitation 
program components:  A randomized controlled trial.  Chest, 128(2):663-672. 
 
O’BRIEN, C.; GUEST, P.J.; HILL, S.L. & STOCKLEY, R.A. (2000).  Physiological 
and radiological characterisation of patients diagnosed with chronic obstructive 
pulmonary disease in primary care.  Thorax, 55:635-642. 
 
O’DONNELL, D.E.; BAIN, D.J. & WEBB, K.A. (1997).  Factors contributing to relief 
of exertional breathlessness during hyperoxia in chronic airflow limitation.  
American Journal of Respiratory and Critical Care Medicine, 155:530-535. 
 
O’DONNELL, D.E.; D’ARSIGNY, C.; FITZPATRICK, M. & WEBB, K.A. (2002).  
Exercise hypercapnia in advanced chronic obstructive pulmonary disease, the 
role of lung hyperinflation.  American Journal of Respiratory and Critical Care 
Medicine, 166:663-668. 
 
O’DONNELL, D.E.; McGUIRE, M.; SAMIS, L. & WEBB, K.A. (1995).  The impact of 
exercise reconditioning on breathlessness in severe chronic airflow limitation.  
American Journal of Respiratory and Critical Care Medicine, 152:2005-2013. 
 
O’DONNELL, D.E.; REVILL, S.M. & WEBB, K.A. (2001).  Dynamic hyperinflation 
and exercise intolerance in chronic obstructive pulmonary disease.  American 
Journal of Respiratory and Critical Care Medicine, 164(5):770-777. 
 
O’DONNELL, D.E. & WEBB, K.A. (1992).  Breathlessness in patients with severe 
chronic airflow limitation:  Physiologic correlations.  Chest, 102:824-831. 
 
 236
OKUBADEJO, A.A.; JONES, P.W. & WEDZICHA, J.A. (1996).  Quality of life in 
patients with chronic obstructive pulmonary disease and severe hypoxaemia.  
Thorax, 51:44-47. 
 
OROZCO-LEVI, M. (2003).  Structure and function of the respiratory muscles in 
patients with COPD: Impaired or adaptation?  European Respiratory Journal, 
22:41S-51S. 
 
O’SHEA, S.D.; TAYLOR, N.F. & PARATZ, J. (2004).  Peripheral muscle strength 
training in COPD:  A systematic review.  Chest, 126(3):903-914. 
 
OSMAN, L.M.; GODDEN, D.J.; FRIEND, J.A.R.; LEGGE, J.S. & DOUGLAS, J.C. 
(1997).  Quality of life and hospital re-admission in patients with chronic 
obstructive pulmonary disease.  Thorax, 52:67-71. 
 
PAEZ, P.N.; PHILLIPSON, E.A.; MASANGKAY, M. & SPROULE, B.J. (1967).  The 
basis of training patients with emphysema.  American Review of Respiratory 
Disease, 95:944-953.   
 
PALANGE, P.; FORTE, S.; ONORATI, P.; MANFREDI, F.; SERRA, P. & 
CARLONE, S. (2000).  Ventilatory and metabolic adaptations to walking and 
cycling in patients with COPD.  Journal of Applied Physiology, 88:1715-1720. 
 
PAUWELS, R.A.; BUIST, A.S.; CALVERLEY, P.M.A.; JENKINS, C.R. & HURD, 
S.S. (2001).  Global strategy for the diagnoses, management, and prevention 
of chronic obstructive pulmonary disease.  American journal of respiratory and 
critical care medicine, 163:1256-1276. 
 
PEINADO, V.I.; BARBERA, J.A.; ABATE, P.; RAMIREZ, J.; ROCA, J.; SANTOS, 
S. & RODRIGUEZ-ROISIN, R. (1999).  Inflammatory reaction in pulmonary 
muscular arteries of patients with mild chronic obstructive pulmonary disease.  
American Journal of Respiratory and Critical Care Medicine, 159:1605-1611. 
 
PETTY, T.L. & WEINMANN, G.G. (1997).  Building a national strategy for the 
prevention and management of and research in chronic obstructive pulmonary 
disease.  The Journal of American Medical Association, 277(3):246-253. 
 
PIERSON, D.J. (2000).  Pathophysiology and clinical effects of chronic hypoxia.  
Respiratory Care, 45(1):39-51. 
 
PINTO-PLATA, V.M.; COTE, C.; CABRAL, H.; TAYLOR, J. & CELLI, B.R. (2004).  
The 6-min walk distance: Change over time and value as a predictor of 
survival in severe COPD.  European Respiratory Journal, 23:28-33. 
 
 237
PORSZASZ, J.; EMTNER, M.; GOTO, S.; SOMFAY, A.; WHIPP, B.J. & 
CASABURI, R. (2005).  Exercise training decreases ventilatory requirements 
and exercise-induced hyperinflation at submaximal intensities in patients with 
COPD.  Chest, 128(4):2025-2034. 
 
PRIDE, N.B. & SORIANO, J.B. (2002).  Chronic obstructive pulmonary disease in 
the United Kingdom: Trends in mortality, morbidity, and smoking.  Current 
Opinion in Pulmonary Medicine, 8:95-101.   
 
PROBST, V.S.; TROOSTERS, T.; PITTA, F.; DECRAMER, M. & GOSSELINK, R. 
(2006).  Cardiopulmonary stress during exercise training in patients with 
COPD.  European Respiratory Journal, 27:1110-1118. 
 
REARDON, J.; ESSAM, A.; NORMANDIN, E.; VALE, F.; CLARK, B. & 
ZuWALLACK, R. (1994).  The effect of comprehensive outpatient pulmonary 
rehabilitation on dyspnea.  Chest, 105(4):1046-1052. 
 
REDELMEIER, D.A.; BAYOUMI, A.M.; GOLDSTEIN, R.S. & GUYATT, G.H. 
(1997).  Interpreting small differences in functional status:  The six minute walk 
test in chronic lung disease patients.  American Journal of Respiratory and 
Critical Care Medicine, 155:1278-1282. 
 
RIES, A.L.; ELLIS, B. & HAWKINS, R.W. (1988).  Upper extremity exercise training 
in chronic obstructive pulmonary disease.  Chest, 93(4):688-692. 
 
RIES, A.L.; KAPLAN, R.M.; LIMBERG, T.M. & PREWITT, L.M. (1995).  Effects of 
pulmonary rehabilitation on physiologic and psychosocial outcomes in patients 
with chronic obstructive pulmonary disease.  Annals of Internal Medicine, 
122(11):823-832.  
 
RIES, A.L.; KAPLAN, R.M.; MYERS, R. & PREWITT, L.M. (2003).  Maintenance 
after pulmonary rehabilitation in chronic lung disease: A randomized trial.  
American Journal of Respiratory and Critical Care Medicine, 167:880-888. 
 
RINGBAEK, T.J.; BROENDUM, E.; HEMINGSEN, L.; LYBECK, K.; NIELSEN, D.; 
ANDERSEN, C. & LANGE, P.  (2000). Rehabilitation of patients with chronic 
obstructive pulmonary disease, exercise twice a week is not sufficient!  
Respiratory medicine, 94:150-154. 
 
ROCHESTER, D.F. (1991).  The diaphragm in COPD:  Better than expected, but 
not good enough.  New England Journal of Medicine, 325:961-962. 
 
ROCHESTER, C.L. (2003).  Exercise training in chronic obstructive pulmonary 
disease.  Journal of Rehabilitation Research and Development, 40(5):59-80. 
 
 238
ROGERS, R.M.; DONAHOE, M. & COSTANTINO, J. (1992).  Physiologic effects of 
oral supplemental feeding in malnourished patients with chronic obstructive 
pulmonary disease.  American Review of Respiratory Disease, 146:1511-
1517.  
 
ROSSI, G.; FLORINI, F.; ROMAGNOLI, M.; BELLANTONE, T.; LUCIC, S.; LUGLI, 
D. & CLINI, E. (2005).  Length and clinical effectiveness of pulmonary 
rehabilitation in outpatients with chronic airway obstruction.  Chest, 
127(1):105-109. 
 
SCANLON, P.D.; CONNETT, J.E.; WALLER, L.A.; ALTOSE, M.D.; BAILEY, W.C.; 
BUIST, S. & TASHKIN, D.P. (2000).  Smoking cessation and lung function in 
mild-to-moderate chronic obstructive pulmonary disease, the lung health study.  
American Journal of Respiratory and Critical Care Medicine, 161:381-390. 
 
SCHARF, S.M. (1992).  Cardiopulmonary physiology in critical care.  Marcel 
Dekker: New York. 
 
SCHERER, Y.K. & SCHMIEDER, L.E. (1997).  The effect of a pulmonary 
rehabilitation program on self-efficacy, perception of dyspnea, and physical 
endurance.  Heart & Lung, 26(1):15-22. 
 
SCHERER, T.A.; SPENGLER, C.M.; OWASSAPIAN, D.; IMHOF, E. & 
BOUTELLIER, U.R.S. (2000).  Respiratory muscle endurance training in 
chronic obstructive pulmonary disease:   Impact on exercise capacity, 
dyspnea, and quality of life.  American Journal of Respiratory and Critical Care 
Medicine, 162:1709-1714. 
 
SCHOLS, A.M.W.J.; MOSTERT, R.; SOETERS, P.B. & WOUTERS, E.F.M. (1991).  
Body composition and exercise performance in patients with chronic 
obstructive pulmonary disease.  Thorax, 46:695-699. 
 
SCHOLS, A.M.W.J.; SLANGEN, J.; VOLOVICS, L. & WOUTERS, E.F.M. (1998).  
Weight loss in a reversible factor in the prognosis of chronic obstructive 
pulmonary disease.  American Journal of Respiratory and Critical Care 
Medicine, 157:1791-1797.   
 
SCHOLS, A.M.W.J.; SOETERS, P.B.; DINGEMANS, A.M.C; MOSTERT, R.; 
FRANTZEN, P.J. & WOUTERS, E.F. (1993).  Prevalence and characteristics 
of nutritional depletion in patients with stable COPD eligible for pulmonary 
rehabilitation.  American Review of Respiratory Diseases, 147:1151-1156. 
 
SCHOLS, A.M.W.J.; SOETERS, P.B.; MOSTERT, R.; PLUYMERS, R.J.; 
FRANTZEN, P.J. & WOUTERS, E.F.M. (1995).  Physiological effects of 
nutritional support and anabolic steroids in COPD patients.  American Journal 
of Respiratory and Critical Care Medicine, 152:1268-1274. 
 
 239
SEALS, D.R.; HURLEY, B.F.; SCHULTZ, J. & HAGBERG, J.M. (1984).  Endurance 
training in older men and women: Blood lactate response to submaximal 
exercise.  Journal of Applied Physiology, 57:1030-1033. 
 
SEEMUNGAL, T.A.; DONALDSON, G.C.; PAUL, E.A.; BESTALL, J.C.; JEFFRIES, 
D.J. & WEDZICHA, J.A. (1998).  Effect of exacerbation on quality of life in 
patients with chronic obstructive pulmonary disease.  American Journal of 
Respiratory and Critical Care Medicine, 157:1418–1422. 
 
SENIOR, R.M & ANTONISEN, N.R. (1998).  Chronic pulmonary disease (COPD).  
American Journal of Respiratory and Critical Care Medicine, 157(4):S139-
S147. 
 
SHERMAN, S.E.; LANTO, A.B.; NIELD, M. & YANO, E.M. (2003).  Smoking 
cessation care received by veterans with chronic obstructive pulmonary 
disease.  Journal of Rehabilitation Research and Development, 40(5):1-12. 
 
SHOUP, R.; DALSKY, G.; WARNER, S.; DAVIES, M.; CONNORS, M.; KHAN, M.; 
KHAN, F. & ZuWALLACK, R. (1997).  Body composition and health-related 
quality of life in patients with obstructive airways disease.  European 
Respiratory Journal, 10:1576-1580. 
 
SIAFAKAS, N.M.; VERMEIRE, P. PRIDE, N.B.; PAOLETTI, P.; GIBSON, J. & 
HOWARD, P. (1995).  Optimal assessment and management of chronic 
obstructive pulmonary disease (COPD).  European Respiratory Journal, 
8:1398-1420. 
 
SIETSEMA, K. (2001).  Cardiovascular limitations in chronic obstructive pulmonary 
disease.  Medicine and Science in Sports and Exercise, 33(7):S656-S661. 
 
SIMPSON, K.; KILLIAN, K.; McCARTNEY, N.; STUBBING, D.G. & JONES, N.L. 
(1992).  Randomised controlled trial of weightlifting exercise in patients with 
chronic airflow limitation.  Thorax, 47:70-75. 
 
SOO HOO, G.W. (2003).  Nonpharmacologic adjuncts to training during pulmonary 
rehabilitation:  The role of supplemental oxygen and non-invasive ventilation.  
Journal of Rehabilitation Research and Development, 40(5):81-98. 
 
SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (2002).  South African 
demographic and health survey 1998: Full report.  Medical Research Council: 
Cape Town.   
 
SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (2003).  Cape Town 
mortality, 2001, Part I:  Cause of death and premature mortality.  Medical 
Research Council: Cape Town. 
 
 240
SPENCER, S.; CALVERLEY, P.M.A.; BURGE, P.S. & JONES, P.W. (2004).  
Impact of preventing exacerbations on deterioration of health status in COPD.  
European Respiratory Journal, 23:698-702. 
 
SPRUIT, M.A.; GOSSELINK, R.; TROOSTERS, T.; DE PAEPE, K. & DECRAMER, 
M. (2002).  Resistance versus endurance training in patients with COPD and 
peripheral muscle weakness.  European Respiratory Journal, 19:1072-1078. 
 
STATISTICS SOUTH AFRICA (2002).  Causes of death in South Africa, 1997 – 
2001:  Advance release of recorded causes of death.  Statistics South Africa: 
Pretoria. 
 
STEINER, M.C. & MORGAN, M.D.L. (2001).  Enhancing physical performance in 
chronic obstructive pulmonary disease.  Thorax, 56:73-77. 
 
STEVENS, D.; ELPERN, E.; SHARMA, K.; SZIDON, P.; ANKIN, M. & KESTEN, S. 
(1999).  Comparison of hallway and treadmill six-minute walk tests.  American 
Journal of Respiratory and Critical Care Medicine, 160:1540-1543. 
 
STEVENS, T.; JANSSEN, P.L. & TUCKER, A. (1992).  Acute and long-term TNF-
alpha administration increases pulmonary vascular reactivity in isolated rat 
lungs.  Journal of Applied Physiology, 73(8):708-712. 
 
STEWART, R.I. (n.d.).  Practical Spirometry.  Tygerberg: Medical Research 
Council & Department of Medical Physiology and Biochemistry, University of 
Stellenbosch.   
 
STEYN, K.; DE WET, T.; RICHTER, L.; CAMERON, N.; LEVITT, N.S. & 
MORRELL, E. (2000).  Cardiovascular disease risk factors in 5-year-old urban 
South African children – The birth to ten study.  South African Medical Journal, 
90(7):719-726. 
 
STORER, T.W. (2001).  Exercise in chronic pulmonary disease: Resistance 
exercise prescription.  Medicine and Science in Sports and Exercise, 
33(7):S680-S686. 
 
STRIJBOS, J.H.; POSTMA, D.S.; VAN ALTENA, R.; GIMENO, F. & KOETER, 
G.H. (1996).  A comparison between an outpatient hospital-based pulmonary 
rehabilitation program and a home-care pulmonary rehabilitation program in 
patients with COPD.  Chest, 109:366-372. 
 
SUE, D.Y.; WASSERMAN, K.; MORICCA, R.B. & CASABURI, R. (1988).  
Metabolic acidosis during exercise in patients with chronic obstructive 
pulmonary disease.  Chest, 94:931-938. 
 
 241
SWINBURN, C.R.; WAKEFIELD, J.M. & JONES, P.W. (1985).  Performance 
ventilation and oxygen consumption in three different types of exercise test in 
patients with chronic obstructive lung disease.  Thorax, 40:581 – 586. 
 
SZAFRANSKI, W.; CUKIER, A.; RAMIREZ, A.; MENGA, G.; SANSORES, R.; 
NAHABEDIAN, S.; PETERSON, S. & OLSSON, H. (2003).  Efficacy and safety 
of budesonide/formoterol in the management of chronic obstructive pulmonary 
disease.  European Respiratory Journal, 21:74-81. 
 
TAGER, I.B.; SEGAL, M.R.; SPEIZER, F.E. & WEISS, S.T. (1988).  The natural 
history of forced expiratory volumes:  Effect of cigarette smoking and 
respiratory symptoms.  American Review of Respiratory Disease, 138:837-
849. 
 
TANTUCCI, C.; DUGUET, A.; SIMILOWSKI, T.; ZELTER, M.; DERENNE, J.P. & 
MILIC-EMILI, J. (1998).  Effect of salbutamol on dynamic hyperinflation in 
chronic obstructive pulmonary disease patients.  European Respiratory 
Journal, 12:799-804.   
 
TASHKIN, D.P.; ALTOSE, M.D.; BLEEKER, E.R.; CONNETT, J.E.; KANNER, 
R.E.; LEE, W.W.; WISE, R. & THE LUNG HEALTH STUDY RESEARCH 
GROUP (1992).  The lung health study:  Airway responsiveness to inhaled 
methacholine in smokers with mild to moderate airflow limitation.  American 
Review of Respiratory Disease, 145:301-310. 
 
THE LUNG HEALTH STUDY RESEARCH GROUP (2000).  Effect of inhaled 
triamcinolone on the decline in pulmonary function in chronic obstructive 
pulmonary disease.  New England Journal of Medicine, 343:1902-1909. 
 
TOSHIMA, M.T.; KAPLAN, R.M. & RIES, A.L. (1990).  Experimental evaluation of 
rehabilitation in chronic obstructive pulmonary disease: Short-term effects on 
exercise endurance and health status.  Health Psychology, 9(3):237-252. 
 
TROOSTERS, T.; GOSSELINK, R. & DECRAMER, M. (2000).  Short- and long-
term effects of outpatient rehabilitation in patients with chronic obstructive 
pulmonary disease: A randomized trial.  American Journal of Medicine, 
109:207-212. 
 
TRUPIN, L.; EARNEST, G.; SAN PEDRO, M.; BALMES, J.R.; EISNER, M.D.; 
YELIN, E.; KATZ, P.P. & BLANC, P.D. (2003).  The occupational burden of 
chronic obstructive pulmonary disease.  European Respiratory Journal, 
22:462-469. 
 
TURNER, S.E.; EASTWOOD, P.R.; CECINS, N.M.; HILLMAN, D.R. & JENKINS, 
S.C. (2004).  Physiologic responses to incremental and self-paced exercise in 
COPD: A comparison of three tests.  Chest, 126(3):766-773. 
 
 242
VALE, F; REARDON, J.Z. & ZuWALLACK, R.L. (1993).  The long-term benefits of 
outpatient pulmonary rehabilitation on exercise endurance and quality of life.  
Chest, 103: 42–45. 
 
VAN SCHALKWYK, E.M.; SCHULTZ, C.; JOUBERT, J.R. & WHITE, N.W. (2004).  
Guide for office spirometry in adults.  South African Thoracic Society 
Standards of Spirometry Committee.  South African Medical Journal, 
94(7):576-587. 
 
VERRILL, D.; BARTON, C.; BEASLEY, W. & LIPPARD, W.M. (2005).  The effects 
of short-term and long-term pulmonary rehabilitation on functional capacity, 
perceived dyspnea, and quality of life.  Chest, 128(2):673-683. 
 
VESTBO, J.; SORENSEN, T.; LANGE, P.; BRIX, A.; TORRE, P. & VISKUM, K. 
(1999).  Long-term effect of inhaled budesonide in mild and moderate chronic 
obstructive pulmonary disease: A randomised controlled trial. Lancet, 
353:1819-1823. 
 
VOGIATIZIS, I.; NANAS, S.; KASTANAKIS, E.; GEORGIADOU, O.; PAPAZAHOU, 
O. & ROUSSOS, C. (2004).  Dynamic hyperinflation and tolerance to interval 
exercise in patients with advanced COPD.  European Respiratory Journal, 
24:385-390. 
 
VOGIATZIS, I.; NANAS, S. & ROUSSOS, C. (2002).  Interval training as an 
alternative modality to continuous exercise in patients with COPD.  European 
Respiratory Journal, 20:12-19.   
 
WATSON, L; MARGETTS, B.; HOWARTH, P.; DORWARD, M.; THOMPSON, R. & 
LITTLE, P. (2002).  The association between diet and chronic obstructive 
pulmonary disease in subjects selected from general practice.  European 
Respiratory Journal, 20:313-318. 
 
WEDZICHA, J.A.; BESTALL, J.C.; GARROD, R.; GARNHAM, R.; PAUL, E.A. & 
JONES, P.W. (1998).  Randomized controlled trial of pulmonary rehabilitation 
in severe chronic obstructive pulmonary disease patients, stratified with the 
MRC dyspnoea scale.  European respiratory journal, 12:363-369. 
 
WEINER, P.; AZGAD, Y. & GANAM, R. (1992).  Inspiratory muscle training 
combined with general exercise reconditioning in patients with COPD.  Chest, 
102:1351-1356. 
 
WEINER, P.; MAGADLE, R.; BECKERMAN, M.; WEINER, M. & BERAR-YANAY, 
N. (2004).  Maintenance of inspiratory muscle training in COPD patients: One 
year follow-up.  European Respiratory Journal, 23:61-65. 
 
WEISS, S.T.; DeMEO, D.L. & POSTMAN, D.S. (2003).  COPD: Problems in 
diagnosis and measurement.  European Respiratory Journal, 21:4S-12S. 
 243
 
WHITTAKER, J.S.; RYAN, C.F.; BUCKLEY, P.A. & ROAD, J.D. (1990).  The 
effects of refeeding on peripheral and respiratory muscle function in 
malnourished chronic obstructive pulmonary disease patients.  American 
Review of Respiratory Disease, 142:283-288. 
 
WIGAL, J.; CREER, T. & KOTSES, H. (1991).  The COPD self-efficacy scale.  
Chest, 99:1193-1196. 
 
WIJKSTRA, P.J.; TEN VERGERT, E.M.; VAN ALTENA, R.; OTTEN, V.; KRAAN, 
J.; POSTMA, D.S. & KOETER, G.H. (1995).  Long-term benefits of 
rehabilitation at home on quality of life and exercise tolerance in patients with 
chronic obstructive pulmonary disease.  Thorax, 50:824-828. 
 
WIJKSTRA, P.J.; VAN ALTENA, R.; KRAAN, J.; OTTEN, V.; POSTMA, D.S. & 
KOETER, G.H. (1994).  Quality of life in patients with chronic obstructive 
pulmonary disease improves after rehabilitation at home.  European 
Respiratory Journal, 7:269-273. 
WILLCOX, P.A. & FERGUSON, A.D. (1989).  Chronic obstructive airways disease 
following treated pulmonary tuberculosis.  Respiratory Medicine, 83(3):195-
198. 
WILLEMSE, B.W.M.; TEN HACKEN, N.H.T.; RUTGERS, B.; LESMAN-LEEGTE, 
I.G.A.T.; TIMENS, W. & POSTMA, D.S. (2004).  Smoking cessation improves 
both direct and indirect airway hyperresponsiveness in COPD.  European 
Respiratory Journal, 24:391-396. 
 
WILSON, D.O.; ROGERS, R.M.; WRIGHT, E.C. & ANTHONISEN, N.R. (1989).  
Body weight in chronic obstructive pulmonary disease:  The national institutes 
of health intermittent positive-pressure breathing trail.  American Review of 
Respiratory Disease, 139:1435-1438. 
 
WITEK, T.J. & MAHLER, D.A. (2003).  Minimal important difference of the 
transition dyspnoea index in a multinational clinical trial.  European Respiratory 
Journal, 21:267-272. 
 
WORLD HEALTH ORGANIZATION (1999).  The world health report 1999.  World 
Health Organization: Geneva. 
 
WORLD HEALTH ORGANIZATION (2002).  The world health report 2002.  World 
Health Organization: Geneva.   
 
WOUTERS, E.F.M. (2002).  Chronic obstructive pulmonary disease 5: Systemic 
effects of COPD.  Thorax, 57(12):1067-1070.  
 
 244
WOUTERS, E.F.M.; CREUTZBERG, E.C. & SCHOLS, A.M.W.J. (2002).  Systemic 
effects in COPD.  Chest, 121(5):S127-S130. 
 
WRIGHT, J.L.; LEVY, R.D. & CHURG, A. (2005).  Pulmonary hypertension in 
chronic obstructive pulmonary disease: Current theories of pathogenesis and 
their implication of treatment.  Thorax, 60(7):605-609. 
 
XU, X.; WEISS, S.T.; RIJCKEN, B. & SCHOUTEN, J.P. (1994).  Smoking, changes 
in smoking habits, and rate of decline in FEV1: New insight to gender 
differences.  European Respiratory Journal, 7:1056-1061. 
 
YERG, J.E.; SEALS, D.R.; HAGBERG, J.M. & HOLLOSZY, J.O. (1985).  Effect of 
endurance exercise training on ventilatory function in older individuals.  Journal 
of Applied Physiology, 58:791-794. 
 
ZuWALLACK, R.L.; PATEL, K.; REARDON, J.Z.; CLARK, B.A. & NORMANDIN, 
E.A. (1991).  Predictors of improvement in the 12-minute walking distance 
following a six-week outpatient pulmonary rehabilitation program.  Chest, 
99(4):805-808. 
 
 
 245
APPENDICES 
__________________________________________________________ 
 
Appendix A: Borg Scales.............................................................................  247 
Appendix B: Pulmonary Rehabilitation Programme Sheets.........................  248 
Appendix C: Standardised Protocol for the 6MWT ......................................  250 
Appendix D: Patient Information and Consent Documents..........................  251 
Appendix E: Standard Karvonen Formula ...................................................  269 
Appendix F: The SGRQ: Guide to Administration and Calculations ............  270 
Appendix G: The Baseline and Transitional Indexes ...................................  279 
Appendix H: Physician’s Global Evaluation .................................................  290 
Appendix I: Subjects’ demographics ..........................................................  291 
Appendix J: Correlations that Delivered Insignificant Results .....................  293 
Appendix K: Correlations combining results form the first part of the  
study with the results of the control group...............................  315 
Appendix L: Significant correlations that was considered circumstantial.....  317 
Appendix M: Analyses of variables based on BDI-scores ............................  327 
 
 246
Appendix A 
 
Borg RPE Scales (Borg, 1982) 
 
 
Borg RPE scale   Modified Borg RPE scale 
0 Nothing at all 
0.5 Very, very slight (just noticeable) 
1 Very slight 
2 Slight 
3 Moderate 
4 Somewhat severe 
5 Severe 
6  
7 Very severe 
8  
9 Very, very severe (almost maximal) 
10 Maximal 
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Instructions for using the Borg RPE scale (ACSM, 2000:79): 
6  
7 Very, very light 
8  
9 Very light 
10  
11 Fairly light 
12  
13 Somewhat hard 
14  
15 Hard 
16  
17 Very hard 
18  
19 Very, very hard 
20  
 
“During the exercise (test) we want you to pay close attention to 
how hard you feel the exercise work rate is.  This feeling should 
reflect your total amount of exertion and fatigue, combining all 
sensations and feelings of physical stress, effort, and fatigue.”
 
PULMONARY REHABILITATION PROGRAMME SHEET 
Date        
 BP       
 RHR       
Exercise Set/rep Wght HR RPE HR RPE HR RPE HR RPE HR RPE HR RPE 
Treadmill; RPE = 5; (HR 60%-75%max) 10 min              
Stretch H Q C 3 x 15sec              
Hip flexion + knee ext 2 x 15              
Shoulder press 3 x 10              
Squats 3 x 10              
Bicep curls 3 x 10              
Getting up out of chair 3 x 10              
Standing pec push 3 x 10              
Standing hip twists 3 x 10              
Step ups 2 x 10              
Arm swings 2 x 10              
Leg swings 2 x 10              
Treadmill;; RPM = 5; (HR 40%-60%max) 10 min              
 
A
ppendix B
 
 BP       
 RHR       
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PULMONARY REHABILITATION PROGRAMME SHEET – ADAPTED MODEL 
Date         
 BP        
 RHR        
Exercise Set/rep Wght HR RPE HR RPE HR RPE HR RPE HR RPE HR RPE HR RPE 
Walking (flat terrain); RPE = 5; (HR 60%-75%max) 10 min                
Stretch H Q C 3 x 15sec                
Hip flexion + knee ext 2 x 15                
Shoulder press 3 x 10                
Squats 3 x 10                
Bicep curls 3 x 10                
Getting up out of chair 3 x 10                
Standing pec push 3 x 10                
Standing hip twists 3 x 10                
Step ups 2 x 10                
Arm swings 2 x 10                
Leg swings 2 x 10                
Walking (flat terrain); RPM = 5; (HR 40%-60%max) 10 min                
 BP        
 RHR        
Appendix C 
 
Standardised Protocol for the 6MWT (ATS, 2002) 
1. Repeat testing should be performed about the same time of day to minimize 
intraday variability.  
2. A “warm-up” period before the test should not be performed.  
3. The patient should sit at rest in a chair, located near the starting position, for 
at least 10 minutes before the test starts.  During this time, check for 
contraindications, measure pulse and blood pressure, and make sure that 
clothing and shoes are appropriate.  
4. Pulse oximetry is optional.  If it is performed, measure and record baseline 
heart rate and oxygen saturation (SpO2) and follow manufacturer’s 
instructions to maximize the signal and to minimize motion artefact.  Make 
sure the readings are stable before recording.  Note pulse regularity and 
whether the oximeter signal quality is acceptable.  
Post-test: 
1. Record the post-walk Borg dyspnoea, fatigue levels and ask this: “What, if 
anything, kept you from walking farther?”  
2. If using a pulse oximeter, measure SpO2 and pulse rate from the oximeter 
and then remove the sensor.  
3. Record the distance covered. 
4. Congratulate the patient on good effort and offer a drink of water.  
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Appendix D 
 
Patient information and consent documents: Primary programme 
 
PATIENT INFORMATION AND CONSENT DOCUMENT 
 
The influence of rehabilitation on the quality of life and exercise capacity of 
patients with chronic obstructive pulmonary disease (COPD) 
 
You are invited to participate in a research project to determine what the influence 
of a rehabilitation programme will be on your quality of life and exercise capacity.  
The evaluations and rehabilitation programme will be monitored and managed by 
professional individuals. 
 
You are aware that you are suffering from chronic obstructive pulmonary disease 
(COPD) and that your exercise capacity is impaired.  For this reason, you are 
requested to participate in the study.  It is important that you understand the 
reasons for the study and you are requested to pose appropriate questions to the 
physician in charge.  You are requested to inform your personal practitioner of your 
participation in the study. 
 
Purpose of the study 
 
The condition known as COPD is an inflammatory process of the airways which is 
characterised by a wheeze and dyspnoea (shortness of breath).  As a result of the 
impairment of your respiratory function, you have limited exercise capacity and this 
contributes to weakening of your thigh and chest muscles.  The purpose of the 
rehabilitation programme is to strengthen these muscle groups and thereby 
improve your exercise tolerance without necessarily improving your lung function.   
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This process of rehabilitation will take place over a period of 12 weeks and will be 
scheduled for three days per week.  It will be conducted under strict supervision of 
the professional staff of the Stellenbosch Biokinetics Centre, Stellenbosch 
University, who will encourage and motivate you to persevere with the programme.  
The study will be conducted according to international standards for medical 
research as determined by the ICH guidelines for good clinical practice and the 
declaration of Helsinki. 
 
All training will take place under personal supervision of one or more honours 
students and/or biokineticist of the Department of Sport Science (Biokinetics) at the 
Stellenbosch Biokinetics Centre.  If you are symptomatic and in need of therapy 
your doctor will be requested to put you on standard treatment for at least two 
weeks before joining the study. 
 
You will remain on your standard medication as prescribed for your lung disease 
by your clinic or hospital.  Smokers will not be excluded, but will be strongly urged 
throughout the study to abstain. 
 
Permission of the project has been obtained form the Ethics Committee of the 
Faculty of Health Sciences of the University of Stellenbosch. 
 
Requirements for participation 
 
You will remain under the treatment of your own doctor who will handle incidents of 
acute exacerbations, hospitalisation and changes to your treatment.  You are 
required to have transport to the Department of Sport Science, Stellenbosch 
University and will have to be telephonically contactable to be included in the 
study.  Up to 50 patients will participate in the study. 
 
Symptomatic COPD patients who get short of breath while walking on a flat surface 
or who are even more dyspnoeic will participate.  The staging of the disease will be 
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determined by means of lung function tests, a set of questionnaires and a six 
minute walk test will be performed.  During the walk test you will be encouraged to 
walk under supervision for as far as you can in a six minute period. 
 
Evaluation: Day 1 
 
You will report by appointment to the consulting rooms of Prof. J.R. Joubert at 
Rattray Lane 7, Stellenbosch.  The consent from will be discussed and you will 
have the opportunity to pose questions and sign it.  A clinical investigation will be 
conducted after which a standard in- and expiratory lung function test and ECG 
(heart investigation) will be conducted.  Your body length to weight ratio (body 
mass index) which indicates the severity of your disease will be determined.  
During the lung function procedure, you will blow into a lung function apparatus.  A 
six minute walk test will then be conducted under supervision of a clinical 
technologist.  During the procedure, your blood oxygen saturation level (saturation) 
and pulse rate will be monitored.  You can conduct the walk test by resting at 
intervals and you will complete it at your own exercise tempo.  Should your blood 
oxygen saturation become to low during the initial six minute walk test (less than 
80%) you will be excluded from the study.  At completion of each six minute walk 
test, your opinion on your degree of exhaustion on a graded Borg scale will be 
required.  Your ability to recover after exercise will be determined by measuring 
your pulse rate and speed of breathing immediately after, three, five and ten 
minutes after walking.  In the event of you having signs of right heart failure or a 
combination of left and right heart failure, your doctor will be requested to 
administer treatment before the rehabilitation process commences.  Should you 
suffer from angina or from uncontrolled hypertension you will be referred to your 
doctor to be treated accordingly.  General advice in connection with the disease, 
the occurrence of complications, particularly acute exacerbations, as well as when 
to report to your doctor, will be discussed. 
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Rehabilitation programme 
 
You will report to the Stellenbosch Biokinetics Centre at Coetzenburg per 
appointment.  The process of rehabilitation will be explained and demonstrated.  
You will complete the St. Georges Respiratory Questionnaire under supervision, 
according to which your quality of life and degree of impairment based on history 
will be determined.  You will participate in the rehabilitation programme as an 
individual.  The exercise programme will be conducted on three to five weekdays 
and will be maintained for 12 weeks.  Every session will last for about one hour.  
Should you indicate that you would not be able to participate uninterrupted to a 12 
week period, you will not be included in the study.  It is very important that you 
attend the rehabilitation programme uninterrupted and should you miss more than 
six appointments, your participation will be terminated.  Goals will be set 
throughout and you will be encouraged to attain them.  Should you encounter a 
temporary exacerbation of your disease, you will not participate in the daily 
exercise programme and your doctor will be required to do a re-evaluation.  The 
exercise programme will be determined from your own baseline functional ability 
and you will compete with no one in your group.  The exercise programme consists 
of walking exercises and muscle strengthening with the help of appropriate 
exercise apparatus.  After the 12-week exercise programme, you will receive 
advice on how to continue with the exercises on your own.  The aim of this is to be 
able to evaluate the patients again six months after the exercise programme has 
ended, in order to determine how many individuals in the group were able to 
maintain their fitness level. 
 
Evaluation: Day 2 
 
After completion of the 12-week rehabilitation, the St. Georges Respiratory 
Questionnaire will be repeated to determine the improvement of your quality of life.  
You will once again report by appointment to the consulting rooms of Prof. J.R. 
Joubert.  The evaluation that was done initially will be repeated.  Your Borg rating 
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and recovery will once again be determined.  Your body mass to length ratio will 
also be repeated.  By this means it will be determined how well you have improved 
on rehabilitation.   
 
Evaluation: Day 3 
 
You will report again by appointment at the consulting rooms of Prof. J.R. Joubert.  
The evaluation that was done initially will be repeated.  Your Borg rating and 
recovery will once again be determined.  Your body mass to length ratio will also 
be repeated.  By this means, it will be determined how well you have improved on 
rehabilitation.  You will be referred back to your physician who will follow-up on 
your disease symptoms, acute exacerbations and hospitalisations over the last six 
months. 
 
Voluntary participation 
 
You should participate voluntary.  Should you find it impossible to continue, you 
may withdraw from the study.  In this case, we will request that you attend the final 
evaluation.  Discontinuation of participation will not influence the normal treatment 
of the disease or an exercise programme which you may choose to follow. 
 
Risks and possible advantages 
 
Weariness after an exercise session and possible stiffness of muscles may be 
encountered.  Risks such as angina incidents, disturbances of heart rhythm or a 
possibility of myocardial infarctions (heart attack) cannot be excluded.  To prevent 
these complications the exercise programme will be adapted to suit each 
individual’s exercise tolerance, or individuals at risk will be excluded until adequate 
treatment has been implemented.   
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Advantages include an improvement of exercise tolerance of every day tasks and 
more confidence in your own ability to participate in physical activity.  An improved 
quality of life as determined by an objective measurement, the St. George’s 
Respiratory Questionnaire, may also be evident.  Decline in the number of acute 
exacerbations of the disease and days spent in hospital have been shown in a 
number of studies.  You will learn a number of facts relating to your disease and 
will be given practical advice on daily preventative measures.   
 
Medical supervision will be available during the rehabilitation programme.  A doctor 
will not be physically present, but telephonic contact will be maintained and a 
doctor will be available within five to ten minutes.  Prof. J.R. Joubert can be 
contacted during working hours (9:00 – 17:00) on (021) 886 7194 or after hours at 
(021) 887 1785.  The Student Health Service’s doctors are present in the 
gymnasium, or are available at (021) 808 3496. 
 
There is no cost involved for the evaluation process or the rehabilitation 
programme.   
 
Confidentiality 
 
All information will be treated confidentially and you will have the opportunity to 
review your own results as requested.  Your doctor will be kept informed as to the 
progress of the project and will receive a final report.  The results may be reported 
anonymously, may be presented at national or international level and publications 
may be forthcoming.  Your identity will be treated as confidential at all times and 
your name will not be associated with the results which may be made public. 
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Insurance 
 
Insurance cover will not be taken for the study as rehabilitation of COPD patients is 
accepted as an international procedure.  You are requested to inform your own 
insurance company of your participation in the study. 
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 PATIENT CONSENT DOCUMENT 
 
The information above was provided by ……………………………………………. 
(name of relevant person) in English and I understand the language well.  I was 
given an opportunity to ask questions and all the questions were answered to my 
satisfaction. 
 
No pressure was placed on me to agree to participate and I understand that my 
participation may be withdrawn at any time without penalisation. 
 
Participation in the project will be at no additional cost to me. 
 
I agree voluntarily to participate in the above mentioned project. 
 
Signed / agreed upon at ………………………………………… on …….............20…. 
      (place)    (date) 
 
 
 
…………………………………………  ……………………………………….. 
Signature of patient     Signature of witness 
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 STATEMENT BY OR ON BEHALF OF RESEARCHER(S) 
 
 
I ………………………………………………………………………. Declare that I (we): 
 
Explained the information in the document to ………………………………….. 
Encouraged him/her to at his/her leisure pose questions 
This conversation took place in English without an interpreter. 
 
 
 
 
 
Signed at ………………………………………………………… on ………….…20…… 
    (place)      (date) 
 
 
 
…………………………………………….  ……………………………………..… 
Signature of Researcher or his representative  Signature of witness 
 
 
 
 
 
 
 
 
(This document was available in English and Afrikaans)  
 259
Patient information and consent documents: Modified programme 
 
PATIENT INFORMATION AND CONSENT DOCUMENT 
 
The influence of rehabilitation by two different techniques on the quality of 
life and functional capacity of patients with chronic obstructive pulmonary 
disease (COPD) 
 
You are invited to participate in a research project to determine what the influence 
of rehabilitation by one of two techniques will be on your quality of life and 
functional ability.  The evaluations and rehabilitation programme will be monitored 
and managed by professional individuals. 
 
You are aware that you are suffering from chronic obstructive pulmonary disease 
(COPD) and that your exercise capacity is impaired.  For this reason, you are 
requested to participate in the study.  It is important that you understand the 
reasons for the study and you are requested to pose appropriate questions to the 
physician in charge.  You are requested to inform your personal practitioner of your 
participation in the study. 
 
Purpose of the study 
 
The condition known as COPD is an inflammatory process of the airways which is 
characterised by a wheeze and dyspnoea (shortness of breath).  As a result of the 
impairment of your respiratory function, you have limited exercise capacity and this 
contributes to weakening of your thigh and chest muscles.  The purpose of the 
rehabilitation programme is to strengthen these muscle groups and thereby 
improve your exercise tolerance without necessarily improving your lung function.   
 
This process of rehabilitation will take place over a period of ten weeks and will be 
scheduled for three days per week.  It will be conducted under strict supervision of 
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the professional staff of the Stellenbosch Biokinetics Centre, Stellenbosch 
University, who will encourage and motivate you to persevere with the programme.  
The study will be conducted according to international standards for medical 
research as determined by the ICH guidelines for good clinical practice and the 
declaration of Helsinki. 
 
A primary purpose of the study is to determine whether the same degree of fitness 
can be achieved by training with generally available and cheap methods, such as 
walking and using sand bags, as with sophisticated gymnasium apparatus.  At the 
end of the study, we may be able to develop an affordable community training 
programme which could replace the more expensive gymnasium orientated 
programmes.  All training will take place under personal supervision of one or more 
honours students and/or biokineticist of the Department of Sport Science 
(Biokinetics) at the Stellenbosch Biokinetics Centre.  Individuals will be enlisted 
voluntarily from predominantly deprived communities by means of the municipal 
clinics and Stellenbosch Hospital.  Patients from the advantaged group will also be 
allowed to join the study although no recruitment campaign will be launched for this 
purpose.  Individuals will be placed in one of the two exercise groups by random 
assignment.  You will remain in this group for the duration of the study.  If your are 
symptomatic and in need of therapy your doctor will be requested to put you on 
standard treatment for at least two weeks before joining the study. 
 
You will remain on your standard medication as prescribed for your lung disease 
by your clinic or hospital.  Smokers will not be excluded, but will be strongly urged 
throughout the study to abstain. 
 
Permission of the project has been obtained form the Ethics Committee of the 
Faculty of Health Sciences of the University of Stellenbosch. 
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Requirements for participation 
 
You will remain under the treatment of your own doctor who will handle incidents of 
acute exacerbations, hospitalisation and changes to your treatment.  You will be 
transported to and from your local clinic or neighbourhood to the Stellenbosch 
Biokinetics Centre at Coetzenburg at no cost.  You will have to be telephonically 
contactable to be included in the study.  Up to 50 patients will participate in the 
study. 
 
Symptomatic COPD patients who get short of breath while walking on a flat surface 
or who are even more dyspnoeic, will participate.  The staging of the disease will 
be determined by means of lung function tests, a set of questionnaires and a six 
minute walk test will be performed.  During the walk test, you will be encouraged to 
walk under supervision for as far as you can in a six minute period. 
 
Pre evaluation 
 
Once your clinic or hospital doctor has identified you, trained nurses from the 
Embrace Nursing Service will meet you by appointment at your clinic, hospital or 
home.  By means of some questions, a preliminary clinical evaluation and a lung 
function measurement will be done and they will invite you to attend a first meeting 
with the rehabilitation team at the rooms of Prof. J.R. Joubert.  This does not mean 
that you have been automatically included, as a second evaluation by means of 
more sophisticated techniques, has to take place after the procedures have been 
explained in depth and you have signed an informed consent document.  Once this 
has been done and you fulfil the programme requirements, the study can proceed. 
 
Evaluation: Day 1 
 
You will report by appointment to the consulting rooms of Prof. J.R. Joubert at 
Rattray Lane 7, Stellenbosch.  The consent form will be discussed and you will 
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have the opportunity to pose questions and sign this form.  A clinical investigation 
will be conducted, after which a standard in- and expiratory lung function test and 
ECG (heart investigation) will be conducted.  Your body length to weight ratio 
(body mass index) which indicates the severity of your disease, will be determined.  
During the lung function procedure, you will blow into a lung function apparatus.  A 
six minute walk test will then be conducted under supervision of a clinical 
technologist.  During the procedure, your blood oxygen saturation level (saturation) 
and pulse rate will be monitored.  You can conduct the walk test by resting at 
intervals and you will complete it at your own exercise tempo.  Should your blood 
oxygen saturation become too low during the initial six minute walk test, (less than 
80%) you will be excluded from the study.  At completion of each six minute walk 
test, your opinion on your degree of exhaustion on a graded Borg scale will be 
required.  Your ability to recover after exercise will be determined by measuring 
your pulse rate and speed of breathing immediately after, three, five and ten 
minutes after walking.  In the event of you having signs of right heart failure or a 
combination of left and right heart failure your doctor will be requested to 
administer treatment before the rehabilitation process commences.  Should you 
suffer from angina or from uncontrolled hypertension you will be referred to your 
doctor to be treated accordingly.  General advice in connection with the disease, 
the occurrence of complications particularly acute exacerbations, as well as when 
to report to your doctor, will be discussed. 
 
Rehabilitation programme 
 
You will report to the Stellenbosch Biokinetics Centre at Coetzenburg per 
appointment.  The process of rehabilitation will be explained and demonstrated.  
You will complete the St. Georges Respiratory Questionnaire under supervision, 
according to which your quality of life and degree of impairment based on history 
will be determined.  You will participate in the rehabilitation programme as an 
individual.  The exercise programme will be conducted on three to five weekdays 
and will be maintained for a minimum period of eight weeks.  Every session will last 
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for about one hour.  Should you indicate that you would not be able to participate 
uninterrupted to a ten week period, you will not be included in the study.  It is very 
important that you attend the rehabilitation programme uninterrupted and should 
you miss more than six appointments, your participation will be terminated.  Goals 
will be set throughout and you will be encouraged to attain them.  Should you 
encounter a temporary exacerbation of your disease, you will not participate in the 
daily exercise programme and your doctor will be required to do a re-evaluation.  
The exercise programme will be determined from your own baseline functional 
ability and you will compete with no one in your group.  For the gymnasium group 
the exercise programme consists of walking exercises and muscle strengthening 
with the help of appropriate exercise apparatus.  The community training 
programme will walk Coetzenburg fields (or indoors if the weather is unfavourable) 
and do muscle training with light objects such as small sand bags. 
 
Evaluation: Day 2 
 
After completion of the ten week rehabilitation, the St. Georges Respiratory 
Questionnaire will be repeated to determine the improvement of your quality of life.  
You will once again report by appointment to the consulting rooms of Prof. J.R. 
Joubert.  The evaluation that was done initially will be repeated.  Your Borg rating 
and recovery will once again be determined.  Your body mass to length ratio will 
also be repeated.  By this means, it will be determined how well you have improved 
on rehabilitation.   
 
Voluntary participation 
 
You should participate voluntary.  Should you find it impossible to continue, you 
may withdraw from the study.  In this case, we will request that you attend the final 
evaluation.  Discontinuation of participation will not influence the normal treatment 
of the disease or an exercise programme which you may choose to follow. 
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Risks and possible advantages 
 
Weariness after an exercise session and possible stiffness of muscles may be 
encountered.  Risks such as angina incidents, disturbances of heart rhythm or a 
possibility of myocardial infarctions (heart attack) cannot be excluded.  To prevent 
these complications the exercise programme will be adapted to suit each 
individual’s exercise tolerance, or individuals at risk will be excluded until adequate 
treatment has been implemented.   
 
Advantages include an improvement of exercise tolerance of every day tasks and 
more confidence in your own ability to participate in physical activity.  An improved 
quality of life as determined by an objective measurement, the St. George’s 
Respiratory Questionnaire, may also be evident.  Decline in the number of acute 
exacerbations of the disease and days spent in hospital have been shown in a 
number of studies.  You will learn a number of facts relating to your disease and 
will be given practical advice on daily preventative measures.   
 
Medical supervision will be available during the rehabilitation programme.  A doctor 
will not be physically present, but telephonic contact will be maintained and a 
doctor will be available within five to ten minutes.  Prof. J.R. Joubert can be 
contacted during working hours (9:00 – 17:00) on (021) 886 7194 or after hours at 
(021) 887 1785.  The Student Health Service doctors are present in the 
gymnasium, or are available at (021) 808 3496. 
 
There is no cost involved for the evaluation process or the rehabilitation 
programme.  Your transport will be arranged to and from your clinic or 
neighbourhood by appointment only, at no cost. 
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Confidentiality 
 
All information will be treated confidentially and you will have the opportunity to 
review your own results as requested.  Your doctor will be kept informed as to the 
progress of the project and will receive a final report.  The results may be reported 
anonymously, may be presented at national or international level and publications 
may be forthcoming.  Your identity will be treated as confidential at all times and 
your name will not be associated with the results which may be made public. 
 
Insurance 
 
Insurance cover will not be taken for the study as rehabilitation of COPD patients is 
accepted as an international procedure.  You are requested to inform your own 
insurance company of your participation in the study. 
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 PATIENT CONSENT DOCUMENT 
 
The information above was provided by ……………………………………………. 
(name of relevant person) in English and I understand the language well.  I was 
given an opportunity to ask questions and all the questions were answered to my 
satisfaction. 
 
No pressure was placed on me to agree to participate and I understand that my 
participation may be withdrawn at any time without penalisation. 
 
Participation in the project will be at no additional cost to me. 
 
I agree voluntarily to participate in the above mentioned project. 
 
Signed / agreed upon at ………………………………………… on …….............20…. 
      (place)    (date) 
 
 
 
…………………………………………  ……………………………………….. 
Signature of patient     Signature of witness 
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 STATEMENT BY OR ON BEHALF OF RESEARCHER(S) 
 
 
I ………………………………………………………………………. Declare that I (we): 
 
Explained the information in the document to ………………………………….. 
Encouraged him/her to at his/her leisure pose questions 
This conversation took place in English without an interpreter. 
 
 
 
 
 
Signed at ………………………………………………………… on ………….…20…… 
    (place)      (date) 
 
 
 
…………………………………………….  ……………………………………..… 
Signature of Researcher or his representative  Signature of witness 
 
 
 
 
 
 
 
 
(This document was available in English and Afrikaans)  
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Appendix E 
 
Standard Karvonen Formula (ACSM, 2000:189-190). 
 
 
THR = (HRmax – HRrest) (target %) + HRrest 
 
 
• THR = training heart rate 
• HRmax = 220 – age 
• Target % = required intensity i.e. 75% 
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Appendix F 
 
The SGRQ: Guide to administration and calculations (Jones, 1991) 
 
 
What is the St. George’s Respiratory Questionnaire? 
 
The St. George’s Respiratory Questionnaire (SGRQ) is designed to measure 
health-related quality of life, which is the impact that chest disease has on daily life 
and wellbeing.  Asthma, chronic bronchitis and emphysema can cause major 
disturbances to daily life, which vary from person to person regardless of lung 
function. 
 
How should it be administered? 
 
The questionnaires should be completed in a quiet room and the patient should be 
sitting at a desk or table.  If the spouse had accompanied the patient, try to 
separate them.  It is important that the patient complete the SGRQ themselves, 
without any advice from their partner. 
 
Explain to the patient why they are completing the questionnaire and how 
important it is for us to understand how they feel about their illness and the affect it 
has on their day-to-day lives.  The SGRQ is designed as a supervised, self-
administered questionnaire.  This means that the patients should complete the 
SGRQ themselves, but someone must be available to give advice if it is needed. 
 
Ask the patient to complete the SGRQ as honestly as they can and stress that 
there are no right and wrong answers, simply the answer that the patient thinks 
applies to them best.  Explain that they must answer every question and that 
someone will be close at hand to answer any queries. 
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Do not let the patients take the SGRQ home to be completed.  It is important that it 
is done in the presence of the investigator and that you can be sure it is answered 
by the patient alone without the help of his/her family.   
 
What should I do about queries? 
 
Answers to some possible queries are given in the guide to completing the SGRQ; 
beneath each question.  Read through this before seeing the patient.  It is worth 
being prepared. 
 
If the patient asks you to help them answer a question, don’t give them an answer.  
The point of quality of life questionnaires is to get an understanding of how the 
patient views his/her illness.  Simply readdress the question back to them. 
 
Questions may be read out to patients who have difficulty in reading, but the 
responses must be theirs alone. 
 
What should I do when the SGRQ has been completed? 
 
Once the patient has completed the questionnaire, read through to check that each 
and every question has been answered.  Don’t send the patient away before you 
have done this.  If any questions have been left unanswered, point them out to the 
patient and ask for answers. 
 
If you see an answer that you disagree with, e.g. the patient tick off that he/she 
coughs a few days a month and you know that they cough more often, do not 
question its accuracy.  By asking the patient “are you sure this is right?” you are 
more or less telling them that you think it is wrong.  Since you are the expert, they 
may change their answer to agree with you, even though they still may feel that 
their first answer was right. 
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Finally, thank the patient for their time and again stress how important and useful 
this information is. 
 
Calculation method for the SGRQ 
 
Three component scores are calculated: Symptoms; Activity; Impacts.  One total 
score is also calculated.  Each questionnaire response has a unique empirical 
derived ‘weight’.  The lowest possible weight is zero and the highest is 100. 
 
Each component of the questionnaire is scored separately in two groups: 
i. The weights for all items with a positive response are summed. 
ii. The score is calculated by dividing the summed weights by the 
maximum possible weight for that component and expressing the 
result as a percentage: 
 
Score =  100 x Summed weights from positive items in that component / Sum of                   
weights for all items in that component 
 
The total score in calculated in similar way: 
 
Score =  100 x Summed weights from positive items in the questionnaire / Sum of                   
weights for all items in the questionnaire 
 
Sum of maximum possible weights for each component and Total (these are the 
maximum possible weights that could be obtained for the worst possible state of 
the patient: 
Symptoms  662.5 
Activity  1209.1 
Impacts  2117.8 
Total   3989.4  
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Symptom component 
 
This consists of all the questions in Part I.  The weights for Question 1 to 8 are 
summed.  It will be noted that the questionnaire requests a single response to 
Questions 1 to 7.  If multiple responses are given to a question, then averaging the 
weights for the positive responses for that question is acceptable.   
 
Activity component 
 
This calculated from the summed weights for the positive responses to Section 2 
and Section 6 in Part 2 of the questionnaire. 
 
Impacts component 
 
This is calculated from Sections 1, 3, 4, 5 and 7.  Again it will be noted from the 
questionnaire that a single response is required fro the two parts of Section 1 and 
the last part of Section 7.  In the case of multiple responses, the mean weights for 
any multiple responses to these parts are used.  
 
Total score 
 
The Total score is calculated by summing all the positive responses in the 
questionnaire and expressing the result as a percentage of weights for all items in 
the questionnaire. 
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 Handling missing items 
 
It is better not to miss items and any missing items are the fault of the 
experimenter, not the patient.  The following methods are recommended: 
 
 Part I 
 
Missed items are treated as if the answer was in the negative. 
 
 Part II 
 
Items in Sections 2, 3, 4, 5, 6 and first part of section 7 all require a response of 
either ‘True’ or ‘False’.  If neither box is ticked, the item should be coded as 
‘missing’.  If this approach is to be used, the scoring program should be written so 
that when an item is coded as ‘missing’ the weight for that item is subtracted from 
the total possible weight for the component of the questionnaire and from the Total 
weight.   
 
This method has been carefully tested and it was found to be a reliable method for 
up to 10 missed items in Part II of the questionnaire. 
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ST. GEORGE’S RESPIRATORY QUESTIONNAIRE 
 
This questionnaire is designed to help us learn much more about how your breathing is troubling you 
and how it affects your life.  We are using it to find out which aspects of your illness cause you the 
most problems. 
PART 1 
 
Questions about how much chest trouble you have had over the last 3 months.  Please tick in one 
box for each question. 
     
most 
days of 
the 
week 
several 
days of 
the 
week 
a few 
days a 
week 
only 
with 
chest 
infections 
not at 
all 
                    
1) Over the last 3 months I have                
 coughed:                     
                 
2) Over the last 3 months, I have                
 brought up phlegm (sputum):                     
                 
3) Over the last 3 months, I have                 
 had shortness of breath:                     
                 
4) Over the last 3 months, I have                 
 attacks of wheezing:                     
                 
5) 
Over the last 3 months, how many severe or very severe unpleasant attacks of chest 
trouble have you had? 
                    
    more than 3 attacks      
         
    3 attacks      
         
    2 attacks      
         
    1 attack      
         
    no attacks      
                    
6) How long did the worst attack of chest trouble last? (Go to Question 7 if you had no attacks) 
                    
    a week or more      
         
    3 or more days      
         
    1 or 2 days      
         
    less than a day      
                    
7) 
Over the last 3 months, in an average week, how many good days (with little chest trouble) 
have you had? 
 
 
 
 
 
 
 
 
            
no good days 
 
 
 
 
 
  
 
 
         
    1 or 2 good days      
         
    3 or 4 good days      
         
    nearly every day was good      
         
    every day was good      
         
8) If you have wheeze, is it worse in the morning? 
 
 
 
 
 
 
 
 
            
no 
 
 
 
 
 
  
 
 
         
    yes      
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PART 2 
 
SECTION 1 
How would you describe your chest conditions? (Please tick in one box only) 
                    
              TRUE FALSE 
                    
 the most important problem that I have          
                    
 causes me quite a few problems          
                    
 causes me a few problems          
                    
 causes no problems          
                    
If you have ever had paid employment, please tick one of these: 
                
              TRUE FALSE 
                    
 my chest trouble made me stop my work          
                    
 my chest trouble interfered with my work or made me change my work          
         
 my chest trouble does not affect my work          
         
SECTION 2                  
                    
Questions about what activities usually make you feel breathless these days.  For each item, please tick either 
true or false as it applies to you. 
         
   TRUE FALSE 
         
 sitting or lying still        
                    
 getting washed or dressed        
                    
 walking around the home        
                    
 walking outside on a level surface        
         
 walking up a flight of stairs        
         
 walking hills        
         
 playing sports or games        
         
SECTION 3        
                    
Some more questions about your cough and breathlessness these days.  For each item, please tick either true or 
false as it applies to you. 
         
              TRUE FALSE 
                    
 my cough or breathing disturbs my sleep        
         
 my cough makes me tired        
         
 my cough hurts        
         
 I get exhausted easily        
         
 I am breathless when I walk        
         
 I am breathless when I bend over        
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SECTION 4                   
                    
Questions about other effects that your chest trouble may have on you these days.  Please tick either true or 
false as it applies to you. 
                    
              TRUE FALSE 
                    
 my coughing or breathing is embarrassing in public          
         
 my chest trouble is a nuisance to my family, friends or neighbours          
         
 I get afraid or panic when I cannot get my breath          
         
 I feel that I am not in control of my chest problem          
         
 I do not expect my chest to get any better          
         
 I have become frail or an invalid because of my chest          
         
 Exercise is not safe for me          
         
 Everything seems too much of an effort          
                    
SECTION 5                   
                    
Questions about your medication.  If you are receiving no medication go straight to Section 6.  To complete 
this section, please tick either true or false as it applies to you. 
                    
              TRUE FALSE 
                    
 my medication does not help me very much          
         
 I get embarrassed using my medication          
         
 I have unpleasant side effects from my medication          
         
 my medication interferes with my life a lot          
         
SECTION 6                   
                    
These are questions about how your activities might be affected by your breathing.  For each question, please 
tick true if one or more parts apply to you because of your breathing, otherwise tick false. 
                    
              TRUE FALSE 
                    
 I take a long time to get washed or dressed          
         
 I cannot take a bath or shower, or I take a long time          
         
 I walk slower than other people, or I stop for rests          
         
 jobs such as housework take a long time, or I have to stop for rests          
         
 if I walk up one flight of stairs, I have to go slowly or stop          
         
 if I hurry or walk fast, I have to stop or slow down          
         
my breathing makes it difficult to do things such as walk up hills, carrying things         
 up stairs, light gardening, such as weeding, dance, play bowls or golf          
         
my breathing makes it difficult to do things such as carry heavy loads, dig the        
 garden or shovel snow, jog or walk at 5 miles an hour, play tennis or swim          
         
 my breathing makes it difficult to do things such as very heavy manual work,         
 run, cycle, swim fast or play competitive sports          
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SECTION 7        
         
We would like to know how your chest trouble usually affects your daily life.  Please tick either true or 
false as it applies to you because of your chest trouble.  (Remember that true only applies to you if you 
cannot do something because of your breathing) 
         
   TRUE FALSE 
         
 I cannot play sports or games          
         
 I cannot go out for entertainment or recreation          
         
 I cannot go out of the house to do the shopping          
         
 I cannot do housework          
         
 I cannot move far from my bed or chair          
         
Here is a list of other activities that your chest trouble may prevent you from doing.  (You do not have 
to tick these, they are just to remind you of ways in which your breathlessness may affect you): 
                    
 going out for walks or walking the dog        
         
 doing things at home or in the garden        
         
 sexual intercourse        
         
 going to church, or place of entertainment        
         
 going out in bad weather or into smoky rooms        
         
 visiting family or friends or playing with children        
         
Please write in any other important activities that your chest trouble may stop you from doing: 
                  
         
                                        
                    
Now, would you tick in the box (one only) which you think best describes how your chest affects you: 
                    
 it does not stop me doing anything I would like to you         
         
 it stops me doing one or two things I would like to do         
         
 it stops me doing most of the things I would like to do         
         
 it stops me doing everything I would like to do         
                    
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE.  BEFORE YOU FINISH WOULD YOU 
PLEASE CHECK TO SEE THAT YOU HAVE ANSWERED ALL THE QUESTIONS. 
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Appendix G 
 
The baseline and transitional indexes (BDI/TDI) (Mahler et al., 1984) 
 
BASELINE DYSPNOEA INDEX 
 
Functional Impairment 
____ Grade 4:  No Impairment.  Able to carry out usual activities and occupation without 
shortness of breath. 
 
____ Grade 3:  Slight Impairment.  Distinct impairment in at least one activity, but no 
activities completely abandoned.  Reduction in activity at work or in usual 
activities that seem slight or not clearly caused by shortness of breath. 
 
____ Grade 2:  Moderate Impairment.  Patient has changed jobs and/or has abandoned at 
least one usual activity due to shortness of breath. 
 
____ Grade 1:  Severe Impairment.  Patient unable to work or give up most or all 
customary activities due to shortness of breath. 
 
____ Grade 0:  Very Severe Impairment.  Unable to work and has given up most or all 
customary activities due to shortness of breath. 
 
____ W:  Amount uncertain.  Patient is impaired due to shortness of breath, but 
amount cannot be specified.  Details are not sufficient to allow impairment to 
be categorised.   
 
____ X:  Unknown.  Information unavailable regarding impairment. 
 
____ Y:  Impaired for reasons other than shortness of breath.  For example, 
musculoskeletal problems or chest pain. 
 
Magnitude of Task 
____ Grade 4:  Extraordinary.  Becomes short of breath only with extraordinary activity, 
such as carrying heavy loads on the level, lighter loads uphill, or running.  
No shortness of breath with ordinary tasks. 
 
____ Grade 3:  Major.  Becomes short of breath only with major activities such as walking 
up a steep hill, climbing more than three flights of stairs or carrying a 
moderate load on the level. 
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_____ Grade 2:  Moderate.  Becomes short of breath with moderate or average tasks, such 
as walking up a gradual hill, climbing less than three flights of stairs or 
carrying a light load on the level. 
 
_____ Grade 1:  Light.  Becomes short of breath with light activities, such as walking on a 
level surface, washing, standing or shopping 
 
_____ Grade 0:  No Task.  Becomes short of breath at rest, while sitting, or lying down. 
 
_____ W:  Amount Uncertain.  Patient has limited exertional capacity due to shortness 
of breath, but amount cannot be specified.  Details are not sufficient to allow 
impairment to be categorised. 
 
_____ X:  Unknown.  Information unavailable regarding limitation of magnitude of task. 
 
_____ Y:  Impaired for reasons other than shortness of breath.  For example, 
musculoskeletal problems or chest pain. 
 
Magnitude of Effort 
_____ Grade 4:  Extraordinary.  Becomes short of breath only with the greatest imaginable 
effort.  No shortness of breath with ordinary effort. 
  
_____ Grade 3:  Major.  Becomes short of breath with effort distinctly submaximal, but of 
major proportion.  Tasks performed without pause unless the task requires 
extraordinary effort that may be performed with pauses. 
 
_____ Grade 2:  Moderate.  Becomes short of breath with moderate effort.  Tasks performed 
with occasional pauses and requiring longer to complete than the average 
person. 
 
_____ Grade 1:  Light.  Becomes short of breath with little effort.  Tasks performed with little 
effort or more difficult tasks with frequent pauses and requiring 50 to 100 
percent longer to complete than the average person might require. 
 
_____ Grade 0:  No Effort.  Becomes short of breath at rest while sitting, or lying down. 
 
_____ W:  Amount Uncertain.  Patient has limited exertional capacity due to shortness 
of breath, but amount cannot be specified.  Details not sufficient to allow 
impairment to be categorised. 
 
_____ X:  Unknown.  Information unavailable regarding limitation of effort. 
 
_____ Y:  Impaired or reasons other than shortness of breath.  For example, 
musculoskeletal problems or chest pain. 
 
 
WORKSHEET TO BE USED FOR ASSEMENT OF BDI 
 
Dyspnoea recordings:  Date: Patient’s Initials: 
 FUNCTIONAL IMPAIRMENT MAGNITUDE OF TASK MAGNITUDE OF EFFORT 
Job 
 
   
Housework, shopping 
 
   
Leisure activities, gardening 
 
   
Social activities 
 
   
Washing, dressing 
 
   
At rest 
 
   
Any other 
 
   
BDI SCORE: 0 - 4 Functional impairment: Magnitude of task: Magnitude of effort: 
 
               TOTAL:           /12    
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TRANSITIONAL DYSPNOEA INDEX 
 
Change in Functional Impairment 
____ -3:  Major Deterioration.  Formerly working and has had to stop working and 
has completely abandoned some of the usual activities due to shortness of 
breath. 
 
____ -2:  Moderate Deterioration.  Formerly working and has had to stop working or 
has completely abandoned some to the usual activities due to shortness of 
breath. 
 
____ -1:  Minor Deterioration.  Has changed to a lighter job and/or has reduced 
activities in number or duration due to shortness of breath.  Any deterioration 
less than preceding categories. 
 
____ 0:  No Change.  No change in functional status due to shortness of breath. 
 
____ +1:  Minor Improvement.  Able to return to work at reduced pace or has 
resumed some customary activities with more vigour than previously due to 
improvement in shortness of breath. 
 
____ +2:  Moderate Improvement.  Able to return to work at former pace and/or able 
to return to most activities with moderate restriction only. 
 
____ +3:  Major Improvement.  Able to return to work at former pace and able to 
return to full activities with only mild restriction due to improvement of 
shortness of breath. 
 
____ Z:  Further impairment for reasons other that shortness of breath.  Patient 
has stopped working, reduced work, or has given up or reduced other 
activities for other reasons.  For example, other medical problems, being 
“laid off” from work, etc. 
 
Magnitude of Task 
____ -3:  Major Deterioration.  Has deteriorated two grades or greater from baseline 
status. 
 
____ -2:  Moderate Deterioration.  Has deteriorated at least one grade but less than 
two grades from baseline. 
 
_____ -1:  Minor Deterioration.  Has deteriorated less than one grade from baseline.  
Patient with distinct deterioration within grade, but has not changed grades. 
 
_____ 0:  No Change.  No change from baseline. 
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_____ +1:  Minor Improvement.  Has improved less than one grade from baseline.  
Patient with distinct improvement within grade, but has not changed grades. 
 
_____ +2:  Moderate Improvement.  Has improved at least one grade but less than 
two grades from baseline. 
 
_____ +3:  Major Improvement.  Has improved two grades or greater from baseline. 
 
_____ Z:  Further impairment for reasons other than shortness of breath.  Patient 
has reduced exertional capacity, but not related to shortness of breath.  For 
example, musculoskeletal problems or chest pain. 
 
Magnitude of Effort 
_____ -3:  Major Deterioration.  Severe decrease in effort from baseline to avoid 
shortness of breath.  Activities now take 50 to 100% longer to complete than 
required at baseline. 
 
_____ -2:  Moderate Deterioration.  Some decrease in effort to avoid shortness of 
breath, although not as great as preceding category.  There is greater 
pausing with some activities. 
 
_____ -1:  Minor Deterioration.  Does not require more pauses to avoid shortness of 
breath, but does things with distinctly less effort than previously to avoid 
breathlessness. 
 
_____ 0:  No Change.  No change in effort to avoid shortness of breath. 
 
_____ +1:  Minor Improvement.  Able to do things with distinctly greater effort without 
shortness of breath.  For example, may be able to carry out tasks somewhat 
more rapidly than previously. 
 
_____ +2:  Moderate Improvement.  Able to do things with fewer pauses and distinctly 
greater effort without shortness of breath.  Improvement is greater than 
preceding category. 
 
_____ +3:  Major Improvement.  Able to do things with much greater effort than 
previously with few, if any, pauses.  For example, activities may be 
performed 50 to 100% more rapidly than at baseline. 
 
_____ Z:  Further impairment for reasons other than shortness of breath.  Patient 
has reduced exertional capacity, but not related to shortness of breath.  For 
example, musculoskeletal problems or chest pain. 
 
 
 
WORKSHEET TO BE USED FOR ASSEMENT OF TDI 
 
Dyspnoea recordings:  Date: Patient’s Initials: 
 FUNCTIONAL IMPAIRMENT MAGNITUDE OF TASK MAGNITUDE OF EFFORT 
Job 
 
   
Housework, shopping 
 
   
Leisure activities, gardening 
 
   
Social activities 
 
   
Washing, dressing 
 
   
At rest 
 
   
Any other 
 
   
BDI SCORE: -3 - +3 Functional impairment: Magnitude of task: Magnitude of effort: 
              TOTAL:                 /-9 - +9    
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Instructions for administration of Baseline and Transitional Dyspnoea Index 
 
The objective of the Baseline and Transitional Dyspnoea Indexes is to measure the 
severity of breathlessness (sensation of breathlessness, shortness of breath) in 
symptomatic patients.  The Baseline Dyspnoea Index (BDI) measures the severity 
of dyspnoea at the beginning of a trial and the Transitional Dyspnoea Index (TDI) 
evaluates changes from this baseline (transition period).  The test is applicable to 
patients with dyspnoea on exertion or at rest, due to respiratory disease.  
Administration of this index should be undertaken before any lung physiologic 
measurement on the test day and the interviewer must be blinded to other 
parameters evaluated for this patient. 
 
The dyspnoea indices were devised such that grading breathlessness could be 
performed as part of obtaining a history from the patient.  The indices include the 
categories “functional impairment”, “magnitude of task” and “magnitude of effort”, 
which provoke breathlessness.  The interviewer asks specific questions based on 
the criteria of the various grades of impairment or change in the mentioned 
categories.  This approach was selected instead of a questionnaire answered by 
the patient himself in order to allow an interviewer with medical training or 
background to grade breathlessness in a simple and brief encounter. 
 
The BDI and TDI are composed of the three categories mentioned.  The BDI 
includes five grades of severity, from zero (severe) to four (unimpaired) and the 
categories are summed up to create the focal score (zero to twelve).  The TDI 
ranges from minus three (major deterioration) to plus three (major improvement) 
including zero score to indicate “no change”.  Also for the TDI, the three categories 
are added to obtain a focal score ranging from minus nine, including zero, to plus 
nine.  Provision is made for circumstances when dyspnoea cannot be rated: In the 
BDI, score “W” if no/insufficient information exists; or “Y if the patient’s capacity is 
compromised by factors other than breathlessness.  In the TDI, score “Z” if 
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reduction of activities, effort or functional impairment is caused by reasons other 
than breathlessness.   
 
An interviewer, who should be experienced in history taking for respiratory disease, 
administers the test.  The interviewer should be a physician, nurse, respiratory 
therapist, cardiopulmonary technician or have similar qualifications with advanced 
knowledge or training concerning dyspnoea in respiratory disease.  Evaluation and 
scoring are performed during the interview and need the same level of experience.  
It is preferred that the same person conducts all evaluations for each patient. 
 
The initial question addressed to the subject should be “Do you experience 
shortness of breath?”  If the subject answers “No”, then the interviewer should ask 
whether any physical activities cause the subject to experience breathlessness.  If 
the answer to the questions is “Yes”, then additional questions follow to achieve 
the specific grading.  Questions concerning the patient’s shortness of breath 
should be open-ended and concentrate on how the shortness of breath affects 
his/her daily life, e.g. the maintenance or upkeep of residence, gardening or 
shopping.  The interviewer should focus on the specific criteria for the severity of 
breathlessness as specified in the indices and the patient should be rated based 
on the responses to the questions.  The interviewer circles one answer in the index 
that best describes how the patient’s daily activities are affected by his/her 
respiratory disease. 
 
The interview process at each visit (baseline and follow-up) should not take longer 
than five minutes. 
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At the baseline visit (BDI) 
 
Functional Impairment: 
 
The first component focuses on finding out which type of everyday life functions, at 
home or in his/her job, the patient is still able to perform.  Are there any activities 
that he/she has had to give up or change due to his/her shortness of breath, 
compared to the level of activity before the onset of his respiratory disease (e.g. 
can he/she mow the lawn or do house work, can he/she climb the stairs to the 
office or apartment as previously, can he/she walk uphill or cycle as previously, can 
he/she do the shopping, can he/she dress him/herself, can he/she care for the 
pet?).  It is important that the interviewer takes notes of the type of activities and 
the attached form may serve as an example of a record of the identified events that 
can be referred to at follow-up visits for the TDI.  Circle the grade of impairment in 
the BDI. 
 
Magnitude of Task: 
 
The second component focuses on the level and extent to which the individual can 
perform tasks until breathlessness is noticed.  Again, it is important to record the 
level on the form to be able to compare at follow-up visits.  Ask which activities 
make the patient feels breathless (e.g. to what extent can he/she do the daily 
household chores, can he/she mow 30sqm of lawn or what portion, can he/she 
cycle on ground level, gentle slopes uphill, moderate slopes uphill, which distance 
can he/she walk).  Provide the examples of the various grades and then circle a 
grade for magnitude of task. 
 
Magnitude of Effort: 
 
The third component focuses on the level of effort (exertion, vigour) that can be 
invested to perform the individual tasks.  Again allude to individual tasks and define 
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that effort that makes a patient feel breathless (e.g. shortness of breath only with 
extraordinary effort when mowing the lawn, or can just be done at normal pace, or 
can do it very slowly, or needs many pauses, can do house work as rapidly as 
usual, or takes much longer than previously, or needs many pauses).  Again, it is 
important to take notes of examples of the various grades for the magnitude of 
effort from the index and circle one. 
 
At Follow-up Visits (TDI) 
 
The TDI measures change from the baseline state in the three categories.  The 
interviewer refers to his records of the individual patient’s reported activities that 
result in breathlessness, the magnitude of the task required to evoke 
breathlessness and the effort of performance possible.  The record sheet and 
grades from the BDI serve as references and for reminding the interviewer, as well 
as the patient, of his/her selections before selecting a grade from the TDI.  At each 
follow-up visit, the interviewer refers back to the BDI and his original records and 
the previous TDI. 
 
Change in Functional Impairment: 
 
Review with the patient his/her functional status and the types of activities 
performed as recorded at baseline.  Ask the patient if there are any changes or 
modifications in his/her activities since the baseline visit (e.g., has he/she given up 
or taken up any activities).  Select a score from the index based on these changes, 
or circle zero if unchanged. 
 
Magnitude of Task: 
 
Review the level, i.e. magnitude of the specified activities that cause 
breathlessness.  Ask the patient which level now causes breathlessness and if 
there is any change from baseline (e.g. can he/she climb less or more flight or 
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stairs, can he/she walk longer or less, can he/she walk steeper or less steep 
slopes than recorded at the baseline visit?).  Select a grade from the index, 
considering that a change of plus/minus one should indicate the minimum that can 
be recognised by the patient, a plus/minus three means a major change and 
plus/minus two mean any change in-between.  
 
Magnitude of Effort: 
 
Review with the patient the effort (exertion, vigour) he/she was able to perform at 
baseline with the recorded activities, until he/she experienced breathlessness.  Ask 
the patient how much effort now causes breathlessness and whether there is a 
change from baseline [e.g. does it take more or less time for certain activities, does 
he/she need to take less or more pauses and can he perform with more or less 
effort (exertion, vigour)?].  Circle a grade for change in the index or select zero if 
there was no change. 
 
Appendix H 
 
Physician’s Global Evaluation 
 
 
It is preferred that the same person conducts all evaluations for the patient.  This 
evaluation MUST be completed prior to pulmonary function testing.  It reflects the 
investigator’s assessment of the overall condition of the patient’s disease. 
 
Circle only one appropriate response below. 
 
Poor Fair Good Excellent 
1 2 3 4 5 6 7 8 
 
 
 
 
 
 
 
Concomitant therapy       
Number and severity of exacerbations 
Severity of cough 
Ability to exercise 
Amount of wheezing, etc. since last visit 
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Appendix I 
 
Subjects’ demographics 
 
Table 7.12 Demographics of subjects included in the primary programme. 
Subject Age Gender Race 
Currently 
smoking 
Stage FEV1 
1 70 male caucasian no severe 0.96 
2 70 male caucasian no moderate 1.67 
3 78 female caucasian no moderate 0.95 
4 70 female caucasian yes moderate 1.22 
5 44 male caucasian yes severe 1.74 
6 73 female caucasian no moderate 1.82 
7 79 female caucasian no very severe 0.59 
8 65 male caucasian yes moderate 2.52 
9 56 female caucasian no severe 0.71 
10 59 female caucasian no very severe 0.76 
11 67 male caucasian yes moderate 1.49 
12 60 male black no very severe 0.7 
13 66 female caucasian no severe 0.67 
14 64 male caucasian no severe 1.44 
15 61 male caucasian no severe 1.4 
16 73 male caucasian no severe 1.11 
17 54 male caucasian yes severe 1.58 
18 42 male caucasian no severe 1.34 
19 63 male black no moderate 1.98 
20 47 male black no severe 1.69 
21 74 male caucasian no moderate 1.95 
22 45 male caucasian no severe 1.23 
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Table 7.13 Demographics of the experimental group in the modified programme. 
Subject Age Gender Race 
Currently 
smoking 
Stage FEV1 
1 74 male black no severe 1.41 
2 70 male caucasian no severe 1.18 
3 67 male caucasian no moderate 1.78 
4 51 female black no moderate 1.15 
5 64 female caucasian no moderate 1.11 
6 70 female black no moderate 1.26 
7 66 female black no moderate 1.37 
8 63 male caucasian no moderate 1.6 
9 72 male black no severe 1.24 
10 60 female caucasian no moderate 1.17 
11 68 male caucasian no severe 0.92 
 
Table 7.14 Demographics of the control group in the modified programme. 
Subject Age Gender Race 
Currently 
smoking 
Stage FEV1 
1 72 male caucasian no moderate 1.71 
2 64 female black no severe 0.66 
3 64 female caucasian no severe 0.86 
4 65 male caucasian no severe 1.21 
5 77 male caucasian no moderate 1.91 
6 71 female caucasian no moderate 1.1 
7 72 female caucasian no moderate 1.09 
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Appendix J 
 
Correlations that delivered insignificant results 
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Figure 7.53 A scatter plot illustrating the correlation between the difference in BMI 
and the physician’s global evaluation from the first to the third 
evaluation. 
 
No significant correlation was found between the difference in BMI and the 
physician’s global evaluation from the first to the third evaluation (p = 0.96) in the 
PP. 
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Figure 7.54 A scatter plot illustrating the correlation between the number of 
exacerbations and FEV1 at the first evaluation. 
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Figure 7.55 A scatter plot illustrating the correlation between the number of 
exacerbations and FEV1 at the second evaluation.  
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No significant correlation was found between the number of exacerbations and 
FEV1 values at the first (p = 0.33) or second evaluation (p = 0.23) in the PP. 
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Figure 7.56 A scatter plot illustrating the correlation between the number of 
exacerbations and the percentage predicted FEV1 at the first 
evaluation. 
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Figure 7.57 A scatter plot illustrating the correlation between the number of 
exacerbations and the percentage predicted FEV1 at the second 
evaluation. 
 
No significant correlation was found between the number of exacerbations and 
FEV1 values at the first (p = 0.62) or second evaluation (p = 0.27) in the PP. 
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Sessions missed due to exacerbations
6M
W
D
 (m
) (
ev
al
ua
tio
n 
1 
- 2
)
-1 0 1 2 3 4 5 6 7
20
40
60
80
100
120
140
160
180
200
220
240
260
280
 
Figure 7.58 A scatter plot illustrating the correlation between the exercise 
sessions missed due to exacerbations and the change in 6MWD from 
the first to the second evaluation. 
 
No significant correlation was found between the exercise sessions missed due to 
exacerbations and the change in 6MWD from the first to the second evaluation in 
the PP (p = 0.86). 
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Figure 7.59 A scatter plot illustrating the correlation between the number of 
exacerbations and SGRQ scores at the second evaluation. 
 
No significant correlation was found between the number of exacerbations and the 
HRQL as assessed by the SGRQ (p = 0.01). 
SGRQ scores (evaluation 1)
BD
I s
co
re
s 
(e
va
lu
at
io
n 
1)
20 30 40 50 60 70 80 90
20
30
40
50
60
70
80
 
Figure 7.60 A scatter plot illustrating the correlation between the BDI and SGRQ 
scores at the first evaluation. 
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No significant correlation was found between the BDI and SGRQ scores at the first 
evaluation in the PP (p = 0.42). 
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Figure 7.61 A scatter plot illustrating the correlation between the number of 
exacerbations and FEV1 at the first evaluation for the experimental 
group. 
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Figure 7.62 A scatter plot illustrating the correlation between the number of 
exacerbations and FEV1 at the first evaluation for the control group. 
 
No significant correlations were found between the number of exacerbations and 
FEV1 for the experimental (p = 0.50) or control group (p = 0.81) at the first 
evaluation. 
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Figure 7.63 A scatter plot illustrating the correlation between the number of 
exacerbations and the percentage predicted FEV1 at the first 
evaluation for the experimental group. 
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Figure 7.64 A scatter plot illustrating the correlation between the number of 
exacerbations and the percentage predicted FEV1 at the first 
evaluation for the control group. 
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 No significant correlations were found between the number of exacerbations and 
the percentage predicted FEV1 at the first evaluation for the experimental (p = 
0.35) or control group (p = 0.83). 
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Figure 7.65 A scatter plot illustrating the correlation between the number of 
exacerbations and FEV1 at the second evaluation for the 
experimental group. 
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Figure 7.66 A scatter plot illustrating the correlation between the number of 
exacerbations and FEV1 at the second evaluation for the control 
group. 
 
No significant correlations were found between the number of exacerbations and 
FEV1 at the second evaluation for the experimental (0.10) or control group (p = 
0.44). 
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Figure 7.67  A scatter plot illustrating the correlation between the number of 
exacerbations and the percentage predicted FEV1 at the second 
evaluation for the experimental group. 
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Figure 7.68 A scatter plot illustrating the correlation between the number of 
exacerbations and the percentage predicted FEV1 at the second 
evaluation for the control group. 
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No significant correlations were found between the number of exacerbations and 
the percentage predicted FEV1 at the second evaluation for the experimental (p = 
0.13) or control group (p = 0.88). 
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Figure 7.69 A scatter plot illustrating the correlation between the exercise 
sessions missed due to exacerbations and the change in 6MWD from 
the first to the second evaluation for the experimental group. 
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Figure 7.70 A scatter plot illustrating the correlation between the exercise 
sessions missed due to exacerbations and the change in 6MWDs 
from the first to the second evaluation for the control group. 
 
No significant correlations were found between the number of exercise sessions 
missed due to exacerbations and the change in 6MWDs from the first to the 
second evaluation for the experimental (p = 0.36) or control group (p = 0.87). 
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Figure 7.71 A scatter plot illustrating the correlation between the SGRQ scores 
and the number of exacerbations for the control group at the first 
evaluation. 
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Figure 7.72 A scatter plot illustrating the correlation between the SGRQ scores 
and the number of exacerbations for the experimental group at the 
second evaluation. 
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 No significant correlations were found between the number of exacerbations and 
the SGRQ scores at the first evaluation of the control group (p = 0.27) and the 
second evaluation of the experimental group (p = 0.30).   
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Figure 7.73 A scatter plot illustrating the correlation between the experimental 
group’s BDI and SGRQ scores at the first evaluation. 
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Figure 7.74 A scatter plot illustrating the correlation between the control group’s 
BDI and SGRQ scores at the first evaluation. 
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 No significant correlation was found between the BDI and SGRQ scores for the 
experimental (p = 0.80) or control group (p = 0.11) at the first evaluation. 
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Figure 7.75 Scatter plots illustrating the correlation between the difference in the 
SGRQ scores and the 6MWDs from the first to the second evaluation 
for the experimental and control group. 
 
No significant correlation was found between the difference in SGRQ scores and 
6MWDs from the first to the second evaluation for the experimental (p = 0.77) or 
control group (p = 0.73). 
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Figure 7.76 Scatter plots illustrating the correlation between the difference in the 
SGRQ scores and the physician’s global evaluation from the first to 
the second evaluation for the experimental and control group. 
 
No significant correlation was found between the difference in SGRQ scores and 
the physician’s global evaluation from the first to the second evaluation for the 
experimental (p = 0.70) or control group (p = 0.84). 
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Figure 7.77 Scatter plots illustrating the correlation between the difference in the 
BDI/TDI scores and the physician’s global evaluation from the first to 
the second evaluation for the experimental and control group. 
 
No significant correlation was found between the difference in BDI/TDI scores and 
the physician’s global evaluation from the first to the second evaluation for the 
experimental (p = 0.50) or control group (p = 0.40). 
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Figure 7.78 Scatter plots illustrating the correlation between the difference in the 
SGRQ scores and the BDI/TDI scores from the first to the second 
evaluation for the experimental and control group. 
 
No significant correlation was found between the difference in SGRQ scores and 
the BDI/TDI scores from the first to the second evaluation for the experimental (p = 
0.24) or control group (p = 0.40). 
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Figure 7.79 Scatter plots illustrating the correlation between the difference in the 
BDI/TDI scores and the 6MWDs from the first to the second 
evaluation for the experimental and control group. 
 
No significant correlation was found between the difference in BDI/TDI scores and 
the 6MWDs from the first to the second evaluation for the experimental (p = 0.57) 
or control group (p = 0.94). 
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Figure 7.80 Scatter plots illustrating the correlation between the difference in 
6MWDs and the physician’s global evaluation from the first to the 
second evaluation for the experimental and control group. 
 
No significant correlation was found between the difference in 6MWDs and the 
physician’s global evaluation from the first to the second evaluation for the 
experimental (p = 0.24) or control group (p = 0.57). 
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Appendix K 
 
Correlations combining results form the primary programme with the results of the 
control group 
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Figure 7.81 A scatter plot illustrating the correlation between the 6MWDs and 
SGRQ scores of the combined results of the subjects in the PP and 
control group at the first evaluation. 
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Figure 7.82 A scatter plot illustrating the correlation between the 6MWDs and 
SGRQ scores of the combined results of the subjects in the PP and 
control group at the second evaluation. 
 
There was a significant correlation between the combined 6MWDs and SGRQ 
results of the subjects in the PP and the control group at the first (p < 0.05) and 
second evaluation (p < 0.05). 
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Appendix L 
 
Significant correlations that was considered circumstantial 
 
When calculating the correlations between various variables, some significant 
correlations were found, but were not consistent throughout the evaluations or 
different groups.  These correlations are presented below, but are considered 
circumstantial. 
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Figure 7.83 A scatter plot illustrating the correlation between TDI and the 
physician’s evaluation at the second evaluation.   
 
A significant correlation was found between the mean TDI and the physician’s 
global scores at the second evaluation (p < 0.01).  This correlation was not present 
at the first or third evaluation (p > 0.05).  In MP, this correlation was only significant 
in the control group at the first evaluation.  Although the assessment of dyspnoea 
forms part of the physician’s global evaluation, other components such as 
medication, exacerbations, severity of cough and ability to exercise, also form an 
 317
integral part of this evaluation.  In the cases where this correlation was present, 
dyspnoea was the primary symptom noted at that stage.  Therefore, a correlation 
would be expected.  The absence of this correlation in the other assessments 
implies that dyspnoea was not the primary concern of the subject at that stage.  
Dyspnoea is perceived as the most important symptom experienced by COPD 
patients and receives most of the attention in the treatment of these patients 
(Franssen, 2003; Gosselink, 2003; Marin et al., 2001; ATS, 1999; Carrieri-Kohlman 
et al., 1996; Lareau et al., 1994).  This correlation or lack thereof, suggests that the 
overall wellbeing of COPD patients might be more strongly influenced by factors 
other than dyspnoea.   
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Figure 7.84 A scatter plot illustrating the correlation between the mean BMI and 
FEV1 at the first evaluation.   
 
A significant correlation was found between BMI and FEV1 at the first evaluation (p 
< 0.05).  This correlation was not present at the second or third evaluation (p > 
0.05).  This correlation was not present at the second evaluation or in the MP.  
Although there was not a significant correlation between these variables at the 
second evaluation, the tendency of the graph is similar to that of the first 
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evaluation.  Even though these variables did not show any significant change from 
the first to the second evaluation, the similarity between these correlations 
suggests that the change was sufficient to reduce the correlation at the second 
evaluation.  Due to the fact that height and weight have an effect on FEV1, a 
correlation between these two variables would be expected.  The absence of this 
correlation in the MP could be explained by the limitations of BMI (Chapter III).   
 
No significant correlation was found between the mean BMI and SGRQ scores at 
any of the three evaluations (p > 0.05).  The lack of correlations found between 
BMI and other variables could be ascribed to the fact that there was no significant 
change in the BMI values of the subjects (p = 0.84). 
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Figure 7.85 A scatter plot illustrating the correlation between the number of 
exacerbations and the SGRQ scores at the first evaluation. 
 
A significant correlation was found between the number of exacerbations and 
HRQL as assessed by the SGRQ (p < 0.05).  This correlation was not present at 
the second evaluation (p = 0.10). 
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Figure 7.86 A scatter plot illustrating the correlation between the SGRQ and FEV1 
means of the control group at the first evaluation.   
 
A weak, but significant correlation was found between the control group’s mean 
SGRQ scores and FEV1 at the first evaluation (p = 0.05).  This correlation was not 
present at the control group’s second evaluation (p = 0.12).  No correlation was 
found between these variables in the experimental group at the first (p = 0.98) or 
second evaluation (p = 0.96).   
 
 
 320
1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5
Physcian's global score (evaluation 1)
20
30
40
50
60
70
80
90
S
G
R
Q
 (e
va
lu
at
io
n 
1)
 
Figure 7.87 A scatter plot illustrating the correlation between the physician’s 
global evaluation and the SGRQ of the control group at the baseline 
evaluation. 
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Figure 7.88 A scatter plot illustrating the correlation between the physician’s 
global evaluation and SGRQ of the control group at the second 
evaluation.   
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A significant correlation was found between the physician’s global evaluation and 
the SGRQ of the control group at the first (p < 0.01) and second evaluation (p < 
0.05).  No significant correlation was found between these values of the 
experimental group at the first (p = 0.59) or second evaluation (p = 0.72).     
 
In the MP, a significant correlation was found between the SGRQ and the 
physician’s global evaluation for the control group.  A high score on the physician’s 
global evaluation indicates a good overall condition of the patient, whereas a high 
score in the SGRQ indicates poor quality of life.  Therefore, a negative correlation 
would be expected between these variables.  However, this correlation was not 
present in the PP or experimental group.  This indicates that an encouraging 
physician’s evaluation does not necessarily translate into quality of life benefits.  
Although the physician’s evaluation is of vital importance when treating COPD 
patients, this affirms the importance of the patient’s own subjective perception of 
his/her disease.   
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Figure 7.89 A scatter plot illustrating the correlation between the mean BDI and 
physician’s global scores for the control group at the first evaluation.   
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A correlation was found between the mean BDI scores and the physician’s global 
evaluation for the control group at the first evaluation (p < 0.05).  No correlation 
was found for this group at the second evaluation (p = 0.68).  No correlation 
between these variables was present for the experimental group at the first (p = 
0.70) or second evaluation (p = 0.91). 
 
No significant correlation was found between the physician’s global evaluation and 
the 6MWT for the experimental group at the first (p = 0.83) or second evaluation (p 
= 0.70).  No significant correlation was found between the physician’s global 
evaluation and the 6MWT for the control group at the first (p = 0.26) or second 
evaluation (p = 0.26).   
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Figure 7.90 A scatter plot illustrating the correlation between the mean BMI and 
SGRQ scores of the control group at the first evaluation. 
 
A significant correlation was found between the mean BMI and SGRQ scores of 
the control group at the first evaluation (p < 0.01).  This correlation was not present 
at the second evaluation (p = 0.20).  No correlation was found between these 
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variables for the experimental group at the first (p = 0.11) or second evaluation (p = 
0.19).   
 
Shoup and co-workers (1997) found that bodyweight has a direct effect on HRQL.  
According to these authors, underweight as well as overweight patients would have 
an impaired HRQL.  This study did find a correlation between BMI and SGRQ 
scores for the control group at the first evaluation.  However, this correlation was 
not present in the PP, or with the experimental group.  The absence of this 
correlation could be attributed to the fact that there was no significant change in 
BMI from the first to the second evaluations.  Furthermore, BMI has several 
limitations (as discussed in Chapter III), which would also influence possible 
correlations.  Contrary to additional findings of Shoup and co-workers (1997), the 
present study found no correlations between SGRQ and BDI (Appendix J). 
 
No significant correlation was found between the mean BMI and FEV1 scores of 
the control group at the first (p = 0.08) or second (p = 0.44).  No significant 
correlation was found between the mean BMI and FEV1 scores of the experimental 
group at the first (p = 0.61) or second evaluation (p = 0.30).   
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Figure 7.91 A scatter plot illustrating the correlation between the number of 
exacerbations and SGRQ scores of the experimental group at the 
first evaluation. 
 
There was a significant correlation between the number of exacerbations and 
HRQL, as assessed by the SGRQ of the experimental group at the first evaluation 
(p < 0.05).  This correlation was not present at the second evaluation of the 
experimental group (p = 0.30). 
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Number of exacerbations (evaluation 2)
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Figure 7.92 A scatter plot illustrating the correlation between the number of 
exacerbations and the SGRQ scores for the control group at the 
second evaluation. 
 
There was a weak, but significant correlation between the number of exacerbations 
and HRQL, as assessed by the SGRQ of the control group at the second 
evaluation (p = 0.05).  This correlation was not present at the first evaluation of the 
control group (p = 0.27). 
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Appendix M 
Analyses of variables based on BDI-score 
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Figure 7.93 ANOVA graphs to illustrate the SGRQ-scores of the subjects when 
divided based on their BDI-scores. 
 
Although figure 4.93 gives the impression that that subjects that were in the group 
that was less dyspnoeic had a greater improvement in SGRQ-scores, there was no 
statistically significant difference between the SGRQ-scores of the subjects in the 
two BDI groups (p > 0.05). 
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Figure 7.94 ANOVA graphs to illustrate the 6MWD of the subjects when divided 
based on their BDI-scores. 
 
As illustrated in figure 7.94, there was no statistically significant difference between 
the 6MWD of the two groups at any of the two evaluations (p > 0.05). 
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Figure 7.95 ANOVA graphs to illustrate the 6MWD of the subjects when divided 
based on their BDI-scores. 
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 As illustrated in figure 7.95, there was no statistically significant difference between 
the physician’s global evaluations of the two groups at any of the two evaluations 
(p > 0.05). 
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Figure 7.96 ANOVA graphs to illustrate the SGRQ of the subjects when divided 
based on their BDI-scores. 
 
As illustrated in figure 7.96, there was no statistically significant difference between 
the SGRQ-scores of the two groups at any of the two evaluations (p > 0.05). 
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Figure 7.97 ANOVA graphs to illustrate the 6MWD of the subjects when divided 
based on their BDI-scores. 
 
As illustrated in figure 7.97, there was no statistically significant difference between 
the 6MWD of the two groups at any of the two evaluations (p > 0.05). 
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Figure 7.98 ANOVA graphs to illustrate the physician’s global evaluations of the 
subjects when divided based on their BDI-scores. 
 
As illustrated in figure 7.98, there was no statistically significant difference between 
the physician’s global evaluations of the two groups at any of the two evaluations 
(p > 0.05). 
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